Hi Jodi—I think I’ll miss this one, but a few items:

Many thanks

Best, Mike
Supporting Statement A for

Generic Clearance for NIH Citizen Science and Crowdsourcing Projects (NIH)

OMB# 0925-0766, exp., date 04/30/2023

Date: March 4, 2020

Check off which applies:

X New
☐ Revision
☐ Reinstatement with Change
☐ Reinstatement without Change
☐ Extension
☐ Emergency
☐ Existing w/o OMB approval

Federal Government Employee Information:

Name: Mikia Currie, Chief, Project Clearance Branch (PCB)
Address: 6705 Rockledge Drive, RK11/803-B
Telephone: 301-435-0941
Fax: 301-435-3509
Email: (b)(6)
**Table of contents**

A. ABSTRACT

A.1 Circumstances Making the Collection of Information Necessary

A.2 Purpose and Use of the Information COLLECTION

A.3 Use of Information Technology and Burden Reduction

A.4 Efforts to Identify Duplication and Use of Similar Information

A.5 Impact on Small Businesses or Other Small Entities

A.6 Consequences of Collecting the Information Less Frequently

A.7 Special Circumstances Relating to the Guidelines of 5 CFR 1320.5

A.8 Comments in Response to the Federal Register Notice and Efforts to Consult Outside Agency

A.9 Explanation of Any Payment of Gift to Respondents

A.10 Assurance of Confidentiality Provided to Respondents

A.11 Justification for Sensitive Questions

A.12 Estimates of Hour Burden Including Annualized Hourly Costs

A.13 Estimate of Other Total Annual Cost Burden to Respondents or Record keepers

A.14 Annualized Cost to the Federal Government

A.15 Explanation for Program Changes or Adjustments

A.16 Plans for Tabulation and Publication and Project Time Schedule

A.17 Reason(s) Display of OMB Expiration Date is Inappropriate

A.18 Exceptions to Certification for Paperwork Reduction Act Submissions

*Attachments (save file names to match what is being referenced: (ex: x.baseline; y.screener)*
ATTACHMENTS

Attachment 1 Sub-study template form

Attachment 2 Mini SSA

Attachment 3 Privacy Act Memo

Attachment 4 published 30-day FRN
A. Justification

This is a new generic collection titled, "Generic Clearance for NIH Citizen Science and Crowdsourcing Projects." Projects under this generic clearance will allow Agency researchers and program staff to test ideas more quickly, respond to the project's needs as they evolve, and incorporate feedback from participants for flexible, innovative research methods. Any collection under this umbrella is expected to be low in burden.

A.1 Circumstances Making the Collection of Information Necessary

Section 413 (b) (3) of the Public Health Service Act, 42 U.S. Code § 285 gives NIH the authority to collect this information.

Pursuant to Section 402 of the American Innovation and Competitiveness Act (P.L. 114-329) federal agencies have broad authority to use crowdsourcing to advance agency missions and facilitate broader public participation in the innovation process. The purpose of this collection is to identify existing research, educational, operational, and project information from the public in order to share more widely with a range of audiences. These types of collections will further the legislation’s purposes of “accelerating scientific research, increasing cost-effectiveness to maximize the return on taxpayer dollars, addressing societal needs, providing hands-on learning in STEM, and connecting members of the public directly to federal science missions and to each other.”

Many federal and non-federal organizations are already using innovative citizen science and crowdsourcing tools to advance their missions. These tools are especially valuable where data are sparsely distributed or when projects rely on large datasets. Successful citizen science and crowdsourcing projects usually result from iteration of the design based on feedback from the participants. Also, there could be uncertainty about whether the time and effort to create a project will capture the interest of the public and yield meaningful public participation.

Citizen science and crowdsourcing are tools that engage, educate and empower the public to apply their curiosity and contribute their talents and feedback to a wide range of scientific and societal issues. Citizen Science is a form of open collaboration where the public can participate actively in the scientific process through methods that include asking research questions, collecting and analyzing data, interpreting results, or engaging in problem solving. Crowdsourcing is a process where individuals or organizations submit an open call for contributions of information from a group of individuals (“the crowd”).

A.2 Purpose and Use of the Information Collection

The purpose of this information collection is to:

- Accelerate scientific research
- Increase cost-effectiveness to maximize the return on taxpayer dollars
• Address societal needs  
• Provide hands-on learning in STEM education  
• Connect members of the public directly to federal science missions and each other  
• Identify and disseminate resources more broadly to the public, on the Institutes’ and Centers’ (ICs) websites, and/or  
• Collect information for agency internal use to improve scientific practices and/or assist in scientific reviews  

Citizen science and crowdsourcing collections under this generic clearance may include the following types of questions or requests of participants:  

• **Personal and Contact Information.** Projects submitted under this generic clearance may solicit contact information. This information may be necessary to organize and analyze data. Projects may request contact information (name and email address, zip code, address and phone number) to provide participants with project updates and share data. Participants would be made aware that the publically available data on contact information will be anonymized and aggregated, for example, by census tract, zip code, city, or some other higher level than individual addresses.  

• **Names and Nominations.** NIH relies on nominations to recruit appropriate scientific expertise, broaden membership of review panels, and receive recommendations for reviewers. Projects submitted under this generic clearance may include public solicitations for nominations, to include project overviews, request for abstracts, or relevant qualifying questions related to the reason for individual’s nomination. This information would only be used by NIH internally to select eligible candidates from the scientific community.  

• **Experience and Expertise.** For data quality purposes, projects submitted under this generic clearance may request information to evaluate the skill level of the participant by asking about their experience with the project topic. Questions may be about a person’s age range, level or topic of education, participation in organizations, or professional experience.  

• **Requests for population characteristics** within crowdsourcing mechanisms, such as institutional affiliation and career level/stage. For example, this mechanism will allow for individuals interested in a certain topic to sign up for alerts that NIH may send in the future, and at the same time allows NIH to identify individuals interested in various topics with a goal to potentially contact them in the future.  

• **Identification or Descriptions of Extramural Research, Research Tools, or Existing Resources.** Projects may include requests to identify and/or describe extramural research, research tools, or existing resources. This will allow NIH to identify best practices and developments within the scientific community that could inform future NIH program development. This could be a means to publicly identify emerging tools, guidance, or research or to review, vet, and encourage the use of public health interventions in the community and clinical settings. Making this information publicly available could enhance the quality, speed, and public health impact of efforts to translate research into practice. It will also help the agency understand resources availability in extramural or other public environments.
To obtain approval for a collection that meets the conditions of this generic clearance, a standardized form, depending on complexity of sub-study, a template or “Mini-Supporting Statement A (Mini-SSA)” will be submitted to OMB along with any other supporting documentation.

A.3 Use of Information Technology and Burden Reduction

If appropriate, programs will collect information electronically and/or use online collaboration tools to reduce burden. Screenshots will be provided for all online data collection instruments. A Privacy Impact Assessment (PIA) will be completed for all online requests.

A.4 Efforts to Identify Duplication and Use of Similar Information

No similar data are gathered or maintained by the agency or available from other sources known to the agency.

A.5 Impact on Small Businesses or Other Small Entities

Small business or other small entities may be involved in these efforts, but the agency will minimize the burden on them of information collections approved under this clearance by sampling, asking for readily available information, and using short, easy-to-complete information collection instruments.

A.6 Consequences of Collecting the Information Less Frequently

Forms will be submitted on an as needed basis.

A.7 Special Circumstances Relating to the Guidelines of 5 CFR 1320.5

There are no special circumstances. The information collected will be voluntary, not generalizable, and will not be used for statistical purposes.

A.8.1 Comments in Response to the Federal Register Notice

The 60-day Federal Register Notice was published on October 4, 2019 (Vol. 84, pg. 53162) and allowed 60 days for public comment. No public comment was received.

A.8.2 Efforts to Consult Outside Agency

No outside consultation is intended.

A.9 Explanation of Any Payment of Gift to Respondents

It is possible that some information collection activities will entail a small payment or gifts to respondents. The agency does not typically provide payment or other forms of remuneration to
participants, however if it is necessary for hard to reach populations, details and a justification will be provided. Instances for offering an incentive will be determined on a case-by-case basis (depending on the particular information collection design).

A.10 Assurance of Confidentiality Provided to Respondents

Personal Identifiable Information (PII) will only be collected to the extent necessary. Respondents will be assured that neither their participation nor lack of participation will have any effect on their eligibility for receipt of services. In addition, respondents will be advised of the purpose of the information collection, the use of information collection, NIH sponsorship, that their participation is voluntary, and that they may choose to discontinue or have their name and/or related information withdrawn at any time. In instances where it is possible, information will be presented in an aggregate form without links to the identity of individual participants. The Privacy Act applies to the information collection per Privacy Act System of Records Notice (SORN) 09-25-0156, "Records of Participants in Programs and Respondents in Surveys Used to Evaluate Program of the Public Health Service, HHS/PHS/NIH/OD".

It may be necessary for some information collections to retain name and contact information to be used to contact potential respondents. In these instances, the rationale for retention of PII will be fully explained. Most of the information collections to be conducted under this clearance is considered exempt from Institutional Review Board (IRB) review at NIH. However, if it is determined that the information collection involves non-exempt activities, the staff will be required to submit the information collection for review to the IRB for approval.

A.11 Justification for Sensitive Questions

This generic will allow for sensitive questions specifically in the context of determining demographics and promoting diversity. NIH values diversity (NOT-OD 20-031) and inclusion, and this data will assist NIH in being more inclusive of culturally, medically, and behaviorally sensitive matters. All questions of a sensitive nature will be justified. The justification will include the reasons why the agency considers the questions necessary, the specific uses to be made of the information, the explanation to be given to persons from whom the information is requested, and any steps to be taken to obtain their consent. All sensitive questions will be voluntary fields.

A.12.1 Estimates of Hour Burden Including Annualized Hourly Costs

Participants in these activities may include research in academia or industry, clinicians, patients and patient’s advocacy organizations, other non-governmental organizations, and members of the public. A variety of instruments and platforms will be used to collect information from respondents and each sub-study will vary by number of respondents and average time per response. However, the annual burden hours requested 18,601 is based on the number of collections we expect to conduct over the requested three-year period for this clearance.
<table>
<thead>
<tr>
<th>Type of Collection</th>
<th>No. of Respondents</th>
<th>No. of Responses per Respondent</th>
<th>Time per Response (in hours)</th>
<th>Total Hours</th>
</tr>
</thead>
<tbody>
<tr>
<td>Call for Nominations/Resources</td>
<td>1,000</td>
<td>1</td>
<td>10/60</td>
<td>167</td>
</tr>
<tr>
<td>Recommendations of scientific reviewers</td>
<td>1,000</td>
<td>1</td>
<td>5/60</td>
<td>83</td>
</tr>
<tr>
<td>Request for Population Characteristics</td>
<td>20,000</td>
<td>1</td>
<td>5/60</td>
<td>1,667</td>
</tr>
<tr>
<td>Repository of Tools and Best Practices</td>
<td>100,000</td>
<td>1</td>
<td>10/60</td>
<td>16,667</td>
</tr>
<tr>
<td>Total</td>
<td>122,000</td>
<td></td>
<td></td>
<td>18,584</td>
</tr>
</tbody>
</table>

A.12-2 ANNUAL COST TO RESPONDENT

These estimates are based on the following data from the Bureau of Labor Statistics: the General Public rate was obtained from the https://www.bls.gov/oes/2018/May/oes_nat.htm#00-0000 occupation title “All occupations” occupation code 00-0000. The Health Professionals wage rate was obtained from https://www.bls.gov/oes/2018/May/oes_nat.htm#00-0000occupation title “Healthcare Practitioners and Technical Occupations”, occupation code 29-0000; and the Health Educators wage rate was obtained from http://www.bls.gov/oes/current/oes211091.htm, occupation code 21-1091.
### Table 12-2 Annualized Cost to Respondents

<table>
<thead>
<tr>
<th>Type of Respondents</th>
<th>Total Annual Burden Hours</th>
<th>Hourly Respondent Wage Rate*</th>
<th>Respondent Cost</th>
</tr>
</thead>
<tbody>
<tr>
<td>General Public</td>
<td>18,334</td>
<td>$24.98</td>
<td>$457,983</td>
</tr>
<tr>
<td>Health Professionals</td>
<td>83</td>
<td>$39.42</td>
<td>$3,272.00</td>
</tr>
<tr>
<td>Health Educators</td>
<td>167</td>
<td>$28.68</td>
<td>$4,789.56</td>
</tr>
<tr>
<td><strong>TOTAL</strong></td>
<td><strong>18,584</strong></td>
<td></td>
<td><strong>$466,044</strong></td>
</tr>
</tbody>
</table>

*The General Public [http://www.bls.gov/oes/2018/may/oes_nat.htm#00-0000](http://www.bls.gov/oes/2018/may/oes_nat.htm#00-0000)

### A.13 Estimate of Other Total Annual Cost Burden to Respondents or Record Keepers

There are no additional costs other than a respondent’s time.

### A.14 Annualized Cost to the Federal Government

The annual cost to the Federal Government for the proposed data collection effort is $11,977.50

<table>
<thead>
<tr>
<th>Cost Descriptions</th>
<th>Grade/Step</th>
<th>Salary*</th>
<th>% of Effort</th>
<th>Fringe (if applicable)</th>
<th>Total Cost to Gov’t</th>
</tr>
</thead>
<tbody>
<tr>
<td>Federal Oversight</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>$11,977.50</td>
</tr>
<tr>
<td>Asst. Project Officer</td>
<td>GS 13/6</td>
<td>$119,775</td>
<td>10%</td>
<td></td>
<td>$11,977.50</td>
</tr>
<tr>
<td>Contractor Cost</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Travel</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Other Cost</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Total</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td><strong>$11,977.50</strong></td>
</tr>
</tbody>
</table>

A.15 Explanation for Program Changes or Adjustments

This is a new information collection request.

A.16 Plans for Tabulation and Publication and Project Time Schedule

The information collected through this collection is primarily for internal review and will not be published. However, for certain activities, information may be published on an NIH website or included in a printed or online program for the activity or subsequent publication describing the activity. Each project submitted under this generic clearance will specify plans for tabulation, timeline, and publication of the information collection.

A.17 Reason(s) Display of OMB Expiration Date is Inappropriate

The OMB control number and expiration date will be displayed.

A.18 Exceptions to Certification for Paperwork Reduction Act Submissions

None
Hi Jodi,

Attached are the updates that I provided to you last week.

Attachment 1: notifies you that I have restricted all funds to WIV from the NIMH grant – the details in this attachment outlines the restricted $660,054k which is the full amount of the subaward to WIF from UC-Irvine it’s total costs, as discussed Friday. They cannot draw down any funds.

Attachment 2: is the letter that was drafted for Mike Lauer to send to UC-Irvine (prime) suspending the sub to WIV. The letter should cc Terri Jarosik/NIMHs CGMO

Michelle

I have no updates. If you could advise on possible next steps that would be helpful:

What are the options?

Thanks

Jodi

Jodi B. Black, PhD, MMSc
Deputy Director
Office of Extramural Research, NIH
Jodi,
Do we have an update on this? Any updates?

From: Black, Jodi (NIH/OD) [E]  
Sent: Thursday, April 30, 2020 8:50 AM  
To: Bulls, Michelle G. (NIH/OD) [E]  
Cc: Tarwater, Robert (NIH/OD) [E]  
Subject: Re: WIV

We are moving towards The letter requests information about what is currently funded and what was funded in the past. Katrina is working the funding aspect.

Days after Trump’s briefing promise, Republican lawmakers wrote to leadership asking that no stimulus funding go to the Wuhan lab, citing State Department cables about safety concerns. The White House did not respond to a request for comment.

Please let me know how I can help

Best,
Jodi

Jodi B. Black, PhD, MMSc  
Deputy Director  
Office of Extramural Research, NIH

From: Michelle Bulls  
Date: Thursday, April 30, 2020 at 8:40 AM  
To: Jodi OER <  
Cc: Robert Tarwater <  
  Michelle Bulls <  
Subject: RE: WIV

I need time to review this and determine what can be done.

Just so I am clear,

Michelle

From: Black, Jodi (NIH/OD) [E]  
Sent: Thursday, April 30, 2020 8:35 AM  
To: Bulls, Michelle G. (NIH/OD) [E]  
Cc: Tarwater, Robert (NIH/OD) [E]  
Subject: WIV

Hi Michelle,  
What are the options?
Thanks
Jodi

Jodi B. Black, PhD, MMSc
Deputy Director
Office of Extramural Research, NIH
Hi,

I have revised Diane’s draft to further refine our language and KT helped me get this on letterhead. It’s prepped for Mike’s signature. Let me know if you need anything additional.
Forwarding, as requested.

Good Morning ladies,

I know that OER has made a request for DPI to contact Diane when DPI receives a request from an OIG Agent or an FBI Agent that is asking for grant-related information. Ashley has already started to send a few requests to Diane.

However, given the impact of this request upon DPI’s SOPs for the OI2 process, before I make any permanent changes to any DPI long-standing processes, I would like to have a meeting to discuss this with all of you. I would like to know more about OERs engagement with the OIG, and in fulfilling OI2 requests.

While I have had discussions with our OIG POC, and the OIG Hotline supervisor about the OIG and OI2 referral process, I have not received any feedback from the ICs or from anyone in NIH that has told me that the process used to fulfill OI2s wasn’t working or needed improvement. However, if that is the case, I would like to hear more about that. I am amenable to processes that work for everyone.

Please let me know if you are free for a 30 minute call:
Today at anytime between 11:00 am – 12:30 pm or 1:30 pm – 3:00 or 4:00 pm
Tomorrow anytime before noon or at 4:00 pm.
Friday anytime between 11:00 am and 4:00 pm

If this week isn’t good for you, we can also look at next week.

Thanks,
Debk

Deborah Kearse, Director
Division of Program Integrity
Office of Management Assessment
National Institutes of Health
6011 Executive Boulevard, Suite 601
Rockville, MD 20852
Desk: (b) (6)
Mobile: (b) (6)
FYI. Note that our vaccine paper is coming out Monday!

From: Holden Thorp <hthorp@aaas.org>
Sent: Friday, May 8, 2020 9:25 AM
To: Collins, Francis (NIH/OD) [E] (b) (6)
Subject: Editorial posting later today

Francis,

Wanted to give you a heads up that I will be posting at 2 pm today an editorial (attached) about the controversy surrounding the origins of the coronavirus and the actions of the Chinese and US governments. It does question the withdrawal of the grant to the EcoHealth Alliance but also expresses my support for you and your colleagues and the difficult situation you are in.

Thank you for all you are doing for us all. We are excited to publish your vaccine paper on Monday!

Holden

Holden Thorp
Editor-in-Chief
Science Family of Journals
American Association for the Advancement of Science
1200 New York Ave NW
Washington, DC. 20005
Landline: (b) (6)
Cell: (b) (6)
hthorp@aaas.org
Both—and problem in an either/or world

Before the coronavirus disease 2019 (COVID-19) pandemic, nuance and candor from governments were in short supply. Now they are almost nonexistent. Protecting the world from severe acute respiratory syndrome-coronavirus 2 (SARS-CoV-2) can’t happen without international scientific collaboration. Progress on vaccines in China and the United States should make us optimistic that science will solve this problem, but the actions of the governments involved are not equally inspiring.

The saber rattling by China and the United States is unnecessary, as the broad impacts of the pandemic in both countries are shared. Isn’t that worth curbing nationalistic tendencies? Apparently not to China, which has rebuffed efforts to understand the origin of SARS-CoV-2. And not to the Trump administration either, which can’t grasp that it’s possible to question the actions of the Chinese government about the early days of the pandemic while embracing collaboration with Chinese science. In a worldwide pandemic, isn’t it best for everyone to cooperate and try to save all of humanity together?

We need a both-and approach, but we are living in an either/or world.

The latest setback is the decision by the U.S. National Institutes of Health (NIH) to terminate the grant “Understanding the Risk of Bat Coronavirus Emergence” to Peter Daszak of the nonprofit EcoHealth Alliance, who, with NIH approval, shared one in five grant dollars with Shi Zhengli, a top coronavirusologist at China’s Wuhan Institute of Virology (WIV). We are asked to believe that the highly ranked project was killed because even though it sought to prevent the next bat-originating pandemic, it did not “align” with the NIH’s goals and priorities. This comes while the administration is propping up and circulating the unproven theory that the virus escaped from the Shi lab at the WIV, when the science is clearly in favor of zoonotic transfer in nature.

The genetic sequence of SARS-CoV-2 rules out a lab-engineered virus. And although escape from a lab of a naturally occurring virus that was isolated from bat specimens collected by scientists cannot be completely eliminated as the origin, the closest laboratory version of the virus (published by Shi and collaborators) is separated from SARS-CoV-2 by at least 20 years of evolutionary time. SARS-CoV-2 would have had to have escaped from the lab decades ago—or, another virus that was brought into the lab and not documented somehow escaped. Either way, only a chain of unlikely events could explain laboratory involvement.

The U.S. administration instructed its intelligence community to investigate this matter. Last week, these intelligence agencies ruled out that the virus was lab-engineered. They have not reached any conclusions about whether a virus might have escaped from the lab. But in the absence of evidence, the administration will likely turn uncertainty into “truth”—a lab escape—that serves its narrative.

Even in the face of the intelligence report to the contrary, U.S. Secretary of State Michael Pompeo initially said that “the best experts so far seem to think it was man-made.” Apparently, the best experts are neither scientists nor intelligence experts. Pompeo claims to have additional evidence that we are unlikely to see, if it even exists.

What would we have learned from the research that got squashed? Daszak and his colleagues were working to pinpoint hotspots in southern China with a high risk of bat-to-human transfer (most likely with an intermediary species involved) of coronaviruses. It might be good to find those hotspots if we don’t want to go through all of this again. And as important, the bat coronavirus sequences identified at the WIV were used in lab tests of the drug remdesivir, currently the only scientifically supported treatment for COVID-19. Vanderbilt University’s Mark Denison, who helped advance the drug, said of the Alliance’s research, “Our work on remdesivir absolutely would not have moved forward” without it.

I feel for, and admire, our scientific colleagues in the U.S. federal government. They are giving all they’ve got to protect the American public and others under impossible circumstances. Before the pandemic, the NIH went overboard to deal with foreign influence in U.S. research because of the nationalistic pressure it was under. Now, the agency is trying to dodge political longes from an administration that puts political success above human life.

The tyranny of either/or is that we only survive on our own. The promise of both/and is that the world is imperfect but we’re all in this together.

—H. Holden Thorp
Click to access online version optimized for different mobile platforms, audio version, and fully searchable archives of NIH News Briefings.
DATE: FRIDAY, MAY 15, 2020 7:30 AM EDT

Today’s Table of Contents

NIH News

• Trump Mobilizing U.S. Military To Deliver Coronavirus Vaccine.
• Fauci Loses Support From Republicans After Trump Criticism, Poll Shows.
• Without Wearing A Mask, Trump Tours Pennsylvania Mask Distribution Center.
• Put Rand Paul In The Penalty Box.
• France Angered By Suggestion U.S. Would Get First Access To Coronavirus Vaccine By French Pharma Company Sanofi.
• After Wisconsin Court Ruling, Crowds Liberated And Thirsty Descend On Bars: ‘We’re The Wild West,’ Gov. Tony Evers Says.
• NIH Starts Study Testing Combination Of Azithromycin And Hydroxychloroquine For Treatment Of COVID-19.
• Trump’s Marks For Handling COVID-19 Outbreak Decline — CBS News Poll.
• Researchers Working On Remdesivir Cocktail.
• Who Needs Science When We Have Trump’s Tremendous Instincts?
• Dr. Deborah Birx Wins Praise For Managing The White House’s Coronavirus Message And Trump.
• Trump Predicts Coronavirus Vaccine Will Come This Year.
• Public Health School Deans Urge Trump To Triple Coronavirus Testing Or Face Cycles Of Shutdown.
• California Tells Hospitals To Consider Having A Lottery For Sought-After Covid-19 Drug.
• Large Majority Of Americans Say Country Lags In Testing Availability: POLL.
• States Are Letting Stay-At-Home Orders Expire, Regardless Of Virus Metrics.
• Is Anthony Fauci Today’s Galileo Galilei, The Champion Of Science?
• Trump’s Plan To Limit The Pandemic’s Death Toll: Undercount The Numbers.
• Fox News Dumps Coronavirus Coverage For Anti-Obama Conspiracy Theory.
• Tensions Rise As Texas Governor Ready To Lift More Rules.
• Coronavirus Question: Let’s Say A Vaccine Proves Safe And Effective. Then What?
• ‘Re-Examine All The Evidence’: Rand Paul Demands Fauci Reconsider Position On School Closures.
• White House To ‘Reconfigure’ Coronavirus Task Force With An Emphasis On Reopening The Country.
• Remdesivir Distribution Causes Confusion, Leaves Some Hospitals Empty-Handed.
• Top Health Officials Vanish From National TV Interviews As White House Refocuses Messaging.
• Trump Is Smearing Fauci.
• Trump Admin Shoots The Messenger As Whistleblower Highlights Ongoing Issues.
• Trump Dismisses Fauci’s Warning Against: Reopening Schools: ‘I Totally Disagree’.
• Trump Is Blaming China For Coronavirus Even As He Employed The Same Authoritarian Tactics As Xi Jinping.
• White House Press Secretary Disputes Poll That Show Americans Trust Dr. Fauci Much More Than Trump.
• Column: We Shut Down The Economy To Make Progress Against COVID-19 — And Then Made No Progress.
• Rand Paul Delivers A Magnificent Reality Smack To Anthony Fauci.
• NIH Begins Trial To Determine How Effective Hydroxychloroquine.
• Interferon Emerges As Potential Treatment For COVID-19.
• U.S. Accuses Chinese-Born Researcher At Cleveland Clinic Of Ties To Chinese Spying.
• Talking In Enclosed Space Can Generate Droplets That Linger For Up 14 Minutes, Study Finds.
• Experimental Injection Of ‘Good’ Bacteria Significantly Cut Bacterial Vaginosis Recurrence Rate.
• NCI Exceptional Responders Initiative Pilot Study Meets Feasibility Goal.
• Researchers Try Combining Remdesivir With A Second Drug To Deliver A “One-Two Punch” To Virus.
• COVID Patients Given Malaria Drug Didn’t See Significant Improvements: Studies.
• Part Of Gilead’s Coronavirus Drug Donation Allocated To Japan.
• Virginia Receives 2nd Shipment Of New Antiviral Drug.
• COVID-19 Is Threat To Our Biomedical Research Enterprise.
• Gilead Should Ditch Remdesivir And Focus On Its Simpler Ancestor.
• Both/And Problem In An Either/Or World.
• Research On TPA Nanoconjugate Aims To Extend Thrombolysis Benefits To More Stroke Patients.

Health & Medical News
• White House Officials Signal Support For COVID-19 Relief For States Despite Opposition From Some GOP Groups.
• As COVID-19 Pandemic Persists, GOP Calls For “Pause” On More Aid.
• About 75% Of US Small Businesses Seek Federal Assistance Amid COVID-19 Pandemic, Survey Shows.
• Prospects For Second Round Of Stimulus Checks Seem “Uncertain.”
• Sanders Wants Senate To “Improve” House Dems’ $3T COVID-19 Relief Package.
• Bipartisan Group Of Lawmakers Proposes Compensation Fund For Essential Workers Impacted By COVID-19.
• Pelosi Pushing For Vote On $3T COVID-19 Relief Bill Despite Objections From Some Dems.
• New York Will No Longer Force Nursing Homes To Accept Recovering COVID-19 Patients.
• Debate Over Reopening US “Increasingly Partisan And Bitter.”
• Newsom Says COVID-19 Forcing Sharp State Budget Cuts.
• Cities, Counties In Texas Take Disparate Approaches To Enforcing Pandemic Restrictions.
• Michigan Closes State Capitol “As Protesters Gather” Against Stay-At-Home Order.
• Attorneys “Threaten Coronavirus Lawsuits” Against Florida Nursing Homes.
• Despite Missing Goal, Nebraska’s Governor Confident In State Testing Program.
• Connecticut Governor “Moving Ahead” With May 20 Reopening “Despite Concerns.”
• Just 4,000 Have Been Tested Under Iowa Program.
• South Dakota Announces Plan To Test “All Long-term Care Facility And Assisted Living Residents” Over Next Month.
• Hawaii’s Governor “Inclined” To Maintain Stay-At-Home Order Until June 30.
• Louisiana Senate Approves Legislation To “Shield Businesses From Virus Lawsuits.”
• States Begin Partially Opening As Residents Grow Restless, Less Willing To Shelter In Place.
• Some School Districts Ending Their Distance Learning Efforts.
• Scientists Say Testing Sewage Holds Promise For Monitoring Outbreaks Of Diseases Including Coronavirus.
• Analysis: Many “Essential” Workers Will See Pay Cuts As Companies Rescind “Hazard Pay” Policies.
• COVID-19 Accelerating Decline Of Retail Industry.
• Navy Continues To Battle Coronavirus Transmission Aboard Theodore Roosevelt Aircraft Carrier.
• Analysis: Gun Stores In Several States Ignored State-Ordered Closures, Initiated Tens Of Thousands Of Background Checks In April.
• Inspection Reports For Several Connecticut Nursing Homes Found Lapses In Infection Control, Prevention Around Coronavirus.
• Analysis: Studies Suggesting Coronavirus Can Be Spread Through Loud Talking Show Need For Face Masks In Public.
• UT Dallas Researchers Design 3D-Printed Disposable Ventilator Valve.
* Interview: Antibiotic-Resistant Microbes Equally Important Issue During Pandemic.
* Infectious Disease Experts Warn Of Potential Dual-Season For COVID-19, Influenza During Winter.
* Norwegian Cruise Line Expects Entire Fleet To Resume Full Operations In Approximately Six Months.
* Analysis: Anti-Vaccination Advocates Mobilizing To Protest Potential Coronavirus Vaccine.
* DC-Area Metro, Metrobus Riders Required To Wear Face Coverings Effective May 18.
* Nursing Home Industry, Residents Clash Over Industry’s Handling Of Pandemic.
* Opinion: Governors Need To Designate Grocery Workers As First Responders.
* WPost: COVID-19 Testing In Nursing Homes And Long-Term Care Facilities Is Essential.
* One-Fourth Of US Restaurants Will Close Due To Stay-At-Home Orders During Pandemic, OpenTable Forecasts.
* Pentagon Examining “Social Distancing Protocols” To Train, Deploy Units Amid Pandemic.
* Some Colleges Push Viral Testing, Alternative Methods To Allow Fall Semester In-Person.
* Columnist: Trump Is “In The Middle Of A Grace Period” With Voters, But That Will Not Last Indefinitely.
* Department Of Labor Issues Coronavirus Guidance To Nursing Homes.
* Trump Signs Executive Order Giving New Authority To US International Development Finance Corporation Amid Pandemic.
* Columnist: US Should Be “Pitied” For Coronavirus Response.
* Analysis: Trump Using Meetings With Governors At White House To Promote US’ Economic Reopening.
* Columnist: “Virus Truthers” Widespread On The Political Right.
* McConnell Walks Back Claim That Obama Administration Left Trump Administration No “Game Plan” For Pandemics.
* Pentagon’s DPA Coordinator Reassigned To Navy Position.
* Trump’s Press Secretary Flashes Pandemic Playbook To Reporters; Calls Obama Administration’s Plan “Insufficient.”
* Number Of COVID-19 Cases In Michigan Nears 50,000.
* Woman Sues Portland Nursing Home After Her Mother Died Of Coronavirus At The Facility.
* New York Governor And New York City Mayor Cannot Agree On Number Of Coronavirus Deaths In The City.
* Study Suggests Pediatric Multi-System Inflammatory Syndrome Is Tied To Coronavirus, As Cases Rise In New York.
* Fishing Boat Crews Reportedly Could Cause Coronavirus Outbreak In Cordova, Alaska.
* Hospital Leaders Approve Of Minnesota Governor’s Decision To Let Stay-At-Home Order Expire.
* Pennsylvania Governor To Announce More Counties That Can Lift Some Pandemic Restrictions On Friday.
* Most Maryland Residents Will Remain Under Stay-At-Home Orders As State Starts Reopening Friday.
* WSJournal Urges Wisconsin Governor To Create Less Restrictive Stay-At-Home Order With Legislature.
* Oxford Vaccine Study Shows Promise In Monkeys.
* Researcher Optimistic About Convalescent Plasma Therapy.
* Plasma Therapy Derived From Recovered COVID-19 Patients Appears Safe, Study Suggests.
* Expert Says It Will Take “Bulk Of A Year” Before Researchers Can Determine Factors In COVID-19 Immunity.
* Data Show COVID-19 Cases Are Generally Decreasing In 17 States, Rising In Nine Others.
- Fox News Host Says Bright Testimony Could Be “Potentially Politically Damaging” For Trump.
- Opinion: Pay Attention To Whistleblower, Because What Trump Disparages Is Often Truth.
- CDC Issues Health Advisory For Physicians On Childhood Illness Linked To COVID-19.
- Maine Governor Allows Out-Of-State Visitors To Reserve Rooms In Lodges, Inns Starting June 1.
- North Dakota Has Exceeded 50,000 Coronavirus Tests.
- In Rural America, COVID-19 Breakouts At Prisons Risk Overwhelming Hospitals.
- Bars And Restaurants Remain Closed Under Local Milwaukee County Order.
- Virginia Officials Plan To Stop Counting Antibody Tests As COVID-19 Tests In Reports.
- As Some States Reopen, Other States Continue To Battle Coronavirus.
- New York Governor Adds Provision To State’s Budget To Prevent Some Residents From Suing Nursing Homes Amid Pandemic.
- Some Small Physician Practices Are Struggling During Pandemic, Unable To Get Coronavirus Relief.
- Pandemic Hits Low-Income Americans Especially Hard, Survey Shows.
- Close To Three Million Americans Applied For Unemployment Last Week.
- Medical Professionals File Lawsuit Against Michigan Governor Over Lockdown Restrictions.
- Transplant Of Brain Cells To A Patient With Parkinson’s Disease Sparks Ethical Questions.
- Reopening Spurs Divide Among State Governors, Legislatures.
- Connecticut Nursing Home Owner Purchases 400K Masks From Makeshift Supplier.
- New Jersey, Delaware Reopen Beaches For Memorial Day With Restrictions.
- Minnesota Malls Begin To Reopen Monday, However, Mall Of America Plans For June 1.
- During Contact Tracing Efforts, New York City Mayor Leans On Aide That Previously Argued Against Closures.
- Trump, EPA Decide Not To Impose Limits On Water Contaminant Linked To Fetal Damage.
- Wyoming To Relax Restrictions On Bars And Restaurants.
- Democrats Present Legislation Aimed At Protecting Health Data During COVID-19 Pandemic.
- White House List Of Coronavirus Testing Labs Not Useful, Nine States Say.
- Testing Project On Tiny Michigan Island Underway.
- Virginia Governor Asks Federal Government To Increase Testing At Two Federal Detention Facilities.
- CVS Plans To Open 1,000 Self-Swab Coronavirus Test Locations By Month’s End.
- US Said To Be Making Progress In Coronavirus Testing Numbers.
- Abbott Lab’s ID Now COVID-19 Misses Up To Half Of Cases Found By Another Test, Study Suggests.
- Bill Gates-Funded Program That Provides At-Home Coronavirus Test Kits Put On Hold Until Federal Approval Is Granted.
- Pandemic Reportedly Reveals Vulnerabilities In American Business Model For Hospitals.
- Biogen Blocks Creative Biolabs From Selling Products That Allegedly Used Antibody From Its Experimental Alzheimer’s Drug.
Global Health News

- Health Groups Ask India To Rescind Gilead’s Patents For COVID-19 Drug Remdesivir.
- Chinese Automaker Backed By Buffett Fails To Gain US Approval For Their Masks.
- Total Number Of Coronavirus Cases Globally Approaches 4.4M.
- European Commission Suspends Delivery Of 10M Chinese Masks Due To Quality Concerns.
- Dental Practices In France Begin Cautiously Re-Opening.
- Italy To Start Testing Campaign Across 2,000 Cities To Understand Extent Of Outbreak.
- France’s Coronavirus Death Toll Surpasses Spain’s Again.
- Prime Minister Abe Lifts State Of Emergency Through Most Of Japan.
- UNICEF Chief Warns Lockdowns Could Cause More Harm Than Actual Virus In Low-, Middle-Income Countries.
- Asian Countries, After Stopping Initial Outbreak, See Second Wave Of Cases.
- China Attempted To Dissuade New Zealand From Imposing Strict Coronavirus Restrictions.
- Canada’s Prime Minister Says World Has Changed Even If Pandemic Ends Or Vaccine Is Found.
- EU’s Foreign Policy Chief Calls For Independent Investigation Into Pandemic’s Origins.
- IOC President Will Not “Fuel Any Speculation” That Tokyo Olympics Might Not Be Held Next Year.
- South Africa To Assign Specific Coronavirus Restrictions For Each Of Its Districts.
- Surge In Number Of People In Yemen Dying With COVID-19 Symptoms.
- Increasing Number Of Physicians In Russia Dying From Pandemic.
- UK Government In Talks With Roche To Buy COVID-19 Antibody Tests.

HHS in the News

- Trump Administration Reportedly Mulling Indefinite Border Restrictions Amid COVID-19 Outbreak.
- Gottlieb Suggests Schools Should Attempt In-Person Education This Fall When Possible.
- Mask Manufacturer Executive Testifies About How Government Allegedly Ignored His Previous Warnings Of Insufficient Mask Production.
- White House To Require Some Essential Drugs To Be Manufactured In US, Sources Say.
- Gottlieb Says He Sees Signs That The Coronavirus Epidemic Is Slowing In US.
- Coronavirus Can Cause Strokes In Young People, Physicians Say.
- Online Pharmacy HealthWarehouse Saw Spike In Demand For Hydroxychloroquine in Mid-March.
- Survivors Of COVID-19 Pandemic In Nursing Homes Remain In Isolation.
- Former BARDA Director Says Trump Official Tried To Fast-Track Funding For His Friend’s Unproven COVID-19 “Treatment.”
- Thousands Volunteer To Be Exposed To Novel Coronavirus In Human Classified Trial Led By 1Day Sooner.
- Former BARDA Head Tells Congress Coronavirus Vaccine Won’t Be Ready In 12 To 18 Months.
- Former BARDA Director Says Administration Ignored Warnings Of Supply Shortages.
- White House Press Secretary, Senior Trump Adviser Dismiss Ousted HHS Official’s Claims.
- HHS Whistleblower’s Attorneys Say Watchdog Finds “Substantial Likelihood Of Wrongdoing.”
- FDA Authorizes Human Trials For AIm ImmunoTech’s Drug To Treat COVID-19 In Patients With Cancer.
- Opinion: Following Science Is Best Path For Our Leaders To Avoid “Darkest Winter.”
- CDC Issues Six Brief Checklists To Guide Businesses, Schools, Others On Reopening.
- Former BARDA Chief Will Start At New Job Next Week, Attorneys Say.
- Texas Paid $45 Million For COVID-19 Tests.
- Rural Hospitals Need Access To Telehealth To Battle Coronavirus Pandemic, Experts Say.
- Trump Announces Plan To “Replenish And Modernize” Strategic National Stockpile.
- Former BARDA Chief Warns Trump Administration Still Has No National Plan For Pandemic.
- FDA Examining Data Showing Abbott’s COVID-19 Test Delivers Inaccurate Results.
- Trump, Azar Slam Former HHS Official Who Filed Whistleblower Complaint As “Disgruntled.”
- Ivanka Trump Says She Wears Mask At White House.
- Taiwan Remains Sidelined From WHO’s World Health Assembly Amid Pandemic.
- HHS Awards $15M For Expanded Use Of Telehealth Amid COVID-19 Pandemic.
- Medical Groups Urge Verma To Provide More COVID-19 Assistance For Medicare ACOs.
- In Reversal, IHS Starting To Hire Traditional Healers.
- HHS, DoD Award $138M Contract For Expanded Production Of Prefilled Syringes To Be Used For Future COVID-19 Vaccine.

**National Front Page News**

- Headlines From Today’s Front Pages.

**Last Laughs**

- Late Night Political Humor.

**National News**

- Trump Retweets Post Questioning Claim He Is A Racist.
- Burr Steps Aside As Chair Of Senate Intelligence Committee Amid FBI Probe.
- Senate Votes To Extend Parts Of FISA.
- Trump Questions Biden’s Mental Fitness.
- Abrams Promoted As Possible Running Mate For Biden.
- Rasmussen: 23% Of Republicans, 28% Of Democrats Would Prefer Different Nominees.
- Trump Touts His “22-0” Record Of Congressional Endorsements.

**NIH News**
Trump Mobilizing U.S. Military To Deliver Coronavirus Vaccine.

Reuters (5/14, Heavey, Chiaucu) reports “President Donald Trump is mobilizing the U.S. military to distribute a novel coronavirus vaccine when one becomes available and will focus first on older Americans.” Trump said on Fox Business Network, “You know it’s a massive job to give this vaccine. … Our military is now being mobilized so at the end of the year, we’re going to be able to give it to a lot of people very, very rapidly.” Trump “said he believes there will be a vaccine by the end of the year and the United States is mobilizing ‘our military and other forces’ on that assumption.” NIAID Director Dr. Anthony Fauci “said the idea that there will be a vaccine available by next fall, when schools and universities resume classes, was ‘a bridge too far.’”

Additional Sources. Similarly, CBS News (5/14, Watson, 3.68M) reports “Trump says he would ‘rapidly’ mobilize the U.S. military to distribute a coronavirus vaccine once it’s ready, focusing first on nursing homes and the elderly.” Trump stated, “We will have a tremendous force because assuming we get it, then you have to distribute it. … And unless you’re mobilized and ready, you’re not going to be able to do it for a long time. So we’re starting now.”

Also reporting on the story are The Hill (5/14, Deese, 2.98M) and Newsweek (5/14, Fink, 1.53M).

Fauci Loses Support From Republicans After Trump Criticism, Poll Shows.

Forbes (5/14, Brewster, 9.71M) reports “Republicans are increasingly less supportive and trusting of” NIAID Director “Anthony Fauci, a new poll shows, a sign that criticism from GOP lawmakers (including [President] Trump) and right-wing media – who have bristled at Fauci’s warnings about reopening too quickly – may be having an effect on public opinion among conservatives.” The CBS News poll “found Fauci’s unfavorable rating among Republicans has climbed to 31% in May, up from just 12% in April.” Trusting the health expert “has also become partisan: 83% of Democrats say they trust Fauci while just 51% of Republicans say they do.”

Additional Sources. CNN (5/14, 83.16M) says in an analysis that “Trump’s repudiation of Dr. Anthony Fauci has long been probable. Once the trusted doctor warned of the human cost of Trump’s push to quickly reopen the country, it became inevitable.” On Wednesday, “Trump broke with Fauci… over the infectious disease expert’s warnings that getting businesses and schools back open too quickly would lead to unnecessary suffering and death.” Trump said, “I was surprised by his answer, actually. … It’s just – to me it’s not an acceptable answer, especially when it comes to schools.”

In a separate analysis, CNN (5/14, Liptak, 83.16M) says that “in the Cabinet Room Wednesday and in a Fox Business Network interview aired Thursday, President Donald Trump is finally airing publicly the complaints about” Fauci “that officials say he’s been airing privately for weeks.” The health expert’s “critics on Fox and in Congress are adjusting their complaints about him to reflect the type of criticism they know appeals to Trump.” However, firing Fauci “would require Trump instructing Fauci’s direct boss (Health and Human Services Secretary Alex Azar) to fire him for cause, of which there isn’t really one.”

The Hill (5/14, Chalfant, 2.98M) reports “Trump said in an interview aired on Fox Business early Thursday that he was criticized by ‘everybody,’ including Anthony Fauci, for restricting travel to China to slow the spread of the novel coronavirus.” Trump said, “I was criticized by everybody, including Dr. Fauci. I put in a wall. We put in a pretty strong wall. Only a small number of people were allowed in and they were all U.S. citizens.”

Without Wearing A Mask, Trump Tours Pennsylvania Mask Distribution Center.
Reuters (5/14) reports that “without wearing a face mask himself, President Donald Trump toured a mask distribution center in Pennsylvania on Thursday and announced plans to replenish the U.S. strategic stockpile of medical equipment depleted by the coronavirus outbreak.” Trump “has resisted wearing a mask in public despite his administration’s guidance to Americans to wear them and new White House rules requiring that staff wear them at work.” He “toured the Owens & Minor Inc distribution center, which the White House said has sent millions of N95 masks, surgical gowns and gloves to hospitals and surgery centers across the United States. Company officials wore masks.”

Additional Sources. USA Today (5/14, Subramanian, Jackson, 10.31M) reports “Trump told a group of Pennsylvania factory employees Thursday: their Democratic governor, Tom Wolf, should ‘start opening up a little bit,’ continuing to press an end to social distancing restrictions as he eyes reopening the struggling U.S. economy.” Trump said at the distribution center, “We have to get your governor of Pennsylvania to start opening up a little bit. You have areas of Pennsylvania that are barely affected, and they want to keep them closed. You can’t do that.” The piece mentions that HHS Secretary Alex Azar was wearing a face covering during the visit.

CNN (5/14, Liptak, 83.16M) reports “Trump’s quick trip to Allentown highlighted a medical equipment distribution company, where he trumpeted his administration’s record on ramping up testing and improving supply chains for personal protective equipment and ventilators.” The President “laced his speech with complaints about how his response to the virus has been covered in the media and lobbed barbs at former Vice President Joe Biden, who was born in Scranton.”

Forbes (5/14, Perez, 9.71M) reports “Trump announced he was invoking the Defense Production Act to direct the U.S. International Development Finance Corporation (DFC) – an agency he signed into being in 2018 that invests in economic development programs in developing countries – to finance domestic companies.” Trump “lavished praise on healthcare workers, saying ‘They’re running into death just like soldiers run into bullets.’”

The Hill (5/14, Samuels, Hellmann, 2.98M) reports “Trump boasted about the United States’ testing capabilities during remarks at a Pennsylvania medical equipment distribution center, where he announced the country has administered 10 million tests since the outbreak began.” Trump said, “We have the best testing in the world. ... Could be that testing’s, frankly, overrated. Maybe it is overrated.”

Politico (5/14, Ward, 4.29M) reports Trump also said, “When you test, you have a case. When you test, you find something is wrong with people. If we didn’t do any testing, we would have very few cases.” The President “said the news media had refused to report this ‘common sense’ explanation for the country’s high case numbers.”

The Washington Times (5/14, Boyer, 492K) reports Trump “faulted the Obama administration, and Democratic rival Joseph R. Biden, for leaving the U.S. unprepared for the coronavirus crisis.” Meanwhile, “Rick Bright, a [former] top coronavirus vaccine researcher at the National Institutes of Health, testified in Congress Thursday that the administration ignored his warnings earlier this year to prepare for the pandemic.”

NJ News (5/14, Salant, 1.72M) reports on the story, and adds that NAID Director Dr. Anthony Fauci “said he was worried about states reopening too soon in testimony before the Senate Health Committee on Tuesday.”

Among other news outlets reporting on the story are ABC World News Tonight (5/14, story 2, 1:05, Muir, 7.42M), the CBS Evening News (5/14, story 2, 0:30, O’Donnell, 5.25M), NBC Nightly News (5/14, story 3, 0:15, Holt, 7.88M), the Washington Post (5/14, 14.2M), another piece in The Hill (5/14, Samuels, 2.98M).
Newsday (NY) (5/14, 932K), the New York Daily News (5/14, Sommerfeldt, 2.52M), and the Allentown (PA) Morning Call (5/14, Olson, Merlin, 555K).

Put Rand Paul In The Penalty Box.

Washington Post (5/14, 14.2M) columnist Karen Tumulty writes that it is “too bad the Senate, unlike a hockey rink, doesn’t have a penalty box. Because that is where Kentucky Republican Rand Paul would be sitting, rather than in a hearing room lecturing the nation’s leading infectious-disease expert that he isn’t the ‘end-all.’” When NIAID Director Dr. Anthony Fauci “testified this week before the Senate Health, Education, Labor and Pensions Committee, Paul recited data that he claimed [suggest] the government’s response to the...novel coronavirus pandemic has been too cautious.” Tumulty concludes, “Paul, of all people, should know that impetuous decisions can put a lot of others at unnecessary risk.”

France Angered By Suggestion U.S. Would Get First Access To Coronavirus Vaccine By French Pharma Company Sanofi.

The Washington Post (5/14, McAuley, 14.2M) reports France’s government said “it would be ‘unacceptable’ for French pharmaceutical giant Sanofi to give the United States first access to a potential COVID-19 vaccine.” The comments came in response to statements by CEO Paul Hudson, who said “the U.S. government has the right to the largest preorder because it’s invested in taking the risk.” The piece suggests that “Hudson’s comments and further messaging from Sanofi on Thursday may be part of an effort to prod European governments to invest more in vaccine research.” However, “by Thursday morning, the company appeared to be backpedaling somewhat.” On this point, “Olivier Bogillot, head of Sanofi’s French division, told France’s BFMTV network that the vaccine would be available to Europeans at the same time as Americans if the European Union were as ‘efficient’ a partner.”

Additional Sources. Reuters (5/14, Brosse, Heavey) reports National Institute of Allergy and Infectious Diseases Director Anthony Fauci “on Tuesday said a vaccine would not likely be available by the autumn but that he was cautiously optimistic there would eventually be one.”

Forbes (5/14, Beer, 9.71M) reports, “The U.S. expanded a vaccine partnership with the drugmaker in February, and Sanofi has received $30 million from an office of the U.S. Department of Health and Human Services.”

Similar coverage of the comments by Hudson, the French government’s response, and an apparent walk back of that initial comments is covered by the Wall Street Journal (5/14, Biserbe, Roland, Subscription Publication, 7.57M), the Associated Press (5/14, Corbet), Reuters (5/14, Andre, Brosse), Reuters (5/14, Blamont, White), The Hill (5/14, Coleman, 2.98M), Forbes (5/14, Beer, 9.71M), Newsweek (5/14, Czachor, 1.53M), Endpoint’s News (5/13, Mast), FiercePharma (5/14, Sagonowsky), STAT (5/14, Silverman, 24K), the Economic Times (IND) (5/14, 1.81M), and Bloomberg Law (5/14, Serafino, Subscription Publication, 4K).

After Wisconsin Court Ruling, Crowds Liberated And Thirsty Descend On Bars. ‘We’re The Wild West,’ Gov. Tony Evers Says.

The Washington Post (5/14, Flynn, 14.2M) reports, “On Wednesday night in the heart of downtown Platteville, Wis., just hours after the Wisconsin Supreme Court threw out the state’s stay-at-home order,” some bars were “packed wall to wall.” Wisconsin’s “high court sided Wednesday with Republican legislators who sued the Evers
administration in April, finding that the Democratic governor 'cannot rely on emergency powers indefinitely' as the pandemic drags on for months." In an opinion, "Justice Rebecca Bradley cited Korematsu v. United States, in which the Supreme Court allowed the internment of Japanese Americans as a way to 'remind the state that urging courts to approve the exercise of extraordinary power during times of emergency may lead to extraordinary abuses of its citizens.'"

Additional Sources. USA Today (5/14, Jansan, 10.31M) reports that the decision "added fuel Thursday to a widening U.S. debate over how and when to lift restrictions put in place to limit the spread of the coronavirus." However, "health experts such as Dr. Anthony Fauci," maintain the lockdowns have saved lives.

The Wall Street Journal (5/14, Calfas, Gershman, Subscription Publication, 7.57M) reports that local governments throughout Wisconsin are now trying to implement their own new public health guidelines following the court's decision.

CNN (5/14, Bradner, 83.16M) and the Milwaukee Journal Sentinel (5/14, Hauer, 632K) also report.

Wisconsin Governor Predicts Confusion Following State Supreme Court Ruling. Reuters (5/14, Gorman, Bernstein) reports, "Wisconsin's governor on Thursday predicted confusion among residents and [businesses] after the state supreme court struck down his sweeping stay-at-home order, fueling a growing political divide over how and when to reopen the shattered U.S. economy." The decision, "which found that Governor Tony Evers and state health officials did not have the authority to unilaterally confine residents to their homes or bar them from work, marked the first time such coronavirus restrictions had been overturned in the United States."

Newsweek (5/14, Jarvis, 1.53M) reports, "President Donald Trump has hailed the Wisconsin Supreme Court decision to overturn coronavirus lockdown measures in the state as a 'win.'"

U.S. News & World Report (5/14, Smith, 2.4M) also reports.

NIH Starts Study Testing Combination Of Azithromycin And Hydroxychloroquine For Treatment Of COVID-19.

Reuters (5/14, Erman, Maddipatla) reports the NIH announced it started a study to evaluate the combination of azithromycin and hydroxychloroquine for the treatment of COVID-19. The National Institute of Allergy and Infectious Diseases "is sponsoring the trial, which is being conducted by the NIAID-funded AIDS Clinical Trials Group (ACTG)."

Additional Sources. The Hill (5/14, Hellmann, 2.98M) reports NIAID Director Anthony Fauci said, "We urgently need a safe and effective treatment for COVID-19. Repurposing existing drugs is an attractive option because these medications have undergone extensive testing, allowing them to move quickly into clinical trials and accelerating their potential approval for COVID-19 treatment."

Also reporting are Bloomberg Law (5/14, Klimasinska, Subscription Publication, 4K) and Fox News (5/14, Carbone, 27.59M).


CBS News (5/14, Khanna, 3.68M) reports that according to a CBS News poll, "Americans continue to say they trust medical professionals for virus information, but Republicans also rank President Trump about as highly among their trusted sources, even as others give him his lowest marks to date for handling the outbreak."

Furthermore, NIAID Director Dr. Anthony Fauci "is trusted by most and viewed favorably by a three-to-one
margin, but he now draws split opinions among Republicans, driven by increasingly negative views from conservatives.” Views of “Trump’s handling of the outbreak continue to drop from March and are now the lowest he has received.”

**Additional Source.** *Newsweek* (5/14, Lemon, 1.53M) reports that “the number of Americans saying Trump is doing a ‘bad job’ handling the pandemic has increased by 10 points since March.” Meanwhile, “the number of Americans who trust Trump for information about the outbreak currently stands at 38 percent, while 62 percent of respondents say they do not trust the president about it.”

**Researchers Working On Remdesivir Cocktail.**

On the *CBS Evening News* (5/14, story 8, 2:05, 5.25M), Norah O’Donnell reported on “a so-called [treatment] ‘cocktail [that] has entered a new phase.” CBS’ Jon Lapook reported a research team is “combining remdesivir to stop the virus from multiplying with a powerful anti-inflammatory drug, a so-called ‘immune modulator’ that aims to prevent organ damage by calming down an inflamed immune system. The remdesivir stops the virus from replicating inside the cell, and the immune modulator puts out the fire.” CBS quotes National Institute of Allergy and Infectious Diseases Director Anthony Fauci regarding past struggles to find drugs for treating HIV.

**Who Needs Science When We Have Trump’s Tremendous Instincts?**

*Washington Post* (5/14, 14.2M) columnist Michael Gerson writes that President “Trump’s version of populism has always included skepticism of medical consensus.” Trump “has a long history of trusting his gut on scientific matters on which he has little knowledge.” These tendencies “are now emerging in the midst of a public health crisis. We have a president who is increasingly critical of advice from infectious disease experts, and who seems increasingly skeptical of the reported death toll from covid-19.” Gerson adds that “Tucker Carlson questions whether” NIAID Director Dr. Anthony Fauci “is right about the science’ and calls him a ‘buffoon.” Gerson concludes, “It does not prove your conservatism, your populism or your patriotism to needlessly endanger your neighbor.”

**Dr. Deborah Birx Wins Praise For Managing The White House’s Coronavirus Message And Trump.**

*USA Today* (5/14, Hjelmaa, Jackson, 10.31M) reports that “while it’s too early to draw conclusions about whether” Dr. Deborah “Birx’s influence has been diminished, she remains one of the major public faces of the administration’s coronavirus response.” The role has “brought her praise – for her command of public health minutiae as well as criticism – for appearing, at times, to fail to run sufficient interference on Trump’s mixed, erratic, and often incorrect messages about the outbreak.” Birx “has managed to maintain her composure – and sometimes correct Trump’s misinformation – without triggering the wrath of the president or his supporters.” Birx’s name has even “surfaced as a potential replacement for” HHS Secretary Alex Azar. The piece adds that “Birx is one of two Obama administration-appointed health officials working for Trump. The other is” NIH Director Francis Collins – NIAID Director Anthony Fauci’s “boss.”

**Trump Predicts Coronavirus Vaccine Will Come This Year.**

*U.S. News & World Report* (5/14, Smith-Schoenwalder, 2.4M) says President “Trump on Thursday said that he expects a coronavirus vaccine by the end of 2020, which is a faster timeline than many health officials have
predicted.” The President stated, “I think we’re going to have a vaccine by the end of the year.” Trump “added that distribution of the vaccine ‘will take place almost simultaneously’ because he is mobilizing the military to help with the process.” His “comments come just a couple days after” NIAID Director Anthony Fauci told Congress that the idea of having therapeutics or a vaccine ready “to facilitate the reentry of students into the fall term would be something that would be a bit of a bridge too far.”

Additional Source. The Atlanta Journal-Constitution (5/14, Darnell, 895K) reports that during “an interview on FOX Business Network, Trump...said he disagrees with” Fauci, “who told a Senate committee earlier this year it is unlikely a vaccine would be ready in time for the school year.”

Public Health School Deans Urge Trump To Triple Coronavirus Testing Or Face Cycles Of Shutdown.

Newsweek (5/15, Martin, 1.53M) reports that four public health school deans on Thursday all signed individual statements urging the Trump Administration Thursday to use the Defense Production Act to require businesses to create more tests for the novel coronavirus. Newsweek adds, “Testing capacity for the coronavirus has been called a priority for reopening the country safely, including U.S. schools.” National Institute of Allergy and Infectious Diseases Director Anthony Fauci told a Senate panel on Tuesday that “he wasn’t sure if schools should reopen in the fall.”

California Tells Hospitals To Consider Having A Lottery For Sought-After Covid-19 Drug.

CNN (5/14, Cohen, Azad, Klein, 83.16M) reports that all 50 states “should have received shipments of the Covid-19 drug remdesivir earlier this week, according to audio obtained by CNN of a call between federal officials and governors.” But there’s “not nearly enough to go around, and on Monday, one state health department directed hospitals to consider holding a lottery for scarce medications.” As part of its guidance, the California Department of Public Health “suggests that ‘random allocation among patients be considered,’ such as ‘using a lottery system to select a certain proportion of patients who become eligible for the drug.’” According to CNN, “It’s been a little over two weeks since top health expert Dr. Anthony Fauci first announced that a large study showed remdesivir worked against Covid-19, calling it the new ‘standard of care’ for patients.”

Large Majority Of Americans Say Country Lags In Testing Availability: POLL.

ABC News (5/15, Karson, 2.97M) reports strong majorities of Americans “believe the country lacks sufficient testing and are also skeptical about returning to pre-pandemic activities, including sending kids back to school,” according to a new ABC News/Ipsos poll released on Friday. According to ABC, “nearly three in four Americans believe there are not enough tests available in the United States, compared to only 26% who said there is adequate testing available right now.” The new poll comes as National Institute of Allergy and Infectious Diseases Dr. Anthony Fauci this week “warned lawmakers that reopening schools and businesses too quickly could trigger an outbreak, and possibly stifle the road to economic recovery.”

States Are Letting Stay-At-Home Orders Expire, Regardless Of Virus Metrics.

Politico (5/15, McCaskill, 4.29M) reports, “Stay-at-home orders or business restrictions are set to expire” in a dozen states across the US, leaving state and local leaders to “grapple with whether to extend expiring stay-at-home orders or assess how much their reopening strategies are fueling new health risks” associated with
COVID-19. Public health experts, including National Institute of Allergy and Infectious Diseases Director Anthony Fauci, “have warned that the virus will continue to spread as more people begin leaving their homes, noting the difficulty of maintaining physical distancing in certain spaces as Americans return to their normal pre-pandemic activities.”

Is Anthony Fauci Today’s Galileo Galilei, The Champion Of Science?
In an opinion piece for STAT (5/14, 24K), astrophysicist Mario Livio says that as he watches NIAID Director Dr. Anthony Fauci defend “science and scientific integrity...on the news, I think of another ‘battler’ who ultimately had the last word.” Livio compares Fauci to Galileo Galilei, who was “sentenced to confinement by the Roman Inquisition because he was ‘vehemently suspected of heresy.’” That supposed heresy “was his support of the Copernican system of planetary movement.” Livio concludes, “It took the Catholic Church more than 350 years to admit that Galileo was right. We can’t afford to wait that long to find out that Fauci is right.”

Trump’s Plan To Limit The Pandemic’s Death Toll: Undercount The Numbers.
In an opinion piece for Vox (5/14, 2.27M), senior correspondent Matthew Yglesias writes that “experts have a range of ideas to suppress the Covid-19 pandemic, save lives, and avert new waves of economic misery.” However, President “Trump seems to be embracing another plan – massaging the numbers to make inconvenient deaths go away.” Still, “experts believe the problem with the numbers is the opposite – official statistics understate the Covid-19 death toll.” Yglesias adds that on Tuesday, NIAID Director “Anthony Fauci expressed the view of most public health professionals that even with the attempted adjustment for probable cases, the official numbers still underestimate the true death toll.” Yglesias concludes that “a strategy focused on juiking the stats is overwhelmingly likely to end with more real-world deaths than necessary.”

Fox News Dumps Coronavirus Coverage For Anti-Obama Conspiracy Theory.
In an analysis, CNN (5/14, Darcy, 83.16M) says that “if you woke up from a coma on Wednesday afternoon and flipped on Fox News, or checked the network’s website, you’d be forgiven if you had no idea the country is currently grappling with a pandemic killing tens-of-thousands of Americans and leaving millions more unemployed.” That is because Fox “largely ignored the virus in the afternoon and into its prime time programming.” After GOP “senators released a list of Obama officials who sought to unmask the name of an unidentified American caught in intelligence reports, who turned out to be Michael Flynn, Fox News went all in on the story.” However, “when Fox News did find time to cover the coronavirus, it was done in part through the lens of criticizing” NIAID Director Dr. Anthony Fauci.

Tensions Rise As Texas Governor Readies To Lift More Rules.
The AP (5/15, Weber, Vertuno) reports that “few states are rebooting quicker than Texas, where stay-at-home orders expired May 1.” With coronavirus “cases still rising, including single-day highs of 1,458 new cases and 58 deaths Thursday, Republican Gov. Greg Abbott has defended the pace by emphasizing steady hospitalization rates and pointing out that Texas’ 1,200 deaths are still behind similarly big states, including California and Florida.” However, “on the cusp of even more restrictions ending Monday, including gyms cleared to reopen, a political confrontation is growing over attempts by big cities to keep some guardrails.” The revamped tensions
come at a time when NIAID Director Dr. Anthony Fauci “warned Congress this week of ‘needless suffering and death’ if the U.S. moves too quickly.”

Coronavirus Question: Let’s Say A Vaccine Proves Safe And Effective. Then What?

In an editorial, USA Today (5/14, 10.31M) says that if a safe and effective coronavirus vaccine is developed, “the issues surrounding how to distribute vaccines present a number of troubling questions that are not getting nearly the attention they deserve. … Even within the USA, there’s little evidence of a plan for how vaccines might be distributed in the early days when there are not enough to go around.” USA Today adds, “With scientists saying that one or more vaccines could complete trials as early as this fall, this is looking like one more area for which the nation is not fully prepared.” USA Today notes that there are at least eight vaccines in clinical development, according to National Institute of Allergy and Infectious Diseases Director Anthony Fauci.

‘Re-Examine All The Evidence’: Rand Paul Demands Fauci Reconsider Position On School Closures.

The Washington Examiner (5/14, Miller, 448K) reports “GOP Kentucky Sen. Rand Paul urged” NIAID Director “Anthony Fauci to reconsider his position that schools should remain closed in the fall to stop the spread of the coronavirus.” Paul tweeted, “Evidence-based scientists around the world argue to open schools. … Please re-examine all the evidence Dr. Fauci!” The senator’s “post came alongside an article from WIRED magazine with the headline, The Case for Reopening Schools.”

White House To ‘Reconfigure’ Coronavirus Task Force With An Emphasis On Reopening The Country.

The Washington Examiner (5/14, Crilly, 448K) says the White House “will add more figures to its coronavirus task force before the end of the week…as it enters the crucial phase of trying to reopen the country safely.” According to a “senior administration official,” the additions would represent a “reconfiguring.” The official said, “There was an initial phase that was more focused on border elements and what are you doing with flights, what are you doing with cruise ships, and how do we do the best to delay its arrival here? The second phase was really more defined by healthcare experts and the strategy to mitigate it and slow the spread…. And now, I think we are sort of entering a new phase, which is, ‘How do you now safely reopen?’” The piece adds that Trump “has been under pressure from conservatives to reduce the influence of scientists on the panel, including” NIAID Director Dr. Anthony Fauci.

Remdesivir Distribution Causes Confusion, Leaves Some Hospitals Empty-Handed.

NPR (5/14, Lupkin, 3.12M) reports the federal government has begun distributing remdesivir, which the FDA has authorized for emergency use as a treatment for COVID-19, but some states and hospitals are confused “about why they’ve been left empty-handed.” Gilead Sciences, the manufacturer of the drug, “said it would donate its initial supply of the medicine,” but “the federal government is in charge of coordinating where the treatment is to be shipped.” National Institute of Allergy and Infectious Diseases Director Anthony Fauci “stressed that the study’s result for remdesivir ‘was statistically significant but really modest. And we must remember it was only a modest result showing that the drug made a 31% faster time to recovery.’”
Top Health Officials Vanish From National TV Interviews As White House Refocuses Messaging.

CNN (5/14, Darcy, 83.16M) reports “the nation’s top physicians have stopped appearing on national television for interviews as the White House exerts increased control over communications during the coronavirus pandemic and refocuses its message toward reopening the economy.” NIAID Director Anthony Fauci “appeared on CNN on May 4 for an interview with Chris Cuomo.” CDC Director Robert Redfield “has not appeared on national television since April 17 when he was interviewed on the Today show on NBC News.” FDA Commissioner Stephen Hahn “has not appeared on national television since April 28 when he spoke with Fox News host Maria Bartiromo.” For his part, Surgeon General Jerome Adams “has not appeared on national television since April 17 when he appeared on Fox & Friends.”

Trump Is Smearing Fauci.

William Saletan writes for Slate (5/14, 1.58M) that the President “is smearing” NIAID Director Dr. Anthony Fauci. The President “wants businesses and schools to reopen sooner than Fauci thinks is safe. So the president has fabricated a story about Fauci giving bad advice. Trump’s goal is to make the public think that Trump, not Fauci, knows best what to do about the novel coronavirus.” However, “his fabrication shows the opposite: While Fauci tells the truth, Trump tells lies.”

Trump Admin Shoots The Messenger As Whistleblower Highlights Ongoing Issues.

Matt Shuham writes for Talking Points Memo (5/14, 260K) that even as Dr. Rick Bright criticized the Trump Administration’s COVID-19 response during his testimony, the Administration returned the favor. President Trump said, “With Bright’s attitude...he should no longer be working for our government!” Meanwhile, HHS “said Bright was ‘using his taxpayer-funded medical leave to work with partisan attorneys who are politicizing the response to COVID-19.’” Indeed, HHS Secretary Alex Azar, “speaking from the White House lawn in the middle of Bright’s testimony, made a similar point. ‘While we’re launching Operation Warp Speed, he’s not showing up for work to be part of that.’” Shuham also mentions NIAID Director Dr. Anthony Fauci.

Trump Dismisses Fauci’s Warning Against Reopening Schools: ‘I Totally Disagree’.

Cristina Cabrera writes for Talking Points Memo (5/14, 260K) that on Thursday, President Trump “rejected White House COVID-19 task force official Dr. Anthony Fauci’s assertion during a Senate hearing that schools could not be expected to reopen by fall.” Trump said, “Anthony is a good person, very good person....I’ve disagreed with him. When I closed the border to China, he disagreed with that, and then ultimately he agreed.” Trump added, “I totally disagree with [Fauci] on schools.”

Trump Is Blaming China For Coronavirus Even As He Employs The Same Authoritarian Tactics As Xi Jinping.

John Haltiwanger writes for Business Insider (5/14, 3.67M) that President Trump “has essentially blamed China for the devastating scale of the coronavirus pandemic, slamming Beijing over its lack of transparency and warning that the US could ‘cut off’ its relationship with the Asian country.” However, the President “is guilty of many of the same behaviors for which he’s condemned China, experts say,” given that his “response to COVID-
19 has often mirrored the approach of authoritarian leaders like Chinese President Xi Jinping.” While “top public health officials like Dr. Anthony Fauci have said that a robust testing system is key to thwarting the virus, for example, Trump in early May said that too much testing for COVID-19 makes the US ‘look bad.’”

**White House Press Secretary Disputes Poll That Show Americans Trust Dr. Fauci Much More Than Trump.**

Eliza Reifer writes for *Business Insider* (5/14, 3.67M) that on Thursday, “White House press secretary Kayleigh McEnany...disputed recent polling that found Americans trust Dr. Anthony Fauci, the nation’s top infectious disease expert, significantly more than they trust President Donald Trump to provide accurate information about the coronavirus.” McEnany said during an interview, “I believe that the American people have a lot more trust in the president than that poll indicates. ... I believe the American people have great confidence in this president’s leadership.”

**Column: We Shut Down The Economy To Make Progress Against COVID-19 – And Then Made No Progress.**

*Los Angeles Times* (5/14, 4.64M) columnist Michael Hiltzik writes that “many people are getting fed up with the” coronavirus “lockdown, and not only because it throws millions of them out of work.” Hiltzik asserts that “we have made scant progress against the virus, or at least not nearly as much as the richest, most powerful and most technically adept nation on Earth should have made.” He adds that that NIAID Director Dr. Anthony Fauci “warned that states that reopen businesses and allow public gatherings too hastily while the pandemic is still in full cry could ‘trigger an outbreak that you may not be able to control.’” Hiltzik concludes that President “Trump is getting what he seems to want: a nation mired in a chaos that benefits only those with the means to insulate themselves from the crisis. The rest of us can do nothing but gnash our teeth at a shutdown without end. amen.”

**Rand Paul Delivers A Magnificent Reality Smack To Anthony Fauci.**

In an opinion piece for the *Washington Times* (5/14, 492K), Cheryl K. Chumley writes that “in case you missed it: Sen. Rand Paul delivered a much-needed, long overdue, thankfully-finally-here reality check to” NIAID Director Dr. Anthony Fauci, reminding the health expert “in a Senate panel hearing earlier this week that hey now, hey guy, you’re just a guy — and your expertise on viruses shouldn’t be taken as expertise on politics, government, economics, policy or the running of a nation and its peoples.” In other words, Chumley says, “the Fauci influence over all walks of American life should fade.”

**Editorial: Fauci’s Caution On Schools Is Sound, No Matter What Non-Physician Trump Says.**

In an editorial, the *St. Louis Post-Dispatch* (5/14, 685K) says “the latest battle between President Donald Trump and” NIAID Director “Anthony Fauci, like previous ones, boils down to ego-based conjecture versus science and fact.” Fauci “argues it would be reckless to rush children back into classrooms in the fall before doctors have a better grasp of the dangers.” Meanwhile, “Trump, whose training in medicine and epidemiology is exactly zero, says it’s time to get back to class.” The Post-Dispatch says, “In the battle between Fauci’s voice of caution versus Trump’s call for throwing caution to the wind, we’ll stick with the guy who actually knows what he’s talking about.”
NIH Begins Trial To Determine How Effective Hydroxychloroquine.

Newsweek (5/14, Silisco, 1.53M) reports the National Institute of Allergy and Infectious Diseases (NIAID) is sponsoring “a clinical trial testing the effectiveness of combining antimalarial drug hydroxychloroquine with antibiotic azithromycin as a treatment for COVID-19.” The controlled trial “will involve 2,000 U.S. adults who are infected with the coronavirus and have symptoms like shortness of breath, cough and fever.” NIAID Director Dr. Anthony Fauci said in a statement. “Although there is anecdotal evidence that hydroxychloroquine and azithromycin may benefit people with COVID-19, we need solid data from a large randomized, controlled clinical trial to determine whether this experimental treatment is safe and can improve clinical outcomes.”

Interferon Emerges As Potential Treatment For COVID-19.

The Globe and Mail (CAN) (5/12, Semeniuk, 1.04M) reported that two newly reported trials show potential for a class of drugs called interferons as a therapy for COVID-19. Toronto’s University Health Network researcher Eleanor Fish, a “senior author on one of the studies, said that awareness of interferon as a potential COVID-19 treatment has been slow to build and should be prioritized for larger-scale clinical trials.” U.S. National Cancer Institute senior investigator Howard Young, “who has studied the anti-viral properties of interferon, echoed the need for more study.” Young “said an important question to be explored is whether mild versus more-severe cases of COVID-19 produce different responses to the drug.”

U.S. Accuses Chinese-Born Researcher At Cleveland Clinic Of Ties To Chinese Spying.

Reuters (5/14, Hosenball) reports the FBI arrested Chinese-born former Cleveland clinic employee Dr. Qing Wang “on fraud charges related to $3.6 million in federal grants, the FBI said on Thursday, the latest move in a U.S. crackdown on alleged attempts by China to steal American scientific advances.” Reuters adds, “Prosecutors said Wang accepted grants from the National Institutes of Health without disclosing that he was serving at same time as dean of the College of Life Sciences and Technology at the Huazhong University of Science and Technology.”

Additional Sources. NPR (5/14, Romo, 3.12M) reports, “The FBI claims Qing Wang...lied to receive more than $3.6 million in grants from the National Institutes of Health while also collecting money for the same research from the Chinese government.”

The Cleveland Plain Dealer (5/14, Eaton, 895K) and the Daily Caller (5/14, Saifi, 718K) also report.

Talking In Enclosed Space Can Generate Droplets That Linger For Up 14 Minutes, Study Finds.

ABC World News Tonight (5/14, story 8, 0:15, Muir, 7.42M) reported new research indicates “when two people talk loudly in an enclosed space with poor air flow, droplets in spit can float in the air for” 8 to 14 minutes with “substantial risk of transmission.”

Additional Source. The New York Times (5/14, Sheikh, 18.61M) reports, “Researchers at the National Institute of Diabetes and Digestive and Kidney Diseases and the University of Pennsylvania, who study the kinetics of biological molecules inside the human body, asked volunteers to repeat the words ‘stay healthy’ several times” and “found that speaking louder could generate larger droplets, as well as greater quantities of them.” The report was published Wednesday in the Proceedings of the National Academy of Sciences.
Experimental Injection Of ‘Good’ Bacteria Significantly Cut Bacterial Vaginosis Recurrence Rate.

Endpoints News (5/14, Grover) reports that injecting a “good” bacterium can reduce the high recurrent rate of bacterial vaginosis (BV) by a third, a 228-patient, placebo-controlled study suggests. The study “evaluated the effect of a ‘good’ bacterium product, called Lactin-V, which was packaged by California-based microbiome company Osell.” The NIH-funded study was published Wednesday in the New England Journal of Medicine.

NCI Exceptional Responders Initiative Pilot Study Meets Feasibility Goal.

Oncology Nurse Advisor (5/14, Bennett) reports the National Cancer Institute Exceptional Responders Initiative pilot study “successfully analyzed tumor specimens from more than 100 cases, deeming the effort feasible.” According to the study’s authors, “This study met its main feasibility goal to identify at least 100 analyzable ER [exceptional responder] cases in less than 3 years.” The results were recently reported in the Journal of the National Cancer Institute. A corresponding editorial said, “Just the ability to gather such a large number of rare and valuable tumor samples with clinical data is remarkable.”

Researchers Try Combining Remdesivir With A Second Drug To Deliver A “One-Two Punch” To Virus.

CBS News (5/14, Lapock, 3.68M) reports Dr. Aneesh Mehta, the lead investigator of an National Institutes of Health (NIH) trial at Emory University that “showed the drug remdesivir reduced average hospitalizations from 15 to 11 days,” said he thinks the drug is “going to be one important tool, but we also need to look for other ways to help our patients.” For the next phase of the trial, Mehta and colleagues are “combining remdesivir, which stops the virus from multiplying, with a powerful anti-inflammatory drug that aims to prevent organ damage by calming down an inflamed immune system.” The NIH “also said researchers are testing another potential coronavirus treatment cocktail: A mix of the malaria drug hydroxychloroquine with an antibiotic used to treat infections like pink eye.”

COVID Patients Given Malaria Drug Didn’t See Significant Improvements: Studies.

Reuters (5/14, Erman, Maddipatla) reports patients given the anti-malarial drug hydroxychloroquine, which President Trump has touted as a potential COVID-19 treatment, “did not improve significantly over those who did not, according to two new studies published in the medical journal BMJ on Thursday.” The National Institutes of Health “said on Thursday it began a study to evaluate the combination of antibiotic azithromycin and hydroxychloroquine, which Trump described as a potential ‘game changer’ for the pandemic.”

Part Of Gilead’s Coronavirus Drug Donation Allocated To Japan.

Reuters (5/14, Swift) reports hospitals in Japan have started treating severely ill patients with COVID-19 using Gilead Sciences’ experimental COVID-19 drug, according to ministry official Yasuyuki Sahara. Sahara “said in an e-mail on Thursday that the U.S. firm’s treatment has been distributed to hospitals in Japan since May 11 and is being used for patients in intensive care or those on ventilators.” A National Institutes of Health trial showed remdesivir “cut hospital stays by 31% compared with a placebo treatment, although it did not significantly improve survival.”
Virginia Receives 2nd Shipment Of New Antiviral Drug.

The Richmond (VA) Times-Dispatch (5/14, Martz, 277K) reports, “Virginia has received a second shipment of the new antiviral drug remdesivir to treat critically ill COVID-19 patients, but the supply is enough for only 36 patients.” The U.S. FDA “issued an emergency use authorization for remdesivir on May 1, but it is still an ‘unapproved product’ that may be used for treating adults and children who are hospitalized with severe cases of confirmed or suspected COVID-19.” The National Institutes of Health and Gilead Sciences “conducted a clinical trial of remdesivir that resulted in preliminary findings that the drug speeds recovery of COVID-19 patients hospitalized with severe cases of the disease, according to a Health Department summary.”


In an op-ed for USA Today (5/14, 10.31M), Senate Minority Leader Schumer, Sen. Todd Young (R-IN), Rep. Mike Gallagher (R-WI), and Rep. Ro Khanna (D-CA) write that “America is no longer the preeminent leader in scientific research as we were for the second half of the 20th Century. We must address this vulnerability.” The lawmakers argue the Endless Frontiers Act “proposes a renewed national investment in public research and development to strengthen our nation’s innovation ecosystem now and into the future.” They add “that every dollar invested in the National Institutes of Health leads to $3 in increased stock market valuation for private companies.” and research indicates “that raising public research and development spending by $100 billion per year on a permanent basis could help generate as much as 4 million new American jobs.”

COVID-19 Is Threat To Our Biomedical Research Enterprise.

In an opinion in The Hill (5/14, 2.98M), contributor Kefui Dzirasa, a National Institutes of Health-funded brain researcher at Duke University, writes, “COVID-19 has placed a unique strain on the U.S. biomedical research enterprise.” Dzirasa says, “COVID-19 has rendered individuals over 65 an at-risk: a population that is overrepresented in our nation’s pool of scientific investigators,” and “behavioral studies over the last three years have also revealed that our nation’s young scientists are a high-risk group for mental health challenges.” Dzirasa adds, “I am unclear whether the U.S. biomedical research enterprise can sustain this dual blow to both young and older scientists.”

Gilead Should Ditch Remdesivir And Focus On Its Simpler Ancestor.

In an opinion in STAT (5/14, 24K), Victoria C. Yan and Florian L. Muller write that Gilead’s antiviral drug remdesivir “has been propelled into the spotlight with the hope that it can stop, or at least curtail, the ravages of SARS-CoV-2, the virus that causes Covid-19.” Yan and Muller say, “Data from the open-label SIMPLE trial, sponsored by Gilead, and the randomized controlled Adaptive Covid-19 Treatment Trial, sponsored by the National Institute of Allergy and Infectious Diseases, show that remdesivir may accelerate recovery rates among patients with advanced Covid-19.” However, they argue that Gilead should focus instead on pro-drug GS-441524, which “is easier to synthesize than remdesivir, requiring three steps instead of the seven needed for remdesivir.”
Both/And Problem In An Either/Or World.

In an editorial in *Science Magazine* (5/15, 427K), H. Holdon Thorp writes that progress on COVID-19 vaccines in China and the U.S. “should make us optimistic that science will solve this problem, but the actions of the governments involved are not equally inspiring.” Thorp says that the Trump Administration “can’t grasp that it’s possible to question the actions of the Chinese government about the early days of the pandemic while embracing collaboration with Chinese science.” Thorp adds, “The latest setback is the decision by the U.S. National Institutes of Health (NIH) to terminate the grant ‘Understanding the Risk of Bat Coronavirus Emergence’ to Peter Daszak of the nonprofit EcoHealth Alliance, who, with NIH approval, shared one in five grant dollars with Shi Zhengli, a top virologist at China’s Wuhan Institute of Virology (WIV).”

Research On TPA Nanoconjugate Aims To Extend Thrombolysis Benefits To More Stroke Patients.

*Cleveland Clinic Consult QD* (5/14) reports the National Institute of Neurological Disorders and Stroke (NINDS) awarded a five-year $2 million grant to researchers at the Cleveland Clinic to study “a novel stroke therapy that uses tissue plasminogen activator (tPA) conjugated to nanoparticles.” The researchers “will assess the ability of a novel dual-action agent combining tPA with antioxidant-loaded nanoparticles to dissolve blood clots and protect the brain from reperfusion injury following stroke.”

Health & Medical News

White House Officials Signal Support For COVID-19 Relief For States Despite Opposition From Some GOP Groups.

The *Washington Post* (5/14, Costa, Stein, Kim, 14.2M) reports officials in the White House “have privately signaled that they are willing to provide tens of billions of dollars in relief to states as part of a bipartisan deal...despite President Trump’s reluctance and strong opposition from conservative groups.” The Post says while “that position is likely to anger some Republicans who have warned that Democrats want: ‘blue state bailouts,’ many White House officials now believe that providing new funding to states...will be necessary if they want to secure their own priorities, such as tax breaks and liability protections for businesses.”

*CNBC* (5/14, Pramuk, 3.62M) reports Senate Minority Leader Chuck Schumer (D-NY) indicated on Thursday that he is “hopeful Congress can strike a deal on more coronavirus relief, as Republicans spike a $3 trillion rescue package House Democrats’ plan to pass Friday.” Schuermer “told CNBC that he believes a worsening crisis will force Republicans to consider more spending to try to rescue the economy,” and “pointed to Wednesday comments from Federal Reserve Chairman Jerome Powell, who said ‘additional fiscal support could be costly, but worth it if it helps avoid long-term economic damage and leaves us with a stronger recovery.’”

In contrast, the *AP* (5/14, Fram) reports Senate Majority Leader Mitch McConnell on Thursday “branded House Democrats’ $3 trillion economic relief bill a ‘totally unserious effort’ to address the coronavirus pandemic, underscoring the deep election-year gulch over what Congress’ next response to the crisis should be.” McConnell “said Democrats had produced a ‘seasonal catalog of left-wing oddities and called it a coronavirus relief bill.’” According to the AP, “Provisions he singled out for criticism included a rollback of GOP-passed tax
increases on residents of states with high taxes, language making it easier for people to vote by mail and what he called ‘the cherry on top’ – provisions helping legal marijuana businesses.”

As COVID-19 Pandemic Persists, GOP Calls For “Pause” On More Aid.
The AP (5/14, Taylor) reports companies “are going belly up, tens of millions have been laid off and, by some measures, the U.S. seems headed for another Great Depression,” however, “Republicans surveying the wreckage aren’t ready for another round of coronavirus aid, instead urging a ‘pause.’” This is “a position based on a confluence of factors.” Surveys indicate “GOP voters think the government is already doing enough. Republicans on Capitol Hill are divided over the best approach. Billions approved by Congress have yet to be spent.” In addition, it remains to be seen what the President will “do next, if anything, to juice the economy – his payroll tax cut idea hasn’t gained any traction on Capitol Hill.” As a result, “GOP leaders see an unfolding crisis that does not yet cry out for further action.”

The Wall Street Journal (5/14, Omeakwe, Subscription Publication, 7.57M) reports a new Census Bureau survey found 75 percent of US small businesses have sought federal assistance to stay afloat during the COVID-19 pandemic. Data show 75 percent of respondents sought Paycheck Protection Program loans, and almost 30 percent said they sought SBA disaster loans.

Prospects For Second Round Of Stimulus Checks Seem “Uncertain.”
The Washington Post (5/14, Werner, 14.2M) reports almost 130 million Americans have received direct payments of up to $1,200 from the U.S. Treasury, a centerpiece of the federal response to the coronavirus pandemic,” however, “prospects are uncertain for another round of these stimulus checks.” The article says, “President Trump has left the door open to the idea,” but the GOP has “declared the House Democratic bill dead on arrival, and some have voiced skepticism about the need for any more individual payments.”

Sanders Wants Senate To “Improve” House Dems’ $3T COVID-19 Relief Package.
The Hill (5/14, Jagoda, 2.98M) reports on Thursday, Sen. Bernie Sanders (I-VT) “said that the Senate should ‘improve’ House Democrats’ $3 trillion coronavirus relief package so that it better addresses families’ health care and economic needs.” These “comments from Sanders, a prominent progressive lawmaker and former Democratic presidential candidate, came one day before the House plans to vote on the bill, despite a push from the leaders of the Congressional Progressive Caucus to delay the vote.”

Bipartisan Group Of Lawmakers Proposes Compensation Fund For Essential Workers Impacted By COVID-19.
USA Today (5/14, Cummings, 10.31M) reports that on Thursday, a group of lawmakers from both parties announced they intend “to introduce a bill that would create a compensation fund for essential workers and their family members who have been struck by the coronavirus.” Reps. Carolyn Maloney (D-NY), Jerry Nadler, (D-NY), and Peter King (R-NY), as well as Sen. Tammy Duckworth (D-IL) unveiled “the Pandemic Heroes Compensation Act during a digital news conference. They were joined by union representatives from the
Pelosi Pushing For Vote On $3T COVID-19 Relief Bill Despite Objections From Some Dems.

Politico (5/14, Ferris, Caygle, 4.29M) reports House Speaker Nancy Pelosi “is projecting confidence that the House will pass Democrats’ massive coronavirus relief bill Friday, even as she and her leadership team are still working to secure the votes.” Liberals and centrists in Pelosi’s party “are grumbling about the roughly $3 trillion measure.” Meanwhile, “House Republicans have overwhelmingly said they oppose the bill, and some Democrats are unable to travel to the Capitol to vote amid the pandemic, leaving Pelosi and her whip operation with tight margins to clear the bill.”

CNN (5/14, Foran, Raju, Byrd, 83.16M) reports that this “pushback underscores how House Democratic leaders are being attacked on all sides over the legislation — by congressional Republicans, who have dismissed the legislation as an liberal wish list, as well as within their own ranks by both progressives and moderates.”

New York Will No Longer Force Nursing Homes To Accept Recovering COVID-19 Patients.

The Wall Street Journal (5/14, Mathews, Subscription Publication, 7.57M) reports New York changed its policy of forcing nursing homes to accept patients recovering from COVID-19 so that now patients must test negative for the virus first.

Debate Over Reopening US “Increasingly Partisan And Bitter.”

The New York Times (5/14, Nolan, Bosman, Robertson, 18.61M) reports that for Wisconsin, Michigan, and Pennsylvania, three states “with Democratic governors and Republican legislatures, ending stay-at-home orders mixes health guidance and partisan politics.” The coronavirus response in those states “is becoming a confused and agitated blend of health guidance, protest and partisan politics — leaving residents to fend for themselves.” The governors, “backed by public health experts, have urged caution before reopening,” while Republican legislatures “in the states have pushed in the opposite direction, citing economic necessity and personal freedom.”

The Los Angeles Times (5/14, Etehad, 4.64M) reports the “mounting pressure comes as the number of jobless Americans continues to grow across the nation,” even as the COVID-19 death toll climbs. Meanwhile, governors in other states including Ohio, Rhode Island, and Minnesota have “announced plans to loosen restrictions in the coming days and weeks.”

Newsom Says COVID-19 Forcing Sharp State Budget Cuts.

The Los Angeles Times (5/14, Myers, 4.64M) reports California Gov. Gavin Newsom (D) “asked state lawmakers Thursday to sharply curtail spending on public schools and an array of government services while directly appealing to President Trump and Congress for help to prevent billions of dollars in additional spending cuts.” Newsom said, “The federal government has a moral and ethical and economic obligation to help support the states. ... After all, what is the point of government, if not to protect people, our safety and the wellbeing of citizens?” Without this help, Newsom “said state officials have few options in the face of a projected $54.3-billion deficit through early next summer.”
The New York Times (5/14, 18.61M) reports the state budget “slashes spending by nine percent overall from the initial proposal the governor made in January.” Newsom wrote to legislators, “Our state is in an unprecedented emergency, facing massive job losses and shortfalls in record time. ... This budget reflects that emergency.” The Times says that “to cushion the blow of a projected 22 percent decline in revenue, the governor proposed drawing down the state’s so-called rainy day reserves of $16 billion over the next three years.” The proposed $203.3 billion budget, “if approved by the Legislature, would bring spending back to around 2018 levels. But it would still be well above the levels seen during the Great Recession a decade ago.”

Los Angeles County Mandates Face Coverings Whenever Outside. The Los Angeles Times (5/14, Money, Fry, Sharp, McGreevy, 4.64M) reports Los Angeles County Public Health Director Barbara Ferrer announced Thursday that all residents must cover their faces when outside at all times. Ferrer said, “Masks are, in fact, mandatory across the entire county when you’re outside of your home, not with members of your household and in any kind of contact with other people.” Even when on a solitary walk or run, Ferrer said you now need to have a face covering with you, because if you came by other people, you were walking by other people, you tried to go into a grocery store, you absolutely have to have that face covering on.”

Following Arrest, California Gym Owner Again “Defies” Lockdown Order. The AP (5/14, Watson) reports from Oceanside, California that around a dozen weightlifters “wearing face coverings did sets Thursday in front of mirrors at a Southern California gym that was reopened by the owner despite his arrest last weekend for violating local coronavirus health orders that closed gyms.” Owner Lou Urielle has “vowed to keep the doors open at Metroflex Gym in the coastal city of Oceanside, north of San Diego,” but “warned his customers they might be handcuffed and hauled off like he was on Sunday.” Urielle may be the first “business owner arrested in California for violating health orders by reopening, although a growing number are doing that.” Authorities wary of a “public backlash have preferred to use warnings to get local businesses to comply.” Forcing one to “shut its doors and citing the owner is rare, and arrests are considered a last resort.”

Cities, Counties In Texas Take Disparate Approaches To Enforcing Pandemic Restrictions. Propublica (5/14, Beauvais, 60K) reports, “As Texas now reopens at Gov. Greg Abbott’s (R) direction, “under a much looser set of restrictions, a Propublica-Texas Tribune analysis of complaint data in a dozen cities shows... disparate approaches to enforcement – particularly among businesses – were incredibly common across the state.” Cities and counties “arrived at dramatically different interpretations of Abbott’s emergency orders.” Austin “has issued just two citations, while others like Laredo and Dallas have written hundreds of tickets, in addition to arresting a handful of business owners who defied orders to close.”

Texas Firefighters, Paramedics Tapped For Nursing Home Coronavirus Testing. The Houston Chronicle (5/14, Foxhall, 730K) reports firefighters and paramedics “across Texas have been tapped to help with coronavirus testing in nursing homes, as state and local officials work through how to meet Gov. Greg Abbott’s directive to test more than 200,000 residents and staff.” Fire departments statewide are “being asked to help with facility inspections and on-site testing, as part of a multi-agency effort, according to a Texas Department of State Health Services email shared with Hearst Newspapers, offering detail on the state’s plan.” In letters to fire departments “Wednesday, the state cleared fire personnel to enter the facilities.” Letters to the facilities “said they would be contacted ‘very soon’ by a testing team that could include first responders or the state national guard.” Local officials were “figuring out Thursday exactly how this testing might work, pushing for further clarification from the state about its broad demands.”
Texas Pays $45 Million For 300,000 Coronavirus Tests. The Austin (TX) American Statesman (5/14, Price, Subscription Publication, 343K) reports the state of Texas “is paying $45 million for 300,000 oral-swab tests — or $150 per test, according to a purchase order obtained by the American-Statesman through an open records request.” The April 30 purchase agreement “is with San Diego-based Gothams LLC, and includes the processing of tests at the private lab of Curative, Inc., according to Seth Christensen, spokesman for the Texas Department of Emergency Management, which made the purchase.” Christensen “said at least 75% of the purchase price, which includes the processing of each test, will be eligible for federal reimbursement.” The Curative tests, “designed to be self-administered, won emergency-use approval in April by the U.S. Food and Drug Administration.” In April, officials at the U.S. Centers for Medicare and Medicaid Services “said they would pay $100 apiece for COVID-19 tests that increase testing capacity and lead to faster results — twice as much as Medicare had announced it would pay in March.”

Michigan Closes State Capitol “As Protesters Gather” Against Stay-At-Home Order. CNN (5/14, Stracqualursi, 83.16M) reports the Michigan state Capitol “was closed Thursday as demonstrators gathered at the steps of the building to protest Gov. Gretchen Whitmer’s (D) stay-at-home order.” Police spokeswoman Shanon Banner “confirmed to CNN that because neither chamber was in session or holding committee meetings,” the Capitol was closed “per the procedures of the Michigan Capitol Commission.” The protest, organized “by Michigan United for Liberty, drew a crowd of roughly 200 ’at the high point of Thursday’s event, according to Michigan State Police estimates.” Attorney General Dana Nessel warned in a statement that “presence of heavily armed protestors at the Capitol unnecessarily creates a powder keg dynamic that is dangerous to protestors, law enforcement and public servants reporting to work at the Capitol.”

Whitmer Again Criticizes Trump Administration’s Coronavirus Response. The Detroit Free Press (5/14, Spangler, 1.52M) reports Michigan Gov. Gretchen Whitmer (D) on Thursday “again criticized the Trump administration’s handling of the coronavirus pandemic, saying it sent the state a shipment of swabs that can’t be used with some kinds of tests for the virus.” Whitmer said, “We’re missing something as simple as a variety of swabs,” adding “that, without them, she can’t move as quickly as she’d like to expand testing in Michigan.” This is the “key to re-engaging sectors of our economy with confidence,” she added. Her remarks came “during an online chat with former Vice President Joe Biden, the presumptive Democratic nominee to face President Donald Trump in the fall election, and Democratic Govs. Ned Lamont of Connecticut and Phil Murphy of New Jersey.”

Attorneys “Threaten Coronavirus Lawsuits” Against Florida Nursing Homes. The Orlando (FL) Sentinel (5/14, Santich, 536K) reports law firm “behemoth” Morgan & Morgan plans to sue “two Florida nursing homes over their alleged mishandling of COVID-19 outbreaks, attorneys for the firm said Thursday.” The firm has been retained “by families whose loved ones died after coronavirus infections at the facilities where they had been patients, including three families at Opis Coquina Center in Ormond Beach and an undisclosed number at Suwannee Health and Rehabilitation Center in Live Oak, near the Georgia border, the attorneys said.” According to attorney Alexander Clem, “These family members are just in the last seven to 10 days learning about what happened to mom and dad... that [their death] was due to COVID-19. The folks that allowed this to happen knowingly — they deserve to be held accountable.” However, Kristen Knapp,
communications director for the Florida Health Care Association, representing the nursing home industry, said the attorneys were “positioning themselves to profit from this tragic situation.”

**Despite Missing Goal, Nebraska’s Governor Confident In State Testing Program.**

The AP (5/14, Schulte) reports Nebraska may not make “its goal of conducting 3,000 coronavirus tests per day by the end of May through the state’s TestNebraska program, but Gov. Pete Ricketts (R) expressed confidence Thursday that testers will reach” that pace “at some point” if residents continue to sign up. His comments came after “state officials reported that the program produced 2,358 results last week — well short of the 3,000 per day that was expected by the end of the month, when the ramp-up period is supposed to end.” Ricketts announced the “$27 million coronavirus testing contract with Utah-based Nomi Health and three other firms on April 21, along with plans for a five-week ramp-up period to reach the estimated 3,000 tests per day.” The state has opened four “mobile testing sites so far in different cities, with plans to open six and a goal that each will see 500 residents daily.” However, the program has faced criticism “from some Nebraska state lawmakers and problems have been reported in Iowa and Utah, which have similar contracts.”

The Omaha (NE) World-Herald (5/14, Stoddard, 641K) reports Ricketts “said he is watching two key measures: the rate of tests that come back positive for the coronavirus and hospital capacity.” Ricketts “said 277 state employees who have been trained to do contact tracing are now helping local health departments.” Felicia Quintana-Zinn, a deputy division director “at the Nebraska Department of Health and Human Services, said tracers contact people who have tested positive for the coronavirus to find out who they might have exposed to the virus.” In most cases, exposure “occurs if people are less than 6 feet from one another for 10 minutes or more.”

**Connecticut Governor “Moving Ahead” With May 20 Reopening “Despite Concerns.”**

The AP (5/14, Haigh) reports despite a call on Thursday “by a group Democratic state senators to delay plans to begin phasing out Connecticut’s COVID-19 restrictions next week,” Connecticut Gov. Ned Lamont (D) “said his administration is still moving ahead carefully toward the planned May 20 partial reopening of certain Connecticut businesses.” Lamont “noted that hospitalizations are in the third week of a downward progression and the state is on pace to ‘blow through’ a projected 42,000 tests per week beginning next week, ramping up to more than 100,000 by June.”

**Democratic Connecticut State Senators “Implore Governor To Delay Reopening.”** The Hill (5/14, Bowden, 2.98M) reports a group of Democratic “state senators in Connecticut have written to Gov. Ned Lamont (D), urging him to delay his plans to begin reopening the state’s economy.” In a letter obtained “by the Hartford Courant, the nine lawmakers noted that the state is still experiencing a rate of new coronavirus infections five times higher than it was recording on the day Lamont issued his executive order closing barber shops and hair salons, along with other nonessential businesses.” The senators also add, “While Connecticut is moving in the right direction in terms of testing capacity, hospitalizations and deaths, the number of new positive tests, while down from the peak, indicates that community transmission of COVID-19 is still occurring in Connecticut at levels far beyond our ability to track, trace and isolate potential contacts.” Connecticut has reported “more than 34,000 cases of coronavirus across the state so far, and just over 3,100 deaths have been recorded.”
Just 4,000 Have Been Tested Under Iowa Program.

The AP (5/14, Foley) reports only 4,000 people have "gotten results through Iowa’s month-old $26 million coronavirus testing contract, but that will increase rapidly now that the equipment has been validated. Gov. Kim Reynolds said Thursday." Reynolds said the State Hygienic Lab has determined that the machines purchased for the TestIowa program are 95% accurate in detecting the virus in samples and 99.7% accurate in determining its absence. "The validation will allow TestIowa "to soon process 3,000 tests per day as originally envisioned, Reynolds said." She said it would also allow tests to be processed faster and the state to broaden the criteria of who can qualify for a test." The announcement came as Iowa reported 12 more deaths from the virus and an uptick in hospitalizations. The state reported that "180 of the 318 deaths to date have been residents of long-term care facilities, where three dozen outbreaks have been confirmed."

South Dakota Announces Plan To Test “All Long-term Care Facility And Assisted Living Residents” Over Next Month.

The Sioux Falls (SD) Argus Leader (5/14, Ferguson, 179K) reports South Dakota public health leaders "on Thursday announced a plan to test all of the state’s long-term care facility residents and staff and other vulnerable populations for the new coronavirus." The four-week plan, a “collaboration between the state department of health, local healthcare providers and commercial testing labs, will attempt to test all residents and staff across the state’s nursing homes and assisted living centers." The "mass-testing" event will begin with "testing residents in about 46 nursing homes in areas of substantial COVID-19 spread," moving next to the "more than 100 other nursing homes across the state." The remaining two weeks "will focus on assisted living centers." South Dakota Health Secretary Kim Malsam-Rysdon "estimated that more than 7,400 residents and staff in nursing homes would be tested in the first week and more than 10,000 in the second week. In the third and fourth weeks, she expected about 4,300 staff and residents in assisted living centers would be tested each week."

The AP (5/14, Groves) reports the state has "acquired more supplies needed for tests, allowing them to hold mass testing events." Health officials also plan to "conduct random testing among vulnerable people to try to catch infections before they spread." Malsam-Rysdon "said the state is also planning to hold mass testing events in Native American tribal communities, starting with a mass testing event with the Sisseton-Wahpeton Oyate next week."

Hawaii’s Governor “Inclined” To Maintain Stay-At-Home Order Until June 30.

The AP (5/14) reports Hawaii Gov. David Ige (D) “said Thursday he’s inclined to extend his “safer-at-home” order through the end of June to slow the spread of the coronavirus." Ige "said he also plans to maintain the state’s requirement that travelers arriving in the state observe 14 days of quarantine." Ige "said he would be examining allowing more businesses to reopen, including hair salons, barber shops and restaurants with dine-in service,” and also “said the state would look at guidance from the U.S. Centers for Disease Control and Prevention for information on how to keep employees and customers safe."

Louisiana Senate Approves Legislation To “Shield Businesses From Virus Lawsuits.”

The AP (5/14, DeSlatte) reports restaurants serving takeout and “delivery orders in Louisiana during the coronavirus outbreak and businesses providing protective gear should be largely shielded from lawsuits for
injuries, the state Senate decided Thursday." State senators overwhelmingly supported "the pair of bills from Republican Sens. Sharon Hewitt and Patrick McMath, which are similar to business-backed measures proposed in other states and in Washington amid the pandemic." The state Senate also backed a measure "aimed at shielding government agencies from lawsuits from employees required to work during the coronavirus outbreak, if they follow the guidance for protective measures issued by the state and the U.S. Centers for Disease Control and Prevention."

**States Begin Partially Opening As Residents Grow Restless, Less Willing To Shelter In Place.**

The **CBS Evening News** (5/14, story 6, 2:00, O'Donnell, 5.25M) reported on growing efforts in a number of states to partially or completely repeal stay-at-home orders due to the coronavirus pandemic. In Michigan, armed protesters marched on the state Capitol building in defiance of the state's order, and the Supreme Court of Wisconsin this week invalidated Gov. Tony Evers' (D) stay-at-home order. Further, some small business owners are protesting the stay-at-home orders as fatally detrimental to their businesses' financial interests.

**Bloomberg Business** (5/14, Rojanasakul, McCartney, 4.73M) reports most states in the US "have lifted at least some restrictions on the types of businesses that can be open, and distancing in nearly every one is on the decline – particularly on weekends – according to data from Unacast, a location data and analytics firm." The data also suggested that states with more reliable stay-at-home orders and higher adherence rates saw lower spread of coronavirus over the past two months.

**Some School Districts Ending Their Distance Learning Efforts.**

The **AP** (5/14, Amy) reports on the growing number of school districts across the US that have "pulled the plug on distance learning, all citing familiar reasons." School officials say "it's too stressful, the lack of devices and internet access is too much to overcome, and what students get from it just isn't worth the struggle." In Georgia, for instance, many district leaders say the "final weeks of the school year would have been dedicated anyway to preparing for and taking standardized tests that are now canceled."

**Scientists Say Testing Sewage Holds Promise For Monitoring Outbreaks Of Diseases Including Coronavirus.**

**Reuters** (5/14, Kelland) reports scientists say testing sewage for pathogens, including coronavirus, could help countries around the world monitor outbreaks of diseases and respond appropriately. Reuters highlights several efforts around the world to use sewage testing as a public health tool to inform officials about how widespread coronavirus is when deciding whether to ease restrictions. Additionally, sewage testing could alleviate the burden of doing widespread testing of individuals, which has proven difficult in many parts of the world.

**Analysis: Many “Essential” Workers Will See Pay Cuts As Companies Rescind “Hazard Pay” Policies.**

**Bloomberg** (5/14, Melin, Steverman, 4.73M) reports many "essential" employees in the US will be facing a pay cut in the coming weeks as the initial push for "hazard pay" around the pandemic begins to fade. Initially, many employees "received bonuses or pay bumps to compensate for the risks that come with clocking in at supermarkets, hospitals and other crowded workplaces during a pandemic," but companies are beginning to end
these programs. For example, Kroger “is rescinding the” pay “raise it gave to store and warehouse workers” while Target and Amazon “will follow later this month, with other firms charting similar moves.” The planned cutbacks “have rankled unions, employees and customers who are accusing companies of putting profits ahead of worker well-being.” The decisions “also raise questions about how to value the essential workers who are keeping society functioning,” as many employees “put their health and safety on the line in exchange for relatively low wages.”

COVID-19 Accelerating Decline Of Retail Industry.

On its front page, the Wall Street Journal (5/14, A1, Kapner, Nassauer, Subscription Publication, 7.57M) reports the COVID-19 pandemic has accelerated the decline of the retail industry as more people move to online shopping. UBS estimates about 100,000 stores will close in the next five years, over triple the number that closed during the last recession.

Navy Continues To Battle Coronavirus Transmission Aboard Theodore Roosevelt Aircraft Carrier.

The New York Times (5/13, Gibbons-Neff, Schmitt, Cooper, 18.61M) reported the Theodore Roosevelt aircraft carrier “continued its monthslong fight against the novel coronavirus, with at least one sailor aboard the ship testing positive, according to crew members.” The sailor “was quickly whisked off the ship, which is docked in Guam as Navy officials make preparation for the vessel to deploy.” However, the episode “underscores the stubborn challenges facing top Navy officials as a second investigation into the service’s handling of the virus – this one by the Defense Department’s inspector general – got underway this week.” Officials “said they had been aggressively screening and testing as crew members return to the Roosevelt after quarantining in Guam over the past month.”

Analysis: Gun Stores In Several States Ignored State-Ordered Closures, Initiated Tens Of Thousands Of Background Checks In April.

USA Today (5/14, 10.31M) reports on how gun stores in several US states “have defied orders to close their doors as the coronavirus pandemic drives historic demand for firearms, according to background check data maintained by the Federal Bureau of Investigation and interviews with shop owners.” Currently, five states have ordered gun stores closed under stay-at-home orders and directives – Massachusetts, Michigan, New Mexico, New York, and Washington. However, FBI data from April show “that dealers in those [states] still initiated tens of thousands of gun background checks.” Washington alone saw 42,000 background checks initiated for gun purchases in April. Additionally, the National Instant Criminal Background Check System processed 2.9 million checks, making it the highest month on record, dating back to 1998.

Inspection Reports For Several Connecticut Nursing Homes Found Lapses In Infection Control, Prevention Around Coronavirus.

The Connecticut Mirror (5/14, Thomas, Carlesso) reports inspections at several Connecticut nursing homes “found lapses in infection control and prevention and poor practices for the prolonged use of protective gear necessary during the COVID-19 pandemic, according to a half-dozen reports released Wednesday.” The reports, provided by Connecticut’s Department of Public health, “are the first detailed accounts of targeted inspections
ordered by the federal government on March 20 and later expanded by Gov. Ned Lamont (D) to cover all 213 skilled nursing homes, where the novel coronavirus has infected 6,000 and is attributed to more than 1,600 deaths. "Additionally, none of the reports "detailed inspections at homes with some of the highest numbers of people dying from COVID-19." Department spokesman Av Harris "said there is a delay in releasing some reports."

Analysis: Studies Suggesting Coronavirus Can Be Spread Through Loud Talking Show Need For Face Masks In Public.

Forbes (5/14, Lee, 9.71M) reports on a new study published in the Proceedings of the National Academy of Sciences which suggests coronavirus could be spread in public through speaking, because the act of speaking can expel fluid droplets that hang in the air for several minutes. A similar study published in Nature has suggested that on average a fluid droplet from [a] contagious person could contain 7 million viruses per milliliter, and the research team then estimated "that just one minute of loud speaking could generate at least a thousand virus-containing little droplets that may hang in the air for over eight minutes." Further, researchers explained that their study showed how "normal speech generates airborne droplets that can remain suspended for tens of minutes or longer and are eminently capable of transmitting disease in confined spaces." Therefore, researchers are encouraging face mask adherence in public areas and enclosed spaces to limit the spread of virus-containing droplets.

UT Dallas Researchers Design 3D-Printed Disposable Ventilator Valve.

The Dallas Morning News (5/14, Arnold, 946K) reports researchers at the University of Texas at Dallas "have designed a 3D-printed ventilator valve that helps patients breathe." The ventilator valves "called positive end-expiratory pressure, also known as PEEP," are disposable "to ensure patients' lungs some air and do not collapse when exhaling." The research team "is seeking emergency approval from the U.S. Food and Drug Administration so it can distribute the parts [to] hospitals that need them, the university said in an announcement." The research team at UT Dallas "is one of several university groups across the country working to increase the supply of ventilators and protective equipment."


Sen. Elizabeth Warren (D-MA) and Rep. Andy Levin (D-MI) write for NBC News (5/14, 6.14M) that they are introducing a proposal "for a federal contact tracing program" for the next relief package from Congress. While House Democrats have a proposal that "already includes pieces of it, including $500 million to hire a diverse group of culturally competent contact tracers," Congress needs "to stand up our whole plan for a national contact tracing strategy." Warren and Levin claim the Administration's "slow and dysfunctional response has been a disaster of epic proportion" and that is why "Congress must step in, and that's why we have proposed the Coronavirus Containment Corps."

The Hill (5/14, Budryk, 2.98M) covers the opinion piece from Warren and Levin.

Interview: Antibiotic-Resistant Microbes Equally Important Issue During Pandemic.

NPR (5/14, 3.12M) interviewed Boston University professor Muhammad Zaman, author of "Biography of Resistance: The Epic Battle Between People and Pathogens," on his new book and what exactly antibiotic
resistance means for US public health. In the interview, Zaman speaks on the dual-issue of antibiotic resistant microbes and the coronavirus pandemic, noting that “we know from history that the majority of deaths during the great 1918 flu pandemic were from secondary bacterial pneumonia.” Zaman also advocates for a more global, collaborative approach to addressing the issue both during and after the pandemic.

**Infectious Disease Experts Warn Of Potential Dual-Season For COVID-19, Influenza During Winter.**

The *San Francisco Chronicle* (5/14, Allday, 2.67M) reports the greater Bay Area “blunted the impact of its first brush [with] the coronavirus, but infectious disease experts warn there are more outbreaks to come once the region eases shelter-in-place restrictions, and one looming event is of particular concern: the flu season.” Currently, no health experts know “what to expect in the fall and winter, when the coronavirus may commingle with seasonal influenza.” However, public health officials are “bracing for a resurgence of cases” for COVID-19 while also dealing with influenza. For example, infectious disease expert David Relman said, “This was a really good practice run for what may be a worse winter,” adding, “We need to be thinking really carefully now about the strategies we can use to address both things at the same time.”

**Norwegian Cruise Line Expects Entire Fleet To Resume Full Operations In Approximately Six Months.**

*USA Today* (5/14, Hines, 10.31M) reports Norwegian Cruise Line “expects its entire fleet will be able to resume full operations in five to six months.” The company “shared the news in its earning report for the first quarter of 2020, which ended on March 31.” CEO Frank Del Rio “said that Norwegian is planning on carrying out a phased relaunch” and “expects it will take up to six months to resume fleet-wide operations across Norwegian Cruise Line Holdings’ 28 ships, which are spread across its three brands: flagship Norwegian Cruise Line, Oceania Cruises and Regent Seven Seas Cruises.”

**Analysis: Anti-Vaccination Advocates Mobilizing To Protest Potential Coronavirus Vaccine.**

*HuffPost* (5/14, Robins, 1.67M) reports that as scientists and researchers “urgently work to develop a vaccine against the coronavirus that would save lives and help societies to safely reopen, the anti-vaccine movement has been mobilizing to convince people they shouldn’t take it.” Anti-vaccination protestors – known as “anti-vaxxers” – “have become a prominent presence at [demonstrations] against lockdowns and social distancing, while spreading conspiracies and misinformation to millions on platforms such as Facebook and YouTube.” The article carries an interview with pro-vaccination activist Dr. Peter Hotez, who works to “push back against anti-vax falsehoods and activists.”

**DC-Area Metro, Metrobus Riders Required To Wear Face Coverings Effective May 18.**

The *Washington Post* (5/14, George, 14.2M) reports that effective May 18, all DC-area Metro and Metrobus riders “will be required to wear masks or face coverings to help prevent the spread of the novel coronavirus, the agency’s chief safety officer said Thursday.” The requirement “follows rules set by leaders in the District and Maryland.” Previously, the agency “had only recommended that riders wear face coverings.” Metro General manager Paul Wiedefeld “said bus and train operators asked for the requirement, as did customers on recent surveys.”
The Hill (5/14, Budryk, 2.98M) also reports.

**Nursing Home Industry, Residents Clash Over Industry’s Handling Of Pandemic.**

*TIME (5/14, 18.47M)* reports nursing home residents and staff in the US “have borne a heavy load of the pandemic’s burden,” with deaths in long-term care facilities now making up “at least one third of coronavirus fatalities in most states.” Some residents “are already starting to take legal action, suing nursing homes for neglect, abuse and wrongful death.” In response, the nursing home industry “has launched a broad and successful lobbying effort to secure immunity from potential lawsuits over the way facilities are treating patients during the pandemic, a move consumer advocates say raises long-term questions about the oversight of an industry that has racked up standards violations for years.”

**Opinion: Governors Need To Designate Grocery Workers As First Responders.**

*UFCW Local 400 President Mark Federici* writes in an opinion piece for the *Washington Post (5/14, 14.2M)* that governors “must designate grocery, pharmacy and food-processing workers as first responders and limit stores to no more than 10 customers per 10,000 square feet, with a maximum of 50 people in any store at the same time.” The designation “needs to include guaranteed free, universal testing and treatment for every worker,” as well as “masks, gloves and other personal protective equipment,” and “free child care, which enables grocery employees to show up for work when schools are closed.” Federici writes that first-responder designation “is the only way to provide the protection needed by our essential grocery workers and their customers,” and “rather than giving grocery workers lip service by calling them heroes, let’s actually do something to protect their health.”

**WPost: COVID-19 Testing In Nursing Homes And Long-Term Care Facilities Is Essential.**

The *Washington Post (5/14, 14.2M)* editorializes, “Residents and staff of nursing homes and other long-term care facilities account for roughly half of 1 percent of the U.S. population, and more than a third” of COVID-19 deaths. The Post says that “justifies extreme measures by federal officials and states, but so far both have balked. On a call Monday with governors, Vice President Pence strongly recommended testing at nursing homes nationwide...yet federal officials and most governors have stopped short of mandating such tests.” The Post says such testing is essential, and “in states where tests are in short supply, they should be prioritized for nursing homes and other elderly care facilities.”

**One-Fourth Of US Restaurants Will Close Due To Stay-At-Home Orders During Pandemic, OpenTable Forecasts.**

*Bloomberg (5/14, Ludlow, 4.73M)* reports 25 percent of US restaurants “will go out of business due to the coronavirus quarantines that have battered the food-service industry, according to a forecast by OpenTable.” The projection “underscores the widespread pain for American restaurants as lockdowns have forced people to cook at home or order takeout rather than eat out.” US restaurants “lost more than $30 billion in sales during March and $50 billion in April, according to National Restaurant Association estimates.” However, data from OpenTable show “that there are growing signs that patrons are willing to dine out again in states like Arizona and Texas where it’s allowed, though the numbers are still far below where they were last year.”

**Pentagon Examining “Social Distancing Protocols” To Train, Deploy Units Amid Pandemic.**
USA Today (5/14, Brook, Babich, 10.31M) reports that senior Pentagon officials are exploring “how to train and deploy units for combat while the virus continues to infect and kill.” Officials are balancing “the risk of returning to normal operations” with “losing the skills troops need to operate lethal weaponry safely and to win in combat.” Army Secretary McCarthy told USA Today, “We were in tremendous posture right as COVID hit with our readiness – over half our brigade combat teams in the highest level of readiness. ... If we don’t turn it back on by this summer, we’re going to start to see atrophy with our readiness posture. So we think we’ve got the right capacity to test. We think we have the social distancing protocols in place where we can do this.” The Army “will soon present the plan to Defense Secretary Mark Esper for approval of what would be a major step toward reopening the military.”

Some Colleges Push Viral Testing, Alternative Methods To Allow Fall Semester In-Person.
The Washington Post (5/14, Anderson, Svrluga, 14.2M) reports many colleges and universities are “pushing to bring students back to campus in the fall, pledging an all-out effort to overcome the extraordinary challenges of housing and teaching them during a public health crisis.” The University of California at San Diego has already set up a “self-serve” COVID-19 testing station and the “experiment is one of many data-gathering initiatives advocates say are needed to reopen.” But health experts “fear some schools may be moving too fast to reopen,” specifically because of the complications and challenges around enforcing reasonable social distancing protocols on campus.

Columnist: Trump Is “In The Middle Of A Grace Period” With Voters, But That Will Not Last Indefinitely.
The Washington Post (5/14, 14.2M) columnist David Byler writes that “President Trump bungled the coronavirus crisis,” so “it would be reasonable to expect Trump’s poll numbers to drop like a rock after this sort of mismanagement.” However, “his approval rating is stable at around 44 percent – roughly where it was before the virus hit.” Byler says that is “because Trump is likely still in the middle of a grace period: Voters aren’t holding him fully accountable for the damage caused by the virus.” Byler asserts “voters might be willing to give a leader leeway in a crisis, but they won’t extend that credit indefinitely.”

Department Of Labor Issues Coronavirus Guidance To Nursing Homes.
Reuters (5/14, Hals) reports “the U.S. Department of Labor issued its first workplace guidance to nursing homes on Thursday since the COVID-19 pandemic swept the country and ravaged care facilities, saying residents, staff and visitors should keep 6 feet (1.83 meters) apart.” The guidance “from the Occupational Safety and Health Administration (OSHA) also said nursing homes should screen residents and staff for symptoms and should find alternatives to group activities.” OSHA “did not recommend testing of residents or workers by nursing homes, which have been hit by the coronavirus since February.”

Trump Signs Executive Order Giving New Authority To US International Development Finance Corporation Amid Pandemic.
U.S. News & World Report (5/14, Smith-Schoenwalder, 2.4M) says President “Trump on Thursday said he signed an executive order to grant new authority to the U.S. International Development Finance Corporation to finance industries vital to the pandemic response.” Trump said, “This federal agency normally invests in
economic development projects in other countries. ... I said, ‘How about investing in our country?’” In a statement, “the White House said...the order will help strengthen the supply chain and provide more financing to ‘key industries producing vital goods and services.”

Columnist: US Should Be “Pitied” For Coronavirus Response.

Washington Post (5/14, 14.2M) columnist Eugene Robinson writes that “only a handful of nations on Earth have arguably done a worse job of handling the coronavirus pandemic than the United States. What has happened to us? How did we become so dysfunctional? When did we become so incompetent?” Robinson says “the phrase ‘American exceptionalism’ has always meant different things to different people – that this nation should be admired, or perhaps that it should be feared. Not until now, at least in my lifetime, has it suggested that the United States should be pitied.”


In an analysis, Politico (5/14, Kumar, 4.29M) reports “President Donald Trump hasn’t been able to go out, so he’s welcoming governors in.” The recent “visits are strikingly similar: Trump touts the governors as ‘special’ and ‘great’ and they in turn thank him for the ‘enormous help in our darkest hour of need.’ The president cracks a joke or two about the governor getting a negative coronavirus test sitting down next to him. And then they all pose for the cameras.” Politico says the meetings “have served as Trump’s workaround to his inability to hit the road and hold rallies and promote the economic reopening of America, which he believes will be key to his reelection in November.”

Columnist: “Virus Trutherism” Widespread On The Political Right.

New York Times (5/14, 18.61M) columnist Paul Krugman writes that “virus trutherism – insisting that Covid-19 deaths are greatly exaggerated and may reflect a vast medical conspiracy – is already widespread on the right. We can expect to see much more of it in the months ahead.” The “right long ago rejected evidence-based policy in favor of policy-based evidence – denying facts that might get in the way of a predetermined agenda.” However, Krugman says, “the right’s determination to ignore the epidemiologists is politically reckless in a way previous denials of reality weren’t.”

McConnell Walks Back Claim That Obama Administration Left Trump Administration No “Game Plan” For Pandemics.

CNN (5/14, Leblanc, 83.16M) reports “Senate Majority Leader Mitch McConnell conceded Thursday night that he was wrong to claim that the Obama administration had not left behind a plan to deal with a pandemic in the US.” McConnell said during a Fox News interview, “I was wrong. They did leave behind a plan, so I clearly made a mistake in that regard.” McConnell’s “concession comes days after he falsely accused the Obama administration of failing to leave the Trump administration ‘any kind of game plan’ for something like the coronavirus pandemic during a Trump campaign online chat with Lara Trump, the President’s daughter-in-law.”

The Hill (5/14, Carney, 2.98M) reports McConnell said, “As to whether or not the plan was followed and who is the critic and all the rest, I don’t have any observation about that because I don’t know enough about the details of that…to comment on it in any detail.”
Pentagon’s DPA Coordinator Reassigned To Navy Position.

*Politico* (5/14, Seligman, Lippman, 4.29M) reports that Jennifer Santos, “the Pentagon's industrial policy chief who oversees efforts to ramp up production of masks and other equipment” to help fight COVID-19, “was fired from her job this week and will move to a position in the Navy.” According to Politico, “Since March, Santos has focused on using the Defense Production Act [DPA] to partner with industry to bolster the nation’s supply of critical medical equipment such as ventilators, personal protective gear and testing materials needed to counter the coronavirus pandemic.” Politico says Scott Baum, “who is DoD’s principal director of industrial policy, will take over Santos’ position on an acting basis.”

Trump’s Press Secretary Flashes Pandemic Playbook To Reporters; Calls Obama Administration’s Plan “Insufficient.”

The *New York Post* (5/14, Bowden, 4.57M) reports “President Trump says his administration did have a plan to deal with the coronavirus pandemic – and his press secretary on Thursday flashed a previously unknown playbook called the ‘Pandemic Crisis Action Plan’ to prove it.” The press secretary “held up the binder for reporters before the president and his staff decamped to Allentown, Pennsylvania.” Furthermore, press secretary Kayleigh McEnany “held up a copy of the plan the Obama administration left for the incoming Trump team – the ‘Playbook for early response to high-consequence emerging infectious disease threats and biological incidents’ – describing it as ‘insufficient.’”

Number Of COVID-19 Cases In Michigan Nears 50,000.

The *Detroit News* (5/14, Mauger, 825K) reports “the number of confirmed COVID-19 cases in Michigan jumped by 1,191 Thursday to 49,582 as the state reported ‘backlogged’ lab results and increased testing at correctional facilities.” But, Michigan’s “new tracking shows that the tally of cases in 26 Michigan counties has been flat in the last seven days. Four of the 26 counties continue to have zero cases.” The 1,191 “cases reported Thursday was the highest daily increase statewide since April 24.”

Woman Sues Portland Nursing Home After Her Mother Died Of Coronavirus At The Facility.

The *AP* (5/14) reports “the daughter of a woman who died after contracting the coronavirus at a Portland long-term care facility filed a $1.8 million lawsuit Thursday claiming elder abuse.” The plaintiff, Angela Brown, “says her 75-year-old mother, Judith Jones, contracted coronavirus and died because of Healthcare at Foster Creek’s negligence, The Oregonian/OregonLive reported.” In her “complaint, Brown listed problems state investigators found at the nursing home, now connected to 29 deaths and 119 cases of COVID-19.”

New York Governor And New York City Mayor Cannot Agree On Number Of Coronavirus Deaths In The City.

*POLITICO New York* (5/14, Durkin) reports “New York City hit a grim milestone this week, recording more than 20,000 coronavirus deaths throughout the five boroughs. Or did it?” According to New York “Gov. Andrew Cuomo’s (D) office, the city is still weeks away from that mark, with thousands fewer deaths in its tally – and public health experts say the state’s lag is a problem.” The constant “feud and routine miscommunication between Cuomo and Mayor Bill de Blasio is among the few things in New York that has not been slowed by the
pandemic.” However, “the fact that the two can’t even agree on how many people have died illustrates the dysfunction between the city and state, even as they try to coordinate a cautious reopening of New York’s economy.”

**Study Suggests Pediatric Multi-System Inflammatory Syndrome Is Tied To Coronavirus, As Cases Rise In New York.**

*Bloomberg* (5/13, Gale, 4.73M) reported that “the coronavirus may have triggered a 30-fold jump in cases of a serious but rare pediatric inflammatory disease, according to an Italian study that provides an ominous warning to other pandemic-affected nations about the risk to children.” An “analysis from Bergamo, the epicenter of the Italian Covid-19 outbreak, found 10 cases of a Kawasaki disease-like illness in children, adding to reports of about 90 similar cases from New York and England.” Although “children remain at lower risk than older adults of developing severe complications after being infected with the Covid-19-causing SARS-CoV-2 virus, the research published Thursday in the Lancet medical journal shows that their risk isn’t zero.”

The *Wall Street Journal* (5/14, King, Subscription Publication, 7.57M) reports officials in New York have now identified 110 cases of pediatric multi-system inflammatory syndrome in young adults and children. The syndrome has killed three young people, and it is potentially tied to COVID-19.

**Fishing Boat Crews Reportedly Could Cause Coronavirus Outbreak In Cordova, Alaska.**

The *New York Times* (5/14, Baker, 18.61M) reports that “the people of Cordova, Alaska, had weathered the coronavirus pandemic with no cases and the comfort of isolation – a coastal town unreachable by road in a state with some of the fewest infections per capita in the country.” However, “that seclusion has come to an abrupt end. Over the past two weeks, fishing boat crews from Seattle and elsewhere have started arriving by the hundreds, positioning for the start of Alaska’s summer seafood rush.” The town’s “conditions are ideal for propagation of the coronavirus: Most of the imported crews work in the close quarters of fishing boats or sleep in crowded bunkhouses next to processing facilities.”

**Hospital Leaders Approve Of Minnesota Governor’s Decision To Let Stay-At-Home Order Expire.**

The *Minneapolis Star Tribune* (5/14, Olson, 1.04M) reports “hospital leaders endorsed Gov. Tim Walz’s (DFL) decision to end the statewide stay-at-home order on Monday, but urged Minnesotans to remain vigilant to reduce the spread of COVID-19 “that could still overwhelm them and leave them unable to care for some patients at the peak of the pandemic.” The state “appears to have a razor-thin margin of critical hospital supplies – including critical care beds and ventilators – to weather the surge of COVID-19 infections that is expected this summer, according to new state modeling results.” However, “if reality proves worse than predicted, hospital officials said the governor will need to be quick about reinstituting restrictions that reduce face-to-face contact and the spread of the virus.”

**Pennsylvania Governor To Announce More Counties That Can Lift Some Pandemic Restrictions On Friday.**

The *AP* (5/14, Levy) reports Pennsylvania “Gov. Tom Wolf (D) will announce Friday that more counties can see some of his tightest pandemic restrictions lifted, as counties and lawmakers kept up pressure on him to ease up
on his orders.” During a “news conference Thursday with reporters, Wolf said he will make his decision on Friday morning.” But, “he has not changed his criteria for deciding which counties can emerge from his stay-at-home order and his order for non-life-sustaining businesses to close, he said.”

***

**Most Maryland Residents Will Remain Under Stay-At-Home Orders As State Starts Reopening Friday.**

The *Washington Times* (5/14, Kaplan, 492K) reports “at least half of Maryland residents will still be under stay-at-home orders Friday, when the state begins to reopen its economy after having shut down for nearly two months to stop the spread of the coronavirus.” Some of Maryland’s “most populous jurisdictions — Montgomery, Prince George’s, Howard and Calvert counties, and the city of Baltimore — will extend their stay-at-home orders due to high concentrations of COVID-19 cases.” Maryland “Gov. Larry Hogan (R) announced this week that phase one of his ‘Maryland Strong Roadmap to Recovery’ plan will begin at 5 p.m. Friday.”

**WSJ** **Journal Urges Wisconsin Governor To Create Less Restrictive Stay-At-Home Order With Legislature.**

In an editorial, the *Wall Street Journal* (5/14, Subscription Publication, 7.57M) urges Wisconsin Gov. Tony Evers (D) to work with the state Legislature to draft a less restrictive stay-at-home order.

**Oxford Vaccine Study Shows Promise In Monkeys.**

*NBC Nightly News* (5/14, story 9, 0:40, Holt, Torres, 7.88M) reported, “Oxford University just released results from a study involving six monkeys,” which “found after four weeks a vaccine-produced antibodies to COVID-19 in all of the monkeys, and prevented them from getting pneumonia when they were exposed to the virus.” According to *NBC*, “The control group that didn’t get the vaccine got sick, so this is certainly promising.” *NBC* added that the “vaccine is also currently being tested in more than 1,000 people, and the first results are expected in June.”

*Reuters* (5/14, Steenhuysen) reports, “After exposure, the vaccine appeared to prevent damage to the lungs and kept the virus from making copies of itself there, but the virus was still actively replicating in the nose.”

**Pompeo: U.S. Condemns China-Linked “Cyber Actors” Trying To Steal COVID Research.**

*Reuters* (5/14, Pamuk) reports Secretary of State Pompeo said Thursday that the U.S. has “condemned attempts by China-linked ‘cyber actors and non-traditional collectors affiliated’ to steal US intellectual property and data related to coronavirus research.” In a statement, Pompeo said, “The PRC’s behavior in cyberspace is an extension of its counterproductive actions throughout the COVID-19 pandemic.”

*Newsweek* (5/14, Stockler, 1.53M) reports Pompeo’s remarks “follow an announcement by the FBI on Wednesday that the bureau is investigating ‘the targeting and compromise’ of organizations conducting research to develop vaccines and other treatments for COVID-19.” The efforts were “attributed to China-affiliated actors.” The U.S. State Department released a statement Thursday “denouncing attempts to infiltrate systems involved in US COVID-19 research that the FBI has attributed to China.”

The *Washington Times* (5/14, Gertz, 492K) also reports.

**Researcher Optimistic About Convalescent Plasma Therapy.**
On NBC Nightly News (5/14, story 10, 2:30, 7.88M). Lester Holt said there is “encouraging news in a new report on an experimental treatment that appears to have helped some patients recover” from COVID-19. NBC’S Cynthia McFadden: “A first look at a promising new report drawn from a nationwide team of more than 5,000 doctors from over 2,000 hospitals and labs, looking at an experimental therapy called convalescent plasma, transfusing the antibody-rich blood from someone who recovered into a current patient.” Michael Joyner, Professor of Anesthesiology at the Mayo Clinic: “We’re very encouraged that the treatment is safe. That was really the first hurdle for us.” McFadden: “Dr. Joyner says the hard data about the effectiveness of the treatment is yet to come. How soon will they have it?” Joyner: “As fast as we can. Our data mining and analytics team is working on data we have currently.”

Plasma Therapy Derived From Recovered COVID-19 Patients Appears Safe, Study Suggests.

The Wall Street Journal (5/14, Marcus, Subscription Publication, 7.57M) reports a study analyzing data from thousands of COVID-19 patients, who received blood plasma transfusions from patients that already recovered, suggests the experimental therapy is safe, setting up the potential for future studies and clinical trials.

Expert Says It Will Take “Bulk Of A Year” Before Researchers Can Determine Factors In COVID-19 Immunity.

McClatchy (5/14, Willner, 19K) reports that University of Maryland School of Medicine Institute of Human Virology Co-Founder and Director Robert Gallo was disturbed by a finding buried deep inside a study by researchers from Los Alamos published last month that “the mutation of the coronavirus’ outer spikes could help the virus escape the grasp of otherwise neutralizing antibodies and ‘make individuals susceptible to a second infection.’” Gallo said that it will likely “take the bulk of a year before” researchers can determine with high confidence whether COVID-19 survivors are naturally protected from a second infection.

Data Show COVID-19 Cases Are Generally Decreasing In 17 States, Rising In Nine Others.

CNN (5/14, Yan, Karimi, 83.16M) reports, “First, the good news: In 24 states, the number of new coronavirus cases reported each day is generally going down.” In 17 states, the numbers “are holding steady, according to an analysis of data from Johns Hopkins University.” And in nine states, “the numbers of new cases are still rising.”

Fox News Host Says Bright Testimony Could Be “Potentially Politically Damaging” For Trump.

The Hill (5/14, Concha, 2.98M) reports Fox News’s “Special Report” anchor Bret Baier “said Thursday that former Biomedical Advanced Research and Development Authority head Rick Bright’s testimony about the federal government’s response to the coronavirus pandemic could be ‘potentially politically damaging’ for President Trump.” Baier “also asserted that the public health official was someone who could not be easily discredited.” On Thursday, Bright “testified to the House Energy and Commerce health subcommittee that his warnings about medical supply shortages were allegedly ‘met with indifference’ by his superiors in January before the coronavirus pandemic gripped the country.”

Fox News (5/14, Halon, 27.59M) reports Bright’s testimony “will have ‘lingering implications’ for the Trump administration, ‘Special Report’ anchor Bret Baier told ‘Bill Hemmer Reports.’” Baier said: “I think he laid out a
pretty compelling case of where he was in his job and I think that is potentially damaging for the Trump administration, as he is saying they didn’t warn people and they weren’t prepared, they could have done more as far as training and preparation as far as January and February.”

Axios (5/14, Rummell, 521K) also reports.

Opinion: Pay Attention To Whistleblower, Because What Trump Disparages Is Often Truth.

In an opinion piece for the Los Angeles Times (5/14, 4.64M), Editorial Writer Scott Martelle writes, “President Trump reverted to form on Thursday when reporters asked him about congressional testimony by Dr. Richard Bright, who says the White House removed him from his position leading the federal Biomedical Advanced Research and Development Authority because he, in essence, stood up to Trump’s political machinery in defense of science.” Martelle writes, “Trump told reporters: ‘To me, he’s nothing more than a really disgruntled, unhappy person.’ Martelle argues, “Trump’s splenetic reaction is all the encouragement we need to pay close attention to what Bright told Congress, because what the president disparages often is the truth.”

CDC Issues Health Advisory For Physicians On Childhood Illness Linked To COVID-19.

CNN (5/14, Fox, 83.19M) reports the CDC “issued a health advisory to thousands of doctors across the country Thursday, advising them to be on the lookout for a troubling new syndrome that may be associated with Covid-19 infection.” The syndrome, “called multisystem inflammatory syndrome in children (MIS-C), has been seen in children across Europe and in at least 18 states, plus Washington, DC.”

The AP (5/14, Tanner) reports the agency’s case definition “includes current or recent COVID-19 infection or exposure to the virus, a fever of at least 100.4 for at least 24 hours, severe illness requiring hospitalization, inflammatory markers in blood tests, and evidence of problems affecting at least two organs that could include the heart, kidneys, lungs, skin or other nervous system.” The condition “has been reported in at least 110 New York children and in several kids in other states,” and “a few children have died.”

Among other media outlets providing coverage are: the CBS Evening News (5/14, story 4, 2:00, O’Donnell, 5.25M), NBC Nightly News (5/14, lead story, 2:25, 7.88M), Reuters (5/14, Steenhuisen, Chander), Forbes (5/14, Perez, 9.71M), the San Francisco Chronicle (5/14, Serrano, 2.67M), The Hill (5/14, Moreno, 2.98M), and the New York Post (5/14, Lapin, 4.57M)

Maine Governor Allows Out-Of-State Visitors To Reserve Rooms In Lodges, Inns Starting June 1.

The AP (5/14) reports, “Maine lodge operators and innkeepers can begin accepting reservations starting June 1 for Maine residents and out-of-state residents who comply with the state’s 14-day quarantine requirement, officials said Thursday.” The change “represents a loosening of restrictions that originally forbade out-of-state residents from reserving a room with an arrival date before July 1,” Commissioner Heather Johnson of the Department of Economic and Community Development said, “We will continue to work closely with the tourism industry to make progress as we head into the summer.”

North Dakota Has Exceeded 50,000 Coronavirus Tests.

The AP (5/14) reports, “North Dakota has gone over 50,000 in the number of tests for the coronavirus and topped 1,700 for the number of people confirmed to have the disease, health officials said Thursday.” Health
“Officials said 87 people tested positive in the last day, including 57 in Cass County, the state’s most populous county that has seen marked COVID-19 increases in the last several days.” The report “showed no new statewide deaths, leaving the total at 40, and one new hospitalization, increasing that number to 38. More than 1,000 people have recovered from the disease.”

**In Rural America, COVID-19 Breakouts At Prisons Risk Overwhelming Hospitals.**

*Kaiser Health News* (5/14, Dawson) reports that “across rural America, prisons and jails sit in places like Toole County,” Montana “that have minimal intensive care unit beds and ventilators and few additional medical resources” and “many hospitals there were strained before the pandemic.” For Toole County, so far, “the dreaded coronavirus hasn’t yet crept into the site of one of the community’s largest employers, the Crossroads Correctional Center prison.” The center “holds almost 15% of the county’s total population with a 712-bed facility for both federal and state inmates.”

**Governor Baker Says State Public Health Officials Have Expanded COVID-19 Testing Eligibility.**

The *Boston Globe* (5/14, 972K) reports, “Speaking during his daily briefing,” Massachusetts Gov. Charlie Baker said CVS is opening 10 new drive-up COVID-19 “testing sites at store locations in Charlton, Worcester, Raynham, Northhampton, Bridgewater, Carver, West Springfield, Danvers, Westport and Wellesley.” Governor Baker noted that “residents who meet testing criteria can schedule appointments starting Friday at CVS.com.” According to Baker, “state public health officials” have “expanded criteria for testing eligibility to symptomatic people and their close contacts.”

**Bars And Restaurants Remain Closed Under Local Milwaukee County Order.**

The *Milwaukee Journal Sentinel* (5/14, 632K) reports, “Bars and restaurants are still closed, and gatherings of more than nine people are still prohibited, under a local order from 18 municipalities in suburban Milwaukee County and their 10 public health officials.” The local “order, which was released shortly before 1 a.m. Thursday, came after the Wisconsin Supreme Court struck down the statewide stay-at-home order.” Some ‘local officials say the order was ‘effective immediately,’ and will remain in effect until 11:59 p.m. on Thursday, May 21.”

**Virginia Officials Plan To Stop Counting Antibody Tests As COVID-19 Tests In Reports.**

The *Washington Post* (5/14, Schneider, 14.2M) reports, “Virginia officials said Thursday they will no longer include the results of antibody tests in their daily counts of who has been tested for the novel coronavirus, a practice that had been criticized as exaggerating the state’s efforts to control the virus’s spread.” The state’s department of health “said the change does not significantly alter the statistical trends that led Gov. Ralph Northam (D) to move toward easing restrictions for most of the state, beginning Friday.” The department has found that “antibody tests had amounted to less than 9 percent of the state’s overall screening for the coronavirus” and “removing them from the total slightly increases the percentage of positive tests among the overall number of tests given, to 15 percent from 14 percent.”

**As Some States Reopen, Other States Continue To Battle Coronavirus.**
The AP (5/14, Kunzelman) reports, “From a hospital on the edge of the Navajo Nation to the suburbs of the nation’s capital, front-line medical workers in coronavirus hot spots are struggling to keep up with a crushing load of patients while lockdown restrictions are lifting in many other parts of the U.S.” Some “Governors are starting to slowly reopen some segments of their local economies, pointing to evidence that the number of COVID-19 deaths and new hospitalizations are peaking or starting to recede in their states.” Many “state and local officials see modest signs of progress in the pandemic fight,” but “coronavirus outbreaks are testing public health networks in pockets of the U.S.”

New York Governor Adds Provision To State’s Budget To Prevent Some Residents From Suing Nursing Homes Amid Pandemic.

The Hill (5/14, Bowden, 2.98M) reports, “Aides to New York Gov. Andrew Cuomo (D) added a provision to the state’s newly approved budget that prevents residents from suing nursing homes over some allegations of negligence related to the coronavirus outbreak.” The “provision, which some lawmakers contended they did not know was in the final bill until after it passed, prevents basic legal action against long-term care homes over issues such as staffing shortages or insufficient equipment,” the New York Times reported.

Some Small Physician Practices Are Struggling During Pandemic, Unable To Get Coronavirus Relief.

The Washington Post (5/14, Weiner, 14.2M) reports, “Many small doctors’ practices...are struggling to survive as many patients shelter at home and put off consultations for all but the most urgent issues.” And, “although they’re still ministering to patients amid a health crisis,” some have “been unable to get loans under the Paycheck Protection Act, passed as part of the coronavirus relief package in late March.” A survey conducted “by a Richmond-based advocacy group for primary care doctors, called the Larry A. Green Center, found that half the doctors who sought such loans were unsuccessful.”

Pandemic Hits Low-Income Americans Especially Hard, Survey Shows.

Bloomberg (5/14, Tanzi, 4.73M) reports, “The economic pain of the coronavirus pandemic is falling especially hard on lower-income Americans, a new Federal Reserve survey showed, with almost 40% of those making less than $40,000 a year reporting a job loss in March.” The annual report “on the economic wellbeing of U.S. households released Thursday, which mainly focuses on conditions at the end of 2019, was supplemented with a survey conducted in early April as the pandemic caused millions to lose their jobs as businesses shuttered across the nation.” The Fed Chairman Jerome Powell has previously “highlighted the heavy burden being born by Americans with the most meager resources to ride out the lockdown.”

Close To Three Million Americans Applied For Unemployment Last Week.

On its front page, the Wall Street Journal (5/14, A1, Chaney, Guilford, Subscription Publication, 7.57M) reports that nearly three million Americans applied for unemployment benefits last week. The announcement reflects the implications of the coronavirus on the US economy.

The New York Times (5/14, A1, Cohen, Hsu, 18.61M) reports on its front page that “the weekly count of new claims has been declining since late March, but that hopeful flicker barely stands out in an otherwise grim and
chaotic economic landscape.” The Times adds that “in places where the fitful reopening has started, workers called back to their jobs often face reduced hours and paychecks as well as a heightened risk of infection.”

According to the Washington Post (5/14, Romm, 14.2M), “The flood of new claims could further inflame tensions between President Trump and public-health officials over how quickly to try to restart parts of the economy, with Trump on Thursday alleging without evidence that some Democrats are trying to slow the process to hurt him politically.” The Post adds that “many Democrats have said the White House is trying to rush states to reopen without an adequate plan to curtail the further spread of the coronavirus.”

Among other news outlets reporting on the story are ABC World News Tonight (5/14, story 4, 2:10, Muir, 7.42M), the CBS Evening News (5/14, story 5, 2:30, O’Donnell, 5.25M), NBC Nightly News (5/14, story 5, 2:40, Hoit, 7.88M), Bloomberg (5/14, Dmitrieva, 4.73M) and the AP (5/14, Rugaber).


The AP (5/14) reports, “The pandemic will cost the insurance industry over $200 billion, according to Lloyds of London, who estimated that its own payouts are now on a par with the Sept. 11, 2001 attacks or the combined impact of hurricanes Harvey, Maria and Irma in 2017.” In general, “losses could widen if lockdowns continue into the next quarter, which would push the overall cost to the insurance industry to $203 billion. Unlike the storms, for example, the pandemic’s impact is global, systemic and long term.” A study by Lloyds also “assumed social distancing and lockdown measures through 2020, as well as the forecasts for the drop in gross domestic product globally.”

Medical Professionals File Lawsuit Against Michigan Governor Over Lockdown Restrictions.

The Washington Times (5/14, Varney, 492K) reports, “Medical professionals and a patient in Michigan have filed a lawsuit against Democratic Gov. Gretchen Whitmer as the battles grow between her and those favoring some relaxation of the economic shutdown she has imposed in response to the coronavirus crisis.” The suit also “names Michigan’s Attorney General Dana Nessel and Robert Gordon, the state’s Department of Health and Human Services director as defendants.” Michigan’s “population of 9.9 million” has “reported 48,391 confirmed cases of COVID-19, according to the state’s Department of Health and Human Services.”

Transplant Of Brain Cells To A Patient With Parkinson’s Disease Sparks Ethical Questions.

STAT (5/14, Begley, 24K) reports, “A secretive experiment revealed this week, in which neurosurgeons transplanted brain cells into a patient with Parkinson’s disease, made medical history.” The transplant was “the first time such ‘reprogrammed’ cells, produced from stem cells that had been created in the lab from the man’s own skin cells, had been used to try to treat the degenerative brain disease.” However, “it was also a bioethics iceberg, with some issues in plain sight and many more lurking.”

Reopening Spurs Divide Among State Governors, Legislatures.

The New York Times (5/14, 18.61M) reports that the Democratic governors in Wisconsin, Michigan and Pennsylvania, “backed by public health experts, have urged caution before reopening,” but the states’
Republican legislatures “have been pushing in the opposite direction, arguing that the extended restrictions are threatening their personal freedom to go back to work and move around as they wish.”

Connecticut Nursing Home Owner Purchases 400K Masks From Makeshift Supplier.

The Wall Street Journal (5/14, Wirz, Hufford, Subscription Publication, 7.57M) reports that nursing homes are struggling to find masks and other important medical supplies. In one instance, a Connecticut nursing home owner purchased 400,000 masks from a Chinese makeshift supplier, without a prior relationship with the supplier.

New Jersey, Delaware Reopen Beaches For Memorial Day With Restrictions.

The Inquirer (PA) (5/14, McDaniel, Rosenberg, Orso, McCarthy, 347K) reports, “New Jersey beaches can reopen in time for Memorial Day - with social distancing measures in place, Gov. Phil Murphy said Thursday.” The order “offered one of the first rays of light to a region worried about a shut-in summer due to the coronavirus pandemic, but drew mixed reviews from the local officials who Murphy said will be responsible for limiting beach capacity and ensuring compliance with social distancing.” Delaware also “said its beaches would reopen with restrictions before the holiday weekend, though the state police will continue stopping drivers with out-of-state license plates to enforce restrictions on travel into the state.” Forbes (5/14, Perez, 9.71M), Bloomberg (5/14, Young, 4.73M) and the AP (5/14) also report.

Minnesota Malls Begin To Reopen Monday, However, Mall Of America Plans For June 1.

The Minneapolis Star Tribune (5/14, Kumar, 1.04M) reports, “While Gov. Tim Walz has given the green light to Minnesota retailers to reopen as soon as Monday, it will take days or weeks before some of them get back up and running as they call back furloughed employees and establish new safety protocols.” Some malls, like the Galleria, will open Monday, while “other shopping malls in the region were in discussions with their owners and tenants this morning to discuss the timing of reopening plans and increased safety measures.” One mall, the Mall of America, “is among those that will take its time” as “the megamall” noted on “Thursday that it will reopen for shopping on June 1.”


The AP (5/14, Peltz, Mustian) reports, “As calls grow nationwide for mandatory coronavirus testing in nursing homes, New York facilities are sounding alarms about the state’s ambitious new demand to test roughly 185,000 workers twice a week.” Some “administrators worry there won’t be enough kits for an estimated 370,000 tests a week on workers at nursing homes and other adult care facilities, nearly double the total of tests done statewide now on people in all walks of life.” Homes have also “questioned who will cover an expense estimated around $100 to $150 per test, though the state suggested Thursday the homes could send workers to free state testing sites.”

During Contact Tracing Efforts, New York City Mayor Leans On Aide That Previously Argued Against Closures.

The New York Times (5/14, Rashbaum, Goodman, Mays, Goldstein, 18.61M) reports, “The head of New York City’s public hospitals pushed to keep the city open in early March,” and “now Mayor de Blasio has put him in
charge of contact tracing, deepening a rift with the Health Department.” According to the Times, Dr. Mitchell Katz, who leads the city’s public hospitals, wrote in an email in March to the mayor’s aides that “there was ‘no proof that closures will help stop the spread.”” Now, the mayor is relying on Dr. Katz and Health Department officials to navigate contact tracing.

**Trump, EPA Decide Not To Impose Limits On Water Contaminant Linked To Fetal Damage.**

The *New York Times* (5/14, Friedman, 18.61M) reports, “The Trump administration will not impose any limits on perchlorate, a toxic chemical compound that contaminates water and has been linked to fetal and infant brain damage, according to two Environmental Protection Agency staff members familiar with the decision.” The decision was made “by Andrew Wheeler, the administrator of the E.P.A.,” and “appears to defy a court order that required the agency to establish a safe drinking-water standard for the chemical by the end of June.” Perchlorate “—which is used in rocket fuel, among other applications—has been under study for more than a decade, but because contamination is widespread, regulations have been difficult.”

The *Washington Post* (5/14, Dennis, Eilperin, 14.2M) reports, “Under President Barack Obama, the EPA had announced in 2011 that it planned to set the first enforceable limits on perchlorate because of its potential health impacts.” However, “both the Defense Department and military manufacturers have long resisted any restrictions on the chemical, which is also used in fireworks, munitions and other ignition devices.”

The AP (5/14, Knickmeyer) reports “the Environmental Protection Agency proposal to drop any federal regulation of” perchlorate “would translate to lower IQs and other problems for an unknown number of American babies, pediatrician and public health groups say.”

**Wyoming To Relax Restrictions On Bars And Restaurants.**

*Newsweek* (5/14, Roos, 1.53M) reports, “Wyoming, the state that has reported the fewest number of COVID-19 deaths so far, will be reopening its bars, restaurants, gyms and more on Friday with social distancing guidelines in place.” The state’s governor, Mark Gordon, “announced the state’s next phase of reopening during a news conference Wednesday.” Gordon said, “It’s important to remember that, even as we ease restrictions, the virus is not gone.” He added, “It is still here, it is still invisible and it is still capable of wreaking havoc. And it’s going to be with us for some time in Wyoming, just like the rest of the country.”

**Democrats Present Legislation Aimed At Protecting Health Data During COVID-19 Pandemic.**

The *Hill* (5/14, Rodrigo, 2.98M) reports, “Democrats in both chambers introduced legislation Thursday aimed at protecting the privacy and security of health data during the coronavirus pandemic.” The legislation, the Public Health Emergency Privacy Act, “would place strict limits on what and by whom data collected for public health purposes can be used, implement data minimization procedures for that info and require opt-in consent for any efforts.” The act “comes as health agencies and tech companies are developing contact tracing and monitoring tools to contain the pandemic.”

**White House List Of Coronavirus Testing Labs Not Useful, Nine States Say.**

*NPR* (5/14, Greenfieldboyce, 3.12M) reports nine state health departments, in response to a query from NPR, say that the list of labs provided by the White House that could potentially test for coronavirus did not actually
help their states achieve more testing. Also, “six states said that the lists hadn’t even been seen or reviewed – at least as far as the responding official knew.” In fact, “Alabama is the only state where officials told NPR that the list had been reviewed and that it had resulted in increased testing.”

**Testing Project On Tiny Michigan Island Underway.**

The Detroit Free Press (5/14, 1.52M) reports Grosse Ile, Michigan, a tiny island in the Detroit River, is taking part in a COVID-19 testing project, data from which will be used by researchers about “how the virus spread – or didn’t spread – among residents whose only connections to the rest of the state are two bridges, one of which is out of commission until December.”

**AMA Warns Physicians Against Using Coronavirus Antibody Tests To Inform Healthcare Decisions.**

Modern Healthcare (5/14, Subscription Publication, 214K) reports “the American Medical Association is warning doctors against using [antibody] tests designed to identify people already exposed to the coronavirus to make healthcare decisions for individual patients.”

**Virginia Governor Asks Federal Government To Increase Testing At Two Federal Detention Facilities.**

The Richmond (VA) Times-Dispatch (5/14, Times-Dispatch, 277K) reports Virginia “Gov. Ralph Northam on Thursday asked that the federal government perform more screening and testing for COVID-19 at the Farmville and Caroline County detention centers.”

**CVS Plans To Open 1,000 Self-Swab Coronavirus Test Locations By Month’s End.**

Forbes (5/14, Japsen, 9.71M) reports “CVS Health is escalating its cross-country effort to expand testing for the Coronavirus strain COVID-19 with plans to open 1,000 locations by the end of the month.”

**US Said To Be Making Progress In Coronavirus Testing Numbers.**

Vox (5/14, 2.27M) says that “after an April that some experts described as ‘wasted,’ it looks like America is finally making some real progress on coronavirus testing in May.” Over the last few “weeks, the United States has seen significant improvements not just with the raw number of Covid-19 tests but also with other metrics experts use to gauge the scope of the US’s coronavirus outbreak and its testing capacity.” Specifically, “during the week of May 5, the US averaged nearly 300,000 new coronavirus tests a day, according to the Covid Tracking Project,” nearly double the approximately “150,000 daily tests performed in early April, although it still falls short of the number of new tests a day experts say is needed to fully control the outbreak.”

**Abbott Lab’s ID Now COVID-19 Misses Up To Half Of Cases Found By Another Test, Study Suggests.**

Modern Healthcare (5/14, Subscription Publication, 214K) reports “a study has found that Abbott Lab’s ID Now COVID-19 test missed as many as half of the cases found to be positive by another test.” Investigators “found that while initially the ID Now COVID-19 assay performed well, as the viral load decreased, the Abbott test produced more false negatives.” The findings were published in Bioxriv.
The Portland (ME) Press Herald (5/14, 244K) also reports.

**Bill Gates-Funded Program That Provides At-Home Coronavirus Test Kits Put On Hold Until Federal Approval Is Granted.**

CBS News (5/13, 3.63M) reports that “Bill Gates is funding a new program to provide at-home coronavirus testing kits to residents in the Seattle area. The initiative aims to help researchers better understand how COVID-19 spreads through communities.” However, “after an initial rollout that Gates said was testing about 300 people a day, the program has been put on ‘pause’ while it awaits federal approval.”

**Pandemic Reportedly Reveals Vulnerabilities In American Business Model For Hospitals.**

The New York Times (5/15, Kliff, 18.61M) reports that “the American health care system for years has provided many hospitals with a clear playbook for turning a profit: Provide surgeries, scans and other well-reimbursed services to privately insured patients, whose plans pay higher prices than public programs like Medicare and Medicaid.” The coronavirus pandemic “has shown the vulnerabilities of this business model, with procedures canceled, tests postponed and millions of newly unemployed Americans expected to lose the health coverage they received at work.” The disruption to medical facilities’ “operations may ultimately leave Americans with less access to medical care, according to financial analysts, health economists and policy experts.”

**Biogen Blocks Creative Biolabs From Selling Products That Allegedly Used Antibody From Its Experimental Alzheimer’s Drug.**

Bloomberg Law (5/14, Decker, Subscription Publication, 4K) reports New York-based Creative Biolabs has agreed to stop selling products that are allegedly “knock-offs of antibodies used in Biogen’s experimental Alzheimer’s drug...according to a court filing.” Creative Biolabs has also agreed “to halt infringing patents Biogen controls, no longer use Biogen’s trademarks to promote products, and destroy any inventory that did so, under the terms of the consent decree posted with the federal court in Boston.” According to Bloomberg, “Biogen has said it plans to seek U.S. Food and Drug Administration approval for a drug using the antibody aducanumab for treatment of early Alzheimer’s.”

**Opinion: New Hampshire Tobacco 21 Policy Will Reduce Chances Of Lifelong Nicotine Addiction, Protect Developing Brains.**

In the New Hampshire Union Leader (5/15, 109K), Dr. Seth Emont, who manages the Tobacco Cessation Program at Cheshire Medical Center, writes that there are “a number of reasons” that a New Hampshire Tobacco 21 policy is “a good idea.” Emont argues that such a policy “will help reduce the chances of lifelong nicotine addiction.” and help to “protect developing brains.”

**Global Health News**

Reuters reports China’s foreign ministry has called U.S. claims that hackers linked to the country are "breaking into U.S. COVID-19 research" slanderous. Spokesman Zhao Lijian said "any action online to sabotage efforts against the disease should be condemned."

**Health Groups Ask India To Rescind Gilead’s Patents For COVID-19 Drug Remdesivir.**

*Reuters* (5/14, Siddiqui) reports, "Two health advocacy groups have written to the Indian government asking it to rescind patents given to Gilead Sciences for the drug remdesivir so it can be distributed more fairly to coronavirus patients around the world, particularly in poorer nations." The health groups argue Gilead’s recent licensing and distribution pacts for remdesivir “mean cheaper forms of the drug may not become available in nations seen as non-profitable to the five drugmakers.” K. Gopakumar, senior legal researcher at Third World Network, said, “The licenses divide the global market into two and profitable markets are retained with Gilead and less profitable markets are given to the five generic companies.”

**Russia’s ChemRar Testing Favipiravir In Second-, Third-phase Testing As Potential COVID-19 Treatment.**

*Reuters* (5/14, Marrow, Stolyarov, Golubkova) reports Russian company ChemRar, which is conducting trials of a potential COVID-19 treatment, “said on Thursday it was testing it on infected patients in what it called second- and third-phase clinical trials based on World Health Organisation (WHO) criteria.” Reuters adds, “The drug, favipiravir, which was first developed in Japan under the name Avigan, secured 150 million roubles ($2 million) in funding from the Russian Direct Investment Fund.”

**Chinese Automaker Backed By Buffett Fails To Gain US Approval For Their Masks.**

*Bloomberg* (5/14, 4.73M) reports, “China’s BYD Co., the carmaker backed by Warren Buffett’s Berkshire Hathaway Inc., was denied a U.S. regulatory certification it needs to sell respirator masks to the state of California.” The agency, the National Institute for Occupational Safety and Health, did not “approve BYD’s masks for a number of factors, according to an emailed statement that doesn’t disclose details for confidentiality reasons.” BYD was notified “on May 4 that a contractor’s assessment of two BYD factories in China found them to be not acceptable.”

**Total Number Of Coronavirus Cases Globally Approaches 4.4M.**

The *Wall Street Journal* (5/14, Hua, Calfas, Subscription Publication, 7.57M) reports the number of coronavirus cases worldwide, according to data compiled by Johns Hopkins University, approached nearly 4.4 million, with nearly 300,000 deaths. Of the total number of cases, close to one third is in the US.

*Forbes* (5/14, Porterfield, 9.71M) also reports.

**European Governments Hoping Antibody Tests Will Help Inform Strategies To Avoid Second Wave Of Infections.**

*Reuters* (5/14, Miller) reports many governments in Europe “are scrambling to buy antibody tests to find out how many of their citizens were infected” with coronavirus, “in the hope that will help them craft strategies to avoid a second wave of COVID-19 cases.” However, “exactly how – or even if – the information will be of use remains unclear, raising the risk that public funds and government time are being wasted.”
European Commission Suspends Delivery Of 10M Chinese Masks Due To Quality Concerns.
The AP (5/14) reports “the European Commission said Thursday it has suspended the delivery of 10 million Chinese masks to member states and Britain after two countries complained about the poor quality of the batches they received.”

Dental Practices In France Begin Cautiously Re-Opening.
The AP (5/14) reports dental practices in France “are cautiously reopening and accepting appointments after the French government eased restrictions on some businesses, services and public activity.”

Italy To Start Testing Campaign Across 2,000 Cities To Understand Extent Of Outbreak.
The Reuters (5/14, Amante) reports “Italy will start testing a representative sample of 150,000 people in 2,000 cities next week to understand the extent of its COVID-19 epidemic, the head of the government’s scientific committee told parliament on Thursday.”

France’s Coronavirus Death Toll Surpasses Spain’s Again.
The Reuters (5/14) reports “France’s cumulative coronavirus death toll edged over Spain’s again as France reported on Thursday the number of people who died of COVID-19 in the past 24 hours increased by 351 or 1.3% to 27,425.”

The Reuters (5/14, Goh) reports “residents in Wuhan braved pouring rain in queues of more than an hour to take part in a government-led exercise to test the city’s 11 million people for the novel coronavirus, a scale health experts describe as unprecedented.”

The New York Times (5/14, Wee, Wang, 18.61M) reports that “the testing drive, which is likely to require the mobilization of thousands of medical and other workers, shows the ruling Communist Party’s resolve to prevent a second wave of infections as it tries to restart China’s economy.” However, “such comprehensive testing poses challenges,” and it remains unclear “how Wuhan will procure enough testing kits and process all the samples, and whether such a broad, systematic approach is the best use of resources when the city’s infections are low.”

Prime Minister Abe Lifts State Of Emergency Through Most Of Japan.
The Wall Street Journal (5/14, Landers, Subscription Publication, 7.57M) reports Japanese Prime Minister Shinzo Abe lifted a state of emergency in most of the country outside of Tokyo and attributed voluntary restrictions for a sharp decrease in the number of new coronavirus infections.

UNICEF Chief Warns Lockdowns Could Cause More Harm Than Actual Virus In Low-, Middle-Income Countries.
The Hill (5/14, Klar, 2.98M) reports “the chief of health at the United Nations International Children’s Emergency Fund (UNICEF) is warning that lockdowns meant to mitigate the spread of the coronavirus could cause more harm than the virus itself in ‘low- and middle-income countries.’”

The Washington Post (5/14, Sly, 14.2M) also reports.

The Hill (5/14, Concha, 2.98M) reports “Russian Foreign Ministry spokeswoman Maria Zakharova is criticizing news outlets for printing ‘disinformation’ after The New York Times and Financial Times reported that the country’s COVID-19 death toll could be considerably higher than what the Kremlin is reporting.”

The AP (5/14) also reports.

Asian Countries, After Stopping Initial Outbreak, See Second Wave Of Cases.

Bloomberg (5/14, 4.73M) reports that “after containing their outbreaks through measures from strict lockdowns to rapid testing regimes...Asian economies that have seen some of the most success quelling the coronavirus – Hong Kong, South Korea and China – are now facing resurgences that underscore how it may be nearly impossible to eradicate it.”

China Attempted To Dissuade New Zealand From Imposing Strict Coronavirus Restrictions.

Newsweek (5/14, 1.53M) reports “China tried to dissuade the New Zealand government from imposing its tough restrictions to mitigate the coronavirus, believing them to be an ‘overreaction,’ New Zealand Minister of Foreign Affairs Winston Peters has said.”

Canada’s Prime Minister Says World Has Changed Even If Pandemic Ends Or Vaccine Is Found.

Reuters (5/14) reports “Canadians should accept the world will change even if a vaccine is found and the coronavirus pandemic ends, Canadian Prime Minister Justin Trudeau said on Thursday, urging people to adjust to a new normal that will require modified behaviour.”

EU’s Foreign Policy Chief Calls For Independent Investigation Into Pandemic’s Origins.

Reuters (5/14) reports “the European Union’s foreign policy chief [Josep Borrell] called on China on Thursday to contribute significantly to the fight against the coronavirus pandemic and said there should be an independent scientific investigation into the origins of the pandemic.”

IOC President Will Not “Fuel Any Speculation” That Tokyo Olympics Might Not Be Held Next Year.

USA Today (5/14, Schad, 10.31M) reports “International Olympic Committee president Thomas Bach said Thursday that he would not ‘fuel any speculation’ that the Tokyo Olympics might not be held in 2021.”

IOC Sets Aside $800M For Loans Related To Postponing Tokyo Olympics. The AP (5/14) reports “the IOC set aside $800 million on Thursday for loans and payments arising from the pandemic that forced the 2020 Tokyo Olympics to be postponed.” It remains “unclear how big the total postponement bill will be with Olympic organizers and public authorities in Japan facing extra costs estimated to run into billions of dollars.”

South Africa To Assign Specific Coronavirus Restrictions For Each Of Its Districts.
Reuters (5/14) reports “South Africa will assign levels of lockdown restrictions for each of the country’s roughly 50 districts, depending on the number of active coronavirus infections there, Health Minister Zweli Mkhize said on Thursday.”

Surge In Number Of People In Yemen Dying With COVID-19 Symptoms.

The Washington Post (5/14, Raghavan, 14.2M) reports “the number of people dying with covid-19 symptoms has dramatically spiked in war-riven Yemen, triggering fears that coronavirus infections are considerably higher than official figures, the Save the Children charity said Thursday.”

Increasing Number Of Physicians In Russia Dying From Pandemic.

The New York Times (5/14, Troianovski, 18.61M) reports an increasing number of physicians in Russia on the front lines of the pandemic are dying, a situation made worse by a general lack of access by healthcare professionals to personal protective gear.

UK Government In Talks With Roche To Buy COVID-19 Antibody Tests.

Reuters (5/14, Faulconbridge, Holton) reports that following its approval by Public Health England, the UK government “is in talks with Swiss drugmaker Roche Holding AG to buy an accurate COVID-19 antibody test, following the lead of the European Union and United States, which had already given preliminary approval to the tests.”

Reuters (5/13, Faulconbridge, Holton) and CNN (5/14, Ramsay, Isaac, 83.16M) provide additional coverage of the original approval.

HHS in the News

Trump Administration Reportedly Mulling Indefinite Border Restrictions Amid COVID-19 Outbreak.

The Hill (5/14, Wise, 2.98M) says, “The Trump administration is reportedly working to unveil a new order that would indefinitely extend border restrictions amid the coronavirus outbreak, according to a report in The New York Times.” This “move, which is reportedly currently being reviewed by several government agencies, would keep legal points of entry shuttered and restrict nonessential travel through Mexico and Canada until the director of the Centers for Disease Prevention and Control (CDC) concluded that the coronavirus no longer posed a threat to public health, the Times reported citing officials and a draft of the public health order.” Officials from the CDC “would continue to assess the threats posed by the virus every 30 days and the new plan would give Robert Redfield, director of the CDC, authority over when the U.S. borders are safe to reopen.”

The Daily Caller (5/14, Hopkins, 716K) and National Review (5/14, Evans, 731K) also cover the story.

Gottlieb Suggests Schools Should Attempt In-Person Education This Fall When Possible.

CNBC (5/14, Stankiewicz, 3.62M) reports former FDA Commissioner Scott Gottlieb on CNBC’s “Squawk Box” said that US schools should be willing to attempt in-person education this fall if the coronavirus pandemic “isn’t rampant.” Gottlieb said, “I do think we’re going to have to contend with Covid going into the fall, but it might not be in September,” adding, “It might occur later into the fall, and we should at least make an attempt to open the
schools if this isn’t spreading widely.” However, he “stressed that decisions on welcoming students back to classrooms will have to be made locally, depending on the scale of Covid-19 outbreaks in states and communities.”

The Hill (5/14, Klar, 2.98M) also reports.


Former CDC Director Tom Frieden writes in the Washington Post (5/14, 14.2M) that the concept of the “five stages of grief” simplifies “a complex process” of “core truths: People tend to accept harsh realities gradually and with difficulty.” However, “recognition of the pandemic’s impact, and widespread embrace of the final stage, acceptance, could speed our collective path to new, post-pandemic normal.” While the pandemic “has upended lives around the world” and the world is collectively “acknowledging, and grieving, these losses and the life rituals…disrupted by the pandemic,” the sooner “people come to terms with the reality of the pandemic, the quicker we can prepare for lasting changes to the ways we can work, learn, relax, govern ourselves and even treat one another.”

Mask Manufacturer Executive Testifies About How Government Allegedly Ignored His Previous Warnings Of Insufficient Mask Production.

CNN (5/14, Kelly, Watts, Gloria, 83.16M) reports “an executive for a US mask producer bemoaned, in heated and emotional testimony Thursday to Congress, how his warnings of insufficient domestic medical mask production had been ignored by the federal government for years until the coronavirus pandemic.” While “speaking before the House Energy and Commerce Committee, Mike Bowen, the vice president of the Texas-based medical supply company Prestige Ameritech, said the US dependence on foreign masks has been a national security issue for years.” According to CNN, “Bowen described conversations over the past 13 years in which he had offered manufacturing deals to the” CDC “that included ‘mak(ing) sure that the Department of Defense and the Veterans Administration always has masks,’ adding that ‘I couldn’t get anybody interested in it.’”

White House To Require Some Essential Drugs To Be Manufactured In US, Sources Say.

The Hill (5/14, Moreno, 2.98M) reports “the White House is preparing to require that some essential drugs be made in the U.S. as the Trump administration tries to limit dependency on China for medical supplies, sources told CNBC.” Earlier in the year, White House trade advisor Peter Navarro “proposed a similar executive order.” Navarro’s order “would streamline regulatory approvals for ‘American-made’ drugs and impose similar Food and Drug Administration (FDA) restrictions on U.S. production facilities as those abroad.” The order “will also encourage government agencies to only buy American-made medical products.” Still, “it is unclear if the executive order the unnamed sources referred to is the same as Navarro’s.”

Bloomberg (5/14, Stein, Capaccio, 4.73M) also reports on the story.

Gottlieb Says He Sees Signs That The Coronavirus Epidemic Is Slowing In US.

Intelligencer (NY) (5/14, Raymond, 1.1M) reports that “as states across the country begin to reopen their economies, the United States is ‘seeing signs of a slowing epidemic,’ former FDA commissioner Scott Gottlieb told a House subcommittee Wednesday.” The piece says “Gottlieb told lawmakers that even as testing for the
coronavirus is becoming more available, the rate of positive tests is going down. 'There are hopeful signs,' he said.

Coronavirus Can Cause Strokes In Young People, Physicians Say.
The New York Times (5/14, Rabin, 18.61M) reports coronavirus infection can cause strokes in young people, something which is very rare. The Times highlights the case of Ravi Sharma, a healthy 27-year-old EMT who had a stroke after becoming infected with coronavirus, and says physicians around the US have reported similar cases.

Senators Ask CDC To Examine Risk Of Strokes In Younger, Middle-Aged Patients With COVID-19. The Hill (5/14, Budryk, 2.98M) reports “Sens. Amy Klobuchar (D-Minn.) and Marco Rubio (R-Fla.) are asking the Centers for Disease Control and Prevention (CDC) to assess the risk of strokes in younger and middle-aged coronavirus patients.” The senators wrote to CDC Director Dr. Robert Redfield, “We believe it is critical that the CDC evaluate the prevalence of stroke in COVID-19 patients, including the potential link to stroke from the development of blood clots caused by the virus.”

Online Pharmacy HealthWarehouse Saw Spike In Demand For Hydroxychloroquine In Mid-March.
NPR (5/14, Horn, 3.12M) reports that, “in mid-March, when the unproven idea of giving coronavirus patients antimalarial drugs emerged on social media and on Fox News, the online pharmacy HealthWarehouse said orders for hydroxychloroquine started to spike.” The FDA “has since put out a warning against using it for COVID-19.”

Survivors Of COVID-19 Pandemic In Nursing Homes Remain In Isolation.
ABC News (5/15, Mosk, Freger, Romero, Pecorin, 2.97M) reports on “one of the unexpected consequences of COVID-19 in nursing homes: the extended isolation of those who have survived.” The majority, “if not all of the 15,000 nursing facilities around the country have prohibited outside visitors since early March – federal regulators announced measures directing nursing homes to ‘significantly restrict visitors and nonessential personnel’ on March 13.” Still, “even with nursing home residents largely cordoned off, the virus has moved effortlessly through many facilities, most likely carried by staff members who were infected but asymptomatic.”

On Thursday, CMS Administrator Seema Verma said in an interview, “We want to make sure that whatever we do, that we are putting the health and safety of the nursing home residents at the top. ... That’s the most important priority. So we’re starting to have those discussions about how we can make sure that nursing homes are safe and that visitors can come back in a safe way.”

Former BARDA Director Says Trump Official Tried To Fast-Track Funding For His Friend’s Unproven COVID-19 “Treatment.”
ProPublica (5/14, Song, 60K) reports former Biomedical Advanced Research and Development Authority Director “Rick Bright says that his Trump-appointed boss tried to fast-track funding for a friend’s coronavirus treatment, and that he was reassigned for insisting that funding be reserved for ‘safe and scientifically vetted solutions.’” A copy of his scheduled testimony, released Wednesday, “spoke generally of how officials at the Department of Health and Human Services...dismissed his early warnings to act quickly against the virus.”
Thousands Volunteer To Be Exposed To Novel Coronavirus In Human Classified Trial Led By 1Day Sooner.

Fox News (5/14, Hein, 27.59M) reports, “More than 20,000 people have signed up to voluntarily be exposed to the novel coronavirus in a yet-to-be formulated ‘human classified trial,’” which is “being led by a group called 1Day Sooner.” According to Fox News, “Human challenge trials for coronavirus have the support of 35 members of the House of Representatives who wrote to the Food and Drug Administration and the Department of Health and Human Services arguing that they should be allowed.”

Former BARDA Head Tells Congress Coronavirus Vaccine Won’t Be Ready In 12 To 18 Months.

CNBC (5/14, Feuer, 3.62M) reports that a coronavirus vaccine “won’t be ready for distribution in 12 to 18 months as White House officials have assured the public, ousted federal vaccine scientist Dr. Rick Bright told Congress Thursday.” Bright told members of the House Energy and Commerce Subcommittee on Health, “A lot of optimism is swirling around a 12-to-18 month timeframe if everything goes perfectly. We’ve never seen everything go perfectly.”

CQ Roll Call (5/14, Kopp, 154K) reports Bright, “who oversaw vaccine development in his BARDA role, warned that the distribution of an eventual vaccine could be delayed by the same supply chain issues that led to mass shortages of personal protective equipment.” Bright said: “If you can imagine a scenario, this fall or this winter or early next spring, when a vaccine becomes available … there’s no one company that can produce enough for the country or for the world. There are going to be limited supplies.”

Among other media outlets providing coverage are: U.S. News & World Report (5/14, Hagen, 2.4M), The Hill (5/14, Budryk, 2.98M), the Washington Examiner (5/14, Morrison, 446K), and the Financial Times (5/14, Stacey, Subscription Publication, 1.34M).

Former BARDA Director Says Administration Ignored Warnings Of Supply Shortages.

The New York Times (5/14, Stolberg, 18.61M) reports the whistleblower “who was ousted as the head of a federal medical research agency charged on Thursday that top Trump administration officials failed to heed his early warnings to stock up on masks and other supplies to combat the coronavirus, and that Americans died as a result.” Dr. Rick Bright, “who was removed in April as the director of the Department of Health and Human Services’s Biomedical Advanced Research and Development Authority, told a House subcommittee: ‘Lives were endangered, and I believe lives were lost.’”

The Hill (5/14, Weixel, 2.98M) reports Bright “told House lawmakers on the Energy and Commerce Health Subcommittee that he began to get alerts from manufacturers that the supply chain for masks and other personal protective equipment was ‘diminishing rapidly’ as early as January.” He “said he warned his superiors about severe shortages of N95 respirators needed for front-line health care workers.”

CBS’ 60 Minutes (5/14, Zubrow, 11.55M) and Axios (5/14, Fernandez, 521K) also report.

White House Press Secretary, Senior Trump Adviser Dismiss Ousted HHS Official’s Claims.

Fox News (5/14, Nelson, 27.59M) reports White House Press Secretary Kayleigh McEnany on Thursday “reacted to ousted Trump administration scientist Rick Bright’s claim that the president was ‘dismissive’ of a warning about
the severity of the coronavirus outbreak.” Bright, the former HHS official who filed a whistleblower complaint claiming he was removed from his post for disagreeing with the Trump administration’s response to coronavirus, said Thursday that officials at the Department of Health and Human Services were ‘dispmissive’ of his warning about the contagion and said that if the government doesn’t follow his guidance ‘2020 will be the darkest winter in modern history.’” McEnany told America’s Newsroom: “It sounds like Mr. Bright hasn’t really been paying that much attention at all.”

The Daily Caller (5/14, Davis, 716K) reports Trump adviser Peter Navarro also “tore into Dr. Rick Bright during a Fox News appearance Thursday after Bright testified on Capitol Hill.” Navarro said: “I find it highly ironic that you’ve got Bright up there on Capitol Hill issuing these dire warnings on the very day President Trump is going to the beautiful Lehigh Valley to announce a tougher, smarter, more resilient strategic national stockpile.”

Among other media outlets reporting are: Fox News (5/14, Kaplan, 27.59M), the Washington Examiner (5/14, Soellner, 448K), the Washington Examiner (5/14, Colton, 448K), in a separate article, and the Daily Caller (5/14, Caruso, 716K).

HHS Whistleblower’s Attorneys Say Watchdog Finds “Substantial Likelihood Of Wrongdoing.”

CNBC (5/14, Mangan, 3.62M) reports that a government watchdog “has found a ‘substantial likelihood of wrongdoing’ in the removal of a vaccine specialist from leading a federal agency handling coronavirus response, his lawyers disclosed Thursday.” The preliminary finding “from the Office of the Special Counsel, which is investigating Rick Bright’s whistleblower complaint, was disclosed just before Bright began testifying before a House panel.”

FDA Authorizes Human Trials For AIM ImmunoTech’s Drug To Treat COVID-19 In Patients With Cancer.

The Ocala (FL) Star-Banner (5/14, Medina, 81K) reports the U.S. FDA “recently authorized human trials for a drug made by a Marion County-based” AIM ImmunoTech’s drug Ampligen “to possibly treat COVID-19 patients who have cancer.” The trial “will be conducted by Roswell Park Comprehensive Cancer Center in Buffalo, New York.”

Opinion: Following Science Is Best Path For Our Leaders To Avoid “Darkest Winter.”

In an article for Forbes (5/14, 9.71M), contributor Seth Cohen writes that Dr. Richard Bright, “the former director of the nation’s Biomedical Advanced Research and Development Authority painted a perilous picture of the trajectory of the coronavirus pandemic – unless leadership of the country undertakes a much more science-focused approach. Yet what is most unsettling about Bright’s testimony before the House Committee on Energy and Commerce is his belief that, absent a course correction by the nation’s leaders, America may face it’s ‘darkest winter in modern history’ later this year.” Cohen argues, “Following science, not fomenting doubt and fear, is the best path for our leaders to follow if we are to avoid, in Dr. Bright’s words, our nation’s darkest winter. Here’s hoping they see the light before its too late.”

CDC Issues Six Brief Checklists To Guide Businesses, Schools, Others On Reopening.
The Washington Post (5/14, A1, Bernstein, Wan, Dawsey, Weiner, 14.2M) reports, "With hundreds of millions of people still seeking advice on resuming their lives safely, the Centers for Disease Control and Prevention issued a scant six pages of recommendations Thursday to guide schools, businesses, day-care facilities and others into the next phase of the coronavirus pandemic." The six "checklists – which also address restaurants, mass transit and camps – come days, and in some cases weeks, after many states have begun to lift restrictions on their own." The advice "is less detailed than draft recommendations the agency sent to the White House for review last month."

The AP (5/14, Stobbe, Dearen) reports the CDC "posted six one-page 'decision tool' documents that use traffic signs and other graphics to tell organizations what they should consider before reopening." The agency "drafted the reopening guidance more than a month ago and it was initially shelved by the administration, the AP reported last week." The CDC "also had prepared even more extensive guidance – about 57 pages of it – that has not been posted."

CBS News (5/15, 3.68M) reports "the published memo on child care facilities completely removes from the draft guidance a warning to, 'be ready to close if there are increased cases.' According to CBS, 'CDC Director Robert Redfield said that the draft guidance had been 'shared prematurely' and 'had not been vetted through the interagency review process.'"

Among other media outlets providing coverage are: the CBS Evening News (5/14, story 3, 0:25, O'Donnell, 5.25M), NBC Nightly News (5/14, story 4, 0:25, Holt, 7.88M), ABC World News Tonight (5/14, story 3, 2:20, Muir, 7.42M), the New York Times (5/15, Bogel-Burroughs, 18.61M), Bloomberg (5/14, Jacobs, Court, Sink, 4.73M), ABC News (5/14, Flaherty, Gittleson, Cathey, 2.97M), Reuters (5/14, Steenhuysen), CNN (5/14, Fox, 83.16M), NPR (5/14, Hagemann, 3.12M), The Hill (5/14, Sullivan, 2.98M), Politico (5/14, Roubein, 4.29M), and Axios (5/14, Rummell, 521K).

Former BARDA Chief Will Start At New Job Next Week, Attorneys Say.

CNN (5/14, Collins, Tapper, 83.16M) reports Dr. Rick Bright, who filed a whistleblower complaint after being removed from his role as the leader of the Biomedical Advanced Research and Development Authority (BARDA), "will start his new job in a role inside the federal government's coronavirus response next week, his attorneys said Thursday." A Department of Health and Human Services source "told CNN that Bright has been offered the job of second-in-command of the Accelerating Covid-19 Therapeutic Interventions and Vaccines partnership." Bright's lawyers "said in a Thursday evening news release that he plans to report to that job next week now that it has been identified."

Texas Paid $45 Million For COVID-19 Tests.

The Austin (TX) American Statesman (5/13, Price, Subscription Publication, 343K) reported, "In a glimpse into the cost of coronavirus testing, the state of Texas is paying $45 million for 300,000 oral-swab tests – or $150 per test, according to a purchase order obtained by the American-Statesman through an open records request." The cost "for healthcare providers and laboratories to test patients for COVID-19, according to the Medicare bulletin, was $35.92 for the tests developed by the U.S. Centers for Disease Control and Prevention and $51.33 for all other commercial tests." The piece said "officials at the U.S. Centers for Medicare and Medicaid Services" said "that they would pay $100 for COVID-19 tests that increase testing capacity and lead to faster results" in April.

The Chicago Tribune (5/14, Bowen, 2.65M) reports, “Nationally, the Centers for Disease Control and Prevention reported about 9,000 cases of COVID-19 among health care personnel, a wide designation that includes pharmacists, laboratory workers, security guards and clerical staff.” Of this group, “90% were not hospitalized, and 27 people died.” However, these data are likely underestimates, “according to a CDC spokeswoman.”

Rural Hospitals Need Access To Telehealth To Battle Coronavirus Pandemic, Experts Say.

Healthcare IT News (5/14, Jercich, 2K) reports that rural hospital leaders said during a webinar Thursday that “COVID-19 has magnified the need for access to telehealth — and that it’s a mistake to rely on one-size, fits-all solutions for virtual care.” In a report that was made available “by the Bipartisan Policy Center in advance of the webinar noted that the steps taken to make services more accessible amid the coronavirus pandemic could be made permanent in order to improve rural healthcare access.” One part of the report highlighted government support, and said, “In March 2020, as coronavirus evolved into a pandemic, Congress voted to temporarily waive telehealth requirements for Medicare providers, allowing the Centers for Medicare and Medicaid Services, or CMS, to reimburse clinicians for telehealth visits with patients at home in an area with a designated emergency.”

Trump Announces Plan To “Replenish And Modernize” Strategic National Stockpile.

The Washington Post (5/14, Goldstein, 14.2M) reports “President Trump announced Thursday a plan to reconfigure the government’s chronically undersupplied stockpile of emergency gear to help combat the coronavirus pandemic, accelerating manufacturing and broadening the array of supplies it houses.” Trump “said his administration is launching what he termed a ‘groundbreaking initiative’ to ‘replenish and modernize’ the government’s stores of masks, ventilators and other essential pandemic-fighting medical equipment to create a 90-day reserve.” While saying “with his ‘America first’ mantra, Trump and his aides said the manufacturing would be carried out by U.S. companies, diminishing the reliance on foreign factories that have been the stockpile’s major sources.”

The Wall Street Journal (5/14, Ballhaus, Levy, Subscription Publication, 7.57M) reports that when the novel coronavirus first started to spread within the US, the Strategic National Stockpile only had one to three weeks of the majority of equipment and did not include many supplies that have been critical while battling the current pandemic.

The AP (5/14, Colvin, Superville) reports Trump said while visiting a medical equipment distributor in Pennsylvania, “Wouldn’t that be nice? ... My goal is to produce everything America needs for ourselves and then export to the world, including medicines.” The President “had complained about supply chains in a television interview that aired before he left Washington for the trip to Owens and Minor Inc. in Allentown.”

Reuters (5/14, Alper) reports “the Trump administration is seeking to add 300 million N95 masks, the respiratory protective devices that are key to protecting medical workers fighting the deadly coronavirus, to the U.S. stockpile by the fall, a senior administration official said on Thursday.” While “speaking to reporters during a telephone briefing, the official said the administration hopes ultimately to replenish its strategic national stockpile, which had only 13 million N95s at the beginning of the outbreak, to 1 billion in total.”
CBS News (5/14, Watson, 3.68M) reports Trump “blames the Obama administration for the shortfall” of the stockpile. Trump said, “Under the previous administration the stockpile was depleted and never fully refilled. ... My administration is taking action to modernize the stockpiles during this crisis.”

Politico (5/14, Lim, 4.29M) reports one senior Administration official said, “Of all the items that a Covid patient in a hospital consumed during a length of stay, we only carried 28 percent of those… We did not carry a lot of critical care drugs, we did not carry testing supplies. These were never in the Strategic National Stockpile. They will be in the Strategic National Stockpile going forward.” Retooling the stockpile “toward pandemic needs could be an important step if a second wave of infections emerges this fall, as many public health experts predict.”

Among other news outlets reporting on the story are a video in the Washington Post (5/14, 14.2M), Bloomberg (5/14, Parker, Sink, Fabian, 4.73M), CNBC (5/14, Macias, 3.62M), Fox News (5/14, O'Reilly, 27.59M), Fox Business (5/14, Manfredi, 1.73M), the Washington Examiner (5/14, Crilly, 448K), the Washington Times (5/14, Boyer, 492K), Newsweek (5/14, Crisp, 1.53M), CQ Roll Call (5/14, Marquette, 154K), Modern Healthcare (5/14, Brady, Subscription Publication, 214K), and the Daily Caller (5/14, Datoc, 716K).

Former BARDA Chief Warns Trump Administration Still Has No National Plan For Pandemic.

The Wall Street Journal (5/14, Armour, Grimaldi, Subscription Publication, 7.57M) reports that Dr. Rick Bright, who was removed as head of the Biomedical Advanced Research and Development Authority (BARDA) and subsequently filed a whistleblower complaint, told a House committee on Thursday that the Trump Administration still has no broad national strategy to address the coronavirus pandemic.

The AP (5/14, Alonso) reports that, “despite White House claims, the U.S. still lacks a comprehensive battle plan against the coronavirus in critical areas including masks, testing, treatments and vaccines,” Bright “told the House Energy and Commerce Committee.” Bright told lawmakers: “There are critical steps that we need to do to prepare ... we do not still have enough personal protective equipment to manage our health care workers ... we still do not have the supply chains ramped up for the drugs and vaccines, and we still don’t have plans in place for how we distribute those drugs and vaccines. We still do not have a comprehensive testing strategy.”

Reuters (5/14, Wolfe) reports Bright “said he was ousted from BARDA because he resisted efforts to push the drugs hydroxychloroquine and the related chloroquine as cures for COVID-19, the respiratory illness caused by the coronavirus.” HHS spokeswoman Caitlin Oakley “has disputed Bright’s account, saying in a statement on Tuesday that he was transferred to a job where he was entrusted to spend around $1 billion to develop diagnostic testing.”


FDA Examining Data Showing Abbott's COVID-19 TestDelivers Inaccurate Results.
Bloomberg (5/15, Sutherland, Armstrong, 4.73M) reports an Abbott Laboratories COVID-19 test has “potential accuracy issues, the U.S. Food and Drug Administration warned, citing a number of studies that have raised doubts about the product’s ability to quickly diagnose patients.” The FDA issued a “public alert Thursday evening, saying that it had become aware of several scientific studies that had raised questions about the device, a printer-sized machine called ID NOW that can take a sample from a nasal swab and diagnose a coronavirus infection.” The agency said “that it was particularly concerned about false-negative results, in which an infected person is told by the test that they don’t have the disease.” The FDA “said that the Abbott test, which has been used at the White House, can still be used to diagnose positive results, often within minutes.” But it “warned that a negative result might need to be confirmed with a different test to be certain the person doesn’t have the virus.”

Axios (5/14, Rumlmer, 521K) reports the tests are widely used, and that the US has “deployed over 235,000 tests to public health laboratories in every state across the U.S., Assistant Secretary of Health Adm. Brett Gircir said on Monday.”

The AP (5/14, Perrone) reports the FDA “said late Thursday it is investigating preliminary data suggesting Abbott Laboratories’ 15-minute test can miss COVID-19 cases, falsely clearing patients of infection.” The warning came “one day after researchers at New York University reported results suggesting Abbott’s test can miss up to half the infections caught by a rival test mace by Cepheid.” The FDA “said in a statement it is reviewing the data with Abbott and working on a letter to health care providers about potential accuracy issues.” The agency “said physicians may need to confirm the results of a negative Abbott test if patients have signs and symptoms of the virus,” and regulators said they are “requiring Abbott to conduct follow-up studies on the test’s accuracy.” FDA Diagnostics Director Dr. Tim Stenzel said, “This test can still be used and can correctly identify many positive cases in minutes.”

NBC News (5/15, Dunn, 6.14M) reports Stenzel said in a statement, “We are still evaluating the information about inaccurate results and are in direct communications with Abbott about this important issue. We will continue to study the data available and are working with the company to create additional mechanisms for studying the test.” The FDA has received “15 adverse event reports about Abbott’s test.”

NPR (5/14, Neel, Hagemann, 3.12M) reports that its investigation found “as many as 15 to 20 out of every 100 tests may produce falsely negative results.” A subsequent study “released this week indicated that the test could be missing as many as 48% of infections.” The followup FDA studies “will include a minimum of 150 people who have previously tested positive for coronavirus, and take place in clinical settings, the FDA release said.”

CNBC (5/14, Rodriguez, 3.62M) reports Abbott’s share price “dropped following the FDA alert, and it is down more than 3% in after-hours trading.” Abbott Labs “rebuted the NYU study’s claims that its rapid coronavirus diagnostic test could be missing nearly half of positive cases.” In a statement Thursday, Abbott said, “While we understand no test is perfect, test outcomes depend on a number of factors including patient selection, specimen type, collection, handling, storage, transport and conformity to the way the test was designed to be run. ID NOW is intended to be used near the patient with a direct swab test method.”

Forbes (5/15, Japsen, 9.71M) reports because the number of adverse event reports “is so far small when compared to the nearly 1.8 million tests Abbott has shipped in the U.S., the FDA said it is reviewing the reports.” The FDA indicated Abbott’s “ID NOW test is still an important diagnostic tool to detect Covid-19.” For its part, Abbott said the ID NOW test “is helping to reduce the risk of infection in society by detecting more positive results than would otherwise be found.”
Among outlets also reporting are the Financial Times (5/14, Stacey, Subscription Publication, 1.34M) and Reuters (5/15, O'Donnell).

**Trump, Azar Siam Former HHS Official Who Filed Whistleblower Complaint As “Disgruntled.”**

Fox News (5/14, O'Reilly, 27.59M) reports President Trump on Thursday “defended the use of the anti-malaria drug hydroxychloroquine to treat the novel coronavirus and slammed the demoted government scientist who filed a whistleblower complaint claiming he was removed from his post for disagreeing with the Trump administration’s response to the contagion.” Making his comments “before boarding Air Force One for a trip to Pennsylvania, Trump said that there was a ‘tremendous response’ to hydroxychloroquine and called Rick Bright – the former director of the Biomedical Advanced Research and Development Authority – a ‘disgruntled person.”’

CNBC (5/14, Breuninger, 3.62M) reports Trump tweeted Thursday morning: “I don’t know the so-called Whistleblower Rick Bright, never met him or even heard of him. But to me he is a disgruntled employee, not liked or respected by people I spoke to and who, with his attitude, should no longer be working for our government!”

The Hill (5/14, Chalfant, 2.98M) reports HHS Secretary Alex Azar “is sharply rebuking remarks from ousted federal vaccine official Rick Bright about the coronavirus response, saying his allegations ‘do not hold water.’” Azar stated, “Everything he is complaining about was achieved. Everything he talked about was done.” The article says he “sought to counter comments Bright made the same day before House lawmakers, warning of the ‘darkest winter in modern history’ without a national plan to fight the pandemic.”

Among other media outlets providing coverage are: the Washington Post (5/14, 14.2M), with a video of the President’s comments, the Washington Post (5/14, 14.2M), with a video of Azar’s comments, Bloomberg (5/14, Edney, Sink, 4.73M), Fox News (5/14, Halon, 27.59M), Fox News (5/14, 27.59M), with a video of Azar’s comments, Fox News (5/14, Garcia, 27.59M), in a separate article, Axios (5/14, Fernandez, 521K), the Washington Examiner (5/14, Miller, 448K), the Daily Caller (5/14, Kruta, 716K), and STAT (5/14, Florko, 24K).

**Ivanka Trump Says She Wears Mask At White House.**

USA Today (5/14, Jackson, Subramanian, 10.31M) reports “Ivanka Trump, daughter and senior adviser to President Donald Trump, says she wears a mask at the White House, and that’s one reason the president doesn’t have to.” Ms. Trump said, “There are different procedures as it relates to interacting with the president.” According to USA Today, “The president is tested on a daily basis – all those who come into contact with him are tested on a daily basis,” she said in an interview. “No one is in close proximity to him that isn’t wearing a mask.” Ms. Trump added, “I always wear a mask when I am with the president, and everyone is instructed to do so as well.”

Newsweek (5/14, Zhao, 1.53M) reports the President: “failed to wear a mask during a visit to a Pennsylvania medical equipment distribution center on Thursday. His decision not to wear a mask was particularly noticeable as other government officials that accompanied him during the trip, including Health and Human Services Secretary Alex Azar and Rear Adm. John Polowczyk, were seen wearing masks in photos.”

**Taiwan Remains Sidelined From WHO’s World Health Assembly Amid Pandemic.**

The Washington Post (5/15, Aspinwall, Rauhala, 14.2M) reports that “with just 440 covid-19 cases and seven deaths, Taiwan looks to have conquered the coronavirus.” However, “one symbol of recognition remains elusive:
an invitation for Taiwan to observe next week’s World Health Assembly.” The Post says that “despite a growing pro-Taiwan coalition backing their inclusion, health officials in this self-ruled democracy remain sidelined from the World Health Organization’s decision-making body at the urging of China’s government, which claims sovereignty over Taiwan and has sought to sever its international contacts.” The piece mentions “an April telephone call between Taiwan health minister Chen Shih-chung and” HHS Secretary Alex Azar.

**HHS Awards $15M For Expanded Use Of Telehealth Amid COVID-19 Pandemic.**

*mHealth Intelligence* (5/14, Wicklund) reports HHS “is dispensing $15 million in funding to almost 160 healthcare providers across the country to help them expand telehealth services to meet demands caused by the Coronavirus pandemic.” The funds, from the CARES Act, are “being issued through the Health Resources and Services Administration (HRSA) and” are “earmarked to ‘train students, physicians, nurses, physician assistants, allied health and other high-demand professionals in telehealth’ and expand connected health platforms to replace or complement in-person care.” HHS Secretary Alex Azar said, “This new funding from Congress will enable more heroic health professionals on the front lines of the COVID-19 pandemic to use telehealth for a broad range of care.”

**Medical Groups Urge Verma To Provide More COVID-19 Assistance For Medicare ACOs.**

*Bloomberg Law* (5/14, Pugh, Subscription Publication, 4K) reports a coalition of medical groups, including the AMA and the Medical Group Management Association, is “asking the Trump Administration to provide additional pandemic-related support for” Medicare ACOs. On April 30, CMS issued an interim final rule aimed at helping ACOs during the pandemic, but the coalition of medical groups wrote a letter to CMS Administrator Seema Verma asking for more help for ACOs.

*FierceHealthcare* (5/14, King, 146K) reports the “groups say accountable care organizations (ACOs) need until Oct. 31 to decide whether to leave the Medicare Shared Savings Program (MSSP) due to the COVID-19 pandemic.” At present, “ACOs have until June 1 to decide whether to terminate their contract with MSSP,” however, “providers have been worried they could soon see an exodus of ACOs leaving the program to avoid losses, especially if the June 1 deadline holds.” The article says “pushing back the timeline will ‘give ACOs more time’ to understand a series of new rules to mitigate the impact of the COVID-19 pandemic, according to a letter from nine groups sent to the Centers for Medicare & Medicaid Services.”

**In Reversal, IHS Starting To Hire Traditional Healers.**

*Kaiser Health News* (5/14, Akridge) reports that certain “plants have been used as medicines for generations by the Assiniboine and Gros Ventre tribes who live” on the Fort Peck and Fort Belknap reservations, respectively. Echinacea “is used to help boost the immune system. Valerian produces a strong sedative that can address nervousness, tension and stress. Licorice root acts as an antihistamine, which treats allergy symptoms.” The article says the Indian Health Service is “starting to embrace” the use of such traditional treatments. The piece adds, “The Fort Belknap IHS hospital is seeking job applicants for two traditional practitioner positions, offering up to $68,000 a year.” Although IHS “has filled similar positions across the Navajo Nation in the past 15 years, these would be the first IHS positions of their kind in Montana.” The article says this “move is surprising because the federal government would essentially be paying for medicine men, or women, to help treat IHS patients, despite punishing and maligning such expertise for generations.”
HHS, DoD Award $138M Contract For Expanded Production Of Prefilled Syringes To Be Used For Future COVID-19 Vaccine.

Homeland Preparedness News (5/14, Kovaleski) reports HHS and the Department of Defense "awarded a $138 million contract to ApiJect Systems America for Project Jumpstart and RAPID USA, two programs designed to expand U.S. production of medical-grade injection devices." This contract will create a U.S.-based supply chain for prefilled syringes by using Blow-Fill-Seal (BFS) aseptic plastics manufacturing technology, suitable for combatting COVID-19 when a vaccine becomes available. By upgrading existing domestic BFS facilities with installations of filling-line and technical improvements, the project will enable the manufacture of more than 100 million prefilled syringes for distribution across the United States by year-end 2020."

National Front Page News

Headlines From Today's Front Pages.

Wall Street Journal:
Nearly Three Million Sought Jobless Benefits Last Week
Coronavirus Finishes The Retail Reckoning That Amazon Started
Why Big Investors Aren't Betting It All On A Coronavirus Cure
New York Sent Recovering Coronavirus Patients To Nursing Homes: "It Was A Fatal Error"
Is That A Rooster On My Customer-Support Call? Yes, Blame Coronavirus.

New York Times:
'Rolling Shock' As Job Losses Mount Even With Reopenings
He Saw No Proof Closures Would Curb Virus, Now He Has De Blasio's Trust
As Coronavirus Overruns Russia, Doctors Are Dying On The Front Lines
India's 'Maximum City' Engulfed By Coronavirus
Changing Subject Amid A Pandemic, Trump Turns To An Old Ploy: Blame Obama
Trump White House Changes Its Story On Michael Flynn
Meat Plant Closures Mean Pigs Are Gassed Or Shot Instead

Washington Post:
How Flynn Case Became A Trump 2020 Keystone
A Dying Man, A Desperate Search
CDC Offers Scant Guidelines For Reopening Safely
Pandemic Is Latest Blow To Sportswriting Profession
Burr Withdrew As Chairman Amid Stock Sale Investigation
In Poor Nations, Hunger May Be The Bigger Killer

Financial Times:
Macron Summons Sanofi Chief For Claim US Has "Right To" First Covid-19 Jab
Banking: The Great Return To The Office
US Jobless Claims Rise To 36M Since Start Of Lockdowns

Washington Times:
Chinese Deception Fuels Fears Of Ethnic Biological Weapons ‘Experiments’
Trump Blames Biden, Obama For Depleted National Stockpile Of Medical Supplies
From Phishing Scams To Fake Tests: Feds Struggle To Knock Down Coronavirus Fraud
MLB, NBA To Return? Youth Sports Could Be First
Coronavirus Crackdowns Around The World Make US Rules Look Lenient
From Asymptomatic To Lethal: Coronavirus Discrepancies Puzzle Scientists

Story Lineup From Last Night’s Network News:
ABC: HHS Whistleblower; Trump-PA Visit; CDC-New Guidelines; Unemployment; FBI-Sen. Burr; Georgia-Ahmoud Arbery Case; Florida-Wildfires; Coronavirus-Transmission; US Army Band Performs Over Video.
CBS: HHS Whistleblower; Trump-PA Visit; CDC-New Guidelines; Pediatric Multi-System Inflammatory Syndrome; Unemployment; Stay-At-Home Fatigue; FBI-Sen. Burr; Coronavirus-Potential Treatment; Georgia-Ahmoud Arbery Case; Coronavirus-USS Theodore Roosevelt; Milwaukee-Twins Graduate 1st & 2nd in Class; Pennsylvania-5-Year-Old Helps Mom Teach Remotely.
NBC: Pediatric Multi-System Inflammatory Syndrome; HHS Whistleblower; Trump-PA Visit; CDC-New Guidelines; Unemployment; Coronavirus-NBC Contributor Ill; Coronavirus-Airlines; FBI-Sen. Burr; Coronavirus-Vaccine; Coronavirus-Potential Treatment; Georgia-Ahmoud Arbery Case; Florida-Severe Weather; Nightly News Kids Edition.

Network TV At A Glance:
HHS Whistleblower – 12 minutes, 50 seconds
Coronavirus – 8 minutes, 30 seconds
Unemployment – 7 minutes, 20 seconds
FBI-Sen. Burr – 4 minutes, 20 seconds
Georgia-Ahmoud Arbery Case – 4 minutes, 0 seconds
CDC-New Guidelines – 3 minutes, 10 seconds
Trump-PA Visit – 1 minute, 50 seconds

Story Lineup From This Morning’s Radio News Broadcasts:
ABC: FDA-Abbott Coronavirus Test; Stay-At-Home Fatigue; Reopening Economy; House-Relief Bill; VA Homes-COVID-19 Deaths Investigation.
CBS: HHS Whistleblower; Trump-PA Visit; FBI-Sen. Burr; Unemployment; JC Penny-Bankruptcy; Wall Street.
FOX: House-Relief Bill; CDC-New Guidelines; Sen. Kelly Loeffler-Docs to DOJ.
NPR: HHS Whistleblower; FDA-Abbott Coronavirus Test; Trump-PA Visit; Wall Street.

Last Laughs
Late Night Political Humor.

Trevor Noah: “Do you remember that story about the senator in North Carolina who dumped his stocks after getting a government briefing that coronavirus was gonna wreck America? Well, now the FBI is getting involved. ... That’s right, like a suspicious spouse, the FBI has decided they want to look through this senator’s phone.”

Trevor Noah: “And to me, maybe the worst part about this scandal is that Senator Richard Burr was telling everyone, telling everyone in America, that things were going to be okay while he and his family were quietly saving [themselves]. It would be like if Noah built the ark but didn’t tell anyone why he was doing it.”

Jimmy Kimmel: “Dr. Rick Bright harshly criticized the White House response to COVID-19. ... He warned us the window is closing to address the pandemic. Unless that window is a drive-through window at KFC, there’s no way Trump’s going to bother.”

Jimmy Kimmel: “The President called that decision to reopen Wisconsin a big win and headed to Allentown, Pennsylvania. ... He went to a factory where they manufacture masks, and did the President wear a mask to the factory where they manufacture masks? Of course not. Everyone else did. He did not. But there’s a good reason why he won’t wear a mask. Wearing a mask is an act of respect, and consideration for others.”

Stephen Colbert: “Today, [Dr. Rick] Bright testified before Congress. But even before the hearing began, Trump went on the offensive, tweeting, ‘I don’t know the so-called whistleblower Rick Bright, never met him or even heard of him, but to me he is a disgruntled employee, not liked or respected by people I spoke to and who, with his attitude, should no longer be working for our government!’ That’s quite a preamble! (As Trump) ’Before I assassinate this guy’s character, let me first say, I have no idea what I’m talking about.’”

Jimmy Fallon: “Today, vaccine exper! Dr. Rick Bright said without better planning, 2020 could be the darkest winter in modern history. It’s not a good sign when our experts sound like the night’s watch on ‘Game of Thrones.’ Winter is coming.”

Seth Meyers: “Former Vice President Joe Biden appeared on Snapchat’s daily political show yesterday, although I’m not sure Snapchat is a good way to prove you haven’t disappeared.”

Seth Meyers: “The FBI has seized the cell phone of Republican Senator Richard Burr as part of an investigation into whether he used information from a coronavirus intelligence briefing to sell stocks. It’s also incriminating that right after the meeting, he signed up for Netflix and Hulu.”

Seth Meyers: “In a new interview, President Trump claimed that his critics would like to keep the country closed during the coronavirus pandemic to damage him politically. I mean, if anyone wants to damage you, they don’t have to keep the country closed. They just have to keep your mic open.”

National News

Trump Retweets Post Questioning Claim He Is A Racist.
President Trump retweeted a post from a Twitter user named Maggie VandenBerghe, which said, “I was told Trump was RACIST but let me get some EVIDENCE to debate Trump supporters! What happens next? MAGA! @realDonaldTrump” The post includes video of VandenBerghe interviewing an African American man who says he was told Trump is a racist but when he did some research, he found that he likes him. Trump wrote in his tweet, “Thanks. You are very cool!”

**Burr Steps Aside As Chair Of Senate Intelligence Committee Amid FBI Probe.**

The AP (5/14, Tucker) reports that Sen. Richard Burr (R-NC) has “temporarily stepped aside as chairman of the Senate Intelligence Committee” after the FBI “served a search warrant for his cellphone as part of an investigation into a well-timed sale of stocks tied to the coronavirus pandemic.” Senate Majority Leader McConnell “announced the move, saying he and Burr had agreed that it was in the committee’s best interests.” Burr told reporters he thought it was “the right thing to do. ... This is a distraction to the hard work of the committee and the members, and I think that the security of the country is too important to have a distraction.” Pierre Thomas said on ABC World News Tonight (5/14, story 5, 2:00, Muir, 7.42M) that the FBI “wants to know if Burr used intelligence information about the coronavirus for financial gain by selling stocks just before the market cratered.” Burr sold “up to $1.7 million in travel and hotel investments just a day after a closed-door briefing on the impact of the virus.”

The New York Times (5/14, Benner, Fandos, 18.61M) says the seizure of Burr’s cellphone “and an accompanying search for his electronic storage accounts, confirmed by an investigator briefed on the case, represented a significant escalation of the inquiry by the Justice Department and the Securities and Exchange Commission. They suggest that Mr. Burr, a Republican and one of the most influential members of Congress, may be in serious legal jeopardy.” The Times says “the sensitivity surrounding the decision to obtain a search warrant on a sitting senator,” indicates “the move was approved at the highest levels of the department, a senior Justice Department official said, meaning that” Attorney General Barr “signed off on it.” Pete Williams said on NBC Nightly News (5/14, story 8, 1:00, Holt, 7.86M) that the investigation “is clearly in a new phase:” A search warrant “would require a judge’s finding that there is probable cause to think the phone could contain evidence of a crime.” The CBS Evening News (5/14, story 7, 1:20, O’Donnell, 5.25M) provided similar coverage.

The Washington Post (5/14, Shepherd, 14.2M) reports that “if McConnell chooses to go by seniority,” Sen. James Risch (R-ID) “would be next in line to chair the committee, but he already leads the Senate Foreign Relations Committee.” The Post adds that after Risch is Sen. Marco Rubio (R-FL), “a national security hawk who had been widely expected to take over the committee once Burr retires.” The Hill (5/14, Bolton, 2.98M) describes Rubio as “a likely successor” to Burr, and says the move would be “a major promotion for a lawmaker who contemplated leaving Congress only a few years ago.”

**Tillis: “Sen. Burr Does Owe All Of Us An Explanation.”** WBT-AM Charlotte, NC (5/14, 4K) reports that in an interview with the station, Sen. Thom Tillis (R-NC), who faces a tight reelection race this year, “remarked that Richard Burr owes everyone an explanation.” Tillis said, “Sen. Burr does owe all of us an explanation and this is clear evidence that an investigation is underway. We need to see where the investigation leads.”

**Loeffler Does Not Answer Questions About FBI Investigation.** The Atlanta Journal-Constitution (5/14, Mitchell, 895K) reports Loeffler “would not say Thursday whether she has been contacted by the FBI in
connection with an investigation into stock trading during the pandemic,” while her spokeswoman “told The Atlanta Journal-Constitution that the senator has not been served any search warrants.”

Feinstein’s Office Says She Was Questioned About Husband’s Stock Trades. The San Francisco Chronicle (5/14, 2.67M) reports the office of Sen. Dianne Feinstein (D-CA) said the senator “was questioned by federal law enforcement agents about stock trades her husband made after the coronavirus hit” the US. Feinstein “also provided documents to federal agents to show she was not involved in the transactions by her husband, investment banker Richard Blum, her spokesman, said.”

Senate Votes To Extend Parts Of FISA.

Reuters (5/14, Zengerle) reports that the Senate voted 80-16 Thursday to approve a 2 1/2-year extension “of parts of the Foreign Intelligence Surveillance Act (FISA)...two months after the divisive provisions allowing government data collection expired.” The measure must be approved by the House “before it can be sent to the White House for President Donald Trump to veto or sign into law” after the Senate “amended the measure approved by the Democratic-led House in March to improve legal protections for those subject to surveillance.” Politico (5/14, Matishak, 4.29M) says the measure’s “chances for swift final approval” in the House “remain cloudy.”


The Washington Post (5/14, Bogage, Dawsey, 14.2M) reports that “weeks before a Republican donor and top White House ally becomes postmaster general, the U.S. Postal Service has quietly begun a review of its package delivery contracts and lost its second-highest executive, leaving its board of governors without any officials who predate President Trump.” According to the Post, “The moves, confirmed by six people with knowledge of the Postal Service’s inner workings but not authorized to speak publicly, underscore how Trump is moving closer to reshaping an independent agency he has dubbed ‘a joke.’” The Post also reports that the Postal Service “in recent weeks has sought bids from consulting firms to reassess what the agency charges companies such as Amazon, UPS and FedEx to deliver products on their behalf.”

Trump Questions Biden’s Mental Fitness.

Salena Zito writes in the Washington Examiner (5/14, 448K) that in comments to the Examiner before his event in Pennsylvania Thursday, President Trump “took aim at Joe Biden’s mental faculties, at one point claiming” the former Vice President “has absolutely no idea what’s happening.” Reacting to word that Biden had named Rep. Alexandria Ocasio-Cortez (D-NY) “co-chairwoman of a climate change panel,” Trump said, “If you asked him who he named, he wouldn’t even know it.... Joe has absolutely no idea what’s happening.” Zito adds that Trump used several issues “to take jabs at Biden’s mental fitness.”

Abrams Promoted As Possible Running Mate For Biden.

In a 6,000-word Washington Post Magazine (5/14, 14.2M) profile of Stacey Abrams, Kevin Powell writes, “I’ve witnessed this level of affection for very few political leaders in the Democratic circles I’ve been in since the 1980s.” Powell says Abrams is “on political pundits’ shortlists of potential running mates for Joe Biden,” and has “a unique space in American politics,” though “a relatively thin political résumé.” Powell adds that she “is the first
black woman in U.S. history to have won the gubernatorial nomination of either major party,” and “garnered more votes than any Democrat who has run statewide in Georgia.”

Prominent Black Women Offer Suggestions For Biden To Earn Support. LaTocha Brown of Black Voters Matter, author Tiffany Cross, Brittany Packnett Cunningham, Alicia Garza of Black Lives Matter Global Network, television personality Sunny Hostin, podcaster Angela Rye, and comedian Amanda Seales write in the Washington Post (5/14, 14.2M) that Biden’s “only path to victory is through black women and the voters we know how to energize.” They add, “You owe us, you need us and you must not take our votes for granted.” They call on Biden to choose “a black woman as vice president.” They also urge him to pledge the necessary resources to win a Democratic majority in the US Senate with the help of “Black voters in Wisconsin, Florida, Michigan, Pennsylvania, North Carolina and Georgia.”

Rasmussen: 23% Of Republicans, 28% Of Democrats Would Prefer Different Nominees.

Rasmussen Reports (5/14, 5K) says on its website, “Republicans overwhelmingly expect President Trump to be their nominee this fall, but nearly one-in-four GOP voters would prefer someone else. The latest Rasmussen Reports national telephone and online survey finds that 23% of Likely Republican Voters think their party should find someone other than Trump to be their presidential nominee. Seventy percent (70%) disagree. Only seven percent (7%) are undecided.... By comparison, 28% of Likely Democratic Voters say their party should find someone other than Joe Biden to be their 2020 presidential nominee. Fifty-four percent (54%) disagree, while another 18% are not sure.”

Trump Touts His “22-0” Record Of Congressional Endorsements.

President Trump tweeted Thursday morning that he is “22-0” in endorsing congressional candidates this season after races this week in California and Wisconsin. Trump wrote, “22-0 in my endorsements of Congressional Candidates this season. California & Wisconsin won big on Tuesday. Thank you to all of those very brilliant Voters. You will not be disappointed!”

Copyright 2020 by Bulletin Intelligence LLC. Reproduction or redistribution without permission prohibited. Content is drawn from thousands of newspapers, national magazines, national and local television programs, radio broadcasts, social-media platforms and additional forms of open-source data. Sources for Bulletin Intelligence audience-size estimates include Scarborough, GfK MRI, comScore, Nielsen, and the Audit Bureau of Circulation. Data from and access to third party social media platforms, including but not limited to Facebook, Twitter, Instagram and others, is subject to the respective platform’s terms of use. Services that include Factiva content are governed by Factiva’s terms of use. Services including embedded Tweets are also subject to Twitter for Website’s information and privacy policies. The NIH News Briefing is published five days a week by Bulletin Intelligence, which creates custom briefings for government and corporate leaders. We can be found on the Web at BulletinIntelligence.com or called at (703) 483-6100.
NIH News
Trump Mobilizing U.S. Military To Deliver Coronavirus Vaccine...5
Fauci Loses Support From Republicans After Trump Criticism, Poll Shows...5
Without Wearing A Mask, Trump Tours Pennsylvania Mask Distribution Center...5
Put Rand Paul In The Penalty Box...6
France Angered By Suggestion U.S. Would Get First Access To Coronavirus Vaccine By French Pharma Company Sanoit.6
After Wisconsin Court Ruling, Crowds Liberated And Thirsty Descend On Bars. We’re The Wild West,” Gov. Tony Evers Says...7
NIH Starts Study Testing Combination Of Azithromycin And Hydroxychloroquine For Treatment Of COVID-19...7
Trump’s Marks For Handling COVID-19 Outbreak Decline – CBS News Poll...7
Researchers Working On Remdesivir Cocktail...8
Who Needs Science When We Have Trump’s Tremendous Instincts?...8
Dr. Deborah Birx Wined Praises For Managing The White House’s Coronavirus Message And Trump...8
Trump Predicts Coronavirus Vaccine Will Come This Year...8
Public Health School Deans Urge Trump To Triple Coronavirus Testing Or Face Cycles Of Shutdown...8
California Tells Hospitals To Consider Having A Lottery For Sought-After Covid-19 Drug...8
Large Majority Of Americans Say Country Lags In Testing Availability POLL...8
States Are Letting Stay-At-Home Orders Expire, Regardless Of Virus Metrics...9
Trump’s Plan To Limit The Pandemic’s Death Toll: Undercount The Numbers...9
Fox News Dumps Coronavirus Coverage For Anti-Obama Conspiracy Theory...9
Tensions Rise As Texas Governor Readies To Lift More Rules...9
Coronavirus Question: Let’s Say A Vaccine Proves Safe And Effective. Then What?...9
‘Re-Examine All The Evidence’ Rand Paul Demands Fauci Reconsider Position On School Closures...9

White House To ‘Reconfigure’ Coronavirus Task Force With An Emphasis On Reopening The Country...10
Remdesivir Distribution Causes Confusion, Leaves Some Hospitals Empty-Handed...10
Top Health Officials Vanish From National TV Interviews As White House Refocuses Messaging...10
Trump Is Smearing Fauci...10
Trump Admin Shoots The Messenger As Whistleblower Highlights Ongoing Issues...10
Trump Dismisses Fauci’s Warning Against Reopening Schools: ‘I Totally Disagree’...10
Trump Is Blaming China For Coronavirus Even As He Employs The Same Authoritarian Tactics As Xi Jinping...11
White House Press Secretary Disputes Poll That Show Americans Trust Dr. Fauci Much More Than Trump...11
Column: We Shut Down The Economy To Make Progress Against COVID-19 – And Then Made No Progress...11
Rand Paul Delivers A Magnificent Reality Smack To Anthony Fauci...11
Editorial: Fauci’s Caution On Schools Is Sound, No Matter What Non-Physician Trump Says...11
NIH Begins Trial To Determine How Effective Hydroxychloroquine...11
Interferon Emerges As Potential Treatment For COVID-19...11
U.S. Accuses Chinese-Born Researcher At Cleveland Clinic Of Ties To Chinese Spying...12
Talking In Enclosed Space Can Generate Droplets That Linger For Up 14 Minutes, Study Finds...12
Experimental Injection Of ‘Good’ Bacteria Significantly Cuts Bacterial Vaginosis Recurrence Rate...12
NCI Exceptional Responders Initiative Pilot Study Meets Feasibility Goal...12
Researchers Try Combining Remdesivir With A Second Drug To Deliver A ‘One-Two Punch’ To Virus...12
COVID Patients Given Malaria Drug Didn’t See Significant Improvements: Studies...12
Part Of Gilead’s Coronavirus Drug Donation Allocated To Japan...12
Virginia Receives 2nd Shipment Of New Antiviral Drug...13
US Needs Bipartisan Push For Scientific Research After Coronavirus: Congressional Leaders...13
COVID-19 Is Threat To Our Biomedical Research Enterprise... 13
Gilead Should Ditch Remdesivir And Focus On Its Simpler
Ancestor...................................................................................... 13
Both/And Problem In An Either/Or World ................................. 13
Research On TPA/Nanocjugate Aims To Extend
Thrombolysis Benefits To More Stroke Patients ................. 13

Health & Medical News
White House Officials Signal Support For COVID-19 Relief For
States Despite Opposition From Some GOP Groups .......... 14
As COVID-19 Pandemic Persists, GOP Calls For "Pause" On
More Aid...................................................................................... 14
About 75% Of US Small Businesses Seek Federal Assistance
Amid COVID-19 Pandemic, Survey Shows................. 14
Prospects For Second Round Of Stimulus Checks Seem
"Uncertain." ........................................................................ 14
Sanders Wants Senate To "Improve" House Dems' $3T
COVID-19 Relief Package ..................................................... 14
Bipartisan Group Of Lawmakers Proposes Compensation Fund
For Essential Workers Impacted By COVID-19.............. 14
Pelosi Pushing For Vote On $3T COVID-19 Relief Bill Despite
Objections From Some Dems.............................................. 15
New York Will No Longer Force Nursing Homes To Accept
Recovering COVID-19 Patients .............................................. 15
Debate Over Reopening US "Increasingly Partisan And Bitter," .... 15
Newsom Says COVID-19 Forcing Sharp State Budget Cuts .... 15
Cities, Counties In Texas Take Disparate Approaches To
Enforcing Pandemic Restrictions ................................. 16
Michigan Closes State Capitol "As Protesters Gather Against
Stay-At-Home Order" ............................................................ 16
Attorneys "threaten Coronavirus lawsuits" Against Florida
Nursing Homes........................................................................ 16
Despite Missing Goal, Nebraska's Governor Confident In State
Testing Program .................................................................... 17
Connecticut Governor "Moving Ahead" With May 20 Reopening
"Despite Concerns." ................................................................ 17
Just 4,000 Have Been Tested Under Iowa Program .......... 17
South Dakota Announces Plan To Test All Long-Term Care
Facility And Assisted Living Residents" Over Next Month .... 17
Hawaii's Governor "inclined" To Maintain Stay-At-Home Order
Until June 30 ........................................................................... 17
Louisiana Senate Approves Legislation To "Shield Businesses
From Virus Lawsuits." ............................................................. 18
States Begin Partially Opening As Residents Grow Restless,
Less Willing To Shelter In Place ........................................... 18
Some School Districts Ending Their Distance Learning Efforts, .... 18
Scientists Say Testing Sewage Holds Promise For Monitoring
Outbreaks Of Diseases Including Coronavirus .............. 18
Analysis: Many "Essential" Workers Will See Pay Cuts As
Companies Resend "Hazard Pay" Policies......................... 18
COVID-19 Accelerating Decline Of Retail Industry .............. 18
Navy Continues To Battle Coronavirus Transmission Aboard
Theodore Roosevelt Aircraft Carrier ................................. 18

Analysis: Gun Stores In Several States Ignored State-Ordered
Closures, Initiated Tens Of Thousands Of Background
Checks In April .................................................................... 19
Inspection Reports For Several Connecticut Nursing Homes
Found Lapses In Infection Control, Prevention Around
Coronavirus.......................................................................... 19
Analysis: Studies Suggesting Coronavirus Can Be Spread
Through Loud Talking Show Need For Face Masks In
Public................................................................................. 19
UT Dallas Researchers Design 3D-Printed Disposable
Ventilator Valve.................................................................... 20
Program .............................................................................. 20
Interview: Antibiotic-Resistant Microbes Equally Important Issue
During Pandemic................................................................. 20
Infectious Disease Experts Warn Of Potential Dual-Season For
COVID-19, Influenza During Winter.............................. 20
Norwegian Cruise Line Expects Entire Fleet To Resume Full
Operations In Approximately Six Months ................. 20
Analysis: Anti-Vaccination Advocates Mobilizing To Protest
Potential Coronavirus Vaccine ............................................. 20
DC-Area Metro, Metrobus Riders Required To Wear Face
Coverings Effective May 18 .................................................. 20
Nursing Home Industry, Residents Clash Over Industry's
Handling Of Pandemic .......................................................... 21
Opinion: Governors Need To Designate Grocery Workers As
First Responders ................................................................. 21
WPost: COVID-19 Testing In Nursing Homes And Long-Term
Care Facilities Is Essential .................................................. 21
One-Fourth Of US Restaurants Will Close Due To Stay-At-
Home Orders During Pandemic, OpenTable Forecasts ........ 21
Pentagon Examining "Social Distancing Protocols" To Train,
Deploy Units Amid Pandemic .............................................. 21
Some Colleges Push Viral Testing, Alternative Methods To
Allow Fall Semester In-Person ............................................. 21
Columnist: Trump Is "In The Middle Of A Grace Period" With
Voters, But That Will Not Last Indefinitely ...................... 22
Department Of Labor Issues Coronavirus Guidance To Nursing
Homes .................................................................................... 22
Trump Signs Executive Order Giving New Authority To US
International Development Finance Corporation Amid
Pandemic .............................................................................. 22
Columnist: US Should Be "Pitied" For Coronavirus Response .. 22
Analysis: Trump Using Meetings With Governors At White
House To Promote US Economic Reopening ................. 22
Columnist: "Virus Truthers" Widespread On The Political
Right ..................................................................................... 22
McConnell Walks Back Claim That Obama Administration Left
Trump Administration No "Game Plan" For Pandemics .......... 22
Pentagon's DPA Coordinator Reassigned To Navy Position .... 23
Trump's Press Secretary Flashes Pandemic Playbook To
Reporters; Calls Obama Administration's Plan
"Insufficient."......................................................................... 23
Number Of COVID-19 Cases In Michigan Nears 50,000 .... 23
Woman Sues Portland Nursing Home After Her Mother Died Of Coronavirus At The Facility ........................................ 23
New York Governor And New York City Mayor Cannot Agree On Number Of Coronavirus Deaths In The City ........ 23
Study Suggests Pediatric Multi-System Inflammatory Syndrome Is Tied To Coronavirus, As Cases Rise In New York ... 23
Fishing Boat Crews Reportedly Could Cause Coronavirus Outbreak In Cordova, Alaska ........................................... 23
Hospital Leaders Approve Of Minnesota Governor’s Decision To Let Stay-At-Home Order Expire ......................... 24
Pennsylvania Governor To Announce More Counties That Can Lift Some Pandemic Restrictions On Friday ............ 24
Most Maryland Residents Will Remain Under Stay-At-Home Orders As State Starts Reopening Friday ............. 24
WSJ: Journal Urges Wisconsin Governor To Create Less Restrictive Stay-At-Home Order With Legislature .......... 24
Researcher Optmistic About Convalescent Plasma Therapy .... 24
Plasma Therapy Derived From Recovered COVID-19 Patients Appears Safe, Study Suggests .................. 25
Expert Says It Will Take “Bulk Of A Year” Before Researchers Can Determine Factors In COVID-19 Immunity . 25
Data Show COVID-19 Cases Are Generally Decreasing In 17 States, Rising In Nine Others......................... 25
Fox News Host Says Bright Testimony Could Be “Potentially Politically Damaging” For Trump ......................... 25
Opinion: Pay Attention To Whistleblower, Because What Trump Disparages Is Often Truth ................................. 25
CDC Issues Health Advisory For Physicians On Childhood Illness Linked To COVID-19 ........................................... 25
Maine Governor Allows Out-Of-State Visitors To Reserve Rooms In Lodges, Inns Starting June 1 ......................... 25
North Dakota Has Exceeded 50,000 Coronavirus Tests .... 26
In Rural America, COVID-19 Breakouts At Prisons Risk Overwhelming Hospitals ............................................ 26
Governor Baker Says State Public Health Officials Have Expanded COVID-19 Testing Eligibility ............ 26
Bars And Restaurants Remain Closed Under Local Milwaukee County Order ............................................... 26
Virginia Officials Plan To Stop Counting Antibody Tests As COVID-19 Tests In Reports ......................... 26
As Some States Reopen, Other States Continue To Battle Coronavirus .............................................................. 26
New York Governor Adds Provision To State’s Budget To Prevent Some Residents From Suing Nursing Homes Amid Pandemic ................................................................. 27
Some Small Physician Practices Are Struggling During Pandemic, Unable To Get Coronavirus Relief .......... 27
Pandemic Hits Low-Income Americans Especially Hard, Survey Shows ............................................................... 27
Close To Three Million Americans Applied For Unemployment Last Week ...................................................... 27

Coronavirus Pandemic Could Cost Insurance Industry Over $200 Billion, According To Lloyds Of London ........... 27
Medical Professionals File Lawsuit Against Michigan Governor Over Lockdown Restrictions ......................... 27
Transplant Of Brain Cells To A Patient With Parkinson’s Disease Sparks Ethical Questions ......................... 28
Reopening Spurs Divide Among State Governors, Legislatures . 28
Connecticut Nursing Home Owner Purchases 400K Masks From Makeshift Supplier .......................................... 28
New Jersey, Delaware Reopen Beaches For Memorial Day With Restrictions .................................................. 28
Minnesota Malls Begin To Reopen Monday, However, Mall Of America Plans For June 1 ................................. 28
New York Nursing Home Administrators Reportedly Worried About The State’s COVID-19 Testing Goal ............ 28
During Contact Tracing Efforts, New York City Mayor Leans On Aide That Previously Argued Against Closures .... 28
Trump, EPA Decide Not To Impose Limits On Water Contaminant Linked To Fetal Damage ................................. 28
Wyoming To Relax Restrictions On Bars And Restaurants .......... 29
Democrats Present Legislation Aimed At Protecting Health Data During COVID-19 Pandemic ..................... 29
White House Lists Coronavirus Testing Labs Not Useful, Nine States Say ................................................................. 29
Testing Project On Tiny Michigan Island Underway ............... 29
AMA Warns Physicians Against Using Coronavirus Antibody Tests To Inform Healthcare Decisions ............... 29
Virginia Governor Asks Federal Government To Increase Testing At Two Federal Detention Facilities ............. 29
CVS Plans To Open 1,000 Self-Swab Coronavirus Test Locations By Month’s End .................................................. 29
US Said To Be Making Progress In Coronavirus Testing Numbers ............................................................... 29
Abbott Lab’s ID Now COVID-19 Misses Up To Half Of Cases Found By Another Test, Study Suggests .......... 29
Bill Gates-Funded Program That Provides At-Home Coronavirus Test Kits Put On Hold Until Federal Approval Is Granted ................................................................. 30
Pandemic Reportedly Reveals Vulnerabilities In American Business Model For Hospitals ........... 30
Biogen Blocks Creative Biolabs From Selling Products That Allegedly Used Antibody From Its Experimental Alzheimer’s Drug ................................................................. 30
Opinion: New Hampshire Tobacco 21 Policy Will Reduce Chances Of Lifelong Nicotine Addiction, Protect Developing Brains ................................................................. 30

Global Health News
China’s Foreign Ministry Says U.S. Claims Regarding Hacking Of COVID-19 Research Are Slander ............... 30
Health Groups Ask India To Rescind Gilead’s Patents For COVID-19 Drug Remdesivir ............................................. 30
Russia’s ChemRar Testing Favipiravir In Second-, Third-phase Testing As Potential COVID-19 Treatment .... 30
NIH NEWS

Trump Mobilizing U.S. Military To Deliver Coronavirus Vaccine. Reuters (5/14, Heavey, Chiacu) reports "President Donald Trump is mobilizing the U.S. military to distribute a novel coronavirus vaccine when one becomes available and will focus first on older Americans." Trump said on Fox Business Network, "You know it's a massive job to give this vaccine... Our military is now being mobilized so at the end of the year, we're going to be able to give it to a lot of people very, very rapidly." Trump "said he believes there will be a vaccine by the end of the year and the United States is mobilizing 'our military and other forces' on that assumption." NIAID Director Dr. Anthony Fauci "said the idea that there will be a vaccine available by next fall, when schools and universities resume classes, was 'a bridge too far.'"

Additional Sources. Similarly, CBS News (5/14, Watson, 3.68M) reports "Trump says he would 'rapidly' mobilize the U.S. military to distribute a coronavirus vaccine once it's ready, focusing first on nursing homes and the elderly." Trump stated, "We will have a tremendous force because assuming we get it, then you have to distribute it... And unless you're mobilized and ready, you're not going to be able to do it for a long time. So we're starting now."

Also reporting on the story are The Hill (5/14, Deese, 2.98M) and Newsweek (5/14, Fink, 1.53M).

Fauci Loses Support From Republicans After Trump Criticism, Poll Shows. Forbes (5/14, Brewster, 9.71M) reports "Republicans are increasingly less supportive and trusting of NIAID Director 'Anthony Fauci, a new poll shows, a sign that criticism from GOP lawmakers (including [President] Trump) and right-wing media—who have bristled at Fauci’s warnings about reopening too quickly—may be having an effect on public opinion among conservatives.' The CBS News poll "found Fauci's unfavorable rating among Republicans has climbed to 31% in May, up from just 12% in April." Trusting the health expert "has also become partisan: 83% of Democrats say they trust Fauci while just 51% of Republicans say they do."

Without Wearing A Mask, Trump Tours Pennsylvania Mask Distribution Center. Reuters (5/14) reports that "without wearing a face mask himself, President Donald Trump toured a mask distribution center in Pennsylvania on Thursday and announced plans to replenish the U.S. strategic stockpile of medical equipment depleted by the coronavirus outbreak." Trump "has resisted wearing a mask in public despite his administration’s guidance to Americans to wear them and new White House rules requiring that staff wear them at work." He "toured the Owens & Minor Inc distribution center, which the White House said has sent millions of N95 masks, surgical gowns and gloves to hospitals and surgery centers across the United States. Company officials wore masks."
Additional Sources. USA Today (5/14, Subramanian, Jackson, 10.31M) reports “Trump told a group of Pennsylvania factory employees Thursday their Democratic governor, Tom Wolf, should ‘start opening up a little bit,’ continuing to press an end to social distancing restrictions as he eyes reopening the struggling U.S. economy.” Trump said at the distribution center, “We have to get your governor of Pennsylvania to start opening up a little bit. You have areas of Pennsylvania that are barely affected, and they want to keep them closed. You can’t do that.” The piece mentions that HHS Secretary Alex Azar was wearing a face covering during the visit.

CNN (5/14, Liptak, 83.16M) reports “Trump’s quick trip to Allentown highlighted a medical equipment distribution company, where he trumpeted his administration’s record on ramping up testing and improving supply chains for personal protective equipment and ventilators.” The President “laced his speech with complaints about how his response to the virus has been covered in the media and lobbed barbs at former Vice President Joe Biden, who was born in Scranton.”

Forbes (5/14, Perez, 9.71M) reports “Trump announced he was invoking the Defense Production Act to direct the U.S. International Development Finance Corporation (DFC) – an agency he signed into being in 2018 that invests in economic development programs in developing countries – to finance domestic companies.” Trump “lavished praise on healthcare workers, saying ‘They’re running into death just like soldiers run into bullets.’”

The Hill (5/14, Samuels, Hellmann, 2.98M) reports “Trump boasted about the United States’ testing capabilities during remarks at a Pennsylvania medical equipment distribution center, where he announced the country has administered 10 million tests since the outbreak began.” Trump said, “We have the best testing in the world. … Could be that testing’s, frankly, overrated. Maybe it’s overrated.”

Politico (5/14, Ward, 4.29M) reports Trump also said, “When you test, you have a case. When you test, you find something is wrong with people. If we didn’t do any testing, we would have very few cases.” The President “said the news media had refused to report his ‘common sense’ explanation for the country’s high case numbers.”

The Washington Times (5/14, Boyer, 492K) reports Trump “faulted the Obama administration, and Democratic rival Joseph R. Biden, for leaving the U.S. unprepared for the coronavirus crisis.” Meanwhile, “Rick Bright, a [former] top coronavirus vaccine researcher at the National Institutes of Health, testified in Congress Thursday that the administration ignored his warnings earlier this year to prepare for the pandemic.”

NJ News (5/14, Salant, 1.72M) reports on the story, and adds that NIAID Director Dr. Anthony Fauci “said he was worried about states reopening too soon in testimony before the Senate Health Committee on Tuesday.”

Among other news outlets reporting on the story are ABC World News Tonight (5/14, story 2, 1:05, Muir, 7.42M), the CBS Evening News (5/14, story 2, 0:30, O’Donnell, 5.25M), NBC Nightly News (5/14, story 3, 0:15, Holt, 7.88M), the Washington Post (5/14, 14.2M), another piece in The Hill (5/14, Samuels, 2.98M), Newsday (NY) (5/14, 932K), the New York Daily News (5/14, Sommerfeldt, 2.52M), and the Allentown (PA) Morning Call (5/14, Olson, Merlin, 555K).

Put Rand Paul In The Penalty Box. Washington Post (5/14, 14.2M) columnist Karen Tumulty writes that it is “too bad the Senate, unlike a hockey rink, doesn’t have a penalty box. Because that is where Kentucky Republican Rand Paul would be sitting, rather than in a hearing room lecturing the nation’s leading infectious-disease expert that he isn’t the ‘end-all.’” When NIAID Director Dr. Anthony Fauci “testified this week before the Senate Health, Education, Labor and Pensions Committee, Paul recited data that he claimed [suggest] the government’s response to the novel coronavirus pandemic has been too cautious.” Tumulty concludes, “Paul, of all people, should know that impetuous decisions can put a lot of others at unnecessary risk.”

France Angered By Suggestion U.S. Would Get First Access To Coronavirus Vaccine By French Pharma Company Sanofi. The Washington Post (5/14, McAuley, 14.2M) reports France’s government said “it would be ‘unacceptable’ for French pharmaceutical giant Sanofi to give the United States first access to a potential COVID-19 vaccine.” The comments came in response to statements by CEO Paul Hudson, who said “the U.S. government has the right to the largest preorder because it’s invested in taking the risk.” The piece suggests that “Hudson’s comments and further messaging from Sanofi on Thursday may be part of an effort to prod European governments to invest more in vaccine research.” However, “by Thursday morning, the company appeared to be backpedaling somewhat.” On this point, “Olivier Bogillot, head of Sanofi’s French division, told France’s BFMTV network that the vaccine would be available to Europeans at the same time as Americans if the European Union were as ‘efficient’ a partner.”

Additional Sources. Reuters (5/14, Brosse, Heavey) reports National Institute of Allergy and Infectious Diseases Director Anthony Fauci “on Tuesday said a vaccine would not likely be available by the autumn but that he was cautiously optimistic there would eventually be one.”

Forbes (5/14, Beer, 9.71M) reports, “The U.S. expanded a vaccine partnership with the drugmaker in February, and Sanofi has received $30 million from an office of the U.S. Department of Health and Human Services.”
residents to their homes or bar them from work, marked the first time such coronavirus restrictions had been overturned in the United States.”

*Newsweek* (5/14, Janis, 1.53M) reports, “President Donald Trump has hailed the Wisconsin Supreme Court decision to overturn coronavirus lockdown measures in the state as a ‘win.’”

*U.S. News & World Report* (5/14, Smith, 2.4M) also reports.

**NIH Starts Study Testing Combination Of Azithromycin And Hydroxychloroquine For Treatment Of COVID-19.** *Reuters* (5/14, Erman, Maddipallla) reports the NIH announced it started a study to evaluate the combination of azithromycin and hydroxychloroquine for the treatment of COVID-19. The National Institute of Allergy and Infectious Diseases “is sponsoring the trial, which is being conducted by the NIAD-funded AIDS Clinical Trials Group (ACTG).”

**Additional Sources.** The *Hill* (5/14, Hellmann, 2.98M) reports NIAD Director Anthony Fauci said, “We urgently need a safe and effective treatment for COVID-19. Repurposing existing drugs is an attractive option because these medications have undergone extensive testing, allowing them to move quickly into clinical trials and accelerating their potential approval for COVID-19 treatment.” Also reporting are *Bloomberg Law* (5/14, Klimasinska, Subscription Publication, 4K) and *Fox News* (5/14, Carbone, 27.59M).

**Trump’s Marks For Handling COVID-19 Outbreak Decline – CBS News Poll.** *CBS News* (5/14, Khanna, 3.68M) reports that according to a CBS News poll, “Americans continue to say they trust medical professionals for virus information, but Republicans also rank President Trump about as highly among their trusted sources, even as others give him his lowest marks to date for handling the outbreak.” Furthermore, NIAD Director Dr. Anthony Fauci “is trusted by most and viewed favorably by a three-to-one margin, but he now draws split opinions among Republicans, driven by increasingly negative views from conservatives.” Views of “Trump’s handling of the outbreak continue to drop from March and are now the lowest he has received.”

**Additional Source.** *Newsweek* (5/14, Lemon, 1.53M) reports that “the number of Americans saying Trump is doing a ‘bad job’ handling the pandemic has increased by 10 points since March.” Meanwhile, “the number of Americans who trust Trump for information about the outbreak currently stands at 38 percent, while 62 percent of respondents say they do not trust the president about it.”
Researchers Working On Remdesivir Cocktail.
On the CBS Evening News (5/14, story 8, 2:05, 5:25M), Norah O'Donnell reported on "a so-called [treatment] 'cocktail' that has entered a new phase." CBS's Jon LaPook reported a research team is "combining remdesivir to stop the virus from multiplying with a powerful anti-inflammatory drug, a so-called 'immune modulator' that aims to prevent organ damage by calming down an inflamed immune system. The remdesivir stops the virus from replicating inside the cell, and the immune modulator puts out the fire." CBS quotes National Institute of Allergy and Infectious Diseases Director Anthony Fauci regarding past struggles to find drugs for treating HIV.

Who Needs Science When We Have Trump's Tremendous Instincts? Washington Post (5/14, 14.2M) columnist Michael Gerson writes that President "Trump's version of populism has always included skepticism of medical consensus." Trump "has a long history of trusting his gut on scientific matters on which he has little knowledge." These tendencies "are now emerging in the midst of a public health crisis. We have a president who is increasingly critical of advice from infectious disease experts, and who seems increasingly skeptical of the reported death toll from covid-19." Gerson adds that "Tucker Carlson questions whether" NIAID Director Dr. Anthony Fauci "is right about the science" and calls him a "buffoon." Gerson concludes, "It does not prove your conservatism, your populism or your patriotism to needlessly endanger your neighbor."

Dr. Deborah Birx Wins Praise For Managing The White House's Coronavirus Message And Trump. USA Today (5/14, Hjelmgard, Jackson, 10.31M) reports that "while it's too early to draw conclusions about whether" Dr. Deborah Birx's influence has diminished, she remains one of the major public faces of the administration's coronavirus response. The role has "brought her praise — for her command of public health minutia as well as criticism — for appearing, at times, to fail to run sufficient interference on Trump's mixed, erratic and often incorrect messages about the outbreak." Birx "has managed to maintain her composure — and sometimes correct Trump's misinformation — without triggering the wrath of the president or his supporters." Birx's name has even "surfaced as a potential replacement for" HHS Secretary Alex Azar. The piece adds that "Birx is one of two Obama administration-appointed health officials working for Trump. The other is" NIH Director Francis Collins — NIAID Director Anthony Fauci's "boss."

Trump Predicts Coronavirus Vaccine Will Come This Year. U.S. News & World Report (5/14, Smith-Schoenwalder, 2.4M) says President "Trump on Thursday said that he expects a coronavirus vaccine by the end of 2020, which is a faster timeline than many health officials have predicted." The President stated, "I think we're going to have a vaccine by the end of the year." Trump "added that distribution of the vaccine 'will take place almost simultaneously' because he is mobilizing the military to help with the process." His "comments come just a couple days after" NIAID Director "Anthony Fauci told Congress that the idea of having therapeutics or a vaccine ready 'to facilitate the reentry of students into the fall term would be something that would be a bit of a bridge too far.'"

Public Health School Deans Urge Trump To Triple Coronavirus Testing Or Face Cycles Of Shutdown. Newsweek (5/15, Martin, 1.53M) reports that four public health school deans on Thursday all signed individual statements urging the Trump Administration Thursday to use the Defense Production Act to require businesses to create more tests for the novel coronavirus. Newsweek adds, "Testing capacity for the coronavirus has been called a priority for reopening the country safely, including U.S. schools." National Institute of Allergy and Infectious Diseases Director Anthony Fauci told a Senate panel on Tuesday that "he wasn't sure if schools should reopen in the fall."

California Tells Hospitals To Consider Having A Lottery For Sought-After Covid-19 Drug. CNN (5/14, Cohen, Azad, Klein, 83.16M) reports that all 50 states "should have received shipments of the Covid-19 drug remdesivir earlier this week, according to audio obtained by CNN of a call between federal officials and governors." But there's "not nearly enough to go around, and on Monday, one state health department directed hospitals to consider holding a lottery for scarce medications." As part of its guidance, the California Department of Public Health "suggests that 'random allocation among patients be considered,' such as 'using a lottery system to select a certain proportion of patients who become eligible for the drug.'" According to CNN, "It's been a little over two weeks since top health expert Dr. Anthony Fauci first announced that a large study showed remdesivir worked against Covid-19, calling it the new 'standard of care' for patients."

Large Majority Of Americans Say Country Lags In Testing Availability: POLL. ABC News (5/15, Karson, 2.97M) reports strong majorities of Americans
believe the country lacks sufficient testing and are also skeptical about returning to pre-pandemic activities, including sending kids back to school," according to a new ABC News/psos poll released on Friday. According to ABC, “nearly three in four Americans believe there are not enough tests available in the United States, compared to only 26% who said there is adequate testing available right now.” The new poll comes as National Institute of Allergy and Infectious Diseases Dr. Anthony Fauci this week “warned lawmakers that reopening schools and businesses too quickly could trigger an outbreak, and possibly stifle the road to economic recovery.”

States Are Letting Stay-At-Home Orders Expire, Regardless Of Virus Metrics. Politico (5/15, McCaskill, 4.29M) reports, “Stay-at-home orders or business restrictions are set to expire” in a dozen states across the US, leaving state and local leaders to “grapple with whether to extend expiring stay-at-home orders or assess how much their reopening strategies are fueling new health risks” associated with COVID-19. Public health experts, including National Institute of Allergy and Infectious Diseases Director Anthony Fauci, “have warned that the virus will continue to spread as more people begin leaving their homes, noting the difficulty of maintaining physical distancing in certain spaces as Americans return to their normal pre-pandemic activities.”

Is Anthony Fauci Today’s Galileo Galilei, The Champion Of Science? In an opinion piece for STAT (5/14, 24K), astrophysicist Mario Livio says that as he watches NIAD Director Dr. Anthony Fauci defend “science and scientific integrity...on the news, I think of another ‘battler’ who ultimately had the last word.” Livio compares Fauci to Galileo Galilei, who was “sentenced to confinement by the Roman Inquisition because he was ‘vehemently suspected of heresy.’” That supposed heresy “was his support of the Copernican system of planetary movement.” Livio concludes, “It took the Catholic Church more than 350 years to admit that Galileo was right. We can’t afford to wait that long to find out that Fauci is right.”

Trump’s Plan To Limit The Pandemic’s Death Toll: Undercount The Numbers. In an opinion piece for Vox (5/14, 2.27M), senior correspondent Matthew Yglesias writes that “experts have a range of ideas to suppress the Covid-19 pandemic, save lives, and avert new waves of economic misery.” However, President “Trump seems to be embracing another plan – massaging the numbers to make inconvenient deaths go away.” Still, “experts believe the problem with the numbers is the opposite – official statistics understake the Covid-19 death toll.” Yglesias adds that on Tuesday, NIAD Director “Anthony Fauci expressed the view of most public health professionals that even with the attempted adjustment for probable cases, the official numbers still underestimate the true death toll.” Yglesias concludes that “a strategy focused on juiking the stats is overwhelmingly likely to end with more real-world deaths than necessary.”

Fox News Dumps Coronavirus Coverage For Anti-Obama Conspiracy Theory. In an analysis, CNN (5/14, Darcy, 83.16M) says that “if you woke up from a coma on Wednesday afternoon and flipped on Fox News, or checked the network’s website, you’d be forgiven if you had no idea the country is currently grappling with a pandemic killing tens-of-thousands of Americans and leaving millions more unemployed.” That is because Fox “largely ignored the virus in the afternoon and into its prime time programming.” After GOP “senators released a list of Obama officials who sought to unmask the name of an unidentified American caught in intelligence reports, who turned out to be Michael Flynn, Fox News went all in on the story.” However, “when Fox News did find time to cover the coronavirus, it was done in part through the lens of criticizing” NIAD Director Dr. Anthony Fauci.

Tensions Rise As Texas Governor Readies To Lift More Rules. The AP (5/15, Weber, Vertuno) reports that “few states are rebooting quicker than Texas, where stay-at-home orders expired May 1.” With coronavirus “cases still rising, including single-day highs of 1,458 new cases and 58 deaths Thursday, Republican Gov. Greg Abbott has defended the pace by emphasizing steady hospitalization rates and pointing out that Texas’ 1,200 deaths are still behind similarly big states, including California and Florida.” However, “on the cusp of even more restrictions ending Monday, including gyms cleared to reopen, a political confrontation is growing over attempts by big cities to keep some guardrails.” The revamped tensions come at a time when NIAD Director Dr. Anthony Fauci “warned Congress this week of ‘needless suffering and death’ if the U.S. moves too quickly.”

Coronavirus Question: Let’s Say A Vaccine Proves Safe And Effective. Then What? In an editorial, USA Today (5/14, 10.31M) says that if a safe and effective coronavirus vaccine is developed, “the issues surrounding how to distribute vaccines present a number of troubling questions that are not getting nearly the attention they deserve. ... Even within the USA, there’s little evidence of a plan for how vaccines might be distributed in the early days when there are not enough to go around.” USA Today adds, “With scientists saying that one or more vaccines could
complete trials as early as this fall, this is looking like one 
more area for which the nation is not fully prepared." USA 
Today notes that there are at least eight vaccines in clinical 
development, according to National Institute of Allergy and 
Infectious Diseases Director Anthony Fauci.

‘Re-Examine All The Evidence’: Rand Paul 
Demands Fauci Reconsider Position On 
School Closures. The Washington Examiner (5/14, 
Miller, 448K) reports “GOP Kentucky Sen. Rand Paul urged” 
NIAD Director “Anthony Fauci to reconsider his position that 
schools should remain closed in the fall to stop the spread of 
the coronavirus.” Paul tweeted, “Evidence-based scientists 
around the world argue to open schools. ... Please re- 
examine all the evidence Dr. Fauci!” The senator’s “post 
came alongside an article from WIRED magazine with the 
headline, ‘The Case for Reopening Schools’.”

White House To ‘Reconfigure’ Coronavirus 
Task Force With An Emphasis On Reopening 
The Country. The Washington Examiner (5/14, Crilly, 
448K) says the White House “will add more figures to its 
coronavirus task force before the end of the week...as it 
enters the crucial phase of trying to reopen the country 
safely.” According to a “senior administration official,” the 
additions would represent a “reconfiguring.” The official said, 
“There was an initial phase that was more focused on border 
elements and what are you doing with flights, what are you 
doing with cruise ships, and how do you do the best to delay 
its arrival here? The second phase was really more defined 
by healthcare experts and the strategy to mitigate it and slow 
the spread. ... And now, I think we are sort of entering a new 
phase, which is, ‘How do you now safely reopen?’” The piece 
adds that Trump “has been under pressure from conservatives to reduce the influence of scientists on the 
panel, including” NIAID Director Dr. Anthony Fauci.

Remdesivir Distribution Causes Confusion, 
Leaves Some Hospitals Empty-Handed. NPR 
(5/14, Lupkin, 3.12M) reports the federal government has 
begun distributing remdesivir, which the FDA has authorized 
for emergency use as a treatment for COVID-19, but some 
states and hospitals are confused “about why they’ve been 
left empty-handed.” Gilead Sciences, the manufacturer of 
the drug, “said it would donate its initial supply of the medicine,” 
but “the federal government is in charge of coordinating where the treatment is to be shipped.” National Institute of 
Allergy and Infectious Diseases Director Anthony Fauci 
“stressed that the study’s result for remdesivir was 
statistically significant but really modest. And we must 
remember it was only a modest result showing that the drug 
made a 31% faster time to recovery.”

Top Health Officials Vanish From National TV 
Interviews As White House Refocuses 
Messaging. CNN (5/14, Darcy, 83.16M) reports “the 
nation’s top physicians have stopped appearing on national 
television for interviews as the White House exerts increased 
control over communications during the coronavirus 
pandemic and refocuses its message toward reopening the 
economy.” NIAID Director Anthony Fauci “appeared on CNN 
on May 4 for an interview with Chris Cuomo.” CDC Director 
Robert Redfield “has not appeared on national television 
since April 17 when he was interviewed on the ‘Today’ show 
on NBC News.” FDA Commissioner Stephen Hahn “has not 
appeared on national television since April 28 when he spoke 
with Fox News host Maria Bartiromo.” For his part, Surgeon 
General Jerome Adams “has not appeared on national 
television since April 17 when he appeared on ‘Fox & 
Friends’.

Trump Is Smearing Fauci. William Saletan writes for 
Slate (5/14, 1.58M) that the President “is smearing” NIAID 
Director Dr. Anthony Fauci. The President “wants businesses 
and schools to reopen sooner than Fauci thinks is safe. So 
the president has fabricated a story about Fauci giving bad 
advice. Trump’s goal is to make the public think that Trump, 
not Fauci, knows best what to do about the novel 
coronavirus.” However, “his fabrication shows the opposite: 
White Fauci tells the truth, Trump tells lies.”

Trump Admin Shoots The Messenger As 
Whistleblower Highlights Ongoing Issues. Matt 
Shuham writes for Talking Points Memo (5/14, 260K) that 
even as Dr. Rick Bright criticized the Trump Administration’s 
COVID-19 response during his testimony, the Administration 
returned the favor. President Trump said, “With Bright’s 
attitude...he ‘should no longer be working for our 
government!” Meanwhile, HHS “said Bright was ‘using his 
taxpayer-funded medical leave to work with partisan 
attorneys who are politicizing the response to COVID-19.” 
Indeed, HHS Secretary Alex Azar, “speaking from the White 
House lawn in the middle of Bright’s testimony, made a 
similar point. ‘While we’re launching Operation Warp 
Speed, he’s not showing up for work to be part of that.” Shuham also 
mentions NIAID Director Dr. Anthony Fauci.

Trump Dismisses Fauci’s Warning Against 
Reopening Schools: ‘I Totally Disagree’. Cristina 
Cabrera writes for Talking Points Memo (5/14, 260K) that on 
Thursday, President Trump “rejected White House COVID-19 
task force official Dr. Anthony Fauci’s assertion during a 
Senate hearing that schools could not be expected to reopen 
by fall.” Trump said, “Anthony is a good person, very good 
person. ... I’ve disagreed with him. When I closed the border
to China, he disagreed with that, and then ultimately he agreed.” Trump added, “I totally disagree with [Fauci] on schools.”

**Trump Is Blaming China For Coronavirus Even As He Employs The Same Authoritarian Tactics As Xi Jinping.** John Hiltz writes for *Business Insider* (5/14, 3.67M) that President Trump “has essentially blamed China for the devastating scale of the coronavirus pandemic, slamming Beijing over its lack of transparency and warning that the US could ‘cut off’ its relationship with the Asian country.” However, the President “is guilty of many of the same behaviors for which he’s condemned China, experts say,” given that his “response to COVID-19 has often mirrored the approach of authoritarian leaders like Chinese President Xi Jinping.” While top public health officials like Dr. Anthony Fauci have said that a robust testing system is key to thwarting the virus, for example, Trump in early May said that too much testing for COVID-19 makes the US ‘look bad’.

**White House Press Secretary Disputes Poll That Show Americans Trust Dr. Fauci Much More Than Trump.** Eliza Relman writes for *Business Insider* (5/14, 3.67M) that on Thursday, “White House press secretary Kayleigh McEnany...disputes recent polling that found Americans trust Dr. Anthony Fauci, the nation’s top infectious disease expert, significantly more than they trust President Donald Trump to provide accurate information about the coronavirus.” McEnany said during an interview, “I believe that the American people have a lot more trust in the president than that poll indicates. ... I believe the American people have great confidence in this president’s leadership.”

**Column: We Shut Down The Economy To Make Progress Against COVID-19 – And Then Made No Progress.** *Los Angeles Times* (5/14, 4.64M) columnist Michael Hiltz writes that “many people are getting fed up with the” coronavirus “lockdown, and not only because it throws millions of them out of work.” Hiltz asserts that “we have made scant progress against the virus, or at least not nearly as much as the richest, most powerful and most technically adept nation on Earth should have made.” He adds that that NIAID Director Dr. Anthony Fauci “warned that states that reopen businesses and allow public gatherings too hastily while the pandemic is still in full cry could ‘trigger an outbreak that you may not be able to control.’” Hiltz concludes that President “Trump is getting what he seems to want: a nation mired in a chaos that benefits only those with the means to insulate themselves from the crisis. The rest of us can do nothing but gnash our teeth at a shutdown without end, amen.”

**Rand Paul Delivers A Magnificent Reality Smack To Anthony Fauci.** In an opinion piece for the Washington Times (5/14, 492K), Cheryl K. Chumley writes that “in case you missed it: Sen. Rand Paul delivered a much-needed, long overdue, thankfully-finally-here reality check to” NIAID Director Dr. Anthony Fauci, reminding the health expert “in a Senate panel hearing earlier this week that hey now, hey guy, you’re just a guy — and your expertise on viruses shouldn’t be taken as expertise on politics, government, economics, policy or the running of a nation and its peoples.” In other words, Chumley says, “the Fauci influence over all walks of American life should fade.”

**Editorial: Fauci’s Caution On Schools Is Sound, No Matter What Non-Physician Trump Says.** In an editorial, the *St Louis Post-Dispatch* (5/14, 685K) says “the latest battle between President Donald Trump and” NIAID Director “Anthony Fauci, like previous ones, boils down to ego-based conjecture versus science and fact.” Fauci “argues it would be reckless to rush children back into classrooms in the fall before doctors have a better grasp of the dangers.” Meanwhile, “Trump, whose training in medicine and epidemiology is exactly zero, says it’s time to get back to class.” The Post-Dispatch says, “In the battle between Fauci’s voice of caution versus Trump’s call for throwing caution to the wind, we’ll stick with the guy who actually knows what he’s talking about.”

**NIH Begins Trial To Determine How Effective Hydroxychloroquine.** *Newsweek* (5/14, Slisco, 1.53M) reports the National Institute of Allergy and Infectious Diseases (NIAID) is sponsoring “a clinical trial testing the effectiveness of combining antimalarial drug hydroxychloroquine with antibiotic azithromycin as a treatment for COVID-19.” The controlled trial “will involve 2,000 U.S. adults who are infected with the coronavirus and have symptoms like shortness of breath, cough and fever.” NIAID Director Dr. Anthony Fauci said in a statement: “Although there is anecdotal evidence that hydroxychloroquine and azithromycin may benefit people with COVID-19, we need solid data from a large randomized, controlled clinical trial to determine whether this experimental treatment is safe and can improve clinical outcomes.”

**Interferon Emerges As Potential Treatment For COVID-19.** The *Globe and Mail* (CAN) (5/12, Semeniuk, 1.04M) reported that two newly reported trials show potential for a class of drugs called interferon as a therapy for COVID-19. Toronto’s University Health Network researcher Eleanor Fish, a “senior author on one of the studies, said that awareness of interferon as a potential COVID-19 treatment has been slow to build and should be prioritized for larger-
scale clinical trials.” U.S. National Cancer Institute senior investigator Howard Young, “who has studied the anti-viral properties of interferon, echoed the need for more study.” Young “said an important question to be explored is whether mild versus more-severe cases of COVID-19 produce different responses to the drug.”

U.S. Accuses Chinese-Born Researcher At Cleveland Clinic Of Ties To Chinese Spying. Reuters (5/14, Hosenball) reports the FBI arrested Chinese-born former Cleveland clinic employee Dr. Qing Wang “on fraud charges related to $3.6 million in federal grants, the FBI said on Thursday, the latest move in a U.S. crackdown on alleged attempts by China to steal American scientific advances.” Reuters adds, “Prosecutors said Wang accepted grants from the National Institutes of Health without disclosing that he was serving at the same time as dean of the College of Life Sciences and Technology at the Huazhong University of Science and Technology.”

Additional Sources. NPR (5/14, Romo, 3.12M) reports, “The FBI claims Qing Wang lied to receive more than $3.6 million in grants from the National Institutes of Health while also collecting money for the same research from the Chinese government.” The Cleveland Plain Dealer (5/14, Eaton, 895K) and The Daily Caller (5/14, Safi, 716K) also report.

Talking In Enclosed Space Can Generate Droplets That Linger For Up 14 Minutes, Study Finds. ABC World News Tonight (5/14, story 8, 0:15, Muir, 7.42M) reported new research indicates “when two people talk loudly in an enclosed space with poor air flow, droplets in spit can float in the air for 8 to 14 minutes with substantial risk of transmission.”

Additional Source. The New York Times (5/14, Sheikh, 18.61M) reports, “Researchers at the National Institute of Diabetes and Digestive and Kidney Diseases and the University of Pennsylvania, who study the kinetics of biological molecules inside the human body, asked volunteers to repeat the words ‘stay healthy’ several times” and “found that speaking louder could generate larger droplets, as well as greater quantities of them.” The report was published Wednesday in the Proceedings of the National Academy of Sciences.

Experimental Injection Of ‘Good’ Bacteria Significantly Cut Bacterial Vaginosis Recurrence Rate. Endpoints News (5/14, Grover) reports that injecting a “good” bacterium can reduce the high recurrent rate of bacterial vaginosis (BV) by a third, a 228-patient, placebo-controlled study suggests. The study “evaluated the effect of a ‘good’ bacterium product, called Lactin-V, which was packaged by California-based microbiome company Osel.” The NIH-funded study was published Wednesday in the New England Journal of Medicine.

NCI Exceptional Responders Initiative Pilot Study Meets Feasibility Goal. Oncology Nurse Advisor (5/14, Bennett) reports the National Cancer Institute Exceptional Responders Initiative pilot study “successfully analyzed tumor specimens from more than 100 cases, deeming the effort feasible.” According to the study’s authors, “This study met its main feasibility goal to identify at least 100 analyzable ER [exceptional responder] cases in less than 3 years.” The results were recently reported in the Journal of the National Cancer Institute. A corresponding editorial said, “Just the ability to gather such a large number of rare and valuable tumor samples with clinical data is remarkable.”

Researchers Try Combining Remdesivir With A Second Drug To Deliver A “One-Two Punch” To Virus. CBS News (5/14, Lapook, 3.68M) reports Dr. Aneesha Mehta, the lead investigator of an National Institutes of Health (NIH) trial at Emory University that “showed the drug remdesivir reduced average hospitalizations from 15 to 11 days,” he said he thinks the is going to be one important tool, but we also need to look for other ways to help our patients.” For the next phase of the trial, Mehta and colleagues are “combining remdesivir, which stops the virus from multiplying, with a powerful anti-inflammatory drug that aims to prevent organ damage by calming down an inflamed immune system.” The NIH “also said researchers are testing another potential coronavirus treatment cocktail: A mix of the malaria drug hydroxychloroquine with an antibiotic used to treat infections like pink eye.”

COVID Patients Given Malaria Drug Didn’t See Significant Improvements: Studies. Reuters (5/14, Erman, Maddipatla) reports patients given the anti-malarial drug hydroxychloroquine, which President Trump has touted as a potential COVID-19 treatment, “did not improve significantly over those who did not, according to two new studies published in the medical journal BMJ on Thursday.” The National Institutes of Health “said on Thursday it began a study to evaluate the combination of antibiotic azithromycin and hydroxychloroquine, which Trump described as a potential ‘game changer’ for the pandemic.”

Part Of Gilead’s Coronavirus Drug Donation Allocated To Japan. Reuters (5/14, Swift) reports hospitals in Japan have started treating severely ill patients with COVID-19 using Gilead Sciences’ experimental COVID-19 drug, according to ministry official Yasuyuki Sahara.
Sahara "said in an e-mail on Thursday that the U.S. firm’s treatment has been distributed to hospitals in Japan since May 11 and is being used for patients in intensive care or those on ventilators." A National Institutes of Health trial showed remdesivir "cut hospital stays by 31% compared with a placebo treatment, although it did not significantly improve survival."

Additional Source. Fox News (5/14, Hein, 27.59M) also reports.

Virginia Receives 2nd Shipment Of New Antiviral Drug. The Richmond (VA) Times-Dispatch (5/14, Martz, 277K) reports, "Virginia has received a second shipment of the new antiviral drug remdesivir to treat critically ill COVID-19 patients, but the supply is enough for only 36 patients." The U.S. FDA "issued an emergency use authorization for remdesivir on May 1, but it is still an "unapproved product" that may be used for treating adults and children who are hospitalized with severe cases of confirmed or suspected COVID-19." The National Institutes of Health and Gilead Sciences "conducted a clinical trial of remdesivir that resulted in preliminary findings that the drug speeds recovery of COVID-19 patients hospitalized with severe cases of the disease, according to a Health Department summary."

US Needs Bipartisan Push For Scientific Research After Coronavirus: Congressional Leaders. In an op-ed for USA Today (5/14, 10.31M), Senate Minority Leader Schumer, Sen. Todd Young (R-IN), Rep. Mike Gallagher (R-WI), and Rep. Ro Khanna (D-CA) write that "America is no longer the preeminent leader in scientific research as we were for the second half of the 20th Century. We must address this vulnerability." The lawmakers argue the Endless Frontiers Act "proposes a renewed national investment in public research and development to strengthen our nation’s innovation ecosystem now and into the future." They add "that every dollar invested in the National Institutes of Health leads to $3 in increased stock market valuation for private companies," and research indicates "that raising public research and development spending by $100 billion per year on a permanent basis could help generate as much as 4 million new American jobs."

COVID-19 Is Threat To Our Biomedical Research Enterprise. In an opinion in The Hill (5/14, 2.98M), contributor Kafui Dzirasa, a National Institutes of Health-funded brain researcher at Duke University, writes, "COVID-19 has placed a unique strain on the U.S. biomedical research enterprise." Dzirasa says, "COVID-19 has rendered individuals over 65 an at-risk: a population that is overrepresented in our nation’s pool of scientific investigators," and "behavioral studies over the last three years have also revealed that our nation’s young scientists are a high-risk group for mental health challenges." Dzirasa adds, "I am unclear whether the U.S. biomedical research enterprise can sustain this dual blow to young and older scientists."

Gilead Should Ditch Remdesivir And Focus On Its Simpler Ancestor. In an opinion in STAT (5/14, 24K), Victoria C. Yan and Florian L. Muller write that Gilead’s antiviral drug remdesivir "has been propelled into the spotlight with the hope that it can stop, or at least curtail, the ravages of SARS-CoV-2, the virus that causes Covid-19." Yan and Muller say, "Data from the open-label SIMPLE trial, sponsored by Gilead, and the randomized controlled Adaptive Covid-19 Treatment Trial, sponsored by the National Institute of Allergy and Infectious Diseases, show that remdesivir may accelerate recovery rates among patients with advanced Covid-19." However, they argue that Gilead should focus instead on pro-drug GS-441524, which "is easier to synthesize than remdesivir, requiring three steps instead of the seven needed for remdesivir."

Both/And Problem In An Either/Or World. In an editorial in Science Magazine (5/15, 427K), H. Holden Thorp writes that progress on COVID-19 vaccines in China and the U.S. "should make us optimistic that science will solve this problem, but the actions of the governments involved are not equally inspiring." Thorp says that the Trump Administration "can’t grasp that it’s possible to question the actions of the Chinese government about the early days of the pandemic while embracing collaboration with Chinese science." Thorp adds, "The latest setback is the decision by the U.S. National Institutes of Health (NIH) to terminate the grant 'Understanding the Risk of Bat Coronavirus Emergence' to Peter Daszak of the nonprofit EcoHealth Alliance, who, with NIH approval, shared one of five grant dollars with Shi Zhengli, a top coronavirologist at China’s Wuhan Institute of Virology (WIV)."

Research On TPA Nanoconjugate Aims To Extend Thrombolysis Benefits To More Stroke Patients. Cleveland Clinic Consultant OD (5/14) reports the National Institute of Neurological Disorders and Stroke (NINDS) awarded a five-year $2 million grant to researchers at the Cleveland Clinic to study "a novel stroke therapy that uses tissue plasminogen activator (tPA) conjugated to nanoparticles." The researchers "will assess the ability of a novel dual-action agent combining tPA with antioxidant-loaded nanoparticles to dissolve clot better and protect the brain from reperfusion injury following stroke."
**Health & Medical News**

White House Officials Signal Support For COVID-19 Relief For States Despite Opposition From Some GOP Groups. The Washington Post (5/14, Costa, Stein, Kim, 14.2M) reports officials in the White House "have privately signaled that they are willing to provide tens of billions of dollars in relief to states as part of a bipartisan deal...despite President Trump’s reluctance and strong opposition from conservative groups." The Post says while "that position is likely to anger some Republicans who have warned that Democrats want ‘blue state bailouts,’ many White House officials now believe that providing new funding to states...will be necessary if they want to secure their own priorities, such as tax breaks and liability protections for businesses."

CNBC (5/14, Pramuk, 3.62M) reports Senate Minority Leader Chuck Schumer (D-NY) indicated on Thursday that he is "hopeful Congress can strike a deal on more coronavirus relief, as Republicans spike a $3 trillion rescue package House Democrats plan to pass Friday." Schumer "told CNBC that he believes a worsening crisis will force Republicans to consider more spending to try to rescue the economy," and "pointed to Wednesday comments from Federal Reserve Chairman Jerome Powell, who said ‘additional fiscal support could be costly, but worth it if it helps avoid long-term economic damage and leaves us with a stronger recovery.’"

In contrast, the AP (5/14, Ram) reports Senate Majority Leader Mitch McConnell on Thursday “branded House Democrats’ $3 trillion economic relief bill a ‘totally unserious effort’ to address the coronavirus pandemic, underscoring the deep election-year grudge over what Congress’ next response to the crisis should be.” McConnell "said Democrats had produced a ‘seasonal catalog of left-wing oddities and called it a coronavirus relief bill.’" According to the AP, "Provisions he singled out for criticism included a rollback of GOP-passed tax increases on residents of states with high taxes, language making it easier for people to vote by mail and what he called ‘the cherry on top’ – provisions helping legal marijuana businesses."

As COVID-19 Pandemic Persists, GOP Calls For “Pause” On More Aid. The AP (5/14, Taylor) reports companies “are going belly up, tens of millions have been laid off and, by some measures, the U.S. seems headed for another Great Depression,” however, "Republicans surveying the wreckage aren’t ready for another round of coronavirus aid, instead urging a ‘pause.’" This is "a position based on a confluence of factors." Surveys indicate "GOP voters think the government is already doing enough.

Republicans on Capitol Hill are divided over the best approach. Billions approved by Congress have yet to be spent.” In addition, it remains to be seen what the President will “do next, if anything, to juice the economy – his payroll tax cut idea hasn’t gained any traction on Capitol Hill.” As a result, "GOP leaders see an unfolding crisis that does not yet cry out for further action."

About 75% Of US Small Businesses Seek Federal Assistance Amid COVID-19 Pandemic, Survey Shows. The Wall Street Journal (5/14, O’Keefe, Subscription Publication, 7.57M) reports a new Census Bureau survey found 75 percent of US small businesses have sought federal assistance to stay afloat during the COVID-19 pandemic. Data show 75 percent of respondents sought Paycheck Protection Program loans, and almost 30 percent said they sought SBA disaster loans.

Prospects For Second Round Of Stimulus Checks Seem “Uncertain.” The Washington Post (5/14, Werner, 14.2M) reports almost “130 million Americans have received direct payments of up to $1,200 from the U.S. Treasury, a centerpiece of the federal response to the coronavirus pandemic,” however, “prospects are uncertain for another round of these stimulus checks.” The article says, “President Trump has left the door open to the idea,” but the GOP has “declared the House Democratic bill dead on arrival, and some have voiced skepticism about the need for any more individual payments.”

Sanders Wants Senate To “Improve” House Dems’ $3T COVID-19 Relief Package. The Hill (5/14, Jagoda, 2.98M) reports on Thursday, Sen. Bernie Sanders (I-VT) “said that the Senate should ‘improve’ House Democrats’ $3 trillion coronavirus relief package so that it better addresses families’ health care and economic needs.” These comments from Sanders, a prominent progressive lawmaker and former Democratic presidential candidate, come one day before the House plans to vote on the bill, despite a push from the leaders of the Congressional Progressive Caucus to delay the vote.

Bipartisan Group Of Lawmakers Proposes Compensation Fund For Essential Workers Impacted By COVID-19. USA Today (5/14, Cummings, 10.31M) reports on Thursday, a group of lawmakers from both parties announced they intend to “introduce a bill that would create a compensation fund for essential workers and their family members who have been struck by the coronavirus.” Reps. Carolyn Maloney (D-NY), Jerry Nadler, (D-NY), and Peter King (R-NY), as well as Sen. Tammy Duckworth (D-IL) unveiled "the Pandemic Heroes
Compensation Act during a digital news conference. They were joined by union representatives from the Uniformed Fire Officers Association, Uniformed Firefighters Association, National Rural Letter Carriers Association, and SMART, the International Association of Sheet Metal, Air, Rail and Transportation Workers.”

Pelosi Pushing For Vote On $3T COVID-19 Relief Bill Despite Objections From Some Dems. Politico (5/14, Ferris, Caygle, 4.29M) reports House Speaker Nancy Pelosi “is projecting confidence that the House will pass Democrats’ massive coronavirus relief bill Friday, even as she and her leadership team are still working to secure the votes.” Liberals and centrists in Pelosi’s party “are grumbling about the roughly $3 trillion measure.” Meanwhile, “House Republicans have overwhelmingly said they oppose the bill, and some Democrats are unable to travel to the Capitol to vote amid the pandemic, leaving Pelosi and her whip operation with tight margins to clear the bill.” CNN (5/14, Foran, Raju, Byrd, 83.16M) reports that this “pushback underscores how House Democratic leaders are being attacked on all sides over the legislation — by congressional Republicans, who have dismissed the legislation as an liberal wish list, as well as within their own ranks by both progressives and moderates.”

New York Will No Longer Force Nursing Homes To Accept Recovering COVID-19 Patients. The Wall Street Journal (5/14, Mathews, Subscription Publication, 7.57M) reports New York changed its policy of forcing nursing homes to accept patients recovering from COVID-19 so that now patients must test negative for the virus first.

Debate Over Reopening US “Increasingly Partisan And Bitter.” The New York Times (5/14, Nolan, Bosman, Robertson, 18.61M) reports that for Wisconsin, Michigan, and Pennsylvania, three states “with Democratic governors and Republican legislatures, ending stay-at-home orders mixes health guidance and partisan politics.” The coronavirus response in those states “is becoming a confused and agitated blend of health guidance, protest and partisan politics — leaving residents to fend for themselves.” The governors, “backed by public health experts, have urged caution before reopening,” while Republican legislatures “in the states have pushed in the opposite direction, citing economic necessity and personal freedom.”

The Los Angeles Times (5/14, Elehad, 4.64M) reports the “mounting pressure comes as the number of jobless Americans continues to grow across the nation,” even as the COVID-19 death toll climbs. Meanwhile, governors in other states including Ohio, Rhode Island, and Minnesota have “announced plans to loosen restrictions in the coming days and weeks.”

Newsom Says COVID-19 Forcing Sharp State Budget Cuts. The Los Angeles Times (5/14, Myers, 4.64M) reports California Gov. Gavin Newsom (D) “asked state lawmakers Thursday to sharply curtail spending on public schools and an array of government services while directly appealing to President Trump and Congress for help to prevent billions of dollars in additional spending cuts.” Newsom said, “The federal government has a moral and ethical and economic obligation to help support states. ... After all, what is the point of government, if not to protect people, our safety and the wellbeing of citizens?” Without this help, Newsom “said state officials have few options in the face of a projected $54.3-billion deficit through early next summer.”

The New York Times (5/14, 18.61M) reports the state budget “slashes spending by nine percent overall from the initial proposal the governor made in January.” Newsom wrote to legislators, “Our state is in an unprecedented emergency, facing massive job losses and shortfalls in record time. ... This budget reflects that emergency.” The Times says that “to cushion the blow of a projected 22 percent decline in revenue, the governor proposed drawing down the state’s so-called rainy day reserves of $16 billion over the next three years.” The proposed $203.3 billion budget, “if approved by the Legislature, would bring spending back to around 2018 levels. But it would still be well above the levels seen during the Great Recession a decade ago.”

Los Angeles County Mandates Face Coverings Whenever Outside. The Los Angeles Times (5/14, Money, Fry, Sharp, McGreevy, 4.64M) reports Los Angeles County Public Health Director Barbara Ferrer announced Thursday that all residents must cover their faces whenever outside at all times. Ferrer said, “Masks are, in fact, mandatory across the entire county when you’re outside of your home, not with members of your household and in any kind of contact with other people.” Even when on “a solitary walk or run, Ferrer said ‘you now need to have a face covering with you, because if you came by other people, you were walking by other people, you tried to go into a grocery store, you absolutely have to have that face covering on.’”

Following Arrest, California Gym Owner Again “Defies” Lockdown Order. The AP (5/14, Watson) reports from Oceanside, California that around a dozen weightlifters “wearing face coverings did sets Thursday in front of mirrors at a Southern California gym that was reopened by the owner despite his arrest last weekend for violating local coronavirus health orders that closed gyms.” Owner Lou Uridel has “vowed to keep the doors open at Metroflex Gym in the
coastal city of Oceanside, north of San Diego,” but “warned his customers they might be handcuffed and hauled off like he was on Sunday.” Undel may be the first “business owner arrested in California for violating health orders by reopening, although a growing number are doing that.” Authorities wary of a “public backlash have preferred to use warnings to get local businesses to comply.” Forcing one to “shut its doors and citing the owner is rare, and arrests are considered a last resort.”

Cities, Counties In Texas Take Disparate Approaches To Enforcing Pandemic Restrictions. ProPublica (5/14, Beavais, 60K) reports, “As Texas now reopens at” Gov. Greg Abbott’s (R) direction, "under a much looser set of restrictions, a ProPublica-Texas Tribune analysis of complaint data in a dozen cites shows...disparate approaches to enforcement — particularly among businesses — were incredibly common across the state.” Cities and counties “arrived at dramatically different interpretations of Abbott’s emergency orders.” Austin “has issued just two citations, while others like Laredo and Dallas have written hundreds of tickets, in addition to arresting a handful of business owners who defied orders to close.”

Texas Firefighters, Paramedics Tapped For Nursing Home Coronavirus Testing. The Houston Chronicle (5/14, Foxhall, 730K) reports firefighters and paramedics “across Texas have been tapped to help with coronavirus testing in nursing homes, as state and local officials work through how to meet Gov. Greg Abbott’s directive to test more than 200,000 residents and staff.” Fire departments statewide are "being asked to help with facility inspections and on-site testing, as part of a multi-agency effort, according to a Texas Department of State Health Services email shared with Hearst Newspapers, offering detail on the state’s plan.” In letters to fire departments "Wednesday, the state cleared fire personnel to enter the facilities." Letters to the facilities “said they would be contacted ‘very soon’ by a testing team that could include first responders or the state national guard.” Local officials were “figuring out Thursday exactly how this testing might work, pushing for further clarification from the state about its broad demands.”

Texas Pays $45 Million For 300,000 Coronavirus Tests. The Austin (TX) American Statesman (5/14, Price, Subscription Publication, 343K) reports the state of Texas “is paying $45 million for 300,000 oral-swat tests – or $150 per test, according to a purchase order obtained by the American-Statesman through an open records request.” The April 30 purchase agreement "is with San Diego-based Gotham LLC, and includes the processing of tests at the private lab of Curative, Inc., according to Seth Christensen, spokesman for the Texas Department of Emergency Management, which made the purchase.” Christensen “said at least 75% of the purchase price, which includes the processing of each test, will be eligible for federal reimbursement.” The Curative tests, “designed to be self-administered, won emergency-use approval in April by the U.S. Food and Drug Administration.” In April, officials at the U.S. Centers for Medicare and Medicaid Services “said they would pay $100 apiece for COVID-19 tests that increase testing capacity and lead to faster results — twice as much as Medicare had announced it would pay in March.”

Michigan Closes State Capitol “As Protesters Gather” Against Stay-At-Home Order. CNN (5/14, Stracqualursi, 83.16M) reports the Michigan state Capitol was closed Thursday as demonstrators gathered at the steps of the building to protest Gov. Gretchen Whitmer’s (D) stay-at-home order.” Police spokeswoman Shanon Banner “confirmed to CNN that because neither chamber was in session or holding committee meetings,” the Capitol was closed “per the procedures of the Michigan Capitol Commission.” The protest, organized “by Michigan United for Liberty, drew a crowd of roughly 200 ‘at the high point’ of Thursday’s event, according to Michigan State Police estimates.” Attorney General Dana Nessel warned in a statement that “presence of heavily armed protestors at the Capitol unnecessarily creates a powder keg dynamic that is dangerous to protestors, law enforcement and public servants reporting to work at the Capitol.”

Whitmer Again Criticizes Trump Administration’s Coronavirus Response. The Detroit Free Press (5/14, Spangler, 1.52M) reports Michigan Gov. Gretchen Whitmer (D) on Thursday “again criticized the Trump administration’s handling of the coronavirus pandemic, saying it sent the state a shipment of swabs that can’t be used with some kinds of tests for the virus.” Whitmer said, “We’re missing something as simple as a variety of swabs,” adding “that, without them, she can’t move as quickly as she’d like to expand testing in Michigan.” This is the “key to re-engaging sectors of our economy with confidence,” she added. Her remarks came “during an online chat with former Vice President Joe Biden, the presumptive Democratic nominee to face President Donald Trump in the fall election,” and Democratic Gov. Ned Lamont of Connecticut and Phil Murphy of New Jersey.

Attorneys “Threaten Coronavirus Lawsuits” Against Florida Nursing Homes. The Orlando (FL) Sentinel (5/14, Sanchir, 536K) reports law firm “behemoth” Morgan & Morgan plans to sue “two Florida nursing homes over their alleged mishandling of COVID-19 outbreaks, attorneys for the firm said Thursday.” The firm has been retained “by families whose loved ones died after coronavirus infections at the facilities where they had been patients, including three families at Opis Coquina Center in Ormond
Beach and an undisclosed number at Suwannee Health and Rehabilitation Center in Live Oak, near the Georgia border, the attorneys said. According to attorney Alexander Clem, “These family members are just in the last seven to 10 days learning about what happened to mom and dad... that [their death] was due to COVID-19. The folks that allowed this to happen knowingly – they deserve to be held accountable.” However, Kristen Knapp, communications director for the Florida Health Care Association, representing the nursing home industry, said the attorneys were “positioning themselves to profit from this tragic situation.”

Despite Missing Goal, Nebraska’s Governor Confident In State Testing Program. The AP (5/14, Schulte) reports Nebraska may not make “its goal of conducting 3,000 coronavirus tests per day by the end of May through the state’s TestNebraska program, but Gov. Pete Ricketts (R) expressed confidence Thursday that tests will reach” that pace “at some point” if residents continue to sign up. His comments came after “state officials reported that the program produced 2,358 results last week – well short of the 3,000 per day that was expected by the end of the month, when the ramp-up period is supposed to end.” Ricketts announced the $27 million coronavirus testing contract with Utah-based Nomi Health and three other firms on April 21, along with plans for a five-week ramp-up period to reach the estimated 3,000 tests per day. The state has opened four “mobile testing sites so far in different cities, with plans to open six and a goal that each will see 500 residents daily.” However, the program has faced criticism “from some Nebraska state lawmakers and problems have been reported in Iowa and Utah, which have similar contracts.”

The Omaha (NE) World-Herald (5/14, Stoddard, 641K) reports Ricketts “said he is watching two key measures: the rate of tests that come back positive for the coronavirus and hospital capacity.” Ricketts “said 277 state employees who have been trained to do contact tracing are now helping local health departments.” Felicia Quintana-Zinn, a deputy division director at the Nebraska Department of Health and Human Services, said tracers contact people who have tested positive for the coronavirus to find out who they might have exposed to the virus. “In most cases, exposure occurs if people are less than 6 feet from one another for 10 minutes or more.”

Connecticut Governor “Moving Ahead” With May 20 Reopening “Despite Concerns.” The AP (5/14, Haigh) reports despite a call on Thursday “by a group of Democratic state senators to delay plans to begin phasing out Connecticut’s COVID-19 restrictions next week,” Connecticut Gov. Ned Lamont (D) “said his administration is still moving ahead carefully toward the planned May 20 partial reopening of certain Connecticut businesses.” Lamont “noted that hospitalizations are in the third week of a downward progression and the state is on pace to ‘blow through’ a projected 42,000 tests per week beginning next week, ramping up to more than 100,000 by June.”

Democratic Connecticut State Senators “Implore Governor To Delay Reopening.” The Hill (5/14, Bowden, 2.98M) reports a group of Democratic “state senators in Connecticut have written to Gov. Ned Lamont (D), urging him to delay his plans to begin reopening the state’s economy.” In a letter obtained “by the Hartford Courant, the nine lawmakers noted that the state is still experiencing a rate of new coronavirus infections five times higher than it was recording on the day Lamont issued his executive order closing barber shops and hair salons, along with other nonessential businesses.” The senators also add, “While Connecticut is moving in the right direction in terms of testing capacity, hospitalizations and deaths, the number of new positive tests, while down from the peak, indicates that community transmission of COVID-19 is still occurring in Connecticut at levels far beyond our ability to track, trace and isolate potential contacts.” Connecticut has reported “more than 34,000 cases of coronavirus across the state so far, and just over 3,100 deaths have been recorded.”

Just 4,000 Have Been Tested Under Iowa Program. The AP (5/14, Foley) reports only 4,000 people have “gotten results through Iowa’s month-old $26 million coronavirus testing contract, but that will increase rapidly now that the equipment has been validated,” Gov. Kim Reynolds said Thursday. Reynolds “said the State Hygienic Lab has determined that the machines purchased for the TestIowa program are 95% accurate in detecting the virus in samples and 99.7% accurate in determining its absence.” The validation will allow TestIowa “to soon process 3,000 tests per day as originally envisioned,” Reynolds said. She “said it would also allow tests to be processed faster and the state to broaden the criteria of who can qualify for a test.” The announcement came as Iowa reported 12 more deaths from the virus and an uptick in hospitalizations. The state reported that “180 of the 318 deaths to date have been residents of long-term care facilities, where three dozen outbreaks have been confirmed.”

South Dakota Announces Plan To Test “All Long-term Care Facility And Assisted Living Residents” Over Next Month. The SiouxFalls (SD) Argus Leader (5/14, Ferguson, 179K) reports South Dakota public health leaders “on Thursday announced a plan to test all of the state’s long-term care facility residents and staff and other vulnerable populations for the new coronavirus.” The four-week plan, a “collaboration between the state
department of health, local healthcare providers and commercial testing labs, will attempt to test all residents and staff across the state’s nursing homes and assisted living centers. The “mass-testing” event will begin with testing residents in about 46 nursing homes in areas of substantial COVID-19 spread, moving next to the more than 100 other nursing homes across the state. The remaining two weeks will focus on assisted living centers.” South Dakota Health Secretary Kim Malsam-Rysdon “estimated that more than 7,400 residents and staff in nursing homes would be tested in the first week and more than 10,000 in the second week. In the third and fourth weeks, she expected about 4,300 staff and residents in assisted living centers would be tested each week.”

The AP (5/14, Groves) reports the state has “acquired more supplies needed for tests, allowing them to hold mass testing events.” Health officials also plan to “conduct random testing among vulnerable people to try to catch infections before they spread.” Malsam-Rysdon “said the state is also planning to hold mass testing events in Native American tribal communities, starting with a mass testing event with the Sisseton-Wahpeton Oyate next week.”

Hawaii’s Governor “Inclined” To Maintain Stay-At-Home Order Until June 30. The AP (5/14) reports Hawaii Gov. David Ige (D) “said Thursday he’s inclined to extend his “safer-at-home” order through the end of June to slow the spread of the coronavirus.” Ige “said he also plans to maintain the state’s requirement that travelers arriving in the state observe 14 days of quarantine.” Ige “said he would be examining allowing more businesses to reopen, including hair salons, barber shops and restaurants with dine-in service,” and also “said the state would look at guidance from the U.S. Centers for Disease Control and Prevention for information on how to keep employees and customers safe.”

Louisiana Senate Approves Legislation To “Shield Businesses From Virus Lawsuits.” The AP (5/14, DeSlatte) reports restaurants serving takeout and delivery orders in Louisiana during the coronavirus outbreak and businesses providing protective gear should be largely shielded from lawsuits for injuries, the state Senate decided Thursday. State senators overwhelmingly supported the pair of bills from Republican Sens. Sharon Hewitt and Patrick McMath, which are similar to business-backed measures proposed in other states and in Washington amid the pandemic. The state Senate also backed a measure “aimed at shielding government agencies from lawsuits from employees required to work during the coronavirus outbreak, if they follow the guidance for protective measures issued by the state and the U.S. Centers for Disease Control and Prevention.”

States Begin Partially Opening As Residents Grow Restless, Less Willing To Shelter In Place. The CBS Evening News (5/14, story 6, 2:00, O’Donnell, 5.25M) reported on growing efforts in a number of states to partially or completely repeal stay-at-home orders due to the coronavirus pandemic. In Michigan, armed protesters marched on the state Capitol building in defiance of the state’s order, and the Supreme Court of Wisconsin this week invalidated Gov. Tony Evers’ (D) stay-at-home order. Further, some small business owners are protesting the stay-at-home orders as fatally detrimental to their business’ financial interests.

Bloomberg Business (5/14, Rojanasakul, McCartney, 4.73M) reports most states in the US “have lifted at least some restrictions on the types of businesses that can be open, and distancing in nearly every one is on the decline — particularly on weekends — according to data from Unacast, a location data and analytics firm.” The data also suggested that states with more reliable stay-at-home orders and higher adherence rates saw lower spread of coronavirus over the past two months.

Some School Districts Ending Their Distance Learning Efforts. The AP (5/14, Amy) reports on the growing number of school districts across the US that have “pulled the plug on distance learning, all citing familiar reasons.” School officials say “it’s too stressful, the lack of devices and internet access is too much to overcome, and what students get from it just isn’t worth the struggle.” In Georgia, for instance, many district leaders say the “final weeks of the school year would have been dedicated anyway to preparing for and taking standardized tests that are now canceled.”

Scientists Say Testing Sewage Holds Promise For Monitoring Outbreaks Of Diseases Including Coronavirus. Reuters (5/14, Kelland) reports scientists say testing sewage for pathogens, including coronavirus, could help countries around the world monitor outbreaks of diseases and respond appropriately. Reuters highlights several efforts around the world to use sewage testing as a public health tool to inform officials about how widespread coronavirus is when deciding whether to ease restrictions. In addition, sewage testing could alleviate the burden of doing widespread testing of individuals, which has proven difficult in many parts of the world.

Analysis: Many “Essential” Workers Will See Pay Cuts As Companies Rescind “Hazard Pay” Policies. Bloomberg (5/14, Melin, Steverman, 4.73M) reports many “essential” employees in the US will be facing a
pay cut in the coming weeks as the initial push for "hazard pay" around the pandemic begins to fade. Initially, many employees received bonuses or pay bumps to compensate for the risk that comes with clocking in at supermarkets, hospitals and other crowded workplaces during a pandemic, but companies are beginning to end these programs. For example, Kroger “is rescinding the” pay “raise it gave to store and warehouse workers” while Target and Amazon “will follow later this month, with other firms charting similar moves.” The planned cutbacks “have rankled unions, employees and customers who are accusing companies of putting profits ahead of worker well-being.” The decisions “also raise questions about how to value the essential workers who are keeping society functioning,” as many employees “put their health and safety on the line in exchange for relatively low wages.”

COVID-19 Accelerating Decline Of Retail Industry. On its front page, the Wall Street Journal (5/14, A1, Kapner, Nassauer, Subscription Publication, 7.57M) reports the COVID-19 pandemic has accelerated the decline of the retail industry as more people move to online shopping. UBS estimates about 100,000 stores will close in the next five years, over triple the number that closed during the last recession.

Navy Continues To Battle Coronavirus Transmission Aboard Theodore Roosevelt Aircraft Carrier. The New York Times (5/13, Gibbons-Neff, Schmitt, Cooper, 18.61M) reported the Theodore Roosevelt aircraft carrier “continued its monthslong fight against the novel coronavirus, with at least one sailor aboard the ship testing positive, according to crew members.” The sailor “was quickly whisked off the ship, which is docked in Guam as Navy officials make preparation for the vessel to deploy.” However, the episode “underscores the stubborn challenges facing top Navy officials as a second investigation into the service’s handling of the virus — this one by the Defense Department’s inspector general — got underway this week.” Officials “said they had been aggressively screening and testing as crew members return to the Roosevelt after quarantining in Guam over the past month.”

Analysis: Gun Stores In Several States Ignored State-Ordered Closures, Initiated Tens Of Thousands Of Background Checks In April. USA Today (5/14, 10.31M) reports on how gun stores in several US states “have defied orders to close their doors as the coronavirus pandemic drives historic demand for firearms, according to background check data maintained by the Federal Bureau of Investigation and interviews with shop owners.” Currently, five states have ordered gun stores closed under stay-at-home orders and directives — Massachusetts, Michigan, New Mexico, New York, and Washington. However, FBI data from April show “that dealers in these [states] still initiated tens of thousands of background checks.” Washington alone saw 42,000 background checks initiated for gun purchases in April. Additionally, the National Instant Criminal Background Check System processed 2.9 million checks, making it the highest month on record, dating back to 1998.

Inspection Reports For Several Connecticut Nursing Homes Found Lapses In Infection Control, Prevention Around Coronavirus. The Connecticut Mirror (5/14, Thomas, Carlesso) reports inspections at several Connecticut nursing homes “found lapses in infection control and prevention and poor practices for the prolonged use of protective gear necessary during the COVID-19 pandemic, according to a half-dozen reports released Wednesday.” The reports, provided by Connecticut’s Department of Public Health, “are the first detailed accounts of targeted inspections ordered by the federal government on March 20 and later expanded by Gov. Ned Lamont (D) to cover all 213 skilled nursing homes, where the novel coronavirus has infected 6,000 and is attributed to more than 1,600 deaths.” Additionally, none of the reports “detailed inspections at homes with some of the highest numbers of people dying from COVID-19.” Department spokesman Av Harris “said there is a delay in releasing some reports.”

Analysis: Studies Suggesting Coronavirus Can Be Spread Through Loud Talking Show Need For Face Masks In Public. Forbes (5/14, Lee, 9.71M) reports on a new study published in the Proceedings of the National Academy of Sciences which suggests coronavirus could be spread in public through speaking, because the act of speaking can expel fluid droplets that hang in the air for several minutes. A similar study “published in Nature has suggested that on average a fluid droplet from [a] contagious person could contain 7 million viruses per milliliter,” and the research team then estimated “that just one minute of loud speaking could generate at least a thousand virus-containing little droplets that may hang in the air for over eight minutes.” Further, researchers explained that their study showed how “normal speech generates airborne droplets that can remain suspended for tens of minutes or longer and are eminently capable of transmitting disease in confined spaces.” Therefore, researchers are encouraging face mask adherence in public areas and enclosed spaces to limit the spread of virus-containing droplets.
UT Dallas Researchers Design 3D-Printed Disposable Ventilator Valve. The Dallas Morning News (5/14, Arnold, 946K) reports researchers at the University of Texas at Dallas “have designed a 3D-printed ventilator valve that helps patients breathe.” The ventilator valves “called positive end-expiratory pressure, also known as PEEP,” are disposable “to ensure patients’ lungs some air and do not collapse when exhaling.” The research team “is seeking emergency approval from the U.S. Food and Drug Administration so it can distribute the parts [to] hospitals that need them, the university said in an announcement.” The research team at UT Dallas “is one of several university groups across the country working to increase the supply of ventilators and protective equipment.”

Sen. Warren, Rep. Levin Propose Federal Contact Tracing Program. Sen. Elizabeth Warren (D-MA) and Rep. Andy Levin (D-MI) write for NBC News (5/14, 6.14M) that they are introducing a proposal “for a federal contact tracing program” for the next relief package from Congress. While House Democrats have a proposal that “already includes pieces of it, including $500 million to hire a diverse group of culturally competent contact tracers,” Congress needs “to stand up our whole plan for a national contact tracing strategy.” Warren and Levin claim the Administration’s “slow and dysfunctional response has been a disaster of epic proportion” and that is why “Congress must step in, and that’s why we have proposed the Coronavirus Contact Tracing Corps.”

The Hill (5/14, Budryk, 2.98M) covers the opinion piece from Warren and Levin.

Interview: Antimicrobial-Resistant Microbes Equally Important Issue During Pandemic. NPR (5/14, 3.12M) interviewed Boston University professor Muhammad Zaman, author of “Biography of Resistance: The Epic Battle Between People and Pathogens,” on his new book and what exactly antibiotic resistance means for US public health. In the interview, Zaman speaks on the dual-issue of antibiotic resistant microbes and the coronavirus pandemic, noting that “we know from history that the majority of deaths during the great 1918 flu pandemic were from secondary bacterial pneumonia.” Zaman also advocates for a more global, collaborative approach to addressing the issue both during and after the pandemic.

Infectious Disease Experts Warn Of Potential Dual-Season For COVID-19, Influenza During Winter. The San Francisco Chronicle (5/14, Allday, 2.67M) reports the greater Bay Area “blunted the impact of its first brush [with] the coronavirus, but infectious disease experts warn there are more outbreaks to come once the region eases shelter-in-place restrictions, and one looming event is of particular concern: the flu season.” Currently, no health experts know “what to expect in the fall and winter, when the coronavirus may congregate with seasonal influenza.” However, public health officials are “bracing for a resurgence of cases” for COVID-19 while also dealing with influenza. For example, infectious disease expert David Relman said, “This was a really good practice run for what may be a worse winter,” adding, “We need to be thinking really carefully now about the strategies we can use to address both things at the same time.”

Norwegian Cruise Line Expects Entire Fleet To Resume Full Operations In Approximately Six Months. USA Today (5/14, Hines, 10.31M) reports Norwegian Cruise Line “expects its entire fleet will be able to resume full operations in five to six months.” The company “shared the news in its earning report for the first quarter of 2020, which ended on March 31.” CEO Frank Del Rio “said that Norwegian is planning on carrying out a phased relaunch” and “expects it will take up to six months to resume fleet-wide operations across Norwegian Cruise Line Holdings’ 28 ships, which are spread across its three brands: flagship Norwegian Cruise Line, Oceania Cruises and Regent Seven Seas Cruises.”

Analysis: Anti-Vaccination Advocates Mobilizing To Protest Potential Coronavirus Vaccine. HuffPost (5/14, Robins, 1.67M) reports that as scientists and researchers “urgently work to develop a vaccine against the coronavirus that would save lives and help societies to safely reopen, the anti-vaccine movement has been mobilizing to convince people they shouldn’t take it.” Anti-vaccination protestors – known as “anti-vaxxers” – “have become a prominent presence at [demonstrations] against lockdowns and social distancing, while spreading conspiracies and misinformation to millions on platforms such as Facebook and YouTube.” The article carries an interview with pro-vaccination activist Dr. Peter Hotez, who works to “push back against anti-vax falsehoods and activists.”

DC-Area Metro, Metrobus Riders Required To Wear Face Coverings Effective May 18. The Washington Post (5/14, George, 14.2M) reports that effective May 18, all DC-area Metro and Metrobus riders “will be required to wear masks or face coverings to help prevent the spread of the novel coronavirus, the agency’s chief safety officer said Thursday.” The requirement “follows rules set by leaders in the District and Maryland.” Previously, the agency “had only recommended that riders wear face coverings.” Metro General manager Paul Wiedefeld “said bus and train
operators asked for the requirement, as did customers on recent surveys."
The Hill (5/14, Budryk, 2.98M) also reports.

**Nursing Home Industry, Residents Clash Over Industry’s Handling Of Pandemic.** TIME (5/14, 18.47M) reports nursing home residents and staff in the US "have borne a heavy load of the pandemic’s burden," with deaths in long-term care facilities now making up "at least one third of coronavirus fatalities in most states." Some residents "are already starting to take legal action, suing nursing homes for neglect, abuse and wrongful death." In response, the nursing home industry "has launched a broad and successful lobbying effort to secure immunity from potential lawsuits over the way facilities are treating patients during the pandemic, a move consumer advocates say raises long-term questions about the oversight of an industry that has racked up standards violations for years."

**Opinion: Governors Need To Designate Grocery Workers As First Responders.** UFCW Local 400 President Mark Federici writes in an opinion piece for the Washington Post (5/14, 14.2M) that governors "must designate grocery, pharmacy and food-processing workers as first responders and limit stores to no more than 10 customers per 10,000 square feet, with a maximum of 50 people in any store at the same time." The designation "needs to include guaranteed free, universal testing and treatment for every worker," as well as "masks, gloves and other personal protective equipment," and "free child care, which enables grocery employees to show up for work when schools are closed." Federici writes that first-responder designation "is the only way to provide the protection needed by our essential grocery workers and their customers," and "rather than giving grocery workers lip service by calling them heroes, let’s actually do something to protect their health."

**WPost: COVID-19 Testing In Nursing Homes And Long-Term Care Facilities Is Essential.** The Washington Post (5/14, 14.2M) editorializes, "Residents and staff of nursing homes and other long-term care facilities account for roughly half of 1 percent of the U.S. population, and more than a third" of COVID-19 deaths. The Post says that "justifies extreme measures by federal officials and states, but so far both have balked. On a call Monday with governors, Vice President Pence strongly recommended testing at nursing homes nationwide...yet federal officials and most governors have stopped short of mandating such tests." The Post says such testing is essential, and "in states where tests are in short supply, they should be prioritized for nursing homes and other elderly care facilities."

**One-Fourth Of US Restaurants Will Close Due To Stay-At-Home Orders During Pandemic, OpenTable Forecasts.** Bloomberg (5/14, Ludlow, 4.73M) reports 25 percent of US restaurants "will go out of business due to the coronavirus quarantines that have battered the food-service industry, according to a forecast by OpenTable." The projection "underscores the widespread pain for American restaurants as lockdowns have forced people to cook at home or order takeout rather than eat out." US restaurants "lost more than $30 billion in sales during March and $50 billion in April, according to National Restaurant Association estimates." However, data from OpenTable show "that there are growing signs that patrons are willing to dine out again in states like Arizona and Texas where it’s allowed, though the numbers are still far below where they were last year."

**Pentagon Examining “Social Distancing Protocols” To Train, Deploy Units Amid Pandemic.** USA Today (5/14, Brook, Babich, 10.31M) reports that senior Pentagon officials are exploring "how to train and deploy units for combat while the virus continues to infect and kill." Officials are balancing "the risk of returning to normal operations" with "losing the skills troops need to operate lethal weaponry safely and to win in combat." Army Secretary McCarthy told USA Today, "We were in tremendous posture right as COVID hit with our readiness – over half our brigade combat teams in the highest level of readiness. ... If we don’t turn it back on by this summer, we’re going to start to see atrophy with our readiness posture. So we think we’ve got the right capacity to test. We think we have the social distancing protocols in place where we can do this." The Army "will soon present the plan to Defense Secretary Mark Esper for approval of what would be a major step toward reopening the military."

**Some Colleges Push Viral Testing, Alternative Methods To Allow Fall Semester In-Person.** The Washington Post (5/14, Anderson, Svrluga, 14.2M) reports many colleges and universities are "pushing to bring students back to campus in the fall, pledging an all-out effort to overcome the extraordinary challenges of housing and teaching them during a public health crisis." The University of California at San Diego has already set up a "self-serve" COVID-19 testing station and the "experiment is one of many data-gathering initiatives advocates say are needed to reopen." But health experts "fear some schools may be moving too fast to reopen," specifically because of the complications and challenges around enforcing reasonable social distancing protocols on campus.
Columnist: Trump Is “In The Middle Of A Grace Period” With Voters, But That Will Not Last Indefinitely. Washington Post (5/14, 14.2M) columnist David Byler writes that “President Trump bungled the coronavirus crisis,” so “it would be reasonable to expect Trump’s poll numbers to drop like a rock after this sort of mismanagement.” However, “his approval rating is stable at around 44 percent — roughly where it was before the virus hit.” Byler says that is “because Trump is likely still in the middle of a grace period: Voters aren’t holding him fully accountable for the damage caused by the virus.” Byler asserts “voters might be willing to give a leader leeway in a crisis, but they won’t extend that credit indefinitely.”

Department Of Labor Issues Coronavirus Guidance To Nursing Homes. Reuters (5/14, 16M) reports “the U.S. Department of Labor issued its first workplace guidance to nursing homes on Thursday since the COVID-19 pandemic swept the country and ravaged care facilities, saying residents, staff and visitors should keep 6 feet (1.83 meters) apart.” The guidance “from the Occupational Safety and Health Administration (OSHA) also said nursing homes should screen residents and staff for symptoms and should find alternatives to group activities.” OSHA “did not recommend testing of residents or workers by nursing homes, which have been hit by the coronavirus since February.”

Trump Signs Executive Order Giving New Authority To US International Development Finance Corporation Amid Pandemic. U.S. News & World Report (5/14, Smith-Schoenwalder, 2.4M) says President Trump on Thursday said he signed an executive order to grant new authority to the U.S. International Development Finance Corporation to finance industries vital to the pandemic response. Trump said, “This federal agency normally invests in economic development projects in other countries. ... I said, ‘How about investing in our country?’” In a statement, “the White House said...the order will help strengthen the supply chain and provide more financing to ‘key industries producing vital goods and services.’”

Columnist: US Should Be “Pitied” For Coronavirus Response. Washington Post (5/14, 14.2M) columnist Eugene Robinson writes that “only a handful of nations on Earth have arguably done a worse job of handling the coronavirus pandemic than the United States. What has happened to us? How did we become so dysfunctional? When did we become so incompetent?” Robinson says “the phrase ‘American exceptionalism’ has always meant different things to different people — that this nation should be admired, or perhaps that it should be feared. Not until now, at least in my lifetime, has it suggested that the United States should be pitied.”

Analysis: Trump Using Meetings With Governors At White House To Promote US’ Economic Reopening. In an analysis, Politico (5/14, Kumar, 4.29M) reports “President Donald Trump hasn’t been able to go out, so he’s welcoming governors in.” The recent “visits are strikingly similar: Trump touts the governors as ‘special’ and ‘great’ and they in turn thank him for the ‘enormous help in our darkest hour of need.’ The president cracks a joke or two about the governor getting a negative coronavirus test sitting down next to him. And then they all pose for the cameras.” Politico says the meetings “have served as Trump’s workaround to his inability to hit the road and hold rallies and promote the economic reopening of America, which he believes will be key to his reelection in November.”

Columnist: “Virus Trutherism” Widespread On The Political Right. New York Times (5/14, 18.61M) columnist Paul Krugman writes that “virus trutherism — insisting that Covid-19 deaths are greatly exaggerated and may reflect a vast medical conspiracy — is already widespread on the right. We can expect to see much more of it in the months ahead.” The “right long ago rejected evidence-based policy in favor of policy-based evidence — denying facts that might get in the way of a predetermined agenda.” However, Krugman says, “the right’s determination to ignore the epidemiologists is politically reckless in a way previous denials of reality weren’t.”

McConnell Walks Back Claim That Obama Administration Left Trump Administration No “Game Plan” For Pandemics. CNN (5/14, Leiblanc, 83.16M) reports “Senate Majority Leader Mitch McConnell conceded Thursday night that he was wrong to claim that the Obama administration had not left behind a plan to deal with a pandemic in the US.” McConnell said during a Fox News interview, “I was wrong. They did leave behind a plan, so I clearly made a mistake in that regard.” McConnell’s “concession comes days after he falsely accused the Obama administration of failing to leave the Trump administration ‘any kind of game plan’ for something like the coronavirus pandemic during a Trump campaign online chat with Lara Trump, the President’s daughter-in-law.”

The Hill (5/14, Carney, 2.98M) reports McConnell said, “As to whether or not the plan was followed and who is the critic and all the rest, I don’t have any observation about that because I don’t know enough about the details of that...to comment on it in any detail.”
Pentagon’s DPA Coordinator Reassigned To Navy Position. Politico (5/14, Seligman, Lippman, 4.29M) reports that Jennifer Santos, “the Pentagon’s industrial policy chief who oversees efforts to ramp up production of masks and other equipment” to help fight COVID-19, “was fired from her job this week and will move to a position in the Navy.” According to Politico, “Since March, Santos has focused on using the Defense Production Act [DPA] to partner with industry to bolster the nation’s supply of critical medical equipment such as ventilators, personal protective gear and testing materials needed to counter the coronavirus pandemic.” Politico says Scott Baun, “who is DoD’s principal director of industrial policy, will take over Santos’ position on an acting basis.”

Trump’s Press Secretary Flashes Pandemic Playbook To Reporters; Calls Obama Administration’s Plan “Insufficient.” The New York Post (5/14, Bowden, 4.57M) reports “President Trump says his administration did have a plan to deal with the coronavirus pandemic — and his press secretary on Thursday flashed a previously unknown playbook called the ‘Pandemic Crisis Action Plan’ to prove it.” The press secretary “held up the binder for reporters before the president and his staff decamped to Allentown, Pennsylvania.” Furthermore, press secretary Kayleigh McEnany “held up a copy of the plan the Obama administration left for the incoming Trump team — the ‘Playbook for early response to high consequence emerging infectious disease threats and biological incidents’ — describing it as ‘insufficient.’”

Number Of COVID-19 Cases In Michigan Nears 50,000. The Detroit News (5/14, Mauger, 825K) reports “the number of confirmed COVID-19 cases in Michigan jumped by 1,191 Thursday to 49,582 as the state reported ‘backlogged’ lab results and increased testing at correctional facilities.” But, Michigan’s “new tracking shows that the tally of cases in 26 Michigan counties has been flat in the last seven days. Four of the 26 counties continue to have zero cases.” The 1,191 “cases reported Thursday was the highest daily increase statewide since April 24.”

Woman Sues Portland Nursing Home After Her Mother Died Of Coronavirus At The Facility. The AP (5/14) reports “the daughter of a woman who died after contracting the coronavirus at a Portland long-term care facility filed a $1.8 million lawsuit Thursday claiming elder abuse.” The plaintiff, Angela Brown, says her 75-year-old mother, Judith Jones, contracted coronavirus and died because of Healthcare at Foster Creek’s negligence, The Oregonian/OregonLive reported. In her "complaint, Brown listed problems state investigators found at the nursing home, now connected to 29 deaths and 119 cases of COVID-19."

New York Governor And New York City Mayor Cannot Agree On Number Of Coronavirus Deaths In The City. POLITICO New York (5/14, Durkin) reports “New York City hit a grim milestone this week, recording more than 20,000 coronavirus deaths throughout the five boroughs. Or did it?” According to New York “Gov. Andrew Cuomo’s (D) office, the city is still weeks away from that mark, with thousands fewer deaths in its tally — and public health experts say the state’s lag is a problem.” The constant “feud and routine miscommunication between Cuomo and Mayor Bill de Blasio is among the few things in New York that has not been slowed by the pandemic.” However, “the fact that the two can’t even agree on how many people have died illustrates the dysfunction between the city and state, even as they try to coordinate a cautious reopening of New York’s economy.”

Study Suggests Pediatric Multi-System Inflammatory Syndrome Is Tied To Coronavirus, As Cases Rise In New York. Bloomberg (5/13, Gale, 4.73M) reported that “the coronavirus may have triggered a 30-fold jump in cases of a serious but rare pediatric inflammatory disease, according to an Italian study that provides an ominous warning to other pandemic-affected nations about the risk to children.” An “analysis from Bergamo, the epicenter of the Italian Covid-19 outbreak, found 10 cases of a Kawasaki disease-like illness in children, adding to reports of about 90 similar cases from New York and England.” Although “children remain at lower risk than older adults of developing severe complications after being infected with the Covid-19-causing SARS-CoV-2 virus, the research published Thursday in the Lancet medical journal shows that their risk isn’t zero.”

The Wall Street Journal (5/14, King, Subscription Publication, 7.57M) reports officials in New York have now identified 110 cases of pediatric multi-system inflammatory syndrome in young adults and children. The syndrome has killed three young people, and it is potentially tied to COVID-19.

Fishing Boat Crews Reportedly Could Cause Coronavirus Outbreak In Cordova, Alaska. The New York Times (5/14, Baker, 18.61M) reports that “the people of Cordova, Alaska, had weathered the coronavirus pandemic with no cases and the comfort of isolation — a coastal town unreachable by road in a state with some of the fewest infections per capita in the country.” However, “that seclusion has come to an abrupt end. Over the past two weeks, fishing boat crews from Seattle and elsewhere have
WSJ Journal Urges Wisconsin Governor To Create Less Restrictive Stay-At-Home Order With Legislature. In an editorial, the Wall Street Journal (5/14, Subscription Publication, 7.57M) urges Wisconsin Gov. Tony Evers (D) to work with the state Legislature to draft a less restrictive stay-at-home order.

Oxford Vaccine Study Shows Promise In Monkeys. NBC Nightly News (5/14, story 9, 0:40, Holt, Torres, 7.88M) reported, “Oxford University just released results from a study involving six monkeys, which "found after four weeks a vaccine-produced antibodies to COVID-19 in all of the monkeys, and prevented them from getting pneumonia when they were exposed to the virus." According to NBC, "The control group that didn't get the vaccine got sick, so this is certainly promising." NBC added that the "vaccine is also currently being tested in more than 1,000 people, and the first results are expected in June."

Reuters (5/14, Steenhuyzen) reports, "After exposure, the vaccine appeared to prevent damage to the lungs and kept the virus from making copies of itself there, but the virus was still actively replicating in the nose."

Pompeo: U.S. Condemns China-Linked “Cyber Actors” Trying To Steal COVID Research. Reuters (5/14, Pamuk) reports Secretary of State Pompeo said Thursday that the U.S. has "condemned attempts by China-linked 'cyber actors and non-traditional collectors affiliated' to steal US intellectual property and data related to coronavirus research." In a statement, Pompeo said, "The PRC’s behavior in cyberspace is an extension of its counterproductive actions throughout the COVID-19 pandemic."

Newsweek (5/14, Stockler, 1.53M) reports Pompeo’s remarks “follow an announcement by the FBI on Wednesday that the bureau is investigating ‘the targeting and compromise of organizations conducting research to develop vaccines and other treatments for COVID-19.’ The efforts were ‘attributed to China-affiliated actors.’ The U.S. State Department released a statement Thursday ‘condemning attempts to infiltrate systems involved in US COVID-19 research that the FBI has attributed to China.”

The Washington Times (5/14, Gertz, 492K) also reports.

Researcher Optimistic About Convalescent Plasma Therapy. On NBC Nightly News (5/14, story 10, 2:30, 7.88M), Lester Holt said there is "encouraging news in a new report on an experimental treatment that appears to have helped some patients recover" from COVID-19. NBC’s Cynthia McFadden: "A first look at a promising new report drawn from a nationwide team of more than 5,000 doctors
from over 2,000 hospitals and labs, looking at an experimental therapy called convalescent plasma, transfusing the antibody-rich blood from someone who recovered into a current patient.” Michael Joyner, Professor of Anesthesiology at the Mayo Clinic: “We’re very encouraged that the treatment is safe. That was really the first hurdle for us.” McFadden: “Dr. Joyner says the hard data about the effectiveness of the treatment is yet to come. How soon will they have it?” Joyner: “As fast as we can. Our data mining and analytics team is working on data we have currently.”

Plasma Therapy Derived From Recovered COVID-19 Patients Appears Safe, Study Suggests. The Wall Street Journal (5/14, Marcus, Subscription Publication, 7.57M) reports a study analyzing data from thousands of COVID-19 patients, who received blood plasma transfusions from patients that already recovered, suggests the experimental therapy is safe, setting up the potential for future studies and clinical trials.

Expert Says It Will Take “Bulk Of A Year” Before Researchers Can Determine Factors In COVID-19 Immunity. McClatchy (5/14, Wilner, 19K) reports that University of Maryland School of Medicine Institute of Human Virology Co-Founder and Director Robert Gallo was disturbed by a finding buried deep inside a study by researchers from Los Alamos published last month that “the mutation of the coronavirus’ outer spikes could help the virus escape the grasp of otherwise neutralizing antibodies and make individuals susceptible to a second infection.” Gallo said that it will likely “take the bulk of a year before researchers can determine with high confidence whether COVID-19 survivors are naturally protected from a second infection.

Data Show COVID-19 Cases Are Generally Decreasing In 17 States, Rising In Nine Others. CNN (5/14, Yan, Karimi, 83.16M) reports, “First, the good news: In 24 states, the number of new coronavirus cases reported each day is generally going down.” In 17 states, the numbers “are holding steady, according to an analysis of data from Johns Hopkins University.” And in nine states, “the numbers of new cases are still rising.”

Fox News Host Says Bright Testimony Could Be “Potentially Politically Damaging” For Trump. The Hill (5/14, Concha, 2.98M) reports Fox News’s “Special Report” anchor Bret Baier “said Thursday that former Biomedical Advanced Research and Development Authority head Rick Bright’s testimony about the federal government’s response to the coronavirus pandemic could be ‘potentially politically damaging’ for President Trump.” Baier “also asserted that the public health official was someone who could not be easily discredited.” On Thursday, Bright “testified to the House Energy and Commerce health subcommittee that his warnings about medical supply shortages were allegedly ‘met with indifference’ by his superiors in January before the coronavirus pandemic gripped the country.” Fox News (5/14, Halon, 27.58M) reports Bright’s testimony “will have ‘lingering implications’ for the Trump administration, Special Report” anchor Bret Baier told ‘Bill Hemmer Reports.’” Baier said: “I think he laid out a pretty compelling case of where he was in his job and I think that is potentially damaging for the Trump administration, as he is saying they didn’t warn people and they weren’t prepared, they could have done more as far as training and preparation as far as January and February.”

Axios (5/14, Rummler, 521K) also reports.

Opinion: Pay Attention To Whistleblower, Because What Trump Disparages Is Often Truth. In an opinion piece for the Los Angeles Times (5/14, 4.64M), Editorial Writer Scott Martelle writes, “President Trump reverted to form on Thursday when reporters asked him about congressional testimony by Dr. Richard Bright, who says the White House removed him from his position leading the federal Biomedical Advanced Research and Development Authority because he, in essence, stood up to Trump’s political machinery in defense of science.” Martelle writes, “Trump told reporters: ‘To me, he’s not nothing more than a really disgruntled, unhappy person.’ Martelle argues, “Trump’s splenetic reaction is all the encouragement we need to pay close attention to what Bright told Congress, because what the president disparages often is the truth.”

CDC Issues Health Advisory For Physicians On Childhood Illness Linked To COVID-19. CNN (5/14, Fox, 83.16M) reports the CDC “issued a health advisory to thousands of doctors across the country Thursday, advising them to be on the lookout for a troubling new syndrome that may be associated with Covid-19 infection.” The syndrome, “called multisystem inflammatory syndrome in children (MIS-C), has been seen in children across Europe and in at least 18 states, plus Washington, DC.” The AP (5/14, Tanner) reports the agency’s case definition “includes current or recent COVID-19 infection or exposure to the virus, a fever of at least 100.4 for at least 24 hours, severe illness requiring hospitalization, inflammatory markers in blood tests, and evidence of problems affecting at least two organs that could include the heart, kidneys, lungs, skin or other nervous system.” The condition “has been reported in at least 110 New York children and in several kids in other states,” and “a few children have died.”
Among other media outlets providing coverage are: the CBS Evening News (5/14, story 4, 2:00, O'Donnell, 5.25M), NBC Nightly News (5/14, lead story, 2:25, 7.88M), Reuters (5/14, Steenhuisen, Chander), Forbes (5/14, Perez, 9.71M), the San Francisco Chronicle (5/14, Serrano, 2.67M), The Hill (5/14, Moreno, 2.98M), and the New York Post (5/14, Lapin, 4.57M)

Maine Governor Allows Out-Of-State Visitors To Reserve Rooms In Lodges, Inns Starting June 1. The AP (5/14) reports, “Maine lodge operators and innkeepers can begin accepting reservations starting June 1 for Maine residents and out-of-state residents who comply with the state’s 14-day quarantine requirement, officials said Thursday.” The change “represents a loosening of restrictions that originally forbade out-of-state residents from reserving a room with an arrival date before July 1,” Commissioner Heather Johnson of the Department of Economic and Community Development said. “We will continue to work closely with the tourism industry to make progress as we head into the summer.”

North Dakota Has Exceeded 50,000 Coronavirus Tests. The AP (5/14) reports, “North Dakota has gone over 50,000 in the number of tests for the coronavirus and topped 1,700 for the number of people confirmed to have the disease, health officials said Thursday.” Health officials said 67 people tested positive in the last day, including 57 in Cass County, the state’s most populous county that has seen marked COVID-19 increases in the last several days. The report “showed no new statewide deaths, leaving the total at 40, and one new hospitalization, increasing that number to 38. More than 1,000 people have recovered from the disease.”

In Rural America, COVID-19 Breakouts At Prisons Risk Overwhelming Hospitals. Kaiser Health News (5/14, Dawson) reports that “across rural America, prisons and jails sit in places like Toole County, Montana “that have minimal intensive care unit beds and ventilators and few additional medical resources” and “many hospitals there were strained before the pandemic.” For Toole County, so far, “the dreaded coronavirus hasn’t yet crept into the site of one of the community’s largest employers, the Crossroads Correctional Center prison.” The center “holds almost 15% of the county’s total population with a 712-bed facility for both federal and state inmates.”


Bars And Restaurants Remain Closed Under Local Milwaukee County Order. The Milwaukee Journal Sentinel (5/14, 632K) reports, “Bars and restaurants are still closed, and gatherings of more than nine people are still prohibited, under a local order from 18 municipalities in suburban Milwaukee County and their 10 public health officials.” The local “order, which was released shortly before 1 a.m. Thursday, came after the Wisconsin Supreme Court struck down the statewide stay-at-home order.” Some “local officials say the order was ‘effective immediately,’ and will remain in effect until 11:59 p.m. on Thursday, May 21.”

Virginia Officials Plan To Stop Counting Antibody Tests As COVID-19 Tests In Reports. The Washington Post (5/14, Schneider, 14.2M) reports, “Virginia officials said Thursday they will no longer include the results of antibody tests in their daily counts of who has been tested for the novel coronavirus, a practice that had been criticized as exaggerating the state’s efforts to control the virus’s spread.” The state’s department of health “said the change does not significantly alter the statistical trends that led Gov. Ralph Northam (D) to move toward easing restrictions for most of the state, beginning Friday.” The department has found that “antibody tests had amounted to less than 9 percent of the state’s overall screening for the coronavirus” and “excluding them from the total slightly increases the percentage of positive tests among the overall number of tests given, to 15 percent from 14 percent.”

As Some States Reopen, Other States Continue To Battle Coronavirus. The AP (5/14, Kunzelman) reports, “From a hospital on the edge of the Navajo Nation to the suburbs of the nation’s capital, front-line medical workers in coronavirus hot spots are struggling to keep up with a crushing load of patients while lockdown restrictions are lifting in many other parts of the U.S.” Some “governors are starting to slowly reopen some segments of their local economies, pointing to evidence that the number of COVID-19 deaths and new hospitalizations are peaking or starting to recede in their states.” Many “state and local officials see modest signs of progress in the pandemic fight,”
but "coronavirus outbreaks are testing public health networks in pockets of the U.S."

New York Governor Adds Provision To State’s Budget To Prevent Some Residents From Suing Nursing Homes Amid Pandemic. The Hill (5/14, Bowden, 2.98M) reports, "Aides to New York Gov. Andrew Cuomo (D) added a provision to the state’s newly approved budget that prevents residents from suing nursing homes over some allegations of negligence related to the coronavirus outbreak." The "provision, which some lawmakers contended they did not know was in the final bill until after it passed, prevents basic legal action against long-term care homes over issues such as staffing shortages or insufficient equipment," the New York Times reported.

Some Small Physician Practices Are Struggling During Pandemic, Unable To Get Coronavirus Relief. The Washington Post (5/14, Weiner, 14.2M) reports, "Many small doctors’ practices... are struggling to survive as many patients shelter at home and put off consultations for all but the most urgent issues." And, "although they’re still ministering to patients amid a health crisis," some have "been unable to get loans under the Paycheck Protection Act, passed as part of the coronavirus relief package in late March." A survey conducted by a Richmond-based advocacy group for primary care doctors, called the Larry A. Green Center, found that half the doctors who sought such loans were unsuccessful.

Pandemic Hits Low-Income Americans Especially Hard, Survey Shows. Bloomberg (5/14, Taná, 4.73M) reports, "The economic pain of the coronavirus pandemic is falling especially hard on lower-income Americans, a new Federal Reserve survey showed, with almost 40% of those making less than $40,000 a year reporting a job loss in March." The annual report "on the economic wellbeing of U.S. households released Thursday, which mainly focuses on conditions at the end of 2019, was supplemented with a survey conducted in early April as the pandemic caused millions to lose their jobs as businesses shuttered across the nation." The Fed Chairman Jerome Powell has previously "highlighted the heavy burden being born by Americans with the most meager resources to ride out the lockdown."

Close To Three Million Americans Applied For Unemployment Last Week. On its front page, the Wall Street Journal (5/14, A1, Chaney, Gulford, Subscription Publication, 7.57M) reports that nearly three million Americans applied for unemployment benefits last week. The announcement reflects the implications of the coronavirus on the US economy.

The New York Times (5/14, A1, Cohen, Hsu, 18.61M) reports on its front page that "the weekly count of new claims has been declining since late March, but that hopeful flicker barely stands out in an otherwise grim and chaotic economic landscape." The Times adds that "in places where the fitful reopening has started, workers called back to their jobs often face reduced hours and paychecks as well as a heightened risk of infection."

According to the Washington Post (5/14, Romm, 14.2M), "The flood of new claims could further intensify tensions between President Trump and public health officials over how quickly to try to restart parts of the economy, with Trump on Thursday alleging without evidence that some Democrats are trying to slow the process to hurt him politically." The Post adds that "many Democrats have said the White House is trying to rush states to reopen without an adequate plan to curtail the further spread of the coronavirus."

Among other news outlets reporting on the story are ABC World News Tonight (5/14, story 4, 2:10, Muir, 7.42M), the CBS Evening News (5/14, story 5, 2:30, O’Donnell, 5.25M), NBC Nightly News (5/14, story 5, 2:40, Holt, 7.88M), Bloomberg (5/14, Dmitrieva, 4.73M) and the AP (5/14, Rugaber).

Coronavirus Pandemic Could Cost Insurance Industry Over $200 Billion, According To Lloyds Of London. The AP (5/14) reports, "The pandemic will cost the insurance industry over $200 billion, according to Lloyds of London, who estimated that its own payouts are now on a par with the Sept. 11, 2001 attacks or the combined impact of hurricanes Harvey, Maria and Irma in 2017." In general, "losses could widen if lockdowns continue into the next quarter, which would push the overall cost to the insurance industry to $203 billion. Unlike the storms, for example, the pandemic’s impact is global, systemic and long term. A study by Lloyds also assumed social distancing and lockdown measures through 2020, as well as the forecasts for the drop in gross domestic product globally."

Medical Professionals File Lawsuit Against Michigan Governor Over Lockdown Restrictions. The Washington Times (5/14, Varney, 492K) reports, "Medical professionals and a patient in Michigan have filed a lawsuit against Democratic Gov. Gretchen Whitmer as the battles grow between her and those favoring some relaxation of the economic shutdown she has imposed in response to the coronavirus crisis." The suit also names Michigan’s Attorney General Dana Nessel and Robert Gordon, the state’s Department of Health and Human
Services director as defendants." Michigan’s "population of 9.9 million" has "reported 48,391 confirmed cases of COVID-19, according to the state’s Department of Health and Human Services."

Transplant Of Brain Cells To A Patient With Parkinson’s Disease Sparks Ethical Questions. STAT (5/14, Begley, 24K) reports, "A secretive experiment revealed this week, in which neurosurgeons transplanted brain cells into a patient with Parkinson’s disease, made medical history." The transplant was "the first time such ‘reprogrammed’ cells, produced from stem cells that had been created in the lab from the man’s own skin cells, had been used to try to treat the degenerative brain disease." However, "it was also a bioethics iceberg, with some issues in plain sight and many more lurking."

Reopening Spurs Divide Among State Governors, Legislatures. The New York Times (5/14, 18.61M) reports that the Democratic governors in Wisconsin, Michigan and Pennsylvania, "backed by public health experts, have urged caution before reopening," but the states’ Republican legislatures "have been pushing in the opposite direction, arguing that the extended restrictions are threatening their personal freedom to go back to work and move around as they wish."

Connecticut Nursing Home Owner Purchases 400K Masks From Makeshift Supplier. The Wall Street Journal (5/14, Wirz, Hufford, Subscription Publication, 7.57M) reports that nursing homes are struggling to find masks and other important medical supplies. In one instance, a Connecticut nursing home owner purchased 400,000 masks from a Chinese makeshift supplier, without a prior relationship with the supplier.

New Jersey, Delaware Reopen Beaches For Memorial Day With Restrictions. The Inquirer (PA) (5/14, McDaniel, Rosenberg, Orso, McCarthy, 347K) reports, "New Jersey beaches can reopen in time for Memorial Day—with social distancing measures in place, Gov. Phil Murphy said Thursday." The order "offered one of the first rays of light to a region worried about a shut-in summer due to the coronavirus pandemic, but drew mixed reviews from the local officials who Murphy said will be responsible for limiting beach capacity and ensuring compliance with social distancing." Delaware also "said its beaches would reopen with restrictions before the holiday weekend, though the state police will continue stopping drivers with out-of-state license plates to enforce restrictions on travel into the state."

 Forbes (5/14, Perez, 9.71M), Bloomberg (5/14, Young, 4.73M) and the AP (5/14) also report.

Minnesota Malls Begin To Reopen Monday, However, Mall Of America Plans For June 1. The Minneapolis Star Tribune (5/14, Kumar, 1.04M) reports, "While Gov. Tim Walz has given the green light to Minnesota retailers to reopen as soon as Monday, it will take days or weeks before some of them get back up and running as they call back furloughed employees and establish new safety protocols." Some malls, like the Galleria, will open Monday, while "other shopping malls in the region were in discussions with their owners and tenants this morning to discuss the timing of reopening plans and increased safety measures."

One mall, the Mall of America, "is among those that will take its time" as "the megamall" noted "Thursday that it will reopen for shopping on June 1."

New York Nursing Home Administrators Reportedly Worried About The State’s COVID-19 Testing Goal. The AP (5/14, Peltz, Muslan) reports, "As calls grow nationwide for mandatory coronavirus testing in nursing homes, New York facilities are sounding alarms about the state’s ambitious new demand to test roughly 185,000 workers twice a week." Some "administrators worry there won’t be enough kits for an estimated 370,000 tests a week on workers at nursing homes and other adult care facilities, nearly double the total of tests done statewide now on people in all walks of life."

Homes have also "questioned whether they have the infrastructure" to conduct new tests in "the next month," with one New York nursing home executive "worried that the state’s order "begins to sound more like a dictate than a request.""

During Contact Tracing Efforts, New York City Mayor Leans On Aide That Previously Argued Against Closures. The New York Times (5/14, Rashbaum, Goodman, Mays, Goldstein, 18.61M) reports, "The head of New York City’s public hospitals pushed to keep the city open in early March," and "now Mayor de Blasio has put him in charge of contact tracing, deepening a rift with the Health Department." According to the Times, Dr. Mitchell Katz, who leads the city’s public hospitals, "wrote in an email in March to the mayor’s aides that "there was ‘no proof that closures will help stop the spread.’” Now, the mayor is relying on Dr. Katz and Health Department officials to navigate contact tracing.

Trump, EPA Decide Not To Impose Limits On Water Contaminant Linked To Fetal Damage. The New York Times (5/14, Friedman, 18.61M) reports, "The Trump administration will not impose any limits on perchlorate, a toxic chemical compound that contaminates water and has been linked to fetal and infant brain damage, according to two Environmental Protection Agency staff members familiar with the decision." The decision was made.
“by Andrew Wheeler, the administrator of the E.P.A.,” and
“appears to defy a court order that required the agency to
establish a safe drinking-water standard for the chemical by
the end of June.” Perchlorate “— which is used in rocket fuel,
among other applications — has been under study for more
than a decade, but because contamination is widespread,
regulations have been difficult.”

The Washington Post (5/14, Dennis, Elperin, 14.2M)
reports, “Under President Barack Obama, the EPA had
announced in 2011 that it planned to set the first enforceable
limits on perchlorate because of its potential health impacts.
However, “both the Defense Department and military
manufacturers have long resisted any restrictions on the
chemical, which is also used in fireworks, munitions and other
ignition devices.”

The AP (5/14, Knickmeyer) reports “the Environmental
Protection Agency proposal to drop any federal regulation of
perchlorate “would translate to lower IQs and other problems
for an unknown number of American babies, pediatrician and
public health groups say.”

Wyoming To Relax Restrictions On Bars And
Restaurants. Newsweek (5/14, Roos, 1.53M) reports,
“Wyoming, the state that has reported the fewest number of
COVID-19 deaths so far, will be reopening its bars,
restaurants, gyms and more on Friday with social distancing
guidelines in place.” The state’s governor, Mark Gordon,
“announced the state’s next phase of reopening during a
news conference Wednesday.” Gordon said, “it’s important to
remember that, even as we ease restrictions, the virus is not
gone.” He added, “it is still here, it is still invisible and it is still
capable of wreaking havoc. And it’s going to be with us for
some time in Wyoming, just like the rest of the country.”

Democrats Present Legislation Aimed At
Protecting Health Data During COVID-19
Pandemic. The Hill (5/14, Rodrigo, 2.98M) reports,
“Democrats in both chambers introduced legislation Thursday
aimed at protecting the privacy and security of health data
during the coronavirus pandemic.” The legislation, the Public
Health Emergency Privacy Act, “would place strict limits on
what and by who data collected for public health purposes
were used, implement data minimization procedures for that
info and require opt-in consent for any efforts.” The act
“comes as health agencies and tech companies are
developing contact tracing and monitoring tools to contain the
pandemic.”

White House List Of Coronavirus Testing Labs
Not Useful, Nine States Say. NPR (5/14,
Greenfieldboyce, 3.12M) reports nine state health
departments, in response to a query from NPR, say that the
list of labs provided by the White House that could potentially
test for coronavirus did not actually help their states achieve
more testing. Also, “six states said that the lists hadn’t even
been seen or reviewed — at least as far as the responding
official knew.” In fact, “Alabama is the only state where
officials told NPR that the list had been reviewed and that it
had resulted in increased testing.”

Testing Project On Tiny Michigan Island
Underway. The Detroit Free Press (5/14, 1.52M) reports
Grosse Ile, Michigan, a tiny island in the Detroit River, is
taking part in a COVID-19 testing project, data from which will
be used by researchers about “how the virus spread — or
didn’t spread — among residents whose only connections to
the rest of the state are two bridges, one of which is out of
commission until December.”

AMA Warns Physicians Against Using
Coronavirus Antibody Tests To Inform
Healthcare Decisions. Modern Healthcare (5/14,
Subscription Publication, 214K) reports “the American
Medical Association is warning doctors against using
[antibody] tests designed to identify people already exposed
to the coronavirus to make healthcare decisions for individual
patients.”

Virginia Governor Asks Federal Government
To Increase Testing At Two Federal Detention
Facilities. The Richmond (VA) Times-Dispatch (5/14,
Times-Dispatch, 277K) reports Virginia “Gov. Ralph Northam
on Thursday asked that the federal government perform more
screening and testing for COVID-19 at the Farmville and
Caroline County detention centers.”

CVS Plans To Open 1,000 Self-Swab
Coronavirus Test Locations By Month’s End.
Forbes (5/14, Japsen, 9.71M) reports “CVS Health is
escalating its cross-country effort to expand testing for the
Coronavirus strain COVID-19 with plans to open 1,000
locations by the end of the month.”

US Said To Be Making Progress In Coronavirus
Testing Numbers. Vox (5/14, 2.27M) says that “after an
April that some experts described as ‘wasted,’ it looks like
America is finally making some real progress on coronavirus
testing in May.” Over the last few “weeks, the United States
has seen significant improvements not just with the raw
number of Covid-19 tests but also with other metrics experts
use to gauge the scope of the US’s coronavirus outbreak and
its testing capacity.” Specifically, “during the week of May 5,
the US averaged nearly 300,000 new coronavirus tests a
day, according to the Covid Tracking Project,” nearly double
the approximately “150,000 daily tests performed in early April, although it still falls short of the number of new tests a day experts say is needed to fully control the outbreak.”

Abbott Lab’s ID Now COVID-19 Misses Up To Half Of Cases Found By Another Test, Study Suggests. Modern Healthcare (5/14, Subscription Publication, 214K) reports “a study has found that Abbott Lab’s ID Now COVID-19 test missed as many as half of the cases found to be positive by another test.” Investigators “found that while initially the ID Now COVID-19 assay performed well, as the viral load decreased, the Abbott test produced more false negatives.” The findings were published in Bioxriv.

The Portland (ME) Press Herald (5/14, 244K) also reports.

Bill Gates-Funded Program That Provides At-Home Coronavirus Test Kits Put On Hold Until Federal Approval Is Granted. CBS News (5/13, 3.68M) reports that “Bill Gates is funding a new program to provide at-home coronavirus testing kits to residents in the Seattle area. The initiative aims to help researchers better understand how COVID-19 spreads through communities.” However, “after an initial rollout that Gates said was testing about 300 people a day, the program has been put on ‘pause’ while it awaits federal approval.”

Pandemic Reportedly Reveals Vulnerabilities In American Business Model For Hospitals. The New York Times (5/15, Kliff, 18.61M) reports that “the American health care system for years has provided many hospitals with a clear playbook for turning a profit: Provide surgeries, scans and other well-reimbursed services to privately insured patients, whose plans pay higher prices than public programs like Medicare and Medicaid.” The coronavirus pandemic “has shown the vulnerabilities of this business model, with procedures canceled, tests postponed and millions of newly unemployed Americans expected to lose the health coverage they received at work.” The disruption to medical facilities’ operations may ultimately leave Americans with less access to medical care, according to financial analysts, health economists and policy experts.

Biogen Blocks Creative Biolabs From Selling Products That Allegedly Used Antibody From Its Experimental Alzheimer’s Drug. Bloomberg Law (5/14, Decker, Subscription Publication, 4K) reports New York-based Creative Biolabs has agreed to stop selling products that are allegedly “knock-offs of antibodies used in Biogen’s experimental Alzheimer’s drug...according to a court filing.” Creative Biolabs has also agreed “to halt infringing patents Biogen controls, no longer use Biogen’s trademarks to promote products, and destroy any inventory that did so, under the terms of the consent decree posted with the federal court in Boston.” According to Bloomberg, “Biogen has said it plans to seek U.S. Food and Drug Administration approval for a drug using the antibody aducanumab for treatment of early Alzheimer’s.”

Opinion: New Hampshire Tobacco 21 Policy Will Reduce Chances Of Lifelong Nicotine Addiction, Protect Developing Brains. In the New Hampshire Union Leader (5/15, 109K), Dr. Seth Emont, who manages the Tobacco Cessation Program at Cheshire Medical Center, writes that there are “a number of reasons” that a New Hampshire Tobacco 21 policy is “a good idea.” Emont argues that such a policy “will help reduce the chances of lifelong nicotine addiction,” and help to protect developing brains.

GLOBAL HEALTH NEWS

China’s Foreign Ministry Says U.S. Claims Regarding Hacking Of COVID-19 Research Are Slander. Reuters reports China’s foreign ministry has called U.S. claims that hackers linked to the country are “breaking into U.S. COVID-19 research” slanderous. Spokesman Zhao Lijian said “any action online to sabotage efforts against the disease should be condemned.”

Health Groups Ask India To Rescind Gilead’s Patents For COVID-19 Drug Remdesivir. Reuters (5/14, Siddiqui) reports, “Two health advocacy groups have written to the Indian government asking it to rescind patents given to Gilead Sciences for the drug remdesivir so it can be distributed more fairly to coronavirus patients around the world, particularly in poorer nations.” The health groups argue Gilead’s recent licensing and distribution pacts for remdesivir “mean cheaper forms of the drug may not become available in nations seen as non-profitable to the five drugmakers.” K. Gopakumar, senior legal researcher at Third World Network, said, “The licenses divide the global market into two and profitable markets are retained with Gilead and less profitable markets are given to the five generic companies.”

Russia’s ChemRar Testing Favipiravir In Second-, Third-phase Testing As Potential COVID-19 Treatment. Reuters (5/14, Marrow, Stolyarov, Golubkova) reports Russian company ChemRar, which is conducting trials of a potential COVID-19 treatment, “said on Thursday it was testing it on infected patients in what it called second- and third-phase clinical trials based on
World Health Organisation (WHO) criteria." Reuters adds, “The drug, favipiravir, which was first developed in Japan under the name Avigan, secured 150 million roubles ($2 million) in funding from the Russian Direct Investment Fund.”

Chinese Automaker Backed By Buffett Fails To Gain US Approval For Their Masks. Bloomberg (5/14, 4.73M) reports, “China’s BYD Co., the carmaker backed by Warren Buffett’s Berkshire Hathaway Inc., was denied a U.S. regulatory certification it needs to sell respirator masks to the state of California.” The agency, the National Institute for Occupational Safety and Health, did not “approve BYD’s masks for a number of factors, according to an emailed statement that doesn’t disclose details for confidentiality reasons.” BYD was notified “on May 4 that a contractor’s assessment of two BYD factories in China found them to be not acceptable.”

Total Number Of Coronavirus Cases Globally Approaches 4.4M. The Wall Street Journal (5/14, Hua, Callas, Subscription Publication, 7.57M) reports the number of coronavirus cases worldwide, according to data compiled by Johns Hopkins University, approached nearly 4.4 million, with nearly 300,000 deaths. Of the total number of cases, close to one third is in the US.

Forbes (5/14, Porterfield, 9.71M) also reports.

European Governments Hoping Antibody Tests Will Help Inform Strategies To Avoid Second Wave Of Infections. Reuters (5/14, Miller) reports many governments in Europe “are scrambling to buy antibody tests to find out how many of their citizens were infected” with coronavirus, “in the hope that will help them craft strategies to avoid a second wave of COVID-19 cases.” However, “exactly how — or even if — the information will be of use remains unclear, raising the risk that public funds and government time are being wasted.”

European Commission Suspends Delivery Of 10M Chinese Masks Due To Quality Concerns. The AP (5/14) reports “the European Commission said Thursday it has suspended the delivery of 10 million Chinese masks to member states and Britain after two countries complained about the poor quality of the batches they received.”

Dental Practices In France Begin Cautiously Re-Opening. The AP (5/14) reports dental practices in France “are cautiously reopening and accepting appointments after the French government eased restrictions on some businesses, services and public activity.”

Italy To Start Testing Campaign Across 2,000 Cities To Understand Extent Of Outbreak. Reuters (5/14, Amante) reports “Italy will start testing a representative sample of 150,000 people in 2,000 cities next week to understand the extent of its COVID-19 epidemic, the head of the government’s scientific committee told parliament on Thursday.”

France’s Coronavirus Death Toll Surpasses Spain’s Again. Reuters (5/14) reports “France’s cumulative coronavirus death toll edged over Spain’s again as France reported on Thursday the number of people who died of COVID-19 in the past 24 hours increased by 351 or 1.3% to 27,425.”

Wuhan Starts Massive Testing Campaign Of Roughly 11M People. Reuters (5/14, Goh) reports “residents in Wuhan braved pouring rain in queues of more than an hour to take part in a government-led exercise to test the city’s 11 million people for the novel coronavirus, a scale health experts describe as unprecedented.”

The New York Times (5/14, Wee, Wang, 18.61M) reports that “the testing drive, which is likely to require the mobilization of thousands of medical and other workers, shows the ruling Communist Party’s resolve to prevent a second wave of infections as it tries to restart China’s economy.” However, “such comprehensive testing poses challenges,” and it remains unclear “how Wuhan will procure enough testing kits and process all the samples, and whether such a broad, systematic approach is the best use of resources when the city’s infections are low.”

Prime Minister Abe Lifts State Of Emergency Through Most Of Japan. The Wall Street Journal (5/14, Landers, Subscription Publication, 7.57M) reports Japanese Prime Minister Shinzo Abe lifted a state of emergency in most of the country outside of Tokyo and attributed voluntary restrictions for a sharp decrease in the number of new coronavirus infections.

UNICEF Chief Warns Lockdowns Could Cause More Harm Than Actual Virus In Low-, Middle-Income Countries. The Hill (5/14, Klar, 2.98M) reports “the chief of health at the United Nations International Children’s Emergency Fund (UNICEF) is warning that lockdowns meant to mitigate the spread of the coronavirus could cause more harm than the virus itself in ‘low- and middle-income countries.’”

The Washington Post (5/14, Sly, 14.2M) also reports.

Russian Government Criticizes Media Reports Claiming Russia’s COVID-19 Deaths Are
Underreported. The Hill (5/14, Concha, 2.98M) reports “Russian Foreign Ministry spokeswoman Maria Zakharova is criticizing news outlets for printing ‘disinformation’ after The New York Times and Financial Times reported that the country’s COVID-19 death toll could be considerably higher than what the Kremlin is reporting.”

The AP (5/14) also reports.

Asian Countries, After Stopping Initial Outbreak, See Second Wave Of Cases. Bloomberg (5/14, 4.73M) reports that “after containing their outbreaks through measures from strict lockdowns to rapid testing regimes...Asian economies have seen some of the most success quelling the coronavirus – Hong Kong, South Korea and China – are now facing resurgences that underscore how it may be nearly impossible to eradicate it.”

China Attempted To Dissuade New Zealand From Imposing Strict Coronavirus Restrictions. Newsweek (5/14, 1.53M) reports “China tried to dissuade the New Zealand government from imposing its tough restrictions to mitigate the coronavirus, believing them to be an ‘overreaction,’ New Zealand Minister of Foreign Affairs Winston Peters has said.”

Canada’s Prime Minister Says World Has Changed Even If Pandemic Ends Or Vaccine Is Found. Reuters (5/14) reports “Canadians should accept the world will change even if a vaccine is found and the coronavirus pandemic ends, Canadian Prime Minister Justin Trudeau said on Thursday, urging people to adjust to a new normal that will require modified behaviour.”

EU’s Foreign Policy Chief Calls For Independent Investigation Into Pandemic’s Origins. Reuters (5/14) reports “the European Union’s foreign policy chief [Josep Borrell] called on China on Thursday to contribute significantly to the fight against the coronavirus pandemic and said there should be an independent scientific investigation into the origins of the pandemic.”

IOC President Will Not “Fuel Any Speculation” That Tokyo Olympics Might Not Be Held Next Year. USA Today (5/14, Schad, 10.31M) reports “International Olympic Committee president Thomas Bach said Thursday that he would not ‘fuel any speculation’ that the Tokyo Olympics might not be held in 2021.”

IOC Sets Aside $800M For Loans Related To Postponing Tokyo Olympics. The AP (5/14) reports “the IOC set aside $800 million on Thursday for loans and payments arising from the pandemic that forced the 2020 Tokyo Olympics to be postponed.” It remains “unclear how big the total postponement bill will be with Olympic organizers and public authorities in Japan facing extra costs estimated to run into billions of dollars.”

South Africa To Assign Specific Coronavirus Restrictions For Each Of Its Districts. Reuters (5/14) reports “South Africa will assign levels of lockdown restrictions for each of the country’s roughly 50 districts, depending on the number of active coronavirus infections there, Health Minister Zweli Mkhize said on Thursday.”

Surge In Number Of People In Yemen Dying With COVID-19 Symptoms. The Washington Post (5/14, Raghavan, 14.2M) reports “the number of people dying with covid-19 symptoms has dramatically spiked in war-riven Yemen, triggering fears that coronavirus infections are considerably higher than official figures, the Save the Children charity said Thursday.”

Increasing Number Of Physicians In Russia Dying From Pandemic. The New York Times (5/14, Troianovski, 18.61M) reports an increasing number of physicians in Russia on the front lines of the pandemic are dying, a situation made worse by a general lack of access by healthcare professionals to personal protective gear.

UK Government In Talks With Roche To Buy COVID-19 Antibody Tests. Reuters (5/14, Faulconbridge, Holton) reports that following its approval by Public Health England, the UK government “is in talks with Swiss drugmaker Roche Holding AG to buy an accurate COVID-19 antibody test, following the lead of the European Union and United States, which had already given preliminary approval to the tests.”

Reuters (5/13, Faulconbridge, Holton) and CNN (5/14, Ramsay, Isaac, 83.16M) provide additional coverage of the original approval.

HHS IN THE NEWS

Trump Administration Reportedly Mulling Indefinite Border Restrictions Amid COVID-19 Outbreak. The Hill (5/14, Wise, 2.98M) says, “The Trump administration is reportedly working to unveil a new order that would indefinitely extend border restrictions amid the coronavirus outbreak, according to a report in The New York Times.” This “move, which is reportedly currently being reviewed by several government agencies, would keep legal points of entry shuttered and restrict nonessential travel through Mexico and Canada until the director of the Centers
for Disease Prevention and Control (CDC) concluded that the coronavirus no longer posed a threat to public health, the Times reported citing officials and a draft of the public health order.” Officials from the CDC “would continue to assess the threats posed by the virus every 30 days and the new plan would give Robert Redfield, director of the CDC, authority over when the U.S. borders are safe to reopen.”

The Daily Caller (5/14, Hopkins, 716K) and National Review (5/14, Evans, 731K) also cover the story.

Gottlieb Suggests Schools Should Attempt In-Person Education This Fall When Possible. CNBC (5/14, Stankiewicz, 3.62M) reports former FDA Commissioner Scott Gottlieb on CNBC’s “Squawk Box” said that US schools should be willing to attempt in-person education this fall if the coronavirus pandemic “isn’t rampant.” Gottlieb said, “I do think we’re going to have to contend with Covid going into the fall, but it might not be in September,” adding, “It might occur later into the fall, and we should at least make an attempt to open the schools if this isn’t spreading widely.” However, he stressed that decisions on welcoming students back to classrooms will have to be made locally, depending on the scale of Covid-19 outbreaks in states and communities.

The Hill (5/14, Klar, 2.98M) also reports.

Opinion: Acceptance Of Pandemic’s Effect On Our Lives Could Speed Up Needed Adjustments. Former CDC Director Tom Frieden writes in the Washington Post (5/14, 14.2M) that the concept of the “five stages of grief” simplifies “a complex process” of “core truths: People tend to accept harsh realities gradually and with difficulty.” However, “recognition of the pandemic’s impact, and widespread embrace of the final stage, acceptance, could speed our collective path to new, post-pandemic normal.” While the pandemic “has upended lives around the world” and the world is collectively “acknowledging, and grieving, these losses and the life rituals...disrupted by the pandemic,” the sooner “people come to terms with the reality of the pandemic, the quicker we can prepare for lasting changes to the ways we can work, learn, relax, govern ourselves and even treat one another.”

Mask Manufacturer Executive Testifies About How Government Allegedly Ignored His Previous Warnings Of Insufficient Mask Production. CNN (5/14, Kelly, Watts, Gloria, 83.16M) reports “an executive for a US mask producer bemoaned, in heated and emotional testimony Thursday to Congress, how his warnings of insufficient domestic medical mask production had been ignored by the federal government for years until the coronavirus pandemic.” While “speaking before the

House Energy and Commerce Committee, Mike Bowen, the vice president of the Texas-based medical supply company Prestige Ameritech, said the US dependence on foreign masks has been a national security issue for years.” According to CNN, “Bowen described conversations over the past 13 years in which he had offered manufacturing deals to the” CDC “that included ‘making sure that the Department of Defense and the Veterans Administration always has masks,’ adding that ‘I couldn’t get anybody interested in it.’”

White House To Require Some Essential Drugs To Be Manufactured In US, Sources Say. The Hill (5/14, Moreno, 2.98M) reports “the White House is preparing to require that some essential drugs be made in the U.S. as the Trump administration tries to limit dependency on China for medical supplies, sources told CNBC.” Earlier in the year, White House trade advisor Peter Navarro “proposed a similar executive order.” Navarro’s order “would streamline regulatory approvals for ‘American-made’ drugs and impose similar Food and Drug Administration (FDA) restrictions on U.S. production facilities as those abroad.” The order “will also encourage government agencies to only buy American-made medical products.” Still, “it is unclear if the executive order the unnamed sources referred to is the same as Navarro’s.”

Bloomberg (5/14, Stein, Capaccio, 4.73M) also reports on the story.

Gottlieb Says He Sees Signs That The Coronavirus Epidemic Is Slowing In US. Intelligencer (NY) (5/14, Raymond, 1.1M) reports that “as states across the country begin to reopen their economies, the United States is ‘seeing signs of a slowing epidemic,’ former FDA commissioner Scott Gottlieb told a House subcommittee Wednesday.” The piece says “Gottlieb told lawmakers that even as testing for the coronavirus is becoming more available, the rate of positive tests is going down. ‘There are hopeful signs,’ he said.”

Coronavirus Can Cause Strokes In Young People, Physicians Say. The New York Times (5/14, Rabin, 18.61M) reports coronavirus infection can cause strokes in young people, something which is very rare. The Times highlights the case of Ravi Sharma, a healthy 27-year-old EMT who had a stroke after becoming infected with coronavirus, and says physicians around the US have reported similar cases.

Senators Ask CDC To Examine Risk Of Strokes In Younger, Middle-Aged Patients With COVID-19. The Hill (5/14, Budryk, 2.98M) reports “Sens. Amy Klobuchar (D-Minn.) and Marco Rubio (R-Fla.) are asking the Centers for Disease Control and Prevention (CDC) to assess the risk of
strokes in younger and middle-aged coronavirus patients.” The senators wrote to CDC Director Dr. Robert Redfield, “We believe it is critical that the CDC evaluate the prevalence of stroke in COVID-19 patients, including the potential link to stroke from the development of blood clots caused by the virus.”

**Online Pharmacy HealthWarehouse Saw Spike In Demand For Hydroxychloroquine In Mid-March.** NPR (5/14, Horn, 3.12M) reports that, “in mid-March, when the unproven idea of giving coronavirus patients anti-malarial drugs emerged on social media and on Fox News, the online pharmacy HealthWarehouse said orders for hydroxychloroquine started to spike.” The FDA has since put out a warning against using it for COVID-19.

**Survivors Of COVID-19 Pandemic In Nursing Homes Remain In Isolation.** ABC News (5/15, Mosk, Freger, Romero, Pecorin, 2.97M) reports on “one of the unexpected consequences of COVID-19 in nursing homes: the extended isolation of those who have survived.” The majority, “if not all of the 15,000 nursing facilities around the country have prohibited outside visitors since early March – federal regulators announced measures directing nursing homes to ‘significantly restrict visitors and nonessential personnel’ on March 13.” Still, “even with nursing home residents largely cordoned off, the virus has moved effortlessly through many facilities, most likely carried by staff members who were infected but asymptomatic.” On Thursday, CMS Administrator Seema Verma said in an interview, “We want to make sure that whatever we do, that we are putting the health and safety of the nursing home residents at the top. ... That’s the most important priority. So we’re starting to have those discussions about how we can make sure that nursing homes are safe and that visitors can come back in a safe way.”

**Thousands Volunteer To Be Exposed To Novel Coronavirus In Human Classified Trial Led By 1 Day Sooner.** Fox News (5/14, Hein, 27.59M) reports, “More than 20,000 people have signed up to voluntarily be exposed to the novel coronavirus in a yet-to-be formulated ‘human classified trial,’ which is ‘being led by a group called 1 Day Sooner.’ According to Fox News, “Human challenge trials for coronavirus have the support of 35 members of the House of Representatives who wrote to the Food and Drug Administration and the Department of Health and Human Services arguing that they should be allowed.”

**Former BARDA Head Tells Congress Coronavirus Vaccine Won’t Be Ready In 12 To 18 Months.** CNBC (5/14, Feuer, 3.62M) reports that a coronavirus vaccine “won’t be ready for distribution in 12 to 18 months as White House officials have assured the public, ousted federal vaccine scientist Dr. Rick Bright told Congress Thursday.” Bright told members of the House Energy and Commerce Subcommittee on Health, “A lot of optimism is swirling around a 12-to-18 month timeframe if everything goes perfectly. We’ve never seen everything go perfectly.”

**CQ Roll Call (5/14, Kopp, 154K) reports Bright, “who oversaw vaccine development in his BARDA role, warned that the distribution of an eventual vaccine could be delayed by the same supply chain issues that led to mass shortages of personal protective equipment.”** Bright said: “If you can imagine a scenario, this fall or this winter or early next spring, when a vaccine becomes available ... there’s no one company that can produce enough for the country or for the world. There are going to be limited supplies.”

Among other media outlets providing coverage are: U.S. News & World Report (5/14, Hagen, 2.4M), The Hill (5/14, Budryk, 2.98M), the Washington Examiner (5/14, Morrison, 448K), and the Financial Times (5/14, Stacey, Subscription Publication, 1.34M).

**Former BARDA Director Says Trump Official Ignored Warnings Of Supply Shortages.** The New York Times (5/14, Stolberg, 18.61M) reports the whistleblower “who was ousted as the head of a federal medical research agency charged on Thursday that top Trump administration officials failed to heed his early warnings to stock up on masks and other supplies to combat the coronavirus, and that Americans died as a result.” Dr. Rick Bright, “who was removed in April as the director of the Department of Health and Human Services’s Biomedical Advanced Research and Development Authority, told a House subcommittee: ‘Lives were endangered, and I believe lives were lost.’”

The Hill (5/14, Weixel, 2.98M) reports Bright “told House lawmakers on the Energy and Commerce Health
Subcommittee that he began to get alerts from manufacturers that the supply chain for masks and other personal protective equipment was “diminishing rapidly” as early as January. He said he warned his superiors about severe shortages of N95 respirators needed for front-line health care workers.” CBS’ 60 Minutes (5/14, Zubrow, 11.55M) and Axios (5/14, Fernandez, 521K) also report.

White House Press Secretary, Senior Trump Adviser Dismiss Ousted HHS Official’s Claims. Fox News (5/14, Nelson, 27.59M) reports White House Press Secretary Kayleigh McEnany on Thursday “reacted to ousted Trump administration scientist Rick Bright’s claim that the president was ‘dismissive’ of a warning about the severity of the coronavirus outbreak.” Bright, the former HHS official who filed a whistleblower complaint claiming he was removed from his post for disagreeing with the Trump administration’s response to coronavirus, said Thursday that officials at the Department of Health and Human Services were ‘dismissive’ of his warning about the contagion and said that if the government doesn’t follow his guidance 2020 will be the darkest winter in modern history.” McEnany told America’s Newsroom: “It sounds like Mr. Bright hasn’t really been paying that much attention at all.”

The Daily Caller (5/14, Davis, 716K) reports Trump adviser Peter Navarro also “bore into Dr. Rick Bright during a Fox News appearance Thursday after Bright testified on Capitol Hill.” Navarro said: “I find it highly ironic that you’ve got Bright up there on Capitol Hill issuing these dire warnings on the very day President Trump is going to the beautiful Lehigh Valley to announce a tougher, smarter, more resilient strategic national stockpile.”

Among other media outlets reporting are: Fox News (5/14, Kaplan, 27.59M), the Washington Examiner (5/14, Soellner, 448K), the Washington Examiner (5/14, Colton, 448K), in a separate article, and the Daily Caller (5/14, Caruso, 716K).

HHS Whistleblower’s Attorneys Say Watchdog Finds “Substantial Likelihood Of Wrongdoing.” CNBC (5/14, Mangan, 3.62M) reports that a government watchdog “has found a ‘substantial likelihood of wrongdoing’ in the removal of a vaccine specialist from leading a federal agency handling coronavirus response, his lawyers disclosed Thursday.” The preliminary finding from the Office of the Special Counsel, which is investigating Rick Bright’s whistleblower complaint, was disclosed just before Bright began testifying before a House panel.

FDA Authorizes Human Trials For AIM ImmunoTech’s Drug To Treat COVID-19 In Patients With Cancer. The Ocala (FL) Star-Banner (5/14, Medina, 81K) reports the U.S. FDA “recently authorized human trials for a drug made by a Marion County-based” AIM ImmunoTech’s drug AmpleGen “to possibly treat COVID-19 patients who have cancer.” The trial will be conducted by Roswell Park Comprehensive Cancer Center in Buffalo, New York.”

Opinion: Following Science Is Best Path For Our Leaders To Avoid “Darkest Winter.” In an article for Forbes (5/14, 9.71M), contributor Seth Cohen writes that Dr. Richard Bright, “the former director of the nation’s Biomedical Advanced Research and Development Authority painted a perilous picture of the trajectory of the coronavirus pandemic – unless leadership of the country undertakes a much more science-focused approach. Yet what is most unsettling about Bright’s testimony before the House Committee on Energy and Commerce is his belief that, absent a course correction by the nation’s leaders, America may face it’s ‘darkest winter in modern history’ later this year.” Cohen argues, “Following science, not fomenting doubt and fear, is the best path for our leaders to follow if we are to avoid, in Dr. Bright’s words, our nation’s darkest winter. Here’s hoping they see the light before it’s too late.”

CDC Issues Six Brief Checklists To Guide Businesses, Schools, Others On Reopening. The Washington Post (5/14, A1, Bernstein, Wan, Dawsey, Weiner, 14.2M) reports, “With hundreds of millions of people still seeking advice on resuming their lives safely, the Centers for Disease Control and Prevention issued a scant six pages of recommendations Thursday to guide schools, businesses, day-care facilities and others into the next phase of the coronavirus pandemic.” The six “checklists – which also address restaurants, mass transit and camps – come days, and in some cases weeks, after many states have begun to lift restrictions on their own.” The advice “is less detailed than draft recommendations the agency sent to the White House for review last month.”

The AP (5/14, Stobbe, Dearen) reports the CDC “posted six one-page ‘decision tool’ documents that use traffic signs and other graphics to tell organizations what they should consider before reopening.” The agency “drafted the reopening guidance more than a month ago and it was initially shelved by the administration, the AP reported last week.” The CDC “also had prepared even more extensive guidance – about 57 pages of it – that has not been posted.”

CBS News (5/15, 3.68M) reports “the published memo on child care facilities completely removes from the draft guidance a warning to, ‘be ready to close if there are increased cases.’” According to CBS, “CDC Director Robert Redfield said that the draft guidance had been ‘shared
prematurely' and 'had not been vetted through the interagency review process.'"

Among other media outlets providing coverage are: the CBS Evening News (5/14, story 3, 0.25, O'Donnell, 5.25M), NBC Nightly News (5/14, story 4, 0.25, Holt, 7.88M), ABC World News Tonight (5/14, story 3, 2.20, Muir, 7.42M), the New York Times (5/15, Bogel-Burroughs, 18.61M), Bloomberg (5/14, Jacobs, Court, Sink, 4.73M), ABC News (5/14, Flaherty, Gittleson, Cathey, 2.97M), Reuters (5/14, Steenhuisen), CNN (5/14, Fox, 83.16M), NPR (5/14, Hagemann, 3.12M), The Hill (5/14, Sullivan, 2.98M), Politico (5/14, Roulbeh, 4.29M), and Axios (5/14, Rummell, 521K).

**Former BARDA Chief Will Start At New Job Next Week, Attorneys Say.** CNN (5/14, Collins, Tapper, 83.16M) reports Dr. Rick Bright, who filed a whistleblower complaint after being removed from his role as the leader of the Biomedical Advanced Research and Development Authority (BARDA), "will start his new job in a role inside the federal government's coronavirus response next week, his attorneys said Thursday." A Department of Health and Human Services source told CNN that Bright has been offered the job of second-in-command of the Accelerating Covid-19 Therapeutic Interventions and Vaccines partnership. Bright's lawyers "said in a Thursday evening news release that he plans to report to that job next week now that it has been identified."

**Texas Paid $45 Million For COVID-19 Tests.** The Austin (TX) American Statesman (5/13, Price, Subscription Publication, 343K) reported, "In a glimpse into the cost of coronavirus testing, the state of Texas is paying $45 million for 300,000 oral-swab tests – or $150 per test, according to a purchase order obtained by the American-Statesman through an open records request." The cost "for healthcare providers and laboratories to test patients for COVID-19, according to the Medicare bulletin, was $35.92 for the tests developed by the U.S. Centers for Disease Control and Prevention and $51.33 for all other commercial tests." The piece said "officials at the U.S. Centers for Medicare and Medicaid Services" said "that they would pay $100 for COVID-19 tests that increase testing capacity and lead to faster results" in April.

**Healthcare Personnel Continue To Report Elevated COVID-19 Infection Rates.** The Chicago Tribune (5/14, Bowen, 2.65M) reports, "Nationally, the Centers for Disease Control and Prevention reported about 9,000 cases of COVID-19 among health care personnel, a wide designation that includes pharmacists, laboratory workers, security guards and clerical staff." Of this group, "90% were not hospitalized, and 27 people died." However, these data are likely underestimates, "according to a CDC spokeswoman."

**Rural Hospitals Need Access To Telehealth To Battle Coronavirus Pandemic, Experts Say.** Healthcare IT News (5/14, Jerchick, 2K) reports that rural hospital leaders said during a webinar Thursday that "COVID-19 has magnified the need for access to telehealth – and that it's a mistake to rely on one-size, fits-all solutions for virtual care." In a report that was made available "by the Bipartisan Policy Center in advance of the webinar noted that the steps taken to make services more accessible amid the coronavirus pandemic could be made permanent in order to improve rural healthcare access." One part of the report highlighted government support, and said, "In March 2020, as coronavirus evolved into a pandemic, Congress voted to temporarily waive telehealth requirements for Medicare providers, allowing the Centers for Medicare and Medicaid Services, or CMS, to reimburse clinicians for telehealth visits with patients at home in an area with a designated emergency."

**Trump Announces Plan To “Replenish And Modernize” Strategic National Stockpile.** The Washington Post (5/14, Goldstein, 14.2M) reports "President Trump announced Thursday a plan to reconfigure the government’s chronically undersupplied stockpile of emergency gear to help combat the coronavirus pandemic, accelerating manufacturing and broadening the array of supplies it houses." Trump "said his administration is launching what he termed a ‘groundbreaking initiative’ to ‘replenish and modernize’ the government’s stores of masks, ventilators and other essential pandemic-fighting medical equipment to create a 90-day reserve." While saying "with his ‘America first’ mantra, Trump and his aides said the manufacturing would be carried out by U.S. companies, diminishing the reliance on foreign factories that have been the stockpile’s major sources."

The Wall Street Journal (5/14, Ballhaus, Lyle, Subscription Publication, 7.57M) reports that when the novel coronavirus first started to spread within the US, the Strategic National Stockpile only had one to three weeks of the majority of equipment and did not include many supplies that have been critical while battling the current pandemic.

The AP (5/14, Colvin, Superville) reports Trump said while visiting a medical equipment distributor in Pennsylvania, "Wouldn't that be nice? ... My goal is to produce everything America needs for ourselves and then export to the world, including medicines." The President "had complained about supply chains in a television interview that aired before he left Washington for the trip to Owens and Minor Inc. in Allentown."
Reuters (5/14, Alper) reports “the Trump administration is seeking to add 300 million N95 masks, the respiratory protective devices that are key to protecting medical workers fighting the deadly coronavirus, to the U.S. stockpile by the fall, a senior administration official said on Thursday.” While “speaking to reporters during a telephone briefing, the official said the administration hopes ultimately to replenish its strategic national stockpile, which had only 13 million N95s at the beginning of the outbreak, to 1 billion in total.”

CBS News (5/14, Watson, 3.68M) reports Trump “blames the Obama administration for the shortfall” of the stockpile. Trump said, “Under the previous administration the stockpile was depleted and never fully refilled. My administration is taking action to modernize the stockpiles during this crisis.”

Politico (5/14, Lim, 4.29M) reports one senior Administration official said, “Of all the items that a Covid patient in a hospital consumed during a length of stay, we only carried 28 percent of those. We did not carry a lot of critical care drugs, we did not carry testing supplies. These were never in the Strategic National Stockpile. They will be in the Strategic National Stockpile going forward.” Retooling the stockpile “toward pandemic needs could be an important step if a second wave of infections emerges this fall, as many public health experts predict.”


Former BARDA Chief Warns Trump Administration Still Has No National Plan For Pandemic. The Wall Street Journal (5/14, Armour, Grimaldi, Subscription Publication, 7.57M) reports that Dr. Rick Bright, who was removed as head of the Biomedical Advanced Research and Development Authority (BARDA) and subsequently filed a whistleblower complaint, told a House committee on Thursday that the Trump Administration still has no broad national strategy to address the coronavirus pandemic.

The AP (5/14, Alonso) reports that, “despite White House claims, the U.S. still lacks a comprehensive battle plan against the coronavirus in critical areas including masks, testing, treatments and vaccines,” Bright “told the House Energy and Commerce Committee.” Bright told lawmakers: “There are critical steps that we need to do to prepare … we do not still have enough personal protective equipment to manage our health care workers … we still do not have the supply chains ramped up for the drugs and vaccines, and we still don’t have plans in place for how we distribute those drugs and vaccines. We still do not have a comprehensive testing strategy.”

Reuters (5/14, Wolfe) reports Bright “said he was ousted from BARDA because he resisted efforts to push the drugs hydroxychloroquine and the related chloroquine as cures for COVID-19, the respiratory illness caused by the coronavirus.” HHS spokeswoman Caitlin Oakley “has disputed Bright’s account, saying in a statement on Tuesday that he was transferred to a job where he was entrusted to spend around $1 billion to develop diagnostic testing.”


FDA Examining Data Showing Abbott’s COVID-19 Test Delivers Inaccurate Results. Bloomberg (5/15, Sutherland, Armstrong, 4.73M) reports an Abbott Laboratories COVID-19 test has “potential accuracy issues, the U.S. Food and Drug Administration warned, citing a number of studies that have raised doubts about the product’s ability to quickly diagnose patients.” The FDA issued a “public alert Thursday evening, saying that it had become aware of several scientific studies that had raised questions about the device, a printer-sized machine called ID Now that can take a sample from a nasal swab and diagnose a coronavirus infection.” The agency said “that it was particularly concerned about false-negative results, in which an infected person is told by the test that they don’t have the disease.” The FDA “said that the Abbott test, which has been used at the White House, can still be used to diagnose positive results, often within minutes.” But it “warned that a negative result might need to be confirmed with a different test to be certain the person doesn’t have the virus.”

Axios (5/14, Rummell, 521K) reports the tests are widely used, and that the US has “deployed over 235,000 tests to public health laboratories in every state across the
Among outlets also reporting are the Financial Times (5/14, Stacey, Subscription Publication, 1.34M) and Reuters (5/15, O'Donnell).

**Trump, Azar Slam Former HHS Official Who Filed Whistleblower Complaint As “Disgruntled.”** Fox News (5/14, O'Reilly, 27.59M) reports President Trump on Thursday “defended the use of the anti-malaria drug hydroxychloroquine to treat the novel coronavirus and slammed the demoted government scientist who filed a whistleblower complaint claiming he was removed from his post for disagreeing with the Trump administration’s response to the contagion.” Making his comments “before boarding Air Force One for a trip to Pennsylvania, Trump said that there was a ‘tremendous response’ to hydroxychloroquine and called Rick Bright – the former director of the Biomedical Advanced Research and Development Authority – a ‘disgruntled person.’”

CNBC (5/14, Breuninger, 3.62M) reports Trump tweeted Thursday morning: “I don’t know the so-called Whistleblower Rick Bright, never met him or even heard of him. But to me he is a disgruntled employee, not liked or respected by people I spoke to and who, with his attitude, should no longer be working for our government.”

The Hill (5/14, Chalfant, 2.98M) reports HHS Secretary Alex Azar “is sharply rebuking remarks from ousted federal vaccine official Rick Bright about the coronavirus response, saying his allegations ‘do not hold water.’” Azar stated, “Everything he is complaining about was achieved. Everything he talked about was done.” The article says he “sought to counter comments Bright made the same day before House lawmakers, warning of the ‘darkest winter in modern history’ without a national play to fight the pandemic.”

Among other media outlets providing coverage are: the Washington Post (5/14, 14.2M), with a video of the President’s comments, the Washington Post (5/14, 14.2M), with a video of Azar’s comments, Bloomberg (5/14, Edney, Sink, 4.73M), Fox News (5/14, Halon, 27.59M), Fox News (5/14, 27.59M), with a video of Azar’s comments, Fox News (5/14, Garcia, 27.59M), in a separate article, Axios (5/14, Fernandez, 521K), the Washington Examiner (5/14, Miller, 448K), the Daily Caller (5/14, Kruta, 716K), and STAT (5/14, Florko, 24K).

**Ivanka Trump Says She Wears Mask At White House.** USA Today (5/14, Jackson, Subramanian, 10.31M) reports "Ivanka Trump, daughter and senior adviser to President Donald Trump, says she wears a mask at the White House, and that’s one reason the president doesn’t have to.” Ms. Trump said, “There are different procedures as it relates to interacting with the president.” According to USA Today, “The president is tested on a daily basis – all those
who come into contact with him are tested on a daily basis,” she said in an interview. “No one is in close proximity to him that isn’t wearing a mask.” Ms. Trump added, “I always wear a mask when I am with the president, and everyone is instructed to do so as well.”

Newsweek (5/14, Zhao, 1.53M) reports the President “failed to wear a mask during a visit to a Pennsylvania medical equipment distribution center on Thursday. His decision not to wear a mask was particularly noticeable as other government officials that accompanied him during the trip, including Health and Human Services Secretary Alex Azar and Rear Adm. John Polowczyk, were seen wearing masks in photos.”

Taiwan Remains Sideline From WHO’s World Health Assembly Amid Pandemic. The Washington Post (5/15, Aspinwall, Rauhala, 14.2M) reports that “with just 440 covid-19 cases and seven deaths, Taiwan looks to have conquered the coronavirus.” However, “one symbol of recognition remains elusive: an invitation for Taiwan to observe next week’s World Health Assembly.” The Post says that “despite a growing pro-Taiwan coalition backing their inclusion, health officials in this self-ruled democracy remain sidelined from the World Health Organization’s decision-making body at the urging of China’s government, which claims sovereignty over Taiwan and has sought to sever its international contacts.” The piece mentions “an April telephone call between Taiwan health minister Chen Shih-chung and” HHS Secretary Alex Azar.

HHS Awards $15M For Expanded Use Of Telehealth Amid COVID-19 Pandemic. mHealth Intelligence (5/14, Wicklund) reports HHS “is dispensing $15 million in funding to almost 160 healthcare providers across the country to help them expand telehealth services to meet demands caused by the Coronavirus pandemic.” The funds, from the CARES Act, are “being issued through the Health Resources and Services Administration (HRSA) and are earmarked to ‘train students, physicians, nurses, physician assistants, allied health and other high-demand professionals in telehealth’ and expand connected health platforms to replace or complement in-person care.” HHS Secretary Alex Azar said, “This new funding from Congress will enable more heroic health professionals on the front lines of the COVID-19 pandemic to use telehealth for a broad range of care.”

Medical Groups Urge Verma To Provide More COVID-19 Assistance For Medicare ACOs. Bloomberg Law (5/14, Pugh, Subscription Publication, 4K) reports a coalition of medical groups, including the AMA and the Medical Group Management Association, is “asking the Trump Administration to provide additional pandemic-related support for” Medicare ACOs. On April 30, CMS issued an interim final rule aimed at helping ACOs during the pandemic, but the coalition of medical groups wrote a letter to CMS Administrator Seema Verma asking for more help for ACOs.

FierceHealthcare (5/14, King, 146K) reports the “groups say accountable care organizations (ACOs) need until Oct. 31 to decide whether to leave the Medicare Shared Savings Program (MSSP) due to the COVID-19 pandemic.” At present, “ACOs have until June 1 to decide whether to terminate their contract with MSSP,” however, “providers have been worried they could soon see an exodus of ACOs leaving the program to avoid losses, especially if the June 1 deadline holds.” The article says “pushing back the timeline will ‘give ACOs more time’ to understand a series of new rules to mitigate the impact of the COVID-19 pandemic, according to a letter from nine groups sent to the Centers for Medicare & Medicaid Services.”

In Reversal, IHS Starting To Hire Traditional Healers. Kaiser Health News (5/14, Akridge) reports that certain “plants have been used as medicines for generations by the Assiniboine and Gros Ventre tribes who live on the Fort Peck and Fort Belknap reservations, respectively. Echinacea is used to help boost the immune system. Valerian produces a strong sedative that can address nervousness, tension and stress. Licorice root acts as an antihistamine, which treats allergy symptoms.” The article says the Indian Health Service is “starting to embrace” the use of such traditional treatments. The piece adds, “The Fort Belknap IHS hospital is seeking job applicants for two traditional practitioner positions, offering up to $68,000 a year.” Although IHS “has filled similar positions across the Navajo Nation in the past 15 years, these would be the first IHS positions of their kind in Montana.” The article says this “move is surprising because the federal government would essentially be paying for medicine men, or women, to help treat IHS patients, despite punishing and maligning such expertise for generations.”

HHS, DoD Award $138M Contract For Expanded Production Of Prefilled Syringes To Be Used For Future COVID-19 Vaccine. Homeland Preparedness News (5/14, Kovalski) reports HHS and the Department of Defense “awarded a $138 million contract to Apoject Systems America for Project Jumpstart and RAPID USA, two programs designed to expand U.S. production of medical-grade injection devices.” This “contract will create a U.S.-based supply chain for prefilled syringes by using Blow-Fill-Seal (BFS) aseptic plastics manufacturing technology, suitable for combating COVID-19 when a vaccine becomes available. By upgrading existing domestic BFS facilities with installations of filling-line and technical...
improvements, the project will enable the manufacture of more than 100 million prefilled syringes for distribution across the United States by year-end 2020."

NATIONAL FRONT PAGE NEWS

Headlines From Today’s Front Pages.

WALL STREET JOURNAL:
Nearly Three Million Sought Jobless Benefits Last Week
Coronavirus Finishes The Retail Reckoning That Amazon Started
Why Big Investors Aren’t Betting It All On A Coronavirus Cure
New York Sent Recovering Coronavirus Patients To Nursing Homes: “It Was A Fatal Error”
Is That A Rooster On My Customer-Support Call? Yes, Blame Coronavirus.

NEW YORK TIMES:
‘Rolling Shock’ As Job Losses Mount Even With Reopenings
He Saw ‘No Proof’ Closures Would Curb Virus. Now He Has De Blasio’s Trust.
As Coronavirus Overruns Russia, Doctors Are Dying On The Front Lines
India’s ‘Maximum City’ Engulfed By Coronavirus
Changing Subject Amid A Pandemic, Trump Turns To An Old Ploy: Blame Obama
Trump White House Changes Its Story On Michael Flynn Meat Plant Closures Mean Pigs Are Gassed Or Shot Instead

WASHINGTON POST:
How Flynn Case Became A Trump 2020 Keystone
A Dying Man, A Desperate Search
CDC Offers Scant Guidelines For Reopening Safely
Pandemic Is Latest Blow To Sportswriting Profession
Burr Withdraws As Chairman Amid Stock Sale Investigation
In Poor Nations, Hunger May Be The Bigger Killer

FINANCIAL TIMES:
Macron Summons Sanofi Chief For Claim US Has “Right To” First Covid-19 Jab
Banking: The Great Return To The Office
US Jobless Claims Rise To 36M Since Start Of Lockdowns

WASHINGTON TIMES:
Chinese Deception Fuels Fears Of Ethnic Biological Weapons ‘Experiments’
Trump Blames Biden, Obama For Depleted National Stockpile Of Medical Supplies
From Phishing Scams To Fake Tests: Feds Struggle To Knock Down Coronavirus Fraud
MLB, NBA To Return? Youth Sports Could Be First

Coronavirus Crackdowns Around The World Make US Rules Look Lenient
From Asymptomatic To Lethal: Coronavirus Discrepancies Puzzle Scientists

STORY LINEUP FROM LAST NIGHT’S NETWORK NEWS:

ABC: HHS Whistleblower; Trump-PA Visit; CDC-New Guidelines; Unemployment; FBI-Sen. Burr; Georgia-Ahmad Arbery Case; Florida-Wildfires; Coronavirus-Transmission; US Army Band Performs Over Video.
CBS: HHS Whistleblower; Trump-PA Visit; CDC-New Guidelines; Pediatric Multi-System Inflammatory Syndrome; Unemployment; Stay-At-Home Fatigue; FBI-Sen. Burr; Coronavirus-Potential Treatment; Georgia-Ahmad Arbery Case; Coronavirus-USS Theodore Roosevelt; Milwaukee-Twins Graduate 1st & 2nd in Class; Pennsylvania-5-Year-Old Helps Mom Teach Remotely.
NBC: Pediatric Multi-System Inflammatory Syndrome; HHS Whistleblower; Trump-PA Visit; CDC-New Guidelines; Unemployment; Coronavirus-NBC Contributor III; Coronavirus-Airlines; FBI-Sen. Burr; Coronavirus-Vaccine; Coronavirus-Potential Treatment; Georgia-Ahmad Arbery Case; Florida-Severe Weather; Nightly News Kids Edition.

NETWORK TV AT A GLANCE:
HHS Whistleblower – 12 minutes, 50 seconds
Coronavirus – 8 minutes, 30 seconds
Unemployment – 7 minutes, 20 seconds
FBI-Sen. Burr – 4 minutes, 20 seconds
Georgia-Ahmad Arbery Case – 4 minutes, 0 seconds
CDC-New Guidelines – 3 minutes, 10 seconds
Trump-PA Visit – 1 minute, 50 seconds

STORY LINEUP FROM THIS MORNING’S RADIO NEWS

BROADCASTS:

ABC: FDA-Abbott Coronavirus Test; Stay-At-Home Fatigue; Reopening Economy; House-Relief Bill; VA Homes-COVID-19 Deaths Investigation.
FOX: House-Relief Bill; CDC-New Guidelines; Sen. Kelly Loeffler-Docs to DOJ.
NPR: HHS Whistleblower; FDA-Abbott Coronavirus Test; Trump-PA Visit; Wall Street.

LAST LAUGHS

Late Night Political Humor.

Trevor Noah: “Do you remember that story about the senator in North Carolina who dumped his stocks after getting a government briefing that coronavirus was gonna wreck America? Well, now the FBI is getting involved... That’s
right, like a suspicious spouse, the FBI has decided they want to look through this senator’s phone.”

**Trevor Noah:** “And to me, maybe the worst part about this scandal is that Senator Richard Burr was telling everyone, telling everyone in America, that things were going to be okay while he and his family were quietly saving themselves. It would be like if Noah built the ark but didn’t tell anyone why he was doing it.”

**Jimmy Kimmel:** “Dr. Rick Bright harshly criticized the White House response to COVID-19. ... He warned us the window is closing to address the pandemic. Unless that window is a drive-through window at KFC, there’s no way Trump’s going to bother.”

**Jimmy Kimmel:** “The President called that decision to reopen Wisconsin a big win and headed to Allentown, Pennsylvania. ... He went to a factory where they manufacture masks, and did the President wear a mask to the factory where they manufacture masks? Of course not. Everyone else did. He did not. But there’s a good reason why he won’t wear a mask. Wearing a mask is an act of respect, and consideration for others.”

**Stephen Colbert:** “Today, [Dr. Rick] Bright testified before Congress. But even before the hearing began, Trump went on the offensive, tweeting, ‘I don’t know the so-called whistleblower Rick Bright, never met him or even heard of him, but to me he is a disgruntled employee, not liked or respected by people I spoke to and who, with his attitude, should no longer be working for our government!’ That’s quite a preambule! (As Trump) ‘Before I assassinate this guy’s character, let me first say, I have no idea what I’m talking about.’”

**Jimmy Fallon:** “Today, vaccine expert Dr. Rick Bright said without better planning, 2020 could be the darkest winter in modern history. It’s not a good sign when our experts sound like the night’s watch on ‘Game of Thrones’. Winter is coming.”

**Seth Meyers:** “Former Vice President Joe Biden appeared on Snapchat’s daily political show yesterday, although I’m not sure Snapchat is a good way to prove you haven’t disappeared.”

**Seth Meyers:** “The FBI has seized the cell phone of Republican Senator Richard Burr as part of an investigation into whether he used information from a coronavirus intelligence briefing to sell stocks. It’s also incriminating that right after the meeting, he signed up for Netflix and Hulu.”

**Seth Meyers:** “In a new interview, President Trump claimed that his critics would like to keep the country closed during the coronavirus pandemic to damage him politically. I mean, if anyone wants to damage you, they don’t have to keep the country closed. They just have to keep your mic open.”

**NATIONAL NEWS**

**Trump Retweets Post Questioning Claim He Is A Racist.** President Trump retweeted a post from a Twitter user named Maggie VandenBerghe, which said, “I was told Trump was RACIST but let me give some EVIDENCE to debate Trump supporters!” What happens next? MAGA! @realDonaldTrump” The post includes video of VandenBerghe interviewing an African American man who says he was told Trump is a racist but when he did some research, he found that he likes him. Trump wrote in his tweet, “Thanks. You are very cool!”

**Burr Steps Aside As Chair Of Senate Intelligence Committee Amid FBI Probe.** The AP (5/14, Tucker) reports that Sen. Richard Burr (R-NC) has “temporarily stepped aside as chairman of the Senate Intelligence Committee” after the FBI “served a search warrant for his cellphone as part of an investigation into a well-timed sale of stocks tied to the coronavirus pandemic.” Senate Majority Leader McConnell “announced the move, saying he and Burr had agreed that it was in the committee’s best interests.” Burr told reporters he thought it was “the right thing to do. ... This is a distraction to the hard work of the committee and the members, and I think that the security of the country is too important to have a distraction.”

Pierre Thomas said on ABC World News Tonight (5/14, story 5, 2:00, Muir, 7.42M) that the FBI “wants to know if Burr used intelligence information about the coronavirus for financial gain by selling stocks just before the market cratered.” Burr sold “up to $1.7 million in travel and hotel investments just a day after a closed-door briefing on the impact of the virus.”

The New York Times (5/14, Benner, Fandos, 18.61M) says the seizure of Burr’s cellphone “and accompanying search for his electronic storage accounts, confirmed by an investigator briefed on the case, represented a significant escalation of the inquiry by the Justice Department and the Securities and Exchange Commission. They suggest that Mr. Burr, a Republican and one of the most influential members of Congress, may be in serious legal jeopardy.” The Times says “the sensitivity surrounding the decision to obtain a search warrant on a sitting senator,” indicates “the move was approved at the highest levels of the department, a senior Justice Department official said, meaning that” Attorney General Barr “signed off on it.” Pete Williams said on NBC Nightly News (5/14, story 8, 1:00, Holt, 7.89M) that the investigation “is clearly in a new phase.” A search warrant “would require a judge’s finding that there is probable cause
to think the phone could contain evidence of a crime.” The CBS Evening News (5/14, story 7, 1:20, O'Donnell, 5.25M) provided similar coverage.

The Washington Post (5/14, Shepherd, 14.2M) reports that “if McConnell chooses to go by seniority,” Sen. James Risch (R-ID) “would be next in line to chair the committee, but he already leads the Senate Foreign Relations Committee.” The Post adds that after Risch is Sen. Marco Rubio (R-FL), “a national security hawk who had been widely expected to take over the committee once Burr retires.” The Hill (5/14, Bolton, 2.98M) describes Rubio as “a likely successor” to Burr, and says the move would be “a major promotion for a lawmaker who contemplated leaving Congress only a few years ago.”

Tillis: “Sen. Burr Does Owe All Of Us An Explanation.” WBT-AM Charlotte, NC (5/14, 4K) reports that in an interview with the station, Sen. Thom Tillis (R-NC), who faces a tight reelection race this year, “remarked that Richard Burr owes everyone an explanation.” Tillis said, “Sen. Burr does owe all of us an explanation and this is clear evidence that an investigation is underway. We need to see where the investigation leads.”

Loeffler Does Not Answer Questions About FBI Investigation. The Atlanta Journal-Constitution (5/14, Mitchell, 895K) reports Loeffler “would not say Thursday whether she has been contacted by the FBI in connection with an investigation into stock trading during the pandemic,” while her spokeswoman “told The Atlanta Journal-Constitution that the senator has not been served any search warrants.”

Feinstein’s Office Says She Was Questioned About Husband’s Stock Trades. The San Francisco Chronicle (5/14, 2.67M) reports the office of Sen. Dianne Feinstein (D-CA) said the senator was “questioned by federal law enforcement agents about stock trades her husband made after the coronavirus hit” the US. Feinstein “also provided documents to federal agents to show she was not involved in the transactions by her husband, investment banker Richard Blum, her spokesman said.”

Senate Votes To Extend Parts Of FISA. Reuters (5/14, Zengerle) reports that the Senate voted 80-16 Thursday to approve a 2 1/2-year extension “of parts of the Foreign Intelligence Surveillance Act (FISA)...two months after the divisive provisions allowing government data collection expired.” The measure must be approved by the House “before it can be sent to the White House for President Donald Trump to veto or sign into law” after the Senate “amended the measure approved by the Democratic-led House in March to improve legal protections for those subject to surveillance.” Politico (5/14, Malishak, 4.29M) says the measure’s “chances for swift final approval” in the House “remain cloudy.”

WPost Report: Trump “Moving Closer To Reshaping” Postal Service. The Washington Post (5/14, Bogage, Dawsey, 14.2M) reports that “weeks before a Republican donor and top White House ally becomes postmaster general, the U.S. Postal Service has quietly begun a review of its package delivery contracts and lost its second-highest executive, leaving its board of governors without any officials who predate President Trump.” According to the Post, “The moves, confirmed by six people with knowledge of the Postal Service’s inner workings but not authorized to speak publicly, underscore how Trump is moving closer to reshaping an independent agency he has dubbed ‘a joke.’” The Post also reports that the Postal Service “in recent weeks has sought bids from consulting firms to reassess what the agency charges companies such as Amazon, UPS and FedEx to deliver products on their behalf.”

Trump Questions Biden’s Mental Fitness. Salena Zito writes in the Washington Examiner (5/14, 448K) that in comments to the Examiner before his event in Pennsylvania Thursday, President Trump “took aim at Joe Biden’s mental faculties, at one point claiming the former Vice President ‘has absolutely no idea what’s happening.’ Reacting to word that Biden had named Rep. Alexandria Ocasio-Cortez (D-NY) “co-chairwoman of a climate change panel,” Trump said, “If you asked him who he named, he wouldn’t even know it... Joe has absolutely no idea what’s happening.” Zito adds that Trump used several issues “to take jabs at Biden’s mental fitness.”

Abrams Promoted As Possible Running Mate For Biden. In a 6,000-word Washington Post Magazine (5/14, 14.2M) profile of Stacey Abrams, Kevin Powell writes, “I’ve witnessed this level of affection for very few political leaders in the Democratic circles I’ve been in since the 1980s.” Powell says Abrams is “on political pundits’ shortlists of potential running mates for Joe Biden,” and has “a unique space in American politics,” though “a relatively thin political résumé.” Powell adds that she “is the first black woman in U.S. history to have won the gubernatorial nomination of either major party,” and “garnered more votes than any Democrat who has run statewide in Georgia.”

Prominent Black Women Offer Suggestions For Biden To Earn Support. LaTasha Brown of Black Voters Matter, author Tiffany Cross, Brittany Packnett Cunningham, Alicia Garza of Black Lives Matter Global Network, television personality Sunny Hostin, podcaster Angela Rye, and comedian Amanda Seales write in the Washington Post (5/14, 14.2M) that Biden’s “only path to victory is through black women and the voters we know how to energize.” They add, “You owe us, you need us and you must not take our
votes for granted." They call on Biden to choose "a black woman as vice president." They also urge him to pledge the necessary resources to win a Democratic majority in the US Senate with the help of "Black voters in Wisconsin, Florida, Michigan, Pennsylvania, North Carolina and Georgia."

**Rasmussen: 23% Of Republicans, 28% Of Democrats Would Prefer Different Nominees.**

Rasmussen Reports (5/14, 5K) says on its website, "Republicans overwhelmingly expect President Trump to be their nominee this fall, but nearly one-in-four GOP voters would prefer someone else. The latest Rasmussen Reports national telephone and online survey finds that 23% of Likely Republican Voters think their party should find someone other than Trump to be their presidential nominee. Seventy percent (70%) disagree. Only seven percent (7%) are undecided. ... By comparison, 28% of Likely Democratic Voters say their party should find someone other than Joe Biden to be their 2020 presidential nominee. Fifty-four percent (54%) disagree, while another 18% are not sure."

**Trump Touts His "22-0" Record Of Congressional Endorsements.** President Trump tweeted Thursday morning that he is "22-0" in endorsing congressional candidates this season after races this week in California and Wisconsin. Trump wrote, "22-0 in my endorsements of Congressional Candidates this season. California & Wisconsin won big on Tuesday. Thank you to all of those very brilliant Voters. You will not be disappointed!"
Hope this helps,

Mike

Michael S. Lauer, MD  
NIH Deputy Director for Extramural Research  
1 Center Drive, Building 1, Room 144  
Bethesda, MD 20892  
Phone: (b) (6)  
Email: (b) (6)

---

From: "Lauer, Michael (NIH/OD) [E]" <(b) (6)>  
Date: Wednesday, April 22, 2020 at 9:56 AM  
To: "Tabak, Lawrence (NIH/OD) [E]" <(b) (6)>  
Cc: "Lauer, Michael (NIH/OD) [E]" <(b) (6)>  
"Black, Jodi (NIH/OD) [E]" <(b) (6)>  
"Schwetz, Tara (NIH/OD) [E]" <(b) (6)>  
Subject: Wuhan Lab

Hi Larry – in follow-up to our 1:1 earlier today, (b) (5)

---

Many thanks,

Mike
Hi Lisa, Alisa, and Les — as we discussed.

- Narrative below (scroll down to my note to Larry).
- Video (need to skip the political ads)
- Two letters (6th and 7th attachments)

Our rationale:

Background:

Hope this helps,

Mike

Michael S. Lauer, MD
NIH Deputy Director for Extramural Research
Hi Larry – in follow-up to our 1:1 earliertoday,

Many thanks,

Mike
State Department cables warned of safety issues at Wuhan lab studying bat coronaviruses

Josh Rogin

A woman wearing a protective suit at a hospital in Wuhan, China. (Aly Song/Reuters)

Two years before the novel coronavirus pandemic upended the world, U.S. Embassy officials visited a Chinese research facility in the city of Wuhan several times and sent two official warnings back to Washington about inadequate safety at the lab, which was conducting risky studies on coronaviruses from bats. The cables have fueled discussions inside the U.S. government about whether this or another Wuhan lab was the source of the virus — even though conclusive proof has yet to emerge.
In January 2018, the U.S. Embassy in Beijing took the unusual step of repeatedly sending U.S. science diplomats to the Wuhan Institute of Virology (WIV), which had in 2015 become China’s first laboratory to achieve the highest level of international bioreserach safety (known as BSL-4). WIV issued a news release in English about the last of these visits, which occurred on March 27, 2018. The U.S. delegation was led by Jamison Fouss, the consul general in Wuhan, and Rick Switzer, the embassy’s counselor of environment, science, technology and health. Last week, WIV erased that statement from its website, though it remains archived on the Internet.

**Full coverage of the coronavirus pandemic**

What the U.S. officials learned during their visits concerned them so much that they dispatched two diplomatic cables categorized as Sensitive But Unclassified back to Washington. The cables warned about safety and management weaknesses at the WIV lab and proposed more attention and help. The first cable, which I obtained, also warns that the lab’s work on bat coronaviruses and their potential human transmission represented a risk of a new SARS-like pandemic.

“During interactions with scientists at the WIV laboratory, they noted the new lab has a serious shortage of appropriately trained technicians and investigators needed to safely operate this high-containment laboratory,” states the Jan. 19, 2018, cable, which was drafted by two officials from the embassy’s environment, science and health sections who met with the WIV scientists. (The State Department declined to comment on this and other details of the story.)

Global Opinions writer Josh Rogin has obtained a 2018 U.S. diplomatic cable urging Washington to better support a Chinese lab researching bat coronaviruses. (Joshua Carroll, Kate Woodsome, Josh Rogin/The Washington Post)
The Chinese researchers at WIV were receiving assistance from the Galveston National Laboratory at the University of Texas Medical Branch and other U.S. organizations, but the Chinese requested additional help. The cables argued that the United States should give the Wuhan lab further support, mainly because its research on bat coronaviruses was important but also dangerous.

As the cable noted, the U.S. visitors met with Shi Zhengli, the head of the research project, who had been publishing studies related to bat coronaviruses for many years. In November 2017, just before the U.S. officials’ visit, Shi’s team had published research showing that horseshoe bats they had collected from a cave in Yunnan province were very likely from the same bat population that spawned the SARS coronavirus in 2003.

Sign up for our Coronavirus Updates newsletter to track the outbreak. All stories linked in the newsletter are free to access.

“Most importantly,” the cable states, “the researchers also showed that various SARS-like coronaviruses can interact with ACE2, the human receptor identified for SARS-coronavirus. This finding strongly suggests that SARS-like coronaviruses from bats can be transmitted to humans to cause SARS-like diseases. From a public health perspective, this makes the continued surveillance of SARS-like coronaviruses in bats and study of the animal-human interface critical to future emerging coronavirus outbreak prediction and prevention.”

The research was designed to prevent the next SARS-like pandemic by anticipating how it might emerge. But even in 2015, other scientists questioned whether Shi’s team was taking unnecessary risks. In October 2014, the U.S. government had imposed a moratorium on funding of any research that makes a virus more deadly or contagious, known as “gain-of-function” experiments.
As many have pointed out, there is no evidence that the virus now plaguing the world was engineered; scientists largely agree it came from animals. But that is not the same as saying it didn’t come from the lab, which spent years testing bat coronaviruses in animals, said Xiao Qiang, a research scientist at the School of Information at the University of California at Berkeley.

“The cable tells us that there have long been concerns about the possibility of the threat to public health that came from this lab’s research, if it was not being adequately conducted and protected,” he said.

There are similar concerns about the nearby Wuhan Center for Disease Control and Prevention lab, which operates at biosecurity level 2, a level significantly less secure than the level-4 standard claimed by the Wuhan Institute of Virology lab, Xiao said. That’s important because the Chinese government still refuses to answer basic questions about the origin of the novel coronavirus while suppressing any attempts to examine whether either lab was involved.

Sources familiar with the cables said they were meant to sound an alarm about the grave safety concerns at the WIV lab, especially regarding its work with bat coronaviruses. The embassy officials were calling for more U.S. attention to this lab and more support for it, to help it fix its problems.

“The cable was a warning shot,” one U.S. official said. “They were begging people to pay attention to what was going on.”

No extra assistance to the labs was provided by the U.S. government in response to these cables. The cables began to circulate again inside the administration over the past two months as officials debated whether the lab could be the origin of the pandemic and what the implications would be for the U.S. pandemic response and relations with China.
Inside the Trump administration, many national security officials have long suspected either the WIV or the Wuhan Center for Disease Control and Prevention lab was the source of the novel coronavirus outbreak. According to the New York Times, the intelligence community has provided no evidence to confirm this. But one senior administration official told me that the cables provide one more piece of evidence to support the possibility that the pandemic is the result of a lab accident in Wuhan.

“The idea that it was just a totally natural occurrence is circumstantial. The evidence it leaked from the lab is circumstantial. Right now, the ledger on the side of it leaking from the lab is packed with bullet points and there’s almost nothing on the other side,” the official said.

As my colleague David Ignatius noted, the Chinese government’s original story — that the virus emerged from a seafood market in Wuhan — is shaky. Research by Chinese experts published in the Lancet in January showed the first known patient, identified on Dec. 1, had no connection to the market, nor did more than one-third of the cases in the first large cluster. Also, the market didn’t sell bats.

The Opinions section is looking for stories of how the coronavirus has affected people of all walks of life. Write to us.

Shi and other WIV researchers have categorically denied this lab was the origin for the novel coronavirus. On Feb. 3, her team was the first to publicly report the virus known as 2019-nCoV was a bat-derived coronavirus.

The Chinese government, meanwhile, has put a total lockdown on information related to the virus origins. Beijing has yet to provide U.S. experts with samples of the novel coronavirus collected from the earliest cases. The Shanghai lab that published the novel coronavirus genome on Jan. 11 was quickly shut down by authorities for “rectification.” Several of the doctors and journalists
who reported on the spread early on have disappeared.

On Feb. 14, Chinese President Xi Jinping called for a new biosecurity law to be accelerated. On Wednesday, CNN reported the Chinese government has placed severe restrictions requiring approval before any research institution publishes anything on the origin of the novel coronavirus.

The origin story is not just about blame. It’s crucial to understanding how the novel coronavirus pandemic started because that informs how to prevent the next one. The Chinese government must be transparent and answer the questions about the Wuhan labs because they are vital to our scientific understanding of the virus, said Xiao.

We don’t know whether the novel coronavirus originated in the Wuhan lab, but the cable pointed to the danger there and increases the impetus to find out, he said.

“I don’t think it’s a conspiracy theory. I think it’s a legitimate question that needs to be investigated and answered,” he said. “To understand exactly how this originated is critical knowledge for preventing this from happening in the future.”

Read this piece in Chinese

Read this piece in Spanish

David Ignatius: How did covid-19 begin? Its initial origin story is shaky.

Marc A. Thiessen: China should be legally liable for the pandemic damage it has done

We need smart solutions to mitigate the coronavirus’s impact. Here are 23.
Michael L. Barnett and David C. Grabowski: Covid-19 is ravaging nursing homes. We’re getting what we paid for.

Megan McArdle: Why the lockdown skeptics are wrong

Xinyan Yu: My hometown showed us how a pandemic begins. Could it also show us how one ends?
China Lab In Focus Of Coronavirus Outbreak

Don Reisinger  05:35pm EDT

People wearing face masks wait to buy roasted duck at a restaurant in Wuhan, China's central Hubei...

AFP via Getty Images

For months, anyone who said the new SARS coronavirus might have come out of a virology research lab in Wuhan, China was dismissed as a right wing xenophobe.

When Zero Hedge — a financial news website whose comment section certainly fits the right wing stereotype — first put out its own bombastic version of the bat-borne virus escaping a research lab, they were banned from
Twitter.

FOX host Tucker Carlson starting banging this drum last week.

But on Tuesday, the narrative flipped. It’s no longer a story shared by China bears and President Trump fans. Today, Josh Rogin, who is said to be as plugged into the State Department as any Washington Post columnist, was shown documents dating back to 2015 revealing how the U.S. government was worried about safety standards at that Wuhan lab. In fact, they were worried that one day, one of these experiments — including the one on bat coronaviruses — could escape and become a global nightmare.

In a best case scenario, Rogin’s reveal may ultimately get China to cooperate more in regards to the origins of the virus, setting the table for better drugs to mitigate or even cure the deadly COVID-19. At the very least, for a government that likes to save face, the fact that the U.S. government helped build and fund the Wuhan virology lab in question should be enough for China to open that info vault to scientists at the World Health Organization.

Washington Post Opinion | State Department cables warned of safety issues at Wuhan lab studying bat coronaviruses

“I don’t think it’s a conspiracy theory. I think it’s a legitimate question that needs to be investigated and answered,” Xiao Qiang, a research scientist at the School of Information at the University of California at Berkeley told Rogin. “To understand exactly how this originated is critical knowledge for preventing this from happening in the future.”

China has not been forthcoming about the new SARS coronavirus origins. They’re not being entirely transparent, despite being heralded as such by some leaders.
An example of that secrecy from Rogin:

“In January 2018, the U.S. Embassy in Beijing took the unusual step of repeatedly sending U.S. science diplomats to the Wuhan Institute of Virology (WIV), which had in 2015 become China’s first laboratory to achieve the highest level of international bioresearch safety (known as BSL-4). WIV issued a news release in English about the last of these visits, which occurred on March 27, 2018. The U.S. delegation was led by Jamison Fouss, the consul general in Wuhan, and Rick Switzer, the embassy’s counselor of environment, science, technology and health. Last week, WIV erased that statement from its website, though it remains archived on the Internet.”

Worth noting, at least one young researcher from the lab — Huang Yanling — a graduate student rumored to be patient zero — was scrubbed from the lab’s website.

The first, mysterious samples from infected individuals arrived at Wuhan Institute of Virology on December 30, 2019.

According to the Scientific American magazine, Shi Zhengli, a renown bat scientist in China, was told by the Institute’s director that the Wuhan Center for Disease Control and Prevention — modeled after our own CDC — had detected a novel coronavirus in two hospital patients. They were suffering from an odd pneumonia. They wanted her laboratory to investigate because the virus belonged to the same family of bat-borne viruses that caused SARS, a disease that — by comparison — only infected 8,100 people and killed just
under 800 in an 8 month period in 2002-03.

“\textit{I had never expected this kind of thing to happen in Wuhan, in central China,}” she was quoted as saying by \textit{Scientific American} on March 11. Her studies had shown that the southern, subtropical areas of Guangdong, Guangxi and Yunnan had the greatest risk of coronaviruses jumping to humans from animals—particularly bats, a known reservoir for many viruses. If bat coronaviruses were the culprit, she recalled to \textit{Scientific American}, “could they have come from our lab?”

She has since promised the world that it did not come from her lab, though how she would know that for sure is unknown. We don’t know where she is. If she is making the media rounds on Chinese television, few in the U.S. would believe her at this point.

Her research on bat coronaviruses goes back to 2015. Here is \textit{one published in 2015} in \textit{Nature} magazine. There is a lot of information about this new SARS, yet the world still seems stuck in the unknowns.

The U.S. government helped build and fund Wuhan virology labs. The thinking was that it was important for China to get up to par in the global life sciences. It was already a known center of previous outbreaks. Investing there and educating them on international safety standards was just preventative medicine.

Rogin’s reporting suggests that government officials were well aware of the research being conducted in the lab on bat coronaviruses and were worried that the lab still had sub-par safety standards.

Rogin writes that, “What the U.S. officials learned during their visits concerned them so much that they dispatched two diplomatic cables categorized as Sensitive But Unclassified back to Washington. The cables warned about
safety and management weaknesses at the WIV lab and proposed more attention and help.
The first cable, which I obtained, also warns that the lab’s work on bat coronaviruses and their potential human transmission represented a risk of a new SARS-like pandemic.”

Rogin’s article probably stemmed from conversations with someone inside the State Department boiling at the rim over many weeks as the U.S. faces a “stop the world” moment because of this pandemic.

Over the weekend, the Chinese government banned academic and other research institutions from publishing its research on coronaviruses on their websites.

The thinking there is, perhaps, that people in the U.S. and Europe are using those studies to place blame on the Chinese government. China has been working overtime to convince people that questioning the origin of the disease is racist.

*The Washington Post* story today brings the possibility of a lab leak into the mainstream. It moves the needle on getting a clearer handle on the origin of the virus, and that could eventually lead to more cooperation between the U.S. and China in making sure this does not happen again.

7 Of The Best Gaming Chairs For The Serious Gamer
Shopping

I write about technology and video games for Forbes Finds.

Forbes and/or the author may earn a commission on sales made from links on this page.

If you’ve been playing video games all this time without cushioning yourself within the comforting confines of a bespoke gaming chair, you’re missing out. Gaming chairs are designed to offer a supportive and cozy experience while looking right at home alongside your gaming PC or console.

With gaming chairs, you’ll find seats that are typically comfortable, look good and offer a variety of color and material options. Maintaining a good posture while sitting for long periods is of paramount importance, and these chairs will help you do just that.
The following were selected as some of the best gaming chairs due to their build quality, support and comfort, as well as style, looks and any additional features. They are also all reasonably priced for what they offer.

**Vertagear Racing Series S-Line SL4000 Gaming Chair Black/Blue Edition**
Vertagear Racing Series S-Line SL4000 Gaming Chair Black/Blue Edition

450

The Vertagear S-Line SL4000 is built for comfort. The chair has supportive padding, which is perfect for gamers who want to game for multiple hours in a single session. The chair is easy to assemble too — one person can put it together within 30 minutes or so.

On the bottom of the chair, there are custom Penta RS1 casters, which are coated with PU for a soft and smooth gliding experience on the chair, so moving around shouldn’t feel bumpy.

The chair is a little expensive depending on the color you get, but it’s still a great choice and should create an awesome gaming experience.

Noblechairs Epic Gaming Chair
Noblechairs Epic Gaming Chair

419

The Noblechairs Epic is an excellent gaming chair that comes in your choice of
PU leather, NAPPA leather or real leather. It has air gaps at the top to improve airflow to help keep you cool and is built with ergonomics in mind, so you can sit more comfortably. In fact, Noblechairs said that the chairs will conform to the shape of your back and has obtained international certifications for the design.

Like the Secret Lab Omega, the Noblechairs Epic has a tilting mechanism that will allow you to lock it into place wherever you see fit. That allows you to obtain the perfect recline while you’re playing games and dramatically enhances the broader experience. It even comes with what Noblechairs calls 4D armrests that let you adjust their height, depth, width and angle to maximize comfort.

**Secretlab Omega 2020 Prime 2.0 PU Leather LCS Gaming Chair**
Secretlab Omega 2020 Prime 2.0 PU Leather LCS Gaming Chair

350

If you like your gaming chair to look a little more refined, a little less colorful and more demure, then the SecretLab Omega is a great choice. Not only is it competitively priced, but it offers heavy discounts if you shop directly, whether you opt for the more affordable PU leather, fabric covering or even its more premium leather option, though that does come at an added cost.

Updated in 2020, the Omega is the mid-size option that SecretLab offers, fitting everyone up to and below 5’11. There are larger and smaller offerings for those who fall outside the standard height and weight range though, with all shapes and sizes catered to.

Whichever size you opt for, you’ll be able to enjoy the Omega’s built-in lumbar support (no pillow required), durable armrests and even a gel-lined neck pillow to help keep you cool during the most intense of gaming sessions.

GTRACING Gaming Chair Racing Chair

https://www.forbes.com/sites/kenrapoza/2020/04/14/the-washington-p...es-rogue-china-lab-in-focus-of-coronavirus-outbreak/#796711a61ee1
GTRACING Gaming Chair Racing Chair
It might not have the catchiest of names, but the GTRacing Pro GTF88 is an excellent gaming chair at an even more excellent price. Reduced to under $150 at the time of writing, it’s supremely affordable when compared with some of its contemporaries, and though it doesn’t have the most high-end of feature sets, it’s still a great gaming chair that will both support and comfort you no matter what game you’re playing and for how long.

With a sturdy metal frame and ergonomic design, your back, shoulders and arms are all well supported, making sure that you don’t develop poor posture habits, the bane of any gamer. That includes pillows for lumbar support and headrest, each of which — and the chair itself — are packed with high-density foam for a superior seating experience.

You can also customize the chair to your heart’s desire, with options for swivel, reclining, rocking and height adjustment. Even the armrests can be rotated and height adjusted.

Available in a variety of colors and coated in 100 percent Grade A PU leather, this racing-inspired seat will be a great addition to your gaming arsenal at an affordable price.

**Corsair CF-9010029-WW T3 RUSH Gaming Chair**
Corsair CF-9010029-WW T3 RUSH Gaming Chair

424

Corsair might be most well known for starting the RGB revolution on PC components, but it also makes fantastic gaming chairs; particularly of the mesh fabric kind. Its T3 Rush is the latest generation of gaming chair from the component company and it’s only improved on what came before.

Designed to help alleviate heat buildup that is all too commonplace on some gaming chairs (particularly with PU leather) the T3 Rush is covered entirely in a soft fabric that makes it breathable, comfortable and soft to the touch.
With included neck cushion and memory foam lumbar support, the T3 Rush sacrifices nothing in its goal to improve comfort and support. Supremely adjustable, you can change the angle of the seat until it’s practically a bed, sit straight up, tweak the height and even adjust the orientation of the armrests through four dimensions to make your T3 look and feel exactly how you like it.

**Arozzi Verona Junior Gaming Chair for Kids**
Amazon
Arozzi Verona Junior Gaming Chair for Kids

249

Not everyone is as hulking as their gaming avatars, and not everyone who needs a gaming chair is an adult. The Arozzi Verona Junior gaming chair is designed for growing gamers and those with a smaller than average physical footprint, with a maximum weight of just 130lbs. But by catering to such a niche, it offers a fantastic experience specifically tailored to that body type.

Ergonomically designed for a healthy posture, the Verona Junior enjoys both lumbar and headrest pillows, as well as armrests that can be tweaked to the exact position you need them to be in. You can rotate them, or adjust them up and down, though there are no lateral movement options.

Available in a variety of color options and with a comfortable, easy-to-clean pleather exterior, the Verona Junior is a fantastic gaming chair for a growing gamer or someone with a slighter build.

Nitro Concepts S300 EX Gaming Chair
NITRO CONCEPTS S300 EX Gaming Chair

300

Designed to be its most comfortable gaming chair yet, Nitro Concepts’ S300
EX builds on its already sterling pedigree for gaming chair production, with a few new additions. Integrating its new Health Enhancing Adjustment Technology, or H.E.A.T., it leverages lumbar and head support pillows for individual adjustment to the unique contours of your body. They’re backed up by cooling holes in the neck-rest, making sure that even with the nylon seat-coating, you’ll never get too hot during intense play.

They’re built atop a steel frame for additional support, which can be leaned back, rocked, height adjusted and rotated, while the armrests can move up, down, forward and backwards, letting you make this gaming chair just right for your particular seating habits. It’s also available in four stylish color options, each with color matching stitching and attractive accents.

Don’t want something gaudy? Nitro Concepts has you covered too. The Stealth color option makes everything black, letting your gaming chair blend into the background so you can focus on your game and not look like a stereotypical “gamer” while doing it. You might even be able to swing it as an office chair upgrade.
I’m a freelance technology, video game, and entertainment journalist. I’ve been writing about the world of technology, video games, and entertainment for the last decade.

...
The Trail Leading Back to the Wuhan Labs

Jim Geraghty  April 3, 2020 1:20 PM

Medical workers in protective suits attend to a patient inside an isolated ward of the Wuhan Red Cross Hospital in Wuhan, the epicenter of the novel coronavirus outbreak, in Hubei Province, China, February 16, 2020. (China Daily via Reuters)

There’s no proof the coronavirus accidentally escaped from a laboratory, but we can’t take the Chinese government’s denials at face value.

It is understandable that many would be wary of the notion that the origin of the coronavirus could be discovered by some documentary filmmaker who used to live in China. Matthew Tye, who creates YouTube videos, contends he has identified the source of the coronavirus — and a great deal of the information that he presents, obtained from public records posted on the
Internet, checks out.

The Wuhan Institute of Virology in China indeed posted a job opening on November 18, 2019, “asking for scientists to come research the relationship between the coronavirus and bats.”

The Google translation of the job posting is: “Taking bats as the research object, I will answer the molecular mechanism that can coexist with Ebola and SARS- associated coronavirus for a long time without disease, and its relationship with flight and longevity. Virology, immunology, cell biology, and multiple omics are used to compare the differences between humans and other mammals.” (“Omics” is a term for a subfield within biology, such as genomics or glycomics.)
PI Introduction:
Peng Zhou, Ph.D., Researcher, Wuhan Institute of Virology, Chinese Academy of Sciences, and Leader of Bat Virus Infection and Immunity. He received his PhD in Wuhan Virus Research Institute in 2010 and has worked on bat virus and immunology in Australia and Singapore. In 2009, he took the lead in starting the research on the immune mechanism of bat long-term carrying and transmitting virus in the world. So far, he has published more than 30 SCI articles, including the first and corresponding author's Nature, Cell Host Microbe and PNAS. At present, research on bat virus and immunology is continuing, and it has received support from the National Excellent Youth Fund, the Pilot Project of the Chinese Academy of Sciences, and the Major Project of the Ministry of Science and Technology.

The main research directions of the research group:
Taking bats as the research object, I will answer the molecular mechanism that can coexist with Ebols and SARS-associated coronavirus for a long time without disease, and its relationship with flight and longevity. Virology, immunology, cell biology, and multiple omics are used to compare the differences between humans and other mammals.

On December 24, 2019, the Wuhan Institute of Virology posted a second job posting. The translation of that posting includes the declaration, “long-term research on the pathogenic biology of bats carrying important viruses has confirmed the origin of bats of major new human and livestock infectious diseases such as SARS and SADS, and a large number of new bat and rodent new viruses have been discovered and identified.”

PI Introduction
Zhengli Shi, Ph.D., Researcher, Leader of Emerging Virus Group, Wuhan Institute of Virology, Chinese Academy of Sciences, Director of Emerging Infectious Disease Research Center of Wuhan Institute of Virology, Chinese Academy of Sciences, Editor-in-Chief, Virologica Sinica. Long-term research on the pathogenic biology of bats carrying important viruses has confirmed the origin of bats of major new human and livestock infectious diseases such as SARS and SADS, and a large number of new bat and rodent new viruses have been discovered and identified. So far in Nature, Science, Nat Rev Microbiol, the Cell Host Microbe, Nat Microbiol, PLoS Pathog and other SCI papers published journals 110 over papers, 2014 onwards for five consecutive years was selected Elsevier China highly cited scholars' list (Immunology and Microbiology). Has won the "advanced worker" of the Chinese Academy of Sciences, the "May 1 Labor Medal", Hubei Province has outstanding contributions to young and middle-aged experts, Chinese Academy of Sciences "Excellent Graduate Instructor", French Palm Education Knight Medal and other honors. As the first person to complete the research on "Chinese bat carrying important viruses", he won the first prize of the 2017 Hubei Natural Science Award and the second prize of the 2018 National Natural Science Award. Elected to the American Academy of Microbiology in 2019.

Tye contends that that posting meant, “we’ve discovered a new and terrible virus, and would like to recruit people to come deal with it.” He also contends that “news didn’t come out about coronavirus until ages after that.” Doctors in
Wuhan knew that they were dealing with a cluster of pneumonia cases as December progressed, but it is accurate to say that a very limited number of people knew about this particular strain of coronavirus and its severity at the time of that job posting. By December 31, about three weeks after doctors first noticed the cases, the Chinese government notified the World Health Organization and the first media reports about a “mystery pneumonia” appeared outside China.

Scientific American verifies much of the information Tye mentions about Shi Zhengli, the Chinese virologist nicknamed “Bat Woman” for her work with that species.

Shi — a virologist who is often called China’s “bat woman” by her colleagues because of her virus-hunting expeditions in bat caves over the past 16 years — walked out of the conference she was attending in Shanghai and hopped on the next train back to Wuhan. “I wondered if [the municipal health authority] got it wrong,” she says. “I had never expected this kind of thing to happen in Wuhan, in central China.” Her studies had shown that the southern, subtropical areas of Guangdong, Guangxi and Yunnan have the greatest risk of coronaviruses jumping to humans from animals — particularly bats, a known reservoir for many viruses. If coronaviruses were the culprit, she remembers thinking, “could they have come from our lab?”

... By January 7 the Wuhan team determined that the new virus had indeed caused the disease those patients suffered — a conclusion based on results from polymerase chain reaction analysis, full genome sequencing, antibody tests of blood samples and the virus’s ability to infect human lung cells in a petri dish. The genomic sequence of the virus — now officially called SARS-CoV-2 because it is related to the SARS pathogen — was 96 percent identical to that of a coronavirus the researchers had identified in
horseshoe bats in Yunnan, they reported in a paper published last month in *Nature*. “It’s crystal clear that bats, once again, are the natural reservoir,” says Daszak, who was not involved in the study.

Some scientists aren’t convinced that the virus jumped straight from bats to human beings, but there are a few problems with the theory that some other animal was an intermediate transmitter of COVID-19 from bats to humans:

Analyses of the SARS-CoV-2 genome indicate a single spillover event, meaning the virus jumped only once from an animal to a person, which makes it likely that the virus was circulating among people before December. Unless more information about the animals at the Wuhan market is released, the transmission chain may never be clear. There are, however, numerous possibilities. A bat hunter or a wildlife trafficker might have brought the virus to the market. Pangolins happen to carry a coronavirus, which they might have picked up from bats years ago, and which is, in one crucial part of its genome, virtually identical to SARS-CoV-2. But no one has yet found evidence that pangolins were at the Wuhan market, or even that vendors there trafficked pangolins.

On February 4 — one week before the World Health Organization decided to officially name this virus “COVID-19” — the journal *Cell Research* posted a notice written by scientists at the Wuhan Institute of Virology about the virus, concluding, “our findings reveal that remdesivir and chloroquine are highly effective in the control of 2019-nCoV infection in vitro. Since these compounds have been used in human patients with a safety track record and shown to be effective against various ailments, we suggest that they should be assessed in human patients suffering from the novel coronavirus disease.” One of the authors of that notice was the “bat woman,” Shi Zhengli.

In his YouTube video, Tye focuses his attention on a researcher at the Wuhan
Institute of Virology named Huang Yanling: "Most people believe her to be patient zero, and most people believe she is dead."

There was enough discussion of rumors about Huang Yanling online in China to spur an official denial. On February 16, the Wuhan Institute of Virology denied that patient zero was one of their employees, and interestingly named her specifically: "Recently there has been fake information about Huang Yanling, a graduate from our institute, claiming that she was patient zero in the novel coronavirus." Press accounts quote the institute as saying, "Huang was a graduate student at the institute until 2015, when she left the province and had not returned since. Huang was in good health and had not been diagnosed with disease, it added.” None of her publicly available research papers are dated after 2015.

The web page for the Wuhan Institute of Virology’s Lab of Diagnostic Microbiology does indeed still have “Huang Yanling” listed as a 2012 graduate student, and her picture and biography appear to have been recently removed — as have those of two other graduate students from 2013, Wang Mengyue and Wei Cuihua.
Her name still has a hyperlink, but the linked page is blank. The pages for Wang Mengyue and Wei Cuihua are blank as well.

(For what it is worth, the South China Morning Post — a newspaper seen as being generally pro-Beijing — reported on March 13 that “according to the
government data seen by the Post, a 55 year-old from Hubei province could have been the first person to have contracted Covid-19 on November 17.

On February 17, Zhen Shuji, a Hong Kong correspondent from the French public-radio service Radio France Internationale, reported: “when a reporter from the Beijing News of the Mainland asked the institute for rumors about patient zero, the institute first denied that there was a researcher Huang Yanling, but after learning that the name of the person on the Internet did exist, acknowledged that the person had worked at the firm but has now left the office and is unaccounted for.”

NOW WATCH: 'Health Officials Warn There Is No Proof Coronavirus Is Impacted By Spring And Summer Weather'
Tye says, "everyone on the Chinese internet is searching for [Huang Yanling] but most believe that her body was quickly cremated and the people working at the crematorium were perhaps infected as they were not given any information about the virus." (The U.S. Centers for Disease Control and
Prevention says that handling the body of someone who has died of coronavirus is safe — including embalming and cremation — as long as the standard safety protocols for handling a decedent are used. It’s anyone’s guess as to whether those safety protocols were sufficiently used in China before the outbreak’s scope was known.

As Tye observes, a public appearance by Huang Yanling would dispel a lot of the public rumors, and is the sort of thing the Chinese government would quickly arrange in normal circumstances — presuming that Huang Yanling was still alive. Several officials at the Wuhan Institute of Virology issued public statements that Huang was in good health and that no one at the institute has been infected with COVID-19. In any case, the mystery around Huang Yanling may be moot, but it does point to the lab covering up something about her.

China Global Television Network, a state-owned television broadcaster, illuminated another rumor while attempting to dispel it in a February 23 report entitled “Rumors Stop With the Wise”:

On February 17, a Weibo user who claimed herself to be Chen Quanjiao, a researcher at the Wuhan Institute of Virology, reported to the public that the Director of the Institute was responsible for leaking the novel coronavirus. The Weibo post threw a bomb in the cyberspace and the public was shocked. Soon Chen herself stepped out and declared that she had never released any report information and expressed great indignation at such identity fraud on Weibo. It has been confirmed that that particular Weibo account had been shut down several times due to the spread of misinformation about COVID-19.

That Radio France Internationale report on February 17 also mentioned the next key part of the Tye’s YouTube video. “Xiaobo Tao, a scholar from South China University of Technology, recently published a report that researchers at
Wuhan Virus Laboratory were splashed with bat blood and urine, and then quarantined for 14 days.” HK01, another Hong Kong-based news site, reported the same claim.

This doctor’s name is spelled in English as both “Xiaobo Tao” and “Botao Xiao.” From 2011 to 2013, Botao Xiao was a postdoctoral research fellow at Harvard Medical School and Boston Children’s Hospital, and his biography is still on the web site of the South China University of Technology.

At some point in February, Botao Xiao posted a research paper onto ResearchGate.net, “The Possible Origins of 2019-nCoV coronavirus.” He is listed as one author, along with Lei Xiao from Tian You Hospital, which is affiliated with the Wuhan University of Science and Technology. The paper was removed a short time after it was posted, but archived images of its pages can be found here and here.
The first conclusion of Botao Xiao’s paper is that the bats suspected of carrying the virus are extremely unlikely to be found naturally in the city, and despite the stories of “bat soup,” they conclude that bats were not sold at the market and were unlikely to be deliberately ingested.

The bats carrying CoV ZC45 were originally found in Yunnan or Zhejiang province, both of which were more than 900 kilometers away from the seafood market. Bats were normally found to live in caves and trees. But the seafood market is in a densely-populated district of Wuhan, a metropolitan [area] of ~15 million people. The probability was very low for the bats to fly to the market. According to municipal reports and the testimonies of 31 residents and 28 visitors, the bat was never a food source in the city, and no bat was traded in the market.

The U.S. Centers for Disease Control and Prevention and the World Health Organization could not confirm if bats were present at the market. Botao Xiao’s paper theorizes that the coronavirus originated from bats being used for research at either one of two research laboratories in Wuhan.

We screened the area around the seafood market and identified two laboratories conducting research on bat coronavirus. Within ~ 280 meters from the market, there was the Wuhan Center for Disease Control & Prevention. WHCDC hosted animals in laboratories for research purpose, one of which was specialized in pathogens collection and identification. In one of their studies, 155 bats including Rhinolophus affinis were captured in Hubei province, and other 450 bats were captured in Zhejiang province. The expert in Collection was noted in the Author Contributions (JHT). Moreover, he was broadcasted for collecting viruses on nation-wide newspapers and websites in 2017 and 2019. He described that he was once by attacked by bats and the blood of a bat shot on his skin. He knew the extreme danger of the infection so he quarantined himself for 14 days.
In another accident, he quarantined himself again because bats peed on him.

Surgery was performed on the caged animals and the tissue samples were collected for DNA and RNA extraction and sequencing. The tissue samples and contaminated trashes were source of pathogens. They were only ~280 meters from the seafood market. The WHCDC was also adjacent to the Union Hospital (Figure 1, bottom) where the first group of doctors were infected during this epidemic. It is plausible that the virus leaked around and some of them contaminated the initial patients in this epidemic, though solid proofs are needed in future study.

The second laboratory was ~12 kilometers from the seafood market and belonged to Wuhan Institute of Virology, Chinese Academy of Sciences . . .

In summary, somebody was entangled with the evolution of 2019-nCoV coronavirus. In addition to origins of natural recombination and intermediate host, the killer coronavirus probably originated from a laboratory in Wuhan. Safety level may need to be reinforced in high risk biohazardous laboratories. Regulations may be taken to relocate these laboratories far away from city center and other densely populated places.

However, Xiao has told the Wall Street Journal that he has withdrawn his paper. “The speculation about the possible origins in the post was based on published papers and media, and was not supported by direct proofs,” he said in a brief email on February 26.

The bat researcher that Xiao’s report refers to is virologist Tian Junhua, who works at the Wuhan Centre for Disease Control. In 2004, the World Health Organization determined that an outbreak of the SARS virus had been caused by two separate leaks at the Chinese Institute of Virology in Beijing. The Chinese government said that the leaks were a result of “negligence” and the
responsible officials had been punished.

In 2017, the Chinese state-owned Shanghai Media Group made a **seven-minute documentary** about Tian Junhua, entitled “Youth in the Wild: Invisible Defender.” Videographers followed Tian Junhua as he traveled deep into caves to collect bats. “Among all known creatures, the bats are rich with various viruses inside,” he says in Chinese. “You can find most viruses responsible for human diseases, like rabies virus, SARS, and Ebola. Accordingly, the caves frequented by bats became our main battlefields.” He emphasizes, “bats usually live in caves humans can hardly reach. Only in these places can we find the most ideal virus vector samples.”

One of his last statements on the video is: “In the past ten-plus years, we have visited every corner of Hubei Province. We explored dozens of undeveloped caves and studied more than 300 types of virus vectors. But I do hope these virus samples will only be preserved for scientific research and will never be used in real life. Because humans need not only the vaccines, but also the protection from the nature.”

The description of Tian Junhua’s self-isolation came from a May 2017 report by Xinhua News Agency, **repeated by the Chinese news site JQKNews.com**:

> The environment for collecting bat samples is extremely bad. There is a stench in the bat cave. Bats carry a large number of viruses in their bodies. If they are not careful, they are at risk of infection. But Tian Junhua is not afraid to go to the mountain with his wife to catch Batman.

> Tian Junhua summed up the experience that the most bats can be caught by using the sky cannon and pulling the net. But in the process of operation, Tian Junhua forgot to take protective measures. Bat urine dripped on him like raindrops from the top. If he was infected, he could not find any medicine. It was written in the report.
The wings of bats carry sharp claws. When the big bats are caught by bat tools, they can easily spray blood. Several times bat blood was sprayed directly on Tian’s skin, but he didn’t flinch at all. After returning home, Tian Junhua took the initiative to isolate for half a month. As long as the incubation period of 14 days does not occur, he will be lucky to escape, the report said.

Bat urine and blood can carry viruses. How likely is it that bat urine or blood got onto a researcher at either Wuhan Center for Disease Control & Prevention or the Wuhan Institute of Virology? Alternatively, what are the odds that some sort of medical waste or other material from the bats was not properly disposed of, and that was the initial transmission vector to a human being?

Virologists have been vehemently skeptical of the theory that COVID-19 was engineered or deliberately constructed in a laboratory; the director of the National Institutes of Health has written that recent genomic research “debunks such claims by providing scientific evidence that this novel coronavirus arose naturally.” And none of the above is definitive proof that COVID-19 originated from a bat at either the Wuhan Center for Disease Control & Prevention or the Wuhan Institute of Virology. Definitive proof would require much broader access to information about what happened in those facilities in the time period before the epidemic in the city.

But it is a remarkable coincidence that the Wuhan Institute of Virology was researching Ebola and SARS-associated coronaviruses in bats before the pandemic outbreak, and that in the month when Wuhan doctors were treating the first patients of COVID-19, the institute announced in a hiring notice that “a large number of new bat and rodent new viruses have been discovered and identified.” And the fact that the Chinese government spent six weeks insisting that COVID-19 could not be spread from person to person means that its denials about Wuhan laboratories cannot be accepted without
independent verification.

Jim Geraghty is the senior political correspondent of National Review. @jimgeraghty
The possible origins of 2019-nCoV coronavirus

Preprint - February 2020

2 authors, including:

Bonao Xiao
South China University of Technology
26 PUBLICATIONS: 265 CITATIONS

Some of the authors of this publication are also working on these related projects:

Axon
National Natural Science Foundation of China (11172318) View project

Axon
National Natural Science Foundation of China (11172313) View project

All content following this page was uploaded by Bonao Xiao on 06 February 2020.
The user has requested enhancement of the downloadable file.
The possible origins of 2019-nCoV coronavirus

Botao Xiao\textsuperscript{1,2,\ast} and Lei Xiao\textsuperscript{3}

\textsuperscript{1} Joint International Research Laboratory of Synthetic Biology and Medicine, School of Biology and Biological Engineering, South China University of Technology, Guangzhou 510006, China

\textsuperscript{2} School of Physics, Huazhong University of Science and Technology, Wuhan 430074, China

\textsuperscript{3} Tian You Hospital, Wuhan University of Science and Technology, Wuhan 430064, China

* Corresponding author: (b) (6)

Tel / Fax: 86-20-3938-0631
The 2019-nCoV coronavirus has caused an epidemic of 28,600 laboratory-confirmed infections in human including 564 deaths in China by February 6, 2020. Two descriptions of the virus published on Nature this week indicated that the genome sequences from patients were 96% or 89% identical to the Bat CoV ZC45 coronavirus originally found in *Rhinolophus affinis* 1,2. It was critical to study where the pathogen came from and how it passed onto human.

An article published on The Lancet reported that 41 people in Wuhan were found to have the acute respiratory syndrome and 27 of them had contact with Huanan Seafood Market3. The 2019-nCoV was found in 33 out of 565 samples collected in the market after the outbreak. The market was suspicious to be the origin of the epidemic, and was shut down according to the rule of quarantine the source during an epidemic.

The bats carrying CoV ZC45 were originally found in Yunnan or Zhejiang province, both of which were more than 900 kilometers away from the seafood market. Bats were normally found to live in caves and trees. But the seafood market is in a densely-populated district of Wuhan, a metropolitan of ~15 million people. The probability was very low for the bats to fly to the market. According to municipal reports and the testimonies of 31 residents and 28 visitors, the bat was never a food source in the city, and no bat was traded in the market. There was possible natural recombination or intermediate host of the coronavirus, yet little proof has been reported.

Was there any other possible pathway? We screened the area around the seafood market and identified two laboratories conducting research on bat coronavirus. Within ~280 meters from the market, there was the Wuhan Center for Disease Control & Prevention (WHCDC) (Figure 1, from Baidu and Google maps). WHCDC hosted animals in laboratories for research purpose, one of which was specialized in pathogens collection and identification 4-6. In one of their studies, 155 bats including *Rhinolophus affinis* were captured in Hubei province, and other 450 bats were captured in Zhejiang province 4. The expert in collection was noted in the Author Contributions (JHT). Moreover, he was broadcasted for collecting viruses on nation-wide newspapers and websites in 2017 and 2019 7,8. He described that he was once attacked by bats and the blood of a bat shot on his skin. He knew the extreme danger of the infection so he quarantined himself for 14 days 7. In another accident, he quarantined himself again because bats peed on him. He was once thrilled for capturing a bat carrying a live tick 8.

Surgery was performed on the caged animals and the tissue samples were collected for DNA and RNA extraction and sequencing 4,5. The tissue samples and contaminated trashes were source of pathogens. They were only ~280 meters from the seafood market. The WHCDC was also adjacent to the Union Hospital (Figure 1, bottom) where the first group of doctors were infected during this epidemic. It is plausible that the virus leaked around and some of them contaminated the initial patients in this epidemic, though solid proofs are needed in future study.

The second laboratory was ~12 kilometers from the seafood market and belonged to Wuhan Institute of Virology, Chinese Academy of Sciences 1,9,10. This laboratory reported that the Chinese horseshoe bats were natural reservoirs for the severe acute respiratory syndrome coronavirus (SARS-CoV) which caused the 2002-3 pandemic 9. The principle investigator participated in a project which generated a chimeric virus using
the SARS-CoV reverse genetics system, and reported the potential for human emergence. A direct speculation was that SARS-CoV or its derivative might leak from the laboratory.

In summary, somebody was entangled with the evolution of 2019-nCoV coronavirus. In addition to origins of natural recombination and intermediate host, the killer coronavirus probably originated from a laboratory in Wuhan. Safety level may need to be reinforced in high risk biohazardous laboratories. Regulations may be taken to relocate these laboratories far away from city center and other densely populated places.

Contributors
BX designed the comment and performed literature search. All authors performed data acquisition and analysis, collected documents, draw the figure, and wrote the papers.

Acknowledgements
This work is supported by the National Natural Science Foundation of China (11772133, 11372116).

Declaration of interests
All authors declare no competing interests.

References
Figure 1. The Huanan Seafood Market is close to the WHCDC (from Baidu and Google maps).
Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China

Chenhui Huang*, Yaming Wang*, Xingxiang Li*, Li Ren*, Jianping Zhao*, Yi Hu*, Li Zhang, Cuowei Fan, Jiyang Xu, Xiaoying Gu, Zhenhui Cheng, Ting Yu, Jian Xie, Yuan Wei, Wenjuan Wu, Xueli Xie, Wen Yin, Hui Li, Min Liu, Yan Xiao, Hong Gao, Li Guo, Jinyang Xie, Guangfei Wang, Renming Jiang, Zhuncheng Gao, Qijin, Jianwei Wang†, Bin Cao†

Summary

Background A recent cluster of pneumonia cases in Wuhan, China, was caused by a novel betacoronavirus, the 2019 novel coronavirus (2019-nCoV). We report the epidemiological, clinical, laboratory, and radiological characteristics and treatment and clinical outcomes of these patients.

Methods All patients with suspected 2019-nCoV were admitted to a designated hospital in Wuhan. We prospectively collected and analysed data on patients with laboratory-confirmed 2019-nCoV infection by real-time RT-PCR and next-generation sequencing. Data were obtained with standardised data collection forms shared by WHO and the International Severe Acute Respiratory and Emerging Infection Consortium from electronic medical records. Researchers also directly communicated with patients or their families to ascertain epidemiological and symptom data. Outcomes were also compared between patients who had been admitted to the intensive care unit (ICU) and those who had not.

Findings By Jan 2, 2020, 41 admitted hospital patients had been identified as having laboratory-confirmed 2019-nCoV infection. Most of the infected patients were men (30 [73%] of 41): less than half had underlying diseases (13 [32%]), including diabetes (eight [20%]), hypertension (six [15%]), and cardiovascular disease (six [15%]). Median age was 49·0 years (IQR 41·0–58·0), 27 (66%) of 41 patients had been exposed to Huanan seafood market. One family cluster was found. Common symptoms at onset of illness were fever (40 [98%] of 41 patients), cough (31 [75%]), and myalgia or fatigue (18 [44%]); less common symptoms were sputum production (11 [28%] of 39), headache (13 [32%] of 39), rhinorrhoea (two [5%] of 39), and diarrhoea (one [3%] of 39). Dyspnoea developed in 22 (55%) of 40 patients (median time from illness onset to dyspnoea 8·0 days [IQR 5·0–13·0]), 26 (63%) of 41 patients had lymphopenia. All 41 patients had pneumonia with abnormalities on chest CT. Complications included acute respiratory distress syndrome (12 [29%], elevated CRP (12 [29%]). All 41 patients were admitted to an ICU and six (15%) died. Compared with non-ICU patients, ICU patients had higher plasma levels of IL-2, IL-7, IL-10, GSCF, IP-10, MCP-1, MIP-1A, and TNF-a.

Interpretation The 2019-nCoV infection caused clusters of severe respiratory illness similar to severe acute respiratory syndrome coronavirus and was associated with ICU admission and high mortality. Major gaps in our knowledge of the origin, epidemiology, duration of human transmission, and clinical spectrum of disease need fulfilment by future studies.

Funding Ministry of Science and Technology, Chinese Academy of Medical Sciences, National Natural Science Foundation of China, and Beijing Municipal Science and Technology Commission.

Copyright © 2020 Elsevier Ltd. All rights reserved.

Introduction

Coronaviruses are enveloped non-segmented positive-sense RNA viruses belonging to the family Coronaviridae and are closely related and broadly distributed in humans and other mammals. Although most human coronavirus infections are mild, the epidemics of the two betacoronaviruses, severe acute respiratory syndrome coronavirus (SARS-CoV) and Middle East respiratory syndrome coronavirus (MERS-CoV), have caused more than 10,000 cumulative cases in the past two decades, with mortality rates of 10% for SARS-CoV and 37% for MERS-CoV. The coronaviruses already identified might only be the tip of the iceberg, with potentially more novel and severe zoonotic events to be revealed.

In December 2019, a series of pneumonia cases of unknown cause emerged in Wuhan, Hubei, China, with clinical presentations greatly resembling viral pneumonia. Deep sequencing analysis from lower respiratory tract samples indicated a novel coronavirus, which was named 2019 novel coronavirus (2019-nCoV). Thus far, more than 800 confirmed cases, including in health-care workers, have been identified in Wuhan, and several exported cases have been confirmed in other provinces in China, and in Thailand, Japan, South Korea, and the USA.
Research in context

Evidence before this study
Human coronaviruses, including hCoV-229E, OC43, NL63, and HKU1, cause mild respiratory diseases. Fatal coronavirus infections that have emerged in the past two decades are severe acute respiratory syndrome coronavirus (SARS-CoV) and the Middle East respiratory syndrome coronavirus. We searched PubMed and the China National Knowledge Infrastructure database for articles published up to Jan 11, 2020, using the keywords “novel coronavirus”, “2019 novel coronavirus”, or “2019-nCoV”. No published work about the human infection caused by the 2019 novel coronavirus (2019-nCoV) could be identified.

Added value of this study
We report the epidemiological, clinical, laboratory, and radiological characteristics, treatment, and clinical outcomes of 41 laboratory-confirmed cases infected with 2019-nCoV.

Procedures
Local centres for disease control and prevention collected respiratory, blood, and faeces specimens, then shipped them to designated authoritative laboratories to detect the pathogen (NHC Key Laboratory of Systems Biology of Pathogens and Christophe Mériaux Laboratory, Beijing, China). A novel coronavirus, which was named 2019-nCoV, was isolated from lower respiratory tract specimen and a diagnostic test for this virus was developed soon after that. Of 59 suspected cases, 41 patients were confirmed to be infected with 2019-nCoV. The presence of 2019-nCoV in respiratory specimens was detected by next-generation sequencing or real-time RT-PCR methods. The primers and probe target to envelope gene of CoV were used and the sequences were as follows: forward primer 5'-ACTCTTTTTTCTTCTTCTGTCGTTG3'; reverse primer 5'-GCACGAGTACACGAACTC3'; and the probe 5'-CCTCCTGTAATACCTCGCCACACAC3'. Conditions for the amplifications were 50°C for 15 min, 95°C for 3 min, followed by 45 cycles of 95°C for 15 s and 60°C for 30 s.

Initial investigations included a complete blood count, coagulation profile, and serum biochemical test (including renal and liver function, creatine kinase, lactate dehydrogenase, and electrolytes). Respiratory specimens, including nasal and pharyngeal swabs, bronchoalveolar lavage fluid, sputum, or bronchial aspirates were tested for common viruses, including influenza, avian influenza, respiratory syncytial virus, adenovirus, parainfluenza virus, SARS-CoV and MERS-CoV using real-time RT-PCR assays approved by the China Food and Drug Administration. Routine bacterial and fungal examinations were also performed.

Given the emergence of the 2019-nCoV pneumonia cases during the influenza season, antibiotics (orally and intravenously) and oseltamivir (orally 75 mg twice daily) were empirically administered. Corticosteroid therapy
(methyl)prednisolone 40-120 mg per day) was given as a combined regimen if severe community-acquired pneumonia was diagnosed by physicians at the designated hospital. Oxygen support (e.g., nasal cannula and invasive mechanical ventilation) was administered to patients according to the severity of hypoxaemia. Repeated tests for 2019-nCoV were done in patients confirmed to have 2019-nCoV infection to show viral clearance before hospital discharge or discontinuation of isolation.

Data collection
We reviewed clinical charts, nursing records, laboratory findings, and chest x-rays for all patients with laboratory-confirmed 2019-nCoV infection who were reported by the local health authority. The admission data of these patients was from Dec 16, 2019, to Jan 2, 2020. Epidemiological, clinical, laboratory, and radiological characteristics and treatment and outcomes data were obtained with standardised data collection forms (modified case record form for severe acute respiratory infection clinical characterisation shared by WHO and the International Severe Acute Respiratory and Emerging Infection Consortium) from electronic medical records. Two researchers also independently reviewed the data collection forms to double check the data collected. To ascertain the epidemiological and symptom data, which were not available from electronic medical records, the researchers also directly communicated with patients or their families to ascertain epidemiological and symptom data.

Cytokine and chemokine measurement
To characterise the effect of coronavirus on the production of cytokines or chemokines in the acute phase of the illness, plasma cytokines and chemokines (IL1, IL1α, IL2, IL4, IL5, IL6, IL7, IL8 (also known as CXCL8), IL9, IL10, IL12p70, IL13, IL15, IL17A, Eotaxin (also known as CCL11), basic FGF2, GCSF (CSF3), GM-CSF (CSF2), IFNγ, IP-10 (CXCL10), MCP1 (CCL2), MIP1A (CCL3), MIP1B (CCL4), PDGF, RANTES (CCL5), TNFα, and VEGFA were measured using Human Cytokine Standard 27-Plex Assays panel and the Bio-Plex 200 system (Bio-Rad, Hercules, CA, USA) for all patients according to the manufacturer’s instructions. The plasma samples from four healthy adults were used as controls for cross-comparison. The median time from being transferred to a designated hospital to the blood sample collection was 4 days (IQR 2-5).

Detection of coronavirus in plasma
Each 80 μL plasma sample from the patients and contacts was added into 240 μL of Trizol LS (10296028; Thermo Fisher Scientific, Carlsbad, CA, USA) in the Biosafety Level 3 laboratory. Total RNA was extracted by Direct-zol RNA Miniprep kit (R2050; Zymo research, Irvine, CA, USA) according to the manufacturer’s instructions and 50 μL elution was obtained for each sample. 5 μL RNA was used for real-time RT-PCR, which targeted the NP gene using AgPath-ID One Step RT-PCR Reagent (AM1005, Thermo Fisher Scientific). The final reaction mix concentration of the primers was 500 nM and probe was 200 nM. Real-time RT-PCR was performed using the following conditions: 50°C for 15 min and 95°C for 3 min, 50 cycles of amplification at 95°C for 10 s and 60°C for 45 s. Since we did not perform tests for detecting infectious virus in blood, we avoided the term viraemia and used RNAemia instead. RNAemia was defined as a positive result for real-time RT-PCR in the plasma sample.

Definitions
Acute respiratory distress syndrome (ARDS) and shock were defined according to the interim guidance of WHO.

Figure 1: Date of illness onset and age distribution of patients with laboratory-confirmed 2019-nCoV infection
(A) Number of hospital admissions by age group. (B) Distribution of symptom onset data for laboratory-confirmed cases. The Wuhan local health authority issued an epidemiological alert on Dec 30, 2019, and closed the Huanan seafood market 2 days later.
### Characteristics

<table>
<thead>
<tr>
<th>Characteristics</th>
<th>All patients (n=43)</th>
<th>ICU care (n=13)</th>
<th>No ICU care (n=29)</th>
<th>p value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age, years (years)</td>
<td>49.0 (41.0–58.0)</td>
<td>49.0 (41.0–61.0)</td>
<td>49.0 (41.0–57.5)</td>
<td>0.50</td>
</tr>
<tr>
<td>Sex</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>0.24</td>
</tr>
<tr>
<td>Age, years</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>0.24</td>
</tr>
<tr>
<td>Men (yes)</td>
<td>48 (73%)</td>
<td>11 (85%)</td>
<td>37 (68%)</td>
<td>–</td>
</tr>
<tr>
<td>Women (yes)</td>
<td>13 (27%)</td>
<td>2 (15%)</td>
<td>11 (22%)</td>
<td>–</td>
</tr>
<tr>
<td>Human seafood market exposure</td>
<td>27 (66%)</td>
<td>9 (96%)</td>
<td>18 (66%)</td>
<td>0.75</td>
</tr>
<tr>
<td>Current smoking</td>
<td>3 (7%)</td>
<td>0</td>
<td>3 (11%)</td>
<td>0.51</td>
</tr>
<tr>
<td>Any comorbidity</td>
<td>13 (30%)</td>
<td>3 (30%)</td>
<td>10 (21%)</td>
<td>0.65</td>
</tr>
<tr>
<td>Diabetes</td>
<td>9 (22%)</td>
<td>1 (8%)</td>
<td>8 (22%)</td>
<td>0.16</td>
</tr>
<tr>
<td>Hypertension</td>
<td>6 (14%)</td>
<td>2 (15%)</td>
<td>4 (16%)</td>
<td>0.33</td>
</tr>
<tr>
<td>Cardiovascular disease</td>
<td>5 (12%)</td>
<td>3 (23%)</td>
<td>2 (12%)</td>
<td>0.32</td>
</tr>
<tr>
<td>Chronic obstructive pulmonary disease</td>
<td>1 (2%)</td>
<td>1 (8%)</td>
<td>0</td>
<td>0.14</td>
</tr>
<tr>
<td>Malignancy</td>
<td>1 (2%)</td>
<td>0</td>
<td>1 (4%)</td>
<td>0.49</td>
</tr>
<tr>
<td>Chronic liver disease</td>
<td>1 (2%)</td>
<td>0</td>
<td>1 (4%)</td>
<td>0.58</td>
</tr>
</tbody>
</table>

### Signs and symptoms

| Fever                                        | 40 (98%)            | 13 (100%)       | 27 (96%)          | 0.08   |
| Signed temperature, °C                       | 37.3 (36.4–38.5)    | 37.3 (36.4–38.5)| 37.3 (36.4–38.5) | 0.53   |
| <37.3                                        | 1 (2%)              | 0              | 1 (4%)            | 0.32   |
| 37.3–38.0                                    | 8 (20%)             | 3 (23%)        | 5 (21%)           | 0.18   |
| >38.0                                        | 5 (12%)             | 1 (8%)         | 4 (16%)           | 0.33   |
| Cough                                        | 31 (76%)            | 11 (85%)       | 20 (71%)          | 0.35   |
| Myalgia or fatigue                           | 18 (44%)            | 7 (54%)        | 11 (39%)          | 0.38   |
| Spaciot production                           | 12 (28%)            | 5 (38%)        | 7 (26%)           | 0.32   |
| Headache                                     | 3 (7%)              | 0              | 3 (13%)           | 0.16   |
| Haemoptysis                                  | 7 (16%)             | 1 (8%)         | 6 (21%)           | 0.18   |
| Diaphores                                     | 12 (28%)            | 1 (8%)         | 11 (39%)          | 0.66   |
| Dyspnoea                                     | 224 (55%)           | 12 (93%)       | 102 (35%)         | 0.001  |
| Days from illness onset to dyspnoea          | 8 (0–24)            | 8 (0–24)       | 5 (0–24)          | 0.003  |
| Days from admission to transfer              | 5 (0–8)             | 5 (0–6)        | 0 (0–5)           | 0.001  |
| Systolic pressure, mm Hg                      | 125 (119–130)       | 145 (137–135)  | 145 (137–132)     | 0.018  |
| Respiratory rate                              | 12 (10–12)          | 8 (5–10)       | 12 (6–15)         | 0.002  |
| ≥24 breaths per min                           | 12 (28%)            | 8 (62%)        | 4 (14%)           | 0.002  |

Data are median [IQR], n (%), or n/N (%), where N is the total number of patients with available data. p values comparing ICU care and non-ICU care are from the Fisher's exact test, or Mann-Whitney U test. 

Table 1: Demographics and baseline characteristics of patients infected with 2019-nCoV

---

for novel coronavirus.  

Hypoxaemia was defined as arterial oxygen tension (PaO₂) over inspiratory oxygen fraction (FIO₂) of less than 300 mm Hg. Acute kidney injury was identified and classified based on the highest serum creatinine level or urine output criteria according to the kidney disease improvement global outcome classification. Secondary infection was diagnosed if the patients had clinical symptoms or signs of nosocomial pneumonia or bacteraemia, and was combined with a positive culture of a new pathogen from a lower respiratory tract specimen (including the sputum, transtracheal aspirates, or bronchoalveolar lavage fluid, or from blood samples taken ≥48 h after admission). Cardiac injury followed the definition used in our previous study in H7N9 patients. In brief, cardiac injury was diagnosed if serum levels of cardiac biomarkers (e.g. troponin I) were above the 99th percentile upper reference limit, or new abnormalities were shown in electrocardiography and echocardiography.

### Statistical analysis

Continuous variables were expressed as median (IQR) and compared with the Mann-Whitney U test. Categorical variables were expressed as number (%) and compared by χ² test or Fisher's exact test between ICU care and no ICU care groups. Boxplots were drawn to describe plasma cytokine and chemokine concentrations.

A two-sided α of less than 0.05 was considered statistically significant. Statistical analyses were done using the SAS software, version 9.4, unless otherwise indicated.

### Role of the funding source

The funder of the study had no role in study design, data collection, data analysis, data interpretation, or writing of the report. The corresponding authors had full access to all the data in the study and had final responsibility for the decision to submit for publication.

### Results

By Jan 2, 2020, 41 admitted hospital patients were identified as laboratory-confirmed 2019-nCoV infection in Wuhan. 20 (49%) of the 2019-nCoV-infected patients were aged 24–49 years, and 14 (34%) were aged 50–64 years (figure 1A). The median age of the patients was 49.0 years (IQR 41.0–58.0; table 1). In our cohort of the first 41 patients as of Jan 2, no children or adolescents were infected. Of the 41 patients, 13 (32%) were admitted to the ICU because they required high-flow nasal cannula or higher-level oxygen support measures to correct hypoxaemia. Most of the infected patients were men (30 [73%]), less than half had underlying diseases (13 [32%]), including diabetes (eight [20%]), hypertension (six [15%]), and cardiovascular disease (six [15%]).

27 (66%) patients had direct exposure to Huanan seafood market (figure 1B). Market exposure was similar between the patients with ICU care (nine [69%]) and those with non-ICU care (18 [64%]). The symptom onset date of the first patient identified was Dec 1, 2019. None of his family members developed fever or any respiratory symptoms. No epidemiological link was found between the first patient and later cases. The first fatal case, who had continuous exposure to the market, was admitted to hospital because of a 7-day history of fever, cough, and dyspnoea. 5 days after illness onset, his wife, a 53-year-old woman who had no known history of exposure to the market, also presented with pneumonia and was hospitalised in the isolation ward.

The most common symptoms at onset of illness were fever (40 [88%] of 41 patients), cough (31 [76%]), and myalgia or fatigue (18 [44%]); less common symptoms...
were sputum production (11 [28%] of 39), headache (three [8%] of 38), haemoptysis (two [5%] of 39), and diarrhoea (one [3%] of 38; table 1). More than half of patients (22 [55%] of 40) developed dyspnoea. The median duration from illness onset to dyspnoea was 8.0 days (IQR 5.0–13.0). The median time from onset of symptoms to first hospital admission was 7.0 days (4.0–9.0), to shortness of breath was 8.0 days (5.0–13.0), to ARDS was 9.0 days (8.0–14.0), to mechanical ventilation was 10.5 days (7.0–14.0), and to ICU admission was 10.5 days (8.0–17.0; figure 2).

The blood counts of patients on admission showed leucopenia (white blood cell count less than 4×10⁹/L; ten [25%] of 40 patients) and lymphopenia (lymphocyte count <1.0×10⁹/L; 26 [63%] patients; table 2). Prothrombin time and D-dimer level on admission were higher in ICU patients (median prothrombin time 12.2 s [IQR 11.2–13.4]; median D-dimer level 2.4 mg/L [0.6–4.4]) than non-ICU patients (median prothrombin time 10.7 s [9.8–12.1], p=0.012; median D-dimer level 0.5 mg/L [0.3–0.8], p=0.0042). Levels of aspartate aminotransferase were increased in 15 (37%) of 41 patients, including eight (62%) of 13 ICU patients and seven (25%) of 28 non-ICU patients. Hypersensitive troponin I (hs-CtI) was increased substantially in five patients, in whom the diagnosis of virus-related cardiac injury was made.

Most patients had normal serum levels of procalcitonin on admission (procalcitonin ≤0.1 mg/mL; 27 [69%] patients; table 2). Four ICU patients developed secondary infections. Three of the four patients with secondary infection had procalcitonin greater than 0.5 mg/mL (0.69 mg/mL, 1.46 mg/mL, and 6.48 mg/mL).

On admission, abnormalities in chest CT images were detected among all patients. Of the 41 patients, 40 (98%) had bilateral involvement (table 2). The typical findings of chest CT images of ICU patients on admission were bilateral multiple lobular and subsegmental areas of consolidation (figure 3A). The representative chest CT findings of non-ICU patients showed bilateral ground-glass opacity and subsegmental areas of consolidation (figure 3B). Later chest CT images showed bilateral ground-glass opacity, whereas the consolidation had been resolved (figure 3C).

Initial plasma IL1B, IL1RA, IL7, IL8, IL9, IL10, basic FGF, GCSF, GMCSF, IFNγ, IP10, MCP1, MIP1A, MIP1B, PDGF, TNFa, and VEGF concentrations were higher in both ICU patients and non-ICU patients than in healthy adults (appendix pp 6–7). Plasma levels of IL5, IL12p70, IL15, Eotaxin, and RANTES were similar between healthy adults and patients infected with 2019-nCoV. Further comparison between ICU and non-ICU patients showed that plasma concentrations of IL2, IL7, IL10, GCSF, IP10, MCP1, MIP1A, and TNFa were higher in ICU patients than non-ICU patients.

All patients had pneumonia. Common complications included ARDS (12 [29%] of 41 patients), followed by RNAemia (six [15%] patients), acute cardiac injury (five [12%] patients), and secondary infection (four [10%] patients; table 3). Invasive mechanical ventilation was required in four (10%) patients, with two of them (5%) had refractory hypoxaemia and received extracorporeal membrane oxygenation as salvage therapy. All patients were administered with empirical antibiotic treatment, and 38 (93%) patients received antiviral therapy (oseltamivir). Additionally, nine (22%) patients were given systemic corticosteroids. A comparison of clinical features between patients who received and did not receive systemic corticosteroids is in the appendix (pp 1–5).

As of Jan 22, 2020, 28 (68%) of 41 patients have been discharged and six (15%) patients have died. Fitness for discharge was based on abatement of fever for at least 10 days, with improvement of chest radiographic evidence and viral clearance in respiratory samples from upper respiratory tract.

Discussion
We report here a cohort of 41 patients with laboratory-confirmed 2019-nCoV infection. Patients had serious, sometimes fatal, pneumonia and were admitted to the designated hospital in Wuhan, China, by Jan 2, 2020. Clinical presentations greatly resemble SARS-CoV. Patients with severe illness developed ARDS and required ICU admission and oxygen therapy. The time between hospital admission and ARDS was as short as 2 days. At this stage, the mortality rate is high for 2019-nCoV, because six (15%) of 41 patients in this cohort died.

The number of deaths is rising quickly. As of Jan 24, 2020, 835 laboratory-confirmed 2019-nCoV infections were reported in China, with 25 fatal cases. Reports have been released of exported cases in many provinces in China, and in other countries;
### Table 2: Laboratory findings of patients infected with 2019-nCoV on admission to hospital

<table>
<thead>
<tr>
<th>Parameter</th>
<th>All patients (n=41)</th>
<th>ICU care (n=13)</th>
<th>No ICU care (n=28)</th>
<th>p value</th>
</tr>
</thead>
<tbody>
<tr>
<td>White blood cell count, x10⁶/L</td>
<td>6.7 (4.4-10.5)</td>
<td>11.3 (5.8-12.4)</td>
<td>5.7 (3.1-7.6)</td>
<td>0.012</td>
</tr>
<tr>
<td>&lt;4</td>
<td>10/40 (75%)</td>
<td>1/13 (8%)</td>
<td>9/37 (33%)</td>
<td>0.041</td>
</tr>
<tr>
<td>4-10</td>
<td>18/40 (45%)</td>
<td>7/13 (54%)</td>
<td>11/27 (41%)</td>
<td>-</td>
</tr>
<tr>
<td>&gt;10</td>
<td>12/40 (30%)</td>
<td>7/13 (54%)</td>
<td>5/27 (19%)</td>
<td>-</td>
</tr>
<tr>
<td>Neutrophil count, x10⁶/L</td>
<td>5.0 (3.0-8.9)</td>
<td>10.6 (5.0-18.8)</td>
<td>4.4 (2.0-6.1)</td>
<td>0.00069</td>
</tr>
<tr>
<td>Lymphocyte count, x10⁶/L</td>
<td>0.8 (0.6-1.0)</td>
<td>0.6 (0.2-0.8)</td>
<td>1.0 (0.7-1.1)</td>
<td>0.0041</td>
</tr>
<tr>
<td>&lt;1</td>
<td>25/41 (63%)</td>
<td>11/13 (85%)</td>
<td>15/26 (58%)</td>
<td>0.045</td>
</tr>
<tr>
<td>&gt;1</td>
<td>15/41 (37%)</td>
<td>2/13 (15%)</td>
<td>12/26 (46%)</td>
<td>-</td>
</tr>
<tr>
<td>Haemoglobin, g/L</td>
<td>12.0 (11.8-14.0)</td>
<td>12.0 (11.0-12.8)</td>
<td>12.0 (12.0-14.0)</td>
<td>0.20</td>
</tr>
<tr>
<td>Platelet count, x10⁹/L</td>
<td>145 (125-263)</td>
<td>160 (165-263)</td>
<td>140 (131-263)</td>
<td>0.45</td>
</tr>
<tr>
<td>&lt;100</td>
<td>2.0 (2.0-3.4)</td>
<td>1.3 (2.0-3.4)</td>
<td>1.0 (1.0-2.3)</td>
<td>0.45</td>
</tr>
<tr>
<td>&gt;100</td>
<td>0.05 (0.03-0.2)</td>
<td>0.05 (0.03-0.8)</td>
<td>0.05 (0.03-0.8)</td>
<td>0.0462</td>
</tr>
<tr>
<td>Activated partial thromboplastin time, sec</td>
<td>27.0 (26.0-28.0)</td>
<td>26.2 (25.5-30.0)</td>
<td>27.7 (26.0-30.0)</td>
<td>0.57</td>
</tr>
<tr>
<td>D-dimer, mg/L</td>
<td>0.5 (0.3-1.1)</td>
<td>0.7 (0.4-1.4)</td>
<td>0.5 (0.3-0.8)</td>
<td>0.012</td>
</tr>
<tr>
<td>Alcohol, g/L</td>
<td>2.0 (1.5-2.5)</td>
<td>2.0 (1.5-2.5)</td>
<td>2.0 (1.5-2.5)</td>
<td>-</td>
</tr>
<tr>
<td>Alkaline phosphatase, U/L</td>
<td>32.4 (21.8-44.0)</td>
<td>31.0 (21.8-44.0)</td>
<td>33.0 (21.8-44.0)</td>
<td>0.00669</td>
</tr>
<tr>
<td>Aspartate aminotransferase, U/L</td>
<td>34.6 (24.0-48.0)</td>
<td>34.0 (24.0-48.0)</td>
<td>34.0 (24.0-48.0)</td>
<td>0.01</td>
</tr>
<tr>
<td>&gt;40</td>
<td>15/41 (37%)</td>
<td>8/13 (62%)</td>
<td>7/28 (25%)</td>
<td>-</td>
</tr>
<tr>
<td>LDH, U/L</td>
<td>117 (95-239)</td>
<td>140 (110-210)</td>
<td>168 (94-333)</td>
<td>0.011</td>
</tr>
<tr>
<td>Potassium, mmol/L</td>
<td>4.2 (3.8-4.8)</td>
<td>4.6 (4.0-5.0)</td>
<td>4.1 (3.8-4.6)</td>
<td>0.27</td>
</tr>
<tr>
<td>Alanine transaminase, U/L</td>
<td>32.0 (27.0-48.0)</td>
<td>31.0 (26.0-48.0)</td>
<td>32.0 (27.0-48.0)</td>
<td>0.038</td>
</tr>
<tr>
<td>Creatinine, µmol/L</td>
<td>74.2 (57.5-85.7)</td>
<td>79.0 (53.0-97.0)</td>
<td>73.3 (57.5-84.7)</td>
<td>0.04</td>
</tr>
<tr>
<td>&gt;135</td>
<td>37/41 (90%)</td>
<td>11/13 (85%)</td>
<td>26/28 (92%)</td>
<td>0.42</td>
</tr>
<tr>
<td>&gt;135</td>
<td>4/11 (36%)</td>
<td>2/13 (15%)</td>
<td>2/13 (15%)</td>
<td>-</td>
</tr>
<tr>
<td>Creatinine kinase, U/L</td>
<td>132.5 (82.0-215.0)</td>
<td>132.0 (82.0-215.0)</td>
<td>132.0 (82.0-215.0)</td>
<td>0.11</td>
</tr>
<tr>
<td>&gt;185</td>
<td>27.0 (8.0-68.0)</td>
<td>7.0 (13.0-44.0)</td>
<td>20.0 (7.0-77.0)</td>
<td>0.21</td>
</tr>
<tr>
<td>Lactate dehydrogenase, U/L</td>
<td>180.0 (120.0-280.0)</td>
<td>180.0 (120.0-280.0)</td>
<td>180.0 (120.0-280.0)</td>
<td>0.0044</td>
</tr>
<tr>
<td>&gt;245</td>
<td>11/41 (27%)</td>
<td>1/13 (8%)</td>
<td>10/27 (37%)</td>
<td>0.035</td>
</tr>
<tr>
<td>&gt;245</td>
<td>29/41 (71%)</td>
<td>12/13 (92%)</td>
<td>17/28 (61%)</td>
<td>-</td>
</tr>
<tr>
<td>Hypersensitive troponin I, pg/mL</td>
<td>3.4 (1.1-9.1)</td>
<td>3.3 (1.0-15.0)</td>
<td>3.5 (0.7-5.6)</td>
<td>0.075</td>
</tr>
<tr>
<td>&gt;28th (99th percentile)</td>
<td>5.0 (1.1-23.0)</td>
<td>4.0 (1.1-19.0)</td>
<td>1.0 (0.7-23.0)</td>
<td>0.017</td>
</tr>
<tr>
<td>Procalcitonin, ng/mL</td>
<td>6.1 (0.1-0.1)</td>
<td>6.1 (0.1-0.1)</td>
<td>6.1 (0.1-0.1)</td>
<td>-</td>
</tr>
<tr>
<td>&gt;0.5</td>
<td>77.0 (6.0-31.0)</td>
<td>77.0 (6.0-31.0)</td>
<td>77.0 (6.0-31.0)</td>
<td>0.038</td>
</tr>
<tr>
<td>&gt;0.5</td>
<td>7.0 (0.1-0.5)</td>
<td>7.0 (0.1-0.5)</td>
<td>7.0 (0.1-0.5)</td>
<td>-</td>
</tr>
<tr>
<td>Bilateral involvement of chest radiographs</td>
<td>40/41 (98%)</td>
<td>12/13 (100%)</td>
<td>28/28 (96%)</td>
<td>0.68</td>
</tr>
</tbody>
</table>

Data are median (IQR) or n/N (%), where N is the total number of patients with available data. p values comparing ICU care and no ICU care are from χ², Fisher’s exact test, or Mann-Whitney U test. 2019-nCoV=2019 novel coronavirus; ICU=intensive care unit; **Complicated typical secondary infection during the test hospitalization.**

Some health-care workers have also been infected in Wuhan. Taken together, evidence so far indicates human transmission for 2019-nCoV. We are concerned that 2019-nCoV could have acquired the ability for efficient human transmission. Airborne precautions, such as a fit-tested N95 respirator, and other personal protective equipment are strongly recommended. To prevent further spread of the disease in health-care settings that are caring for infected patients with 2019-nCoV, onset of fever and respiratory symptoms should be closely monitored among health-care workers. Testing of respiratory specimens should be done immediately once a diagnosis is suspected. Serum antibodies should be tested among health-care workers.
before and after their exposure to 2019-nCoV for identification of asymptomatic infections.

Similarities of clinical features between 2019-nCoV and previous betacoronavirus infections have been noted. In this cohort, most patients presented with fever, dry cough, dyspnoea, and bilateral ground-glass opacities on chest CT scans. These features of 2019-nCoV infection bear some resemblance to SARS-CoV and MERS-CoV infections. However, few patients with 2019-nCoV infection had prominent upper respiratory tract signs and symptoms (eg, rhinorrhea, sneezing, or sore throat), indicating that the target cells might be located in the lower airway. Furthermore, 2019-nCoV patients rarely developed intestinal signs and symptoms (eg, diarrhoea), whereas about 20–25% of patients with MERS-CoV or SARS-CoV infection had diarrhoea. Faecal and urine samples should be tested to exclude a potential alternative route of transmission that is unknown at this stage.

The pathophysiology of unusually high pathogenicity for SARS-CoV or MERS-CoV has not been completely understood. Early studies have shown that increased amounts of proinflammatory cytokines in serum (eg, IL-1B, IL-6, IL-12, IFNγ, IP10, and MCP1) were associated with pulmonary inflammation and extensive lung damage in SARS patients. MERS-CoV infection was also reported to increase concentrations of proinflammatory cytokines (IFNγ, TNFα, IL15, and IL17). We noted that patients infected with 2019-nCoV also had high amounts of IL1B, IFNγ, IP10, and MCP1, probably leading to activated T-helper-1 (Th1) cell responses. Moreover, patients requiring ICU admission had higher concentrations of GCSF, IP10, MCP1, MIP1A, and TNFα than those not requiring ICU admission, suggesting that the cytokine storm was associated with disease severity. However, 2019-nCoV infection also initiated increased secretion of T-helper-2 (Th2) cytokines (eg, IL4 and IL10) that suppress inflammation, which differs from SARS-CoV infection. Further studies are necessary to characterise the Th1 and Th2 responses in 2019-nCoV infection and to elucidate the pathogenesis. Autopsy or biopsy studies would be the key to understanding the disease.

In view of the high amount of cytokines induced by SARS-CoV, MERS-CoV, and 2019-nCoV infections, corticosteroids were used frequently for treatment of patients with severe illness, for possible benefit by reducing inflammatory-induced lung injury. However, current evidence in patients with SARS and MERS

Figure 3: Chest CT images

(A) Transverse chest CT images from a 40-year-old man showing bilateral multiple nodular and subsegmental areas of consolidation on day 15 after symptom onset. Transverse chest CT images from a 55-year-old woman showing bilateral ground-glass opacity and subsegmental areas of consolidation on day 3 after symptom onset (B), and bilateral ground-glass opacity on day 12 after symptom onset (C).
suggests that receiving corticosteroids did not have an effect on mortality, but rather delayed viral clearance. Therefore, corticosteroids should not be routinely given systemically, according to WHO interim guidance. Among our cohort of 41 laboratory-confirmed patients with 2019-nCoV infection, corticosteroids were given to very few non-ICU cases, and low-to-moderate dose of corticosteroids were given to less than half of severely ill patients with ARDS. Further evidence is urgently needed to assess whether systemic corticosteroid treatment is beneficial or harmful for patients infected with 2019-nCoV.

No antiviral treatment for coronavirus infection has been proven to be effective. In a historical control study, the combination of lopinavir and ritonavir among SARS-CoV patients was associated with substantial clinical benefit (fewer adverse clinical outcomes). Arabi and colleagues initiated a placebo-controlled trial of interferon beta-1b, lopinavir, and ritonavir among patients with MERS infection in Saudi Arabia. Preclinical evidence showed the potent efficacy of remdesivir (a broad-spectrum antiviral nucleotide prodrug) to treat MERS-CoV and SARS-CoV infections. As 2019-nCoV is an emerging virus, an effective treatment has not been developed for disease resulting from this virus. Since the combination of lopinavir and ritonavir was already available in the designated hospital, a randomised controlled trial has been initiated quickly to assess the efficacy and safety of combined use of lopinavir and ritonavir in patients hospitalised with 2019-nCoV infection.

Our study has some limitations. First, for most of the 41 patients, the diagnosis was confirmed with lower respiratory tract specimens and no paired nasopharyngeal swabs were obtained to investigate the difference in the viral RNA detection rate between upper and lower respiratory tract specimens. Serological detection was not done to look for 2019-nCoV antibody rises in 18 patients with undetectable viral RNA. Second, with the limited number of cases, it is difficult to assess host risk factors for disease severity and mortality with multivariable-adjusted methods. This is a modest-sized case series of patients admitted to hospital; collection of standardised data for a larger cohort would help to further define the clinical presentation, natural history, and risk factors. Further studies in outpatient, primary care, or community settings are needed to get a full picture of the spectrum of clinical severity. At the same time, finding of statistical tests and p values should be interpreted with caution, and non-significant p values do not necessarily rule out difference between ICU and non-ICU patients. Third, since the causative pathogen has just been identified, kinetics of viral load and antibody titres were not available. Finally, the potential exposure bias in our study might account for why no paediatric or adolescent patients were reported in this cohort. More effort should be made to answer these questions in future studies.

Both SARS-CoV and MERS-CoV were believed to originate in bats, and these infections were transmitted directly to humans from market civets and dromedary camels, respectively. Extensive research on SARS-CoV and MERS-CoV has driven the discovery of many SARS-like and MERS-like coronaviruses in bats. In 2013, Ge and colleagues reported the whole genome sequence of a SARS-like coronavirus in bats with that ability to use human ACE2 as a receptor, thus having replication potentials in human cells. 2019-nCoV still needs to be studied deeply in case it becomes a global health threat. Reliable quick pathogen tests and feasible differential diagnosis based on clinical description are crucial for clinicians in their first contact with suspected patients. Because of the pandemic potential of 2019-nCoV, careful surveillance is essential to monitor its future host adaption, viral evolution, infectivity, transmissibility, and pathogenicity.
data and the accuracy of the data analysis. YWA, GF, XG, JXa, H1, and BC contributed to writing of the report. BC contributed to critical revision of the report. YWA, GF, XG, JXa, H1, and BC contributed to the statistical analysis. All authors contributed to data acquisition, data analysis, or data interpretation, and reviewed and approved the final version.

Declaration of interests
All authors declare no competing interests.

Data sharing
The data that support the findings of this study are available from the corresponding author on reasonable request. Participants data without names and identities will be made available after approval from the corresponding author and the National Health Commission. After publication of study findings, the data will be available for others to request. The research team will provide an email address for communication once the data are approved to be shared with others. The proposal with detailed description of study objectives and statistical analysis plan will be needed in the application to request for our data. The corresponding author and National Health Commission will make a decision based on these materials. Additional materials may also be required during the process.

Acknowledgments
This work is funded by the Special Project for Emergency of the Ministry of Science and Technology (2020YFC0841300) Chinese Academy of Medical Sciences (CAMS) Innovation Fund for Medical Sciences (CIFMS 2018-12M-1-603), a National Science Grant for Distinguished Young Scholars (81425002/8140906), the National Key Research and Development Program of China (2018YFC0108600, CAMS Innovation Fund for Medical Sciences (2016-L2M-00-2), and National Natural Science Foundation of China (81903002). We sincerely appreciate all the efforts contributed by all the members of our team. We thank all the patients and their families. We also thank all the health care workers who cared for the patients and provided invaluable information.

References


24 April 2020

Drs. Aleksei Chmura and Peter Daszak
EcoHealth Alliance, Inc.
460 W 34th St
Suite 1701
New York, NY 10001

Re: Termination of NIH Grant R01 AI 110964

Dear Drs. Chmura and Daszak:

I am writing to notify you that the National Institute of Allergy and Infectious Diseases (NIAID), an Institute within the National Institutes of Health (NIH), under the Department of Health and Human Services (HHS) has elected to terminate the project Understanding the Risk of Bat Coronaviruses Emergence, funded under grant R01 AI 110964, for convenience. This grant project was issued under the authorization of Sections 301 and 405 of the Public Health Service Act as amended (42 USC 241 and 284). This grant was funded as a discretionary grant as outlined in the NIH Grants Policy Statement, which states that the decision not to award a grant, or to award a grant at a particular funding level, is at the discretion of the agency, in accordance with NIH's dual review system.

At this time, NIH does not believe that the current project outcomes align with the program goals and agency priorities. NIAID has determined there are no animal and human ethical considerations, as this project is not a clinical trial, but rather an observational study.

As a result of this termination, a total of $369,819.56 will be remitted to NIAID and additional drawdowns will not be supported. The remaining funds have been restricted in the HHS Payment Management System, effective immediately.

Please let me know if you have any questions concerning the information in this letter.

Sincerely,

Michael S Lauer, MD
NIH Deputy Director for Extramural Research

cc: Dr. Erik Stemmy
Ms. Emily Linde
Date: April 19, 2020

From: Michael S Lauer, MD
NIH Deputy Director for Extramural Research

To: Kevin Olival, PhD
Vice-President for Research
EcoHealth Alliance

Naomi Schrag, JD
Vice-President for Research Compliance, Training, and Policy
Columbia University

Subject: Project Number 2R01AI110964-06

Dear Dr. Olival and Ms. Schrag:

EcoHealth Alliance, Inc. is the recipient, as grantee, of an NIH grant entitled “Understanding the Risk of Bat Coronavirus Emergence.” It is our understanding that one of the sub-recipients of the grant funds is the Wuhan Institute of Virology (“WIV”). It is our understanding that WIV studies the interaction between corona viruses and bats. The scientific community believes that the coronavirus causing COVID-19 jumped from bats to humans likely in Wuhan where the COVID-19 pandemic began. There are now allegations that the current crisis was precipitated by the release from WIV of the coronavirus responsible for COVID-19. Given these concerns, we are pursuing suspension of WIV from participation in Federal programs.

While we review these allegations during the period of suspension, you are instructed to cease providing any funds from the above noted grant to the WIV. This temporary action is authorized by 45 C.F.R. § 75.371(d) (“Initiate suspension or debarment proceedings as authorized under 2 C.F.R. part 180”). The incorporated OMB provision provides that the funding agency may, through suspension, immediately and temporarily exclude from Federal programs persons who are not presently responsible where “immediate action is necessary to protect the public interest.” 2 C.F.R. § 180.700(c). It is in the public interest that NIH ensure that a sub-recipient has taken all appropriate precautions to prevent the release of pathogens that it is studying. This suspension of the sub-recipient does not affect the remainder of your grant assuming that no grant funds are provided to WIV following receipt of this email during the period of suspension.
The new coronavirus (2019-nCoV) pneumonia epidemic continues, and WHO experts point out that the virus may originate from bats, especially Rhinolophus Bat. Xiaobo Tao, a professor at South China University of Technology, published a report entitled "Possibility of New Coronavirus (2019-nCoV) Source", pointing out that the Wuhan Disease Control Centre, less than 300 meters away from the South China Seafood Market, which was allegedly the source of the outbreak, had captured bat. To study coronavirus, more researchers were splashed by the blood and urine of bats. The researchers had to isolate themselves for 14 days.
academic journal, but only on the scientific paper sharing website. The paper has not been found. "Hong Kong 01" reporter wanted to call Xiao Botao for verification, but the other party did not listen to the call. Earlier it was suspected that the epidemic was related to another laboratory in Wuhan and the Wuhan Institute of Virology, Chinese Academy of Sciences, but officials denied it many times.

▼ The process of capturing bats in Wuhan CDC ▼
The scholar who wrote this report is Professor Xiao Botao of the School of Biological Science and Engineering of South China University of Technology. He used to work at Harvard Medical School and has collaborated with Northwestern University in the United States. He has been awarded the National Natural Science Foundation many times. Fund support. As of February 6, the report refers to the new coronavirus gene sequencing found that 96% and 89% are similar to the coronavirus (CoV ZC45) found in the head bat (CoV ZC45), but it is necessary to study the pathogen and how to pass it to humans. The report cited medical journal research, stating that 27 of the 41 people infected in Wuhan were linked to South China Seafood City, and 33 of the 585 samples collected in South China Seafood City had detected new coronaviruses.

However, the bat carrying CoV ZC45 was first discovered in Yunnan and Zhejiang provinces, more than 900 kilometers away from South China Seafood City. In addition, bats usually live in the wild, and the population is dense. The possibility of bats flying to the place is "very low." Although the South China Seafood Market sells game meat, it does not sell bats.

market and identified two laboratories conducting research on bat coronavirus. Within ~280 meters from the market, there was the Wuhan Center for Disease Control & Prevention (WHCDC) (Figure 1, from Baidu and Google maps). WHCDC hosted animals in laboratories for research purposes, one of which was specialized in pathogens collection and identification. In one of their studies, 155 bats including Rhinolophus affinis were captured in Hubei province, and other 450 bats were captured in Zhejiang province. The expert in collection was noted in the Author Contributions (JHT). Moreover, he was broadcasted for collecting viruses on nation-wide newspapers and websites in 2017 and 2019. He described that he was once by attacked by bats and the blood of a bat shot on his skin. He knew the extreme danger of the infection so he quarantined himself for 14 days. In another accident, he quarantined himself again because bats peed on him. He was once thrilled for capturing a bat carrying a live tick.

Surgery was performed on the caged animals and the tissue samples were collected for DNA and RNA extraction and sequencing. The tissue samples and contaminated trash were source of pathogens. They were only ~280 meters from the seafood market. The WHCDC was also adjacent to the Union Hospital (Figure 1, bottom) where the first group of doctors were infected during this epidemic. It is plausible that the virus leaked around and some of them contaminated the initial patients in this epidemic, though solid proofs...
The report mentions the possibility of other ways, noting that there are two laboratories in Wuhan, in addition to the Wuhan Institute of Virology of the Chinese Academy of Sciences, which is 30 kilometers away from the South China Seafood Market and at the P4 level. WHCDC), the center possesses animals for research purposes including collecting and distinguishing pathogens.

The report quotes past official information that the Wuhan CDC once captured 155 bats from Hubei Province, including the chrysanthemum bat, and another 450 bats from Zhejiang Province. However, the researcher in charge of the research had been interviewed by the media in 2017 and 2019 to mention two accidents, including that he had been attacked by a bat, and the blood of the bat splashed on his skin, so he was isolated for 14 days; The bat urinates and must be isolated; he has found a live tick on the bat.
As for the Wuhan Institute of Virology, Chinese Academy of Sciences, 50 kilometers away from South China Seafood City, it has been tracking SARS-CoV virus research in 2003, such as using reverse genetics methods. Therefore, "direct speculation" refers to the possibility that the laboratory has leaked SARS-CoV or its derivatives.

Professor Xiao Botao of South China University of Technology Full Paper

Originsof2019-nCoV XiaoB Res by Zerohedge on Scribd
Summary quoted opinion that high-risk laboratories should stay away from people

The report concluded that some people are concerned about the evolution of the 2019-nCoV coronavirus. In addition to the natural reorganization and the origin of the intermediate host, the lethal coronavirus may also come from the Wuhan laboratory. The safety level of the high-risk biological laboratory may need to be strengthened. Regulations should be taken to keep the laboratory location away from the city center and other densely populated places.

This report was published on the research sharing website Research Gate on February 6, and was not published in an authoritative academic journal, but Research Gate has not found the article. "Hong Kong 01" reporter called Xiao Botao for enquiries, but the other party did not answer the call.
The city of Wuhan was closed, public transportation stopped, tens of thousands of people were infected, people in the city were panicked, residents wore masks when they went out, and even more people went to the supermarket to protect themselves with plastic bags. (Chinatopix / Associated Press)

**WHO: No intermediate host found**

A World Health Organization official said on February 11th that after the Chinese health department disclosed the viral gene sequencing, scientists found that the new coronavirus may have come from bats, and then transferred to an intermediate host, and then infected humans. However, it is temporarily unknown which animal the intermediate host is. Sylvie Briand, director of the Infectious Diseases Hazard Management Department, attended a press conference at the Geneva headquarters and said that after the scientists arrived at the South China Seafood Market in Wuhan, the epidemic-stricken area, a large number of bats were not found, and further research is needed.

▼ Wuhan pneumonia epidemic spread more than 60,000 people diagnosed
Virus researcher "guaranteed by life" denied laboratory leak

There have been doubts about the epidemic related to the laboratories in the Mainland, including the laboratory of the Wuhan Institute of Virology, the Chinese Academy of Sciences, which is 30 kilometers away from the South China Seafood Market and the highest level 4 (P4).

Shi Zhengli, a researcher at the Wuhan Institute of Virology, Chinese Academy of Sciences, said on February 2 that the "guarantee of life" was not leak from the laboratory, referring to "the new coronavirus is nature's punishment to humans' uncivilized living habits," meaning it is related to wild game. Peter Daszak, a long-time partner of Shi Zhengli and a disease ecologist of the American non-profit organization Environmental Ecology and Health Alliance,
At the press conference of the State Council's Joint Defense and Joint Control Mechanism today (15th), Wu Yuanbin, director of the Department of Social Development and Technology of the Ministry of Science and Technology, said, "Guiding Opinions on Strengthening the Biosafety Management of the New Coronavirus High-grade Viral Microbiology Laboratory" is issued, requiring all competent departments to strengthen the management of laboratories, especially viruses, to ensure biosecurity.

\[\text{Wuhan CDC captures and studies bat documentary}\]

[Wuhan Pneumonia] WHO: Viruses or bats infect humans through intermediate hosts

China releases new coronavirus resource library 80% similar to SARS

[Wuhan Pneumonia · Multiple Images] The latest virus exposure looks SARS and MERS

【Wuhan Pneumonia】 Researcher of the Institute of Virology: Using life to
Coronavirus disease

全部評論 (146)

用戶_6454556
吹吹風，試試反應。
2020年2月16日 07:23。回覆，讚好

用戶_9894522
有證據嗎，有，不要亂作。
2020年2月16日 04:48。回覆，讚好

更多評論
originated from the Wuhan Laboratory Ministry of Foreign Affairs: no scientific basis

New Coronary Pneumonia | Experts from Wuhan Virus Institute deny artificial synthesis: humans do not have such wisdom

New Coronary Pneumonia] US media: The embassy in China warned the Wuhan laboratory of safety problems two years ago

Chinese viruses, laboratory leaks, and plague: who can bear the heinous guilt?

【Wuhan Pneumonia】 The postgraduate on the Internet is "Patient Zero" Wuhan Virus Institute: No one is infected

【Wuhan Pneumonia】 WHO: Viruses or bats infect humans through intermediate hosts

【Wuhan Pneumonia】 Get the complete poison chain from snake bite to pneumonia
[Wuhan Pneumonia] New discovery in virus-infected potential intermediary host inland research: pangolin

Instant China 2020-02-06

[Wuhan Pneumonia] Has the questioned Wuhan Virus Research Institute edited the virus manually?

Social News 2020-01-24

[Wuhan Pneumonia] Mainland research refers to snake as virus intermediary host Xu Shuchang: only inference is not true

Chamber 2020-03-10

【Wuhan Pneumonia】Deeply caught in the eye of public opinion storm to deconstruct the development history of Wuhan Institute of Virology, Chinese Academy of Sciences

【Wuhan Pneumonia】Researcher of the Institute of Virology: Using life to guarantee the epidemic has nothing to do with the laboratory

Instant China 2020-02-04

[Wuhan pneumonia] CCTV has reported a new coronavirus expert in
【Wuhan Pneumonia】Wrong bat?
Latest research by mainland scholars: Coronavirus may be the source

Instant China 2020-01-23

【Wuhan Pneumonia】Research by the Chinese Academy of Sciences:
Viruses have a strong ability to infect humans or bats

Featured Instant China 2020-01-22

【New Coronary Pneumonia】The US intelligence community examines whether the virus has accidentally flowed out from Chinese experiments

Instant International 2020-04-18

【Wuhan pneumonia】New virus and bats in Zhoushan most resemble experts: Tracing game is not easy

Featured Social News 2020-01-11

【Wuhan Pneumonia】First exposure expert of coronavirus gene sequencing: 73% identical to SARS gene

Featured Social News 2020-01-11

【Wuhan Pneumonia】South China Agricultural University: Pangolin is a potential intermediate host for the virus

Featured Instant China 2020-02-07

【Wuhan Pneumonia】New coronavirus material and two new viruses discovered...
Notice of Award

Department of Health and Human Services
National Institutes of Health
NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES

Grant Number: 1R01AI110964-01
FAIN: R01AI110964

Principal Investigator(s):
PETER DASZAK, PHD

Project Title: Understanding the Risk of Bat Coronavirus Emergence

Aleksei
President
460 West 34th Street
17th Floor
New York, NY 100012317

Award e-mailed to: [redacted]

Budget Period: 06/01/2014 – 05/31/2015
Project Period: 06/01/2014 – 05/31/2019

Dear Business Official:

The National Institutes of Health hereby awards a grant in the amount of $666,442 (see "Award Calculation" in Section I and "Terms and Conditions" in Section III) to ECOHEALTH ALLIANCE, INC. in support of the above referenced project. This award is pursuant to the authority of 42 USC 241 42 CFR 52 and is subject to the requirements of this statute and regulation and of other referenced, incorporated or attached terms and conditions.

Acceptance of this award including the "Terms and Conditions" is acknowledged by the grantee when funds are drawn down or otherwise obtained from the grant payment system.

Each publication, press release, or other document about research supported by an NIH award must include an acknowledgment of NIH award support and a disclaimer such as "Research reported in this publication was supported by the National Institute Of Allergy And Infectious Diseases of the National Institutes of Health under Award Number R01AI110964. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health." Prior to issuing a press release concerning the outcome of this research, please notify the NIH awarding IC in advance to allow for coordination.

Award recipients must promote objectivity in research by establishing standards that provide a reasonable expectation that the design, conduct and reporting of research funded under NIH awards will be free from bias resulting from an Investigator's Financial Conflict of Interest (FCOI), in accordance with the 2011 revised regulation at 42 CFR Part 50 Subpart F. The Institution shall submit all FCOI reports to the NIH through the eRA Commons FCOI Module. The regulation does not apply to Phase I Small Business Innovative Research (SBIR) and Small Business Technology Transfer (STTR) awards. Consult the NIH website http://grants.nih.gov/grants/policy/coi/ for a link to the regulation and additional important information.

If you have any questions about this award, please contact the individual(s) referenced in Section IV.

Sincerely yours,
Additional information follows
SECTION I – AWARD DATA – 1R01AI110964-01

Award Calculation (U.S. Dollars)

Salaries and Wages $167,708
Fringe Benefits $54,168
Supplies $21,400
Travel Costs $35,918
Other Costs $10,000
Consortium/Contractual Cost $227,663

Federal Direct Costs $516,857
Federal F&A Costs $149,585
Approved Budget $666,442
Federal Share $666,442
TOTAL FEDERAL AWARD AMOUNT $666,442
AMOUNT OF THIS ACTION (FEDERAL SHARE) $666,442

<table>
<thead>
<tr>
<th>YR</th>
<th>THIS AWARD</th>
<th>CUMULATIVE TOTALS</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>$666,442</td>
<td>$666,442</td>
</tr>
<tr>
<td>2</td>
<td>$630,445</td>
<td>$630,445</td>
</tr>
<tr>
<td>3</td>
<td>$611,090</td>
<td>$611,090</td>
</tr>
<tr>
<td>4</td>
<td>$597,112</td>
<td>$597,112</td>
</tr>
<tr>
<td>5</td>
<td>$581,646</td>
<td>$581,646</td>
</tr>
</tbody>
</table>

Recommended future year total cost support, subject to the availability of funds and satisfactory progress of the project.

Fiscal Information:

CFDA Number: 93.855
EIN: 1311728494A1
Document Number: RAI110964A

PMS Account Type: P (Subaccount)
Fiscal Year: 2014


<table>
<thead>
<tr>
<th>IC</th>
<th>CAN</th>
<th>2014</th>
<th>2015</th>
<th>2016</th>
<th>2017</th>
<th>2018</th>
</tr>
</thead>
<tbody>
<tr>
<td>AI</td>
<td>8472350</td>
<td>$666,442</td>
<td>$630,445</td>
<td>$611,090</td>
<td>$597,112</td>
<td>$581,646</td>
</tr>
</tbody>
</table>

Recommended future year total cost support, subject to the availability of funds and satisfactory progress of the project.

NIH Administrative Data:

PCC: M51C / OC: 414A / Released: 05/20/2014
Award Processed: 05/08/2014 01:52:21 PM

SECTION II – PAYMENT/HOTLINE INFORMATION – 1R01AI110964-01

For payment and HHS Office of Inspector General Hotline information, see the NIH Home Page at http://grants.nih.gov/grants/policy/awardconditions.htm

SECTION III – TERMS AND CONDITIONS – 1R01AI110964-01

This award is based on the application submitted to, and as approved by, NIH on the above-titled project and is subject to the terms and conditions incorporated either directly or by reference in the following:

a. The grant program legislation and program regulation cited in this Notice of Award.
b. Conditions on activities and expenditure of funds in other statutory requirements, such as those included in appropriations acts.
c. 45 CFR Part 74 or 45 CFR Part 92 as applicable.
d. The NIH Grants Policy Statement, including addenda in effect as of the beginning date of the budget period.
e. This award notice, INCLUDING THE TERMS AND CONDITIONS CITED BELOW.


An unobligated balance may be carried over into the next budget period without Grants Management Officer prior approval.

This grant is subject to Streamlined Noncompeting Award Procedures (SNAP).

This award is subject to the requirements of 2 CFR Part 25 for institutions to receive a Dun & Bradstreet Universal Numbering System (DUNS) number and maintain an active registration in the Central Contractor Registration. Should a consortium/subaward be issued under this award, a DUNS requirement must be included. See [http://grants.nih.gov/grants/policy/awardconditions.htm](http://grants.nih.gov/grants/policy/awardconditions.htm) for the full NIH award term implementing this requirement and other additional information.

This award has been assigned the Federal Award Identification Number (FAIN) R01AI110964. Recipients must document the assigned FAIN on each consortium/subaward issued under this award.

Based on the project period start date of this project, this award is likely subject to the Transparency Act subaward and executive compensation reporting requirement of 2 CFR Part 170. There are conditions that may exclude this award; see [http://grants.nih.gov/grants/policy/awardconditions.htm](http://grants.nih.gov/grants/policy/awardconditions.htm) for additional award applicability information.

In accordance with P.L. 110-161, compliance with the NIH Public Access Policy is now mandatory. For more information, see NOT-OD-08-033 and the Public Access website: [http://publicaccess.nih.gov/](http://publicaccess.nih.gov/).

Treatment of Program Income:
Additional Costs

SECTION IV – AI Special Terms and Conditions – 1R01AI110964-01

THIS AWARD CONTAINS GRANT SPECIFIC RESTRICTIONS. THESE RESTRICTIONS MAY ONLY BE LIFTED BY A REVISED NOTICE OF AWARD.

RESTRICTION: This award is issued with the knowledge that subjects may be involved within the period of support, but definite plans were not set forth in the application as per 45 CFR 46.118. No human subjects may be involved in any project supported by this award until all requirements for Human Subjects research as identified in the PHS398/SF424 Instructions have been provided to and approved by NIH.

RESTRICTION: The present award is being made without a currently valid certification of IRB approval for this project with the following restriction: Only activities that are clearly severable and independent from activities that involve human subjects may be conducted pending the NIAID's acceptance of the certification of IRB review and approval.

No funds may be drawn down from the payment system and no obligations may be made against Federal funds for any research involving human subjects prior to the NIAID's notification to the grantee that the identified issues have been resolved and this restriction removed.
This award includes funds for subcontract/consortium activity with Wuhan Institute of Virology, CHINA and is budgeted as follows:

<table>
<thead>
<tr>
<th></th>
<th>-Yr 1</th>
<th>-Yr 2</th>
<th>-Yr 3</th>
<th>-Yr 4</th>
<th>-Yr 5</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Direct Costs</td>
<td>$123,699</td>
<td>$128,718</td>
<td>$147,335</td>
<td>$147,335</td>
<td>$147,335</td>
</tr>
<tr>
<td>F&amp;A Costs @ 8% (MTDC)</td>
<td>$9,690</td>
<td>$10,297</td>
<td>$11,787</td>
<td>$11,787</td>
<td>$11,787</td>
</tr>
<tr>
<td>TOTAL COSTS</td>
<td>$133,595</td>
<td>$139,015</td>
<td>$159,122</td>
<td>$159,122</td>
<td>$159,122</td>
</tr>
</tbody>
</table>

Consortiums are to be established and administered as described in the NIH Grants Policy Statement. This written agreement with the consortium must address the negotiated arrangements for meeting the scientific, administrative, financial, and reporting requirements for this grant.

This award includes funds for subcontract/consortium activity with East China Normal University, CHINA and is budgeted as follows:

<table>
<thead>
<tr>
<th></th>
<th>-Yr 1</th>
<th>-Yr 2</th>
<th>-Yr 3</th>
<th>-Yr 4</th>
<th>-Yr 5</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Direct Costs</td>
<td>$87,100</td>
<td>$87,300</td>
<td>$50,108</td>
<td>$39,167</td>
<td>$14,850</td>
</tr>
<tr>
<td>F&amp;A Costs @ 8% (MTDC)</td>
<td>$6,968</td>
<td>$5,364</td>
<td>$4,009</td>
<td>$3,133</td>
<td>$2,404</td>
</tr>
<tr>
<td>TOTAL COSTS</td>
<td>$94,068</td>
<td>$92,664</td>
<td>$54,117</td>
<td>$42,300</td>
<td>$32,454</td>
</tr>
</tbody>
</table>

Consortiums are to be established and administered as described in the NIH Grants Policy Statement. This written agreement with the consortium must address the negotiated arrangements for meeting the scientific, administrative, financial, and reporting requirements for this grant.

Select Agents:
Awardee of a project that at any time involves a restricted experiment with a select agent, is responsible for notifying and receiving prior approval from the NIAID. Please be advised that changes in the use of a Select Agent will be considered a change in scope and require NIH awarding office prior approval. The approval is necessary for new select agent experiments as well as changes in on-going experiments that would require change in the biosafety plan and/or biosafety containment level. An approval to conduct a restricted experiment granted to an individual cannot be assumed an approval to other individuals who conduct the same restricted experiment as defined in the Select Agents Regulation 42 CFR Part 73, Section 13.b (http://www.selectagents.gov/Regulations.html).

Highly Pathogenic Agent:
NIAID defines a Highly Pathogenic Agent as an infectious Agent or Toxin that may warrant a biosafety containment level of BSL3 or higher according to the current edition of the CDC/NIH Biosafety in Microbiological and Biomedical Laboratories (BMBL) (http://www.cdc.gov/OD/ohs/biosfty/bmbl5/bmbl5toc.htm). Research funded under this grant must adhere to the BMBL, including using the BMBL-recommended biosafety containment level at a minimum. If your Institutional Biosafety Committee (or equivalent body) or designated institutional biosafety official recommend a higher biosafety containment level, the highest recommended containment level must be used.

When submitting future Progress Reports indicate at the beginning of the report:

If no research with a Highly Pathogenic Agent or Select Agent has been performed or is planned to be performed under this grant.

If your IBC or equivalent body or official has determined, for example, by conducting a risk assessment, that the work being planned or performed under this grant may be conducted at a biosafety containment level that is lower than BSL3.

If the work involves Select Agents and/or Highly Pathogenic Agents, also address the following points:

Any changes in the use of the Agent(s) or Toxin(s) including its restricted experiments that have resulted in a change in the required biosafety level, and any resultant change in location, if applicable, as determined by your IBC or equivalent body or official.
If work with a new or additional Agent(s)/Toxin(s) is proposed in the upcoming project period, provide:

- A list of the new and/or additional Agent(s) that will be studied;
- A description of the work that will be done with the Agent(s), and whether or not the work is a restricted experiment;
- The title and location for each biocontainment resource/facility, including the name of the organization that operates the facility, and the biocontainment level at which the work will be conducted, with documentation of approval by your IBC or equivalent body or official. It is important to note if the work is being done in a new location.

**STAFF CONTACTS**

The Grants Management Specialist is responsible for the negotiation, award and administration of this project and for interpretation of Grant Administration policies and provisions. The Program Official is responsible for the scientific, programmatic and technical aspects of this project. These individuals work together in overall project administration. Prior approval requests (signed by an Authorized Organizational Representative) should be submitted in writing to the Grants Management Specialist. Requests may be made via e-mail.

**Grants Management Specialist:** Laura A. Pone  
**Email:** [Contact Info]  
**Phone:** [Contact Info]  
**Fax:** 301-493-0597

**Program Official:** Erik J. Stemmy  
**Email:** [Contact Info]  
**Phone:** [Contact Info]

**SPREADSHEET SUMMARY**  
**GRANT NUMBER:** 1R01AI110964-01

**INSTITUTION:** ECOHEALTH ALLIANCE, INC.

<table>
<thead>
<tr>
<th>Budget</th>
<th>Year 1</th>
<th>Year 2</th>
<th>Year 3</th>
<th>Year 4</th>
<th>Year 5</th>
</tr>
</thead>
<tbody>
<tr>
<td>Salaries and Wages</td>
<td>$167,708</td>
<td>$167,708</td>
<td>$167,708</td>
<td>$167,708</td>
<td>$167,708</td>
</tr>
<tr>
<td>Fringe Benefits</td>
<td>$54,168</td>
<td>$54,168</td>
<td>$54,168</td>
<td>$54,168</td>
<td>$54,168</td>
</tr>
<tr>
<td>Supplies</td>
<td>$21,400</td>
<td>$19,250</td>
<td>$7,250</td>
<td>$7,000</td>
<td>$3,500</td>
</tr>
<tr>
<td>Travel Costs</td>
<td>$35,918</td>
<td>$35,918</td>
<td>$35,918</td>
<td>$35,918</td>
<td>$35,918</td>
</tr>
<tr>
<td>Other Costs</td>
<td>$10,000</td>
<td>$13,550</td>
<td>$11,050</td>
<td>$9,800</td>
<td>$9,400</td>
</tr>
<tr>
<td>Consortium/Contractual Cost</td>
<td>$227,863</td>
<td>$211,699</td>
<td>$213,239</td>
<td>$201,422</td>
<td>$191,576</td>
</tr>
<tr>
<td>TOTAL FEDERAL DC</td>
<td>$516,857</td>
<td>$502,293</td>
<td>$489,333</td>
<td>$476,016</td>
<td>$462,270</td>
</tr>
<tr>
<td>TOTAL FEDERAL F&amp;A</td>
<td>$149,565</td>
<td>$128,152</td>
<td>$121,757</td>
<td>$121,096</td>
<td>$119,376</td>
</tr>
<tr>
<td>TOTAL COST</td>
<td>$666,442</td>
<td>$630,445</td>
<td>$611,090</td>
<td>$597,112</td>
<td>$581,646</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Facilities and Administrative Costs</th>
<th>Year 1</th>
<th>Year 2</th>
<th>Year 3</th>
<th>Year 4</th>
<th>Year 5</th>
</tr>
</thead>
<tbody>
<tr>
<td>F&amp;A Cost Rate 1</td>
<td>44.1%</td>
<td>44.1%</td>
<td>44.1%</td>
<td>44.1%</td>
<td>44.1%</td>
</tr>
<tr>
<td>F&amp;A Cost Base 1</td>
<td>$339,194</td>
<td>$290,594</td>
<td>$276,094</td>
<td>$274,594</td>
<td>$270,594</td>
</tr>
<tr>
<td>F&amp;A Costs 1</td>
<td>$149,585</td>
<td>$128,152</td>
<td>$121,757</td>
<td>$121,096</td>
<td>$119,376</td>
</tr>
</tbody>
</table>
Grant Number: 2R01AI110964-06 REVISED
FAIN: R01AI110964

Principal Investigator(s):
PETER DASZAK, PHD

Project Title: Understanding the Risk of Bat Coronavirus Emergence

Dr. Daszak, Peter
PD/PI
480 West 34th Street
Suite 1701
New York, NY 100012320

Award e-mailed to: [Redacted]

Period Of Performance:
Budget Period: 07/24/2019 – 06/30/2020
Project Period: 06/01/2014 – 06/30/2024

Dear Business Official:

The National Institutes of Health hereby revises this award to reflect a decrease in the amount of $71,770 (see “Award Calculation” in Section I and “Terms and Conditions” in Section III) to ECOHEALTH ALLIANCE, INC. in support of the above referenced project. This award is pursuant to the authority of 42 USC 241 42 CFR 52 and is subject to the requirements of this statute and regulation and of other referenced, incorporated or attached terms and conditions.

Acceptance of this award including the “Terms and Conditions” is acknowledged by the grantee when funds are drawn down or otherwise obtained from the grant payment system.

Each publication, press release, or other document about research supported by an NIH award must include an acknowledgment of NIH award support and a disclaimer such as “Research reported in this publication was supported by the National Institute Of Allergy And Infectious Diseases of the National Institutes of Health under Award Number R01AI110964. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.” Prior to issuing a press release concerning the outcome of this research, please notify the NIH awarding IC in advance to allow for coordination.

Award recipients must promote objectivity in research by establishing standards that provide a reasonable expectation that the design, conduct and reporting of research funded under NIH awards will be free from bias resulting from an Investigator's Financial Conflict of Interest (FCOI), in accordance with the 2011 revised regulation at 42 CFR Part 50 Subpart F. The Institution shall submit all FCOI reports to the NIH through the eRA Commons FCOI Module. The regulation does not apply to Phase I Small Business Innovative Research (SBIR) and Small Business Technology Transfer (STTR) awards. Consult the NIH website http://grants.nih.gov/grants/policy/coi/ for a link to the regulation and additional important information.

If you have any questions about this award, please contact the individual(s) referenced in Section IV.

Sincerely yours,
Additional information follows
SECTION I – AWARD DATA – 2R01AI110964-06 REVISED

Award Calculation (U.S. Dollars)
Salaries and Wages $170,123
Fringe Benefits $53,590
Personnel Costs (Subtotal) $223,713
Consultant Services $49,750
Materials & Supplies $20,850
Travel $15,027
Subawards/Consortium/Contractual Costs $229,651

Federal Direct Costs $538,991
Federal F&A Costs $122,989
Approved Budget $661,980
Total Amount of Federal Funds Obligated (Federal Share) $661,980
TOTAL FEDERAL AWARD AMOUNT $661,980

AMOUNT OF THIS ACTION (FEDERAL SHARE) ($-71,770)

<table>
<thead>
<tr>
<th>YR</th>
<th>THIS AWARD</th>
<th>CUMULATIVE TOTALS</th>
</tr>
</thead>
<tbody>
<tr>
<td>6</td>
<td>$661,980</td>
<td>$661,980</td>
</tr>
<tr>
<td>7</td>
<td>$637,980</td>
<td>$637,980</td>
</tr>
<tr>
<td>8</td>
<td>$637,980</td>
<td>$637,980</td>
</tr>
<tr>
<td>9</td>
<td>$637,980</td>
<td>$637,980</td>
</tr>
<tr>
<td>10</td>
<td>$637,980</td>
<td>$637,980</td>
</tr>
</tbody>
</table>

Recommended future year total cost support, subject to the availability of funds and satisfactory
progress of the project.

Fiscal Information:
CFDA Name: Allergy and Infectious Diseases Research
CFDA Number: 93.855
EIN: 1311726494A1
Document Number: RAI110964B
PMS Account Type: P (Subaccount)
Fiscal Year: 2019

IC | CAN | 2019     | 2020     | 2021     | 2022     | 2023     |
---|-----|----------|----------|----------|----------|----------|
AI | 8472364 | $661,980 | $637,980 | $637,980 | $637,980 | $637,980 |

Recommended future year total cost support, subject to the availability of funds and satisfactory
progress of the project.

NIH Administrative Data:
PCC: M51C B / OC: 414B / Released: (b)(6) 08/02/2019
Award Processed: 08/05/2019 12:01:51 AM

SECTION II – PAYMENT/HOTLINE INFORMATION – 2R01AI110964-06 REVISED

For payment and HHS Office of Inspector General Hotline information, see the NIH Home Page

SECTION III – TERMS AND CONDITIONS – 2R01AI110964-06 REVISED

This award is based on the application submitted to, and as approved by, NIH on the above-titled
project and is subject to the terms and conditions incorporated either directly or by reference in
the following:

a. The grant program legislation and program regulation cited in this Notice of Award.
b. Conditions on activities and expenditure of funds in other statutory requirements, such as
those included in appropriations acts.
Research and Development (R&D): All awards issued by the National Institutes of Health (NIH) meet the definition of "Research and Development" at 45 CFR Part § 75.2. As such, auditees should identify NIH awards as part of the R&D cluster on the Schedule of Expenditures of Federal Awards (SEFA). The auditor should test NIH awards for compliance as instructed in Part V, Clusters of Programs. NIH recognizes that some awards may have another classification for purposes of indirect costs. The auditor is not required to report the disconnect (i.e., the award is classified as R&D for Federal Audit Requirement purposes but non-research for indirect cost rate purposes), unless the auditee is charging indirect costs at a rate other than the rate(s) specified in the award document(s).

An unobligated balance may be carried over into the next budget period without Grants Management Officer prior approval.

This grant is subject to Streamlined Noncompeting Award Procedures (SNAP).

This award is subject to the requirements of 2 CFR Part 25 for institutions to receive a Dun & Bradstreet Universal Numbering System (DUNS) number and maintain an active registration in the System for Award Management (SAM). Should a consortium/subaward be issued under this award, a DUNS requirement must be included. See http://grants.nih.gov/grants/policy/awardconditions.htm for the full NIH award term implementing this requirement and other additional information.

This award has been assigned the Federal Award Identification Number (FAIN) R01AI110964. Recipients must document the assigned FAIN on each consortium/subaward issued under this award.

Based on the project period start date of this project, this award is likely subject to the Transparency Act subaward and executive compensation reporting requirement of 2 CFR Part 170. There are conditions that may exclude this award; see http://grants.nih.gov/grants/policy/awardconditions.htm for additional award applicability information.

In accordance with P.L. 110-161, compliance with the NIH Public Access Policy is now mandatory. For more information, see NOT-OD-08-033 and the Public Access website: http://publicaccess.nih.gov.

In accordance with the regulatory requirements provided at 45 CFR 75.113 and Appendix XII to 45 CFR Part 75, recipients that have currently active Federal grants, cooperative agreements, and procurement contracts with cumulative total value greater than $10,000,000 must report and maintain information in the System for Award Management (SAM) about civil, criminal, and administrative proceedings in connection with the award or performance of a Federal award that reached final disposition within the most recent five-year period. The recipient must also make semiannual disclosures regarding such proceedings. Proceedings information will be made publicly available in the designated integrity and performance system (currently the Federal Awardee Performance and Integrity Information System (FAPIIS)). Full reporting requirements and procedures are found in Appendix XII to 45 CFR Part 75. This term does not apply to NIH fellowships.
SECTION IV - All Special Terms and Conditions – 2R01AI110964-06 REVISED

Clinical Trial Indicator: No
This award does not support any NIH-defined Clinical Trials. See the NIH Grants Policy Statement Section 1.2 for NIH definition of Clinical Trial.

REVISED AWARD: This award is revised to adjust the budget in accordance with the letter from Aleksei Chnrara/ECOHealth Alliance.

Supersedes previous Notice of Award dated 07/24/2019.

This Notice of Award (NoA) includes funds for activity with The University of North Carolina at Chapel Hill in the amount of $77,750 ($50,000 direct costs + $27,750 F&A costs).

This Notice of Award (NoA) includes funds for activity with Wuhan Institute of Virology in the amount of $76,301 ($70,649 direct costs + $5,652 F&A costs).

This Notice of Award (NoA) includes funds for activity with Institute of Pathogen Biology in the amount of $75,600 ($70,000 direct costs + $5,600 F&A costs).

The Research Performance Progress Report (RPPR), Section G.9 (Foreign component), includes reporting requirements for all research performed outside of the United States. Research conducted at the following site(s) must be reported in your RPPR:

Wuhan Institute of Virology, CHINA
Institute of Pathogen Biology, CHINA
East China Normal University, CHINA
Duke-NUS Medical School, SINGAPORE

This award reflects current Federal policies regarding Facilities & Administrative (F&A) Costs for foreign grantees including foreign sub-awardees, and domestic awards with foreign sub-awardees. Please see: Chapter 16 Grants to Foreign Organizations, International Organizations, and Domestic Grants with Foreign Components, Section 16.8 “Allowable and Unallowable Cost” of the NIH Grants Policy.

This award may include collaborations with and/or between foreign organizations. Please be advised that short term travel visa expenses are an allowable expense on this grant, if justified as critical and necessary for the conduct of the project.

The budget period anniversary start date for future year(s) will be July 1.

Dissemination of study data will be in accord with the Recipient’s accepted genomic data sharing plan as stated in the page(s) 203 of the application. Failure to adhere to the sharing plan as mutually agreed upon by the Recipient and the NIAID may result in Enforcement Actions as described in the NIH Grants Policy Statement.

This award is subject to the Clinical Terms of Award referenced in the NIH Guide for Grants and Contracts, July 8, 2002, NOT AI-02-032. These terms and conditions are hereby incorporated by
reference, and can be accessed via the following World Wide Web address: https://www.niaid.nih.gov/grants-contracts/nniaid-clinical-terms-award All submissions required by the NIAID Clinical Terms of Award must be forwarded electronically or by mail to the responsible NIAID Program Official identified on this Notice of Award.

***************
Awardees who conduct research involving Select Agents (see 42 CFR 73 for the Select Agent list; and 7 CFR 331 and 9 CFR 121 for the relevant animal and plant pathogens at http://www.selectagents.gov/Regulations.html) must complete registration with CDC (or APHIS, depending on the agent) before using NIH funds. No funds can be used for research involving Select Agents if the final registration certificate is denied.

Prior to conducting a restricted experiment with a Select Agent or Toxin, awardees must notify the NIAID and must request and receive approval from CDC or APHIS.

***************
Select Agents:
Awardee of a project that at any time involves a restricted experiment with a select agent, is responsible for notifying and receiving prior approval from the NIAID. Please be advised that changes in the use of a Select Agent will be considered a change in scope and require NIH awarding office prior approval. The approval is necessary for new select agent experiments as well as changes in on-going experiments that would require change in the biosafety plan and/or biosafety containment level. An approval to conduct a restricted experiment granted to an individual cannot be assumed an approval to other individuals who conduct the same restricted experiment as defined in the Select Agents Regulation 42 CFR Part 73, Section 13.b (http://www.selectagents.gov/Regulations.html).

Highly Pathogenic Agent:
NIAID defines a Highly Pathogenic Agent as an infectious Agent or Toxin that may warrant a biosafety containment level of BSL3 or higher according to the current edition of the CDC/NIH Biosafety in Microbiological and Biomedical Laboratories (BMBL) (http://www.cdc.gov/ODohs/biosafety/bmbl5/bmbl5toc.htm). Research funded under this grant must adhere to the BMBL, including using the BMBL-recommended biosafety containment level at a minimum. If your Institutional Biosafety Committee (or equivalent body) or designated institutional biosafety official recommend a higher biosafety containment level, the highest recommended containment level must be used. When submitting future Progress Reports indicate at the beginning of the report:

If no research with a Highly Pathogenic Agent or Select Agent has been performed or is planned to be performed under this grant.

If your IBC or equivalent body or official has determined, for example, by conducting a risk assessment, that the work being planned or performed under this grant may be conducted at a biosafety containment safety level that is lower than BSL3.

If the work involves Select Agents and/or Highly Pathogenic Agents, also address the following points:

Any changes in the use of the Agent(s) or Toxin(s) including its restricted experiments that have resulted in a change in the required biosafety containment level, and any resultant change in location, if applicable, as determined by your IBC or equivalent body or official.

If work with a new or additional Agent(s)/Toxin(s) is proposed in the upcoming project period, provide:

- A list of the new and/or additional Agent(s) that will be studied;
- A description of the work that will be done with the Agent(s), and whether or not the work is a restricted experiment;
- The title and location for each biosafety containment resource/facility, including the name of the organization that operates the facility, and the biosafety containment level at which the work will be conducted, with documentation of approval by your IBC or equivalent body or official. It is important to note if the work is being done in a new location.
STAFF CONTACTS

The Grants Management Specialist is responsible for the negotiation, award and administration of this project and for interpretation of Grants Administration policies and provisions. The Program Official is responsible for the scientific, programmatic and technical aspects of this project. These individuals work together in overall project administration. Prior approval requests (signed by an Authorized Organizational Representative) should be submitted in writing to the Grants Management Specialist. Requests may be made via e-mail.

Grants Management Specialist: Tsehay Girma
Email: (b)(6) Phone: (b)(6) Fax: 301-493-0597

Program Official: Erik J. Stemmy
Email: (b)(6) Phone: (b)(6)

SPREADSHEET SUMMARY

GRANT NUMBER: 2R01AI110964-06 REVISED

INSTITUTION: ECOHEALTH ALLIANCE, INC.

<table>
<thead>
<tr>
<th>Budget</th>
<th>Year 6</th>
<th>Year 7</th>
<th>Year 8</th>
<th>Year 9</th>
<th>Year 10</th>
</tr>
</thead>
<tbody>
<tr>
<td>Salaries and Wages</td>
<td>$170,123</td>
<td>$170,123</td>
<td>$170,123</td>
<td>$170,123</td>
<td>$170,123</td>
</tr>
<tr>
<td>Fringe Benefits</td>
<td>$53,590</td>
<td>$53,590</td>
<td>$53,590</td>
<td>$53,590</td>
<td>$53,590</td>
</tr>
<tr>
<td>Personnel Costs (Subtotal)</td>
<td>$223,713</td>
<td>$223,713</td>
<td>$223,713</td>
<td>$223,713</td>
<td>$223,713</td>
</tr>
<tr>
<td>Consultant Services</td>
<td>$49,750</td>
<td>$49,750</td>
<td>$49,750</td>
<td>$49,750</td>
<td>$49,750</td>
</tr>
<tr>
<td>Materials &amp; Supplies</td>
<td>$20,850</td>
<td>$14,850</td>
<td>$14,850</td>
<td>$14,850</td>
<td>$14,850</td>
</tr>
<tr>
<td>Travel</td>
<td>$15,027</td>
<td>$15,027</td>
<td>$15,027</td>
<td>$15,027</td>
<td>$15,027</td>
</tr>
<tr>
<td>Subawards/Consortium/Contractual Costs</td>
<td>$229,651</td>
<td>$229,651</td>
<td>$229,651</td>
<td>$229,651</td>
<td>$229,651</td>
</tr>
<tr>
<td>Publication Costs</td>
<td>$6,000</td>
<td>$6,000</td>
<td>$6,000</td>
<td>$6,000</td>
<td>$6,000</td>
</tr>
<tr>
<td>TOTAL FEDERAL DC</td>
<td>$538,991</td>
<td>$538,991</td>
<td>$538,991</td>
<td>$538,991</td>
<td>$538,991</td>
</tr>
<tr>
<td>TOTAL FEDERAL F&amp;A</td>
<td>$122,989</td>
<td>$98,989</td>
<td>$98,989</td>
<td>$98,989</td>
<td>$98,989</td>
</tr>
<tr>
<td>TOTAL COST</td>
<td>$661,980</td>
<td>$637,980</td>
<td>$637,980</td>
<td>$637,980</td>
<td>$637,980</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Facilities and Administrative Costs</th>
<th>Year 6</th>
<th>Year 7</th>
<th>Year 8</th>
<th>Year 9</th>
<th>Year 10</th>
</tr>
</thead>
<tbody>
<tr>
<td>F&amp;A Cost Rate 1</td>
<td>32%</td>
<td>32%</td>
<td>32%</td>
<td>32%</td>
<td>32%</td>
</tr>
<tr>
<td>F&amp;A Costs 1</td>
<td>$122,989</td>
<td>$98,989</td>
<td>$98,989</td>
<td>$98,989</td>
<td>$98,989</td>
</tr>
</tbody>
</table>
May 22, 2020

Via Email, Certified Mail, & FedEx

Michael S. Lauer, MD
NIH Deputy Director for Extramural Research
National Institutes of Health
National Institute of Allergy and Infectious Diseases
1 Center Drive, Building 1, Room 144
Bethesda, Maryland 20892

Re: Termination of NIH Grant 2R01 AI 110964-6

Dear Dr. Lauer:

This firm represents EcoHealth Alliance, Inc. (“EcoHealth Alliance”) with regard to the post-award decision by the National Institute of Allergy and Infectious Diseases (“NIAID”), an Institute within the National Institute of Health (“NIH”), under the Department of Health and Human Services (“HHS”), to terminate the project Understanding the Risk of Bat Coronavirus Emergence, funded under grant R01 AI 110964, on April 24, 2020 (the “Termination”).

This letter, pursuant to NIH Grants Policy Statement Section 8.7 and 42 CFR 50, Subpart D, constitutes EcoHealth Alliance’s first-level appeal of the Termination, which was “for convenience.” As set forth in more detail below, the Termination is not authorized under the NIH Grants Policy Statement, arbitrary and capricious and an indefensible attack on public health and welfare given that it undermines a pivotal 10-year research project involving the origins, spread and threat of emerging bat coronaviruses during the peak of an unprecedented worldwide coronavirus pandemic. Accordingly, EcoHealth Alliance hereby demands that grant 2R01 AI 110964-6 be reinstated immediately.

BACKGROUND

A. EcoHealth Alliance

EcoHealth Alliance is a prominent New York-based nonprofit institution dedicated to protecting the health of people, animals, and the environment from emerging zoonotic diseases. For more than a decade, EcoHealth Alliance has been conducting cutting edge scientific research to identify hundreds of new coronaviruses (“CoVs”) in bats and to study the capacity of these viruses to infect human cells. The purpose of this research is to identify high risk populations so international actors can leverage their resources to address potential pandemics. In cooperation with a global network of over seventy partners, including academic institutions, intergovernmental
and governmental agencies, infectious disease surveillance laboratories, and other international and national organizations in over thirty countries, EcoHealth Alliance’s work has led to numerous scientific papers published in high impact journals. These publications have been critical in raising awareness of the threat that CoVs pose to global health, the global economy, and U.S. National Security.

EcoHealth Alliance has a long history of successful cooperation with NIH including multiple Research Project Grant R01 awards. In particular, Peter Daszak, EcoHealth Alliance’s President and Chief Scientist, has been the Principal Investigator on five multidisciplinary R01s. All of these projects used modeling, epidemiology, laboratory, and field science to test hypotheses on the emergence of wildlife-origin viral zoonoses, including SARS-CoV, the Nipah and Hendra viruses, Avian influenza, and other bat-origin viruses. EcoHealth Alliance, a 501(c)(3) organization, is unique in that it goes one step further by leveraging its research goals to create an alliance of international collaborators that can advocate for real-world changes to protect high risk populations.

Notably, in collaboration with virologists in China, EcoHealth Alliance isolated and characterized SARSr-CoVs from bats that use the same human host cell receptor (ACE2) as SARS-CoV. This work provided critical reagents and resources that have advanced scientific understanding of virus-host binding and contributed to vaccine development. For example, the genetic sequences of the bat viruses that EcoHealth Alliance discovered under its NIH research funding, which were published online (Genbank & GISAID), have been used to test the effectiveness of the drug Remdesivir against not only SARS-CoV, but also MERS, and other potentially zoonotic or pre-pandemic bat CoVs. Significantly, this type of testing can be performed without the need for viral cultures or shipping viruses internationally.

B. **NIH Awards And Extends EcoHealth Alliance Research Grant R01 AI 110964**

In 2014, NIH issued EcoHealth Alliance a five-year research award for the project *Understanding the Risk of Bat Coronavirus Emergence*, funded under grant R01 AI 110964 (the “Project”). EcoHealth Alliance received additional awards for the Project each year between 2015 and 2018. Between 2015 and 2019, the Project resulted in the publication of more than twenty papers.

In 2019, EcoHealth Alliance submitted a renewal application to NIH through NIAID to extend the Project period for an additional five years. Upon filing of its renewal application, the Project was ranked as an “extremely high priority” (in the top 3%) by NIAID during its external review process. In light of its success and the importance of EcoHealth Alliance’s work, on July 24, 2019, NIH reauthorized grant R01 AI 110964 and increased EcoHealth Alliance’s funding. EcoHealth Alliance was issued a notice of award in the amount of $733,750.00 (the “2019 Award”). The notice of award also extended the Project period for an additional five years to 2024. A copy of the notice of award is attached hereto as Exhibit A.

C. **EcoHealth Alliance Agrees Not To Fund The Wuhan Institute Of Virology**

During the pendency of the Project, in December of 2019, China reported a cluster of cases of pneumonia in Wuhan, Hubei Province. It was later determined that the cause of this pneumonia
was a novel CoV, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), causing coronavirus disease (COVID-19). Thereafter, SARS-CoV-2 spread to nearly every country throughout the world. In response, EcoHealth Alliance has prioritized its efforts in conducting research that will be integral to developing an effective strategy to combat SARS-CoV-2.

On April 19, 2020, Michael S. Lauer, MD, NIH Deputy Director for Extramural Research, sent a letter to EcoHealth Alliance on behalf of NIH regarding a laboratory in China, the Wuhan Institute of Virology (“WIV”). WIV was a prior sub-recipient of a small portion of the R01 AI 110964 grant funds. The letter stated that, given allegations that COVID-19 “was precipitated by the release from WIV of the coronavirus responsible for COVID-19”, NIH was pursuing suspension of WIV from participating in Federal programs. However, Mr. Lauer assured EcoHealth Alliance that “[t]his suspension of the sub-recipient does not affect the remainder of [EcoHealth Alliance’s] grant assuming that no grant funds are provided to WIV following receipt of this email during the period of suspension.” A copy of the letter is attached hereto as Exhibit B.

On April 21, 2020, Dr. Daszak of EcoHealth Alliance responded by email to Dr. Lauer stating that he could “categorically state that no funds from [sic] 2R01 AI 110964-6 have been sent to Wuhan Institute of Virology, nor has any contract been signed.” Dr. Daszak further represented that EcoHealth Alliance would comply with all NIAID requirements. Dr. Lauer acknowledged (1) that no monies from grant 2R01 AI 110964-6 had gone to WIV and no contract between EcoHealth Alliance and WIV had been signed and (2) EcoHealth Alliance’s agreement that it would not provide any funds to WIV until and unless directed otherwise by NIH. A copy of the email correspondence between NIH and EcoHealth Alliance is attached hereto as Exhibit C.

D. NIH Abruptly Terminates Research Grant 2R01 AI 110964-6 “For Convenience”

Notwithstanding NIH’s representation that suspension of WIV would not affect the remainder of EcoHealth Alliance’s 2019 Award, on April 24, 2020, NIH notified EcoHealth Alliance by letter that, effective immediately, the 2019 Award had been terminated by NIAID. The stated grounds for the Termination were: (1) convenience; (2) NIH’s discretion not to award a grant, or to award a grant at a particular funding level; and (3) NIH’s belief that the Project outcomes did not align with the program goals and agency priorities. A copy of the Termination is attached hereto as Exhibit D.

ARGUMENT

A. NIH Research Grants Are Not Subject To Termination For Convenience

“Termination for convenience” refers to the exercise of the government’s right to bring to an end the performance of all or part of the work provided for under a contract prior to the expiration of the contract “when it is in the Government’s interest” to do so. Federal agencies typically incorporate clauses in their procurement contracts which give them the right to terminate for convenience. Here, there is no clause in the terms and conditions applicable to the 2019 Award, or in the NIH Grants Policy Statement, that permits NIAID or NIH to issue a post-award decision to terminate a NIH research grant award “for convenience.”
Moreover, the unprecedented assertion by NIH that active research grants can be terminated “for convenience” during the subject budget period renders Section 8.5.2 of the NIH Grants Policy Statement meaningless. See, e.g., *Li v. Eddy*, 324 F.3d 1109, 1110 (9th Cir. 2003) (rejecting suggested statutory interpretation on the grounds that the interpretation ran squarely against the canon of construction that courts interpret statutes so as not to render any section meaningless). Section 8.5.2 of the NIH Grants Policy Statement governs, *inter alia*, modification or termination of an award for misconduct. If NIH grants were terminable for convenience, NIH could always choose to terminate for convenience to avoid (1) the “for cause” restriction on grant terminations and (2) the labor intensive task of enforcing compliance through disallowing costs, withholding further awards, or wholly suspending the grant, pending corrective action.

B. NIH’s Discretion Not To Award A Grant, Or To Award a Grant At A Particular Funding Level, Does Not Authorize A Post-Award Decision To Terminate

NIH’s discretion regarding the “decision not to award a grant, or to award a grant at a particular funding level” does not give NIH the authority to issue a post-award decision terminating a duly awarded grant during the budget period. This purported discretion, which is based on language in the last paragraph of NIH Grants Policy Statement Section 2.4.4, entitled *Disposition of Applications*, concerns NIH’s authority to reject incomplete or otherwise undesirable grant applications in the first instance only. The provisions of Section 2, generally, have no bearing on post-award decisions affecting duly approved grants for which specified funds have already been allocated. As the 2019 Grant in the amount of $733,750.00 was awarded to EcoHealth Alliance on July 24, 2019, NIH’s authority to deny initial grant applications does not allow NIH to terminate the 2019 Grant.

C. The Research Goals Of EcoHealth Alliance And NIAID Are Virtually Identical

NIH’s contention that the Project’s outcomes do not align with the agency’s priorities is demonstrably false. First, the Project was ranked as “extremely high priority” on external review by NIAID less than nine months ago, before the discovery of SARS-CoV-2. Since this discovery, NIH has promulgated new grants seeking applicants to conduct research on the same issues covered by the Project and the 2019 Award.

In addition, there is substantial overlap between the four strategic research priorities on page 1 of NIAID’s Strategic Plan for COVID-19 Research, published April 22, 2020, and the three Specific Aims of the Project. Both NIAID and EcoHealth Alliance seek to: (1) improve fundamental knowledge of SARS-Cov-2; (2) develop methods to assess the rate of infection and disease incidence; (3) contribute to the development of an effective vaccine; and (4) increase public health preparedness. Copies of the Project’s Specific Aims and the NIAID Strategic Plan’s four strategic research priorities for COVID-19 research are attached hereto as Exhibit E.

D. There Is No Rational Basis To Terminate The 2019 Award For Cause

The grounds and procedures for suspension and termination of awards are specified in NIH Grants Policy Statement Section 8.5.2 and 45 CFR Parts 75.371 through 75.373. Notably, Section
8.5.2 provides, *inter alia*, that NIH will generally suspend (rather than immediately terminate) a grant and allow the recipient an opportunity to take appropriate corrective action before NIH makes a termination decision. Through this lens, 45 CFR 75.372 provides that NIH may terminate a Federal award, in whole or in part, if: (1) the non-Federal entity fails to comply with the terms and conditions of the award; (2) for cause; (3) by the HHS awarding agency or pass-through entity with the consent of the non-Federal entity; or (4) by the non-Federal entity upon written notice to the HHS awarding agency setting forth the reasons for such termination, and other information. None of the foregoing predicate conditions exist here.

As of the date of the Termination, EcoHealth Alliance had not received any notice from NIH, NIAID, or HHS that it either failed to comply with any of the terms or conditions of the 2019 Award, or committed any misconduct in connection with the award. To the contrary, in email correspondence following EcoHealth Alliance’s representation that it had not and would not give any funds from the 2019 Award to WIV, Aleksi Chmura, EcoHealth Alliance’s Chief of Staff, memorialized the mutual agreement between NIH and EcoHealth Alliance that EcoHealth Alliance was in compliance with all requests. (Ex. C, #8). To be clear, EcoHealth Alliance clearly and unequivocally stated that it had not and will not distribute any funds from the 2019 Award to WIV.

In sum, there is no statutory, regulatory, or contractual basis for NIAID’s termination of the Project, *Understanding the Risk of Bat Coronavirus Emergence*, funded under grant 2R01 AI 110964-6. However, please note that this letter is not intended to provide an exhaustive list of all possible grounds for reversal of the Termination and may not reflect all arguments and claims that EcoHealth Alliance will assert in the event that a formal second-level appeal of the Termination is required.

Should you wish to present evidence in an effort to refute any of the factual assertions made in this letter and/or to engage in good faith negotiations regarding appropriate terms and conditions for the resumption of funding for grant 2R01 AI 110964-6, we are prepared to review such evidence and to participate in such negotiations.

We await your response to this letter.

Very truly yours,

Andrew R. Krinsky

cc: (by email)

Dr. Erik Stemmy
Ms. Emily Linde

5
Exhibit A
Grant Number: 2R01AI110964-06
FAIN: R01AI110964

Principal Investigator(s):
PETER DASZAK, PHD

Project Title: Understanding the Risk of Bat Coronavirus Emergence

Dr. Daszak, Peter
PD/PI
480 West 34th Street
Suite 1701
New York, NY 100012320

Award e-mailed to: (b)(6)

Period Of Performance:
Budget Period: 07/24/2019 – 06/30/2020
Project Period: 06/01/2014 – 06/30/2024

Dear Business Official:

The National Institutes of Health hereby awards a grant in the amount of $733,750 (see “Award Calculation” in Section I and “Terms and Conditions” in Section III) to ECOHEALTH ALLIANCE, INC. in support of the above referenced project. This award is pursuant to the authority of 42 USC 241 42 CFR 52 and is subject to the requirements of this statute and regulation and of other referenced, incorporated or attached terms and conditions.

Acceptance of this award including the “Terms and Conditions” is acknowledged by the grantee when funds are drawn down or otherwise obtained from the grant payment system.

Each publication, press release, or other document about research supported by an NIH award must include an acknowledgment of NIH award support and a disclaimer such as “Research reported in this publication was supported by the National Institute Of Allergy And Infectious Diseases of the National Institutes of Health under Award Number R01AI110964. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.” Prior to issuing a press release concerning the outcome of this research, please notify the NIH awarding IC in advance to allow for coordination.

Award recipients must promote objectivity in research by establishing standards that provide a reasonable expectation that the design, conduct and reporting of research funded under NIH awards will be free from bias resulting from an Investigator’s Financial Conflict of Interest (FCOI), in accordance with the 2011 revised regulation at 42 CFR Part 50 Subpart F. The Institution shall submit all FCOI reports to the NIH through the eRA Commons FCOI Module. The regulation does not apply to Phase I Small Business Innovative Research (SBIR) and Small Business Technology Transfer (STTR) awards. Consult the NIH website http://grants.nih.gov/grants/policy/coi/ for a link to the regulation and additional important information.

If you have any questions about this award, please contact the individual(s) referenced in Section IV.

Sincerely yours,
Tseday G Girma
Grants Management Officer
NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES

Additional information follows
Approved Budget: $733,750
Total Amount of Federal Funds Obligated (Federal Share): $733,750
TOTAL FEDERAL AWARD AMOUNT: $733,750
AMOUNT OF THIS ACTION (FEDERAL SHARE): $733,750

<table>
<thead>
<tr>
<th>YR</th>
<th>THIS AWARD</th>
<th>CUMULATIVE TOTALS</th>
</tr>
</thead>
<tbody>
<tr>
<td>6</td>
<td>$733,750</td>
<td>$733,750</td>
</tr>
<tr>
<td>7</td>
<td>$709,750</td>
<td>$709,750</td>
</tr>
<tr>
<td>8</td>
<td>$709,750</td>
<td>$709,750</td>
</tr>
<tr>
<td>9</td>
<td>$709,750</td>
<td>$709,750</td>
</tr>
<tr>
<td>10</td>
<td>$709,750</td>
<td>$709,750</td>
</tr>
</tbody>
</table>

Recommended future year total cost support, subject to the availability of funds and satisfactory progress of the project.

Fiscal Information:
- CFDA Name: Allergy and Infectious Diseases Research
- CFDA Number: 93.855
- EIN: 1311728494A1
- Document Number: RAI110964B
- PMS Account Type: P (Subaccount)
- Fiscal Year: 2019

<table>
<thead>
<tr>
<th>IC</th>
<th>CAN</th>
<th>2019</th>
<th>2020</th>
<th>2021</th>
<th>2022</th>
<th>2023</th>
</tr>
</thead>
<tbody>
<tr>
<td>AI</td>
<td>8472364</td>
<td>$733,750</td>
<td>$709,750</td>
<td>$709,750</td>
<td>$709,750</td>
<td>$709,750</td>
</tr>
</tbody>
</table>

Recommended future year total cost support, subject to the availability of funds and satisfactory progress of the project.

NIH Administrative Data:
- PCC: M51C B / OC: 414B / Released: (b)(6) 07/18/2019
- Award Processed: 07/24/2019 12:03:26 AM

SECTION II – PAYMENT/HOTLINE INFORMATION – 2R01AI110964-06

For payment and HHS Office of Inspector General Hotline information, see the NIH Home Page at http://grants.nih.gov/grants/policy/awardconditions.htm

SECTION III – TERMS AND CONDITIONS – 2R01AI110964-06

This award is based on the application submitted to, and as approved by, NIH on the above-titled project and is subject to the terms and conditions incorporated either directly or by reference in the following:

a. The grant program legislation and program regulation cited in this Notice of Award.
b. Conditions on activities and expenditure of funds in other statutory requirements, such as those included in appropriations acts.
c. 45 CFR Part 75.

d. National Policy Requirements and all other requirements described in the NIH Grants Policy Statement, including addenda in effect as of the beginning date of the budget period.

e. Federal Award Performance Goals: As required by the periodic report in the RPPR or in the final progress report when applicable.

f. This award notice, INCLUDING THE TERMS AND CONDITIONS CITED BELOW.

(See NIH Home Page at http://grants.nih.gov/grants/policy/awardconditions.htm for certain references cited above.)

Research and Development (R&D): All awards issued by the National Institutes of Health (NIH) meet the definition of "Research and Development" at 45 CFR Part§ 75.2. As such, auditees should identify NIH awards as part of the R&D cluster on the Schedule of Expenditures of Federal Awards (SEFA). The auditor should test NIH awards for compliance as instructed in Part V, Clusters of Programs. NIH recognizes that some awards may have another classification for purposes of indirect costs. The auditor is not required to report the disconnect (i.e., the award is classified as R&D for Federal Audit Requirement purposes but non-research for indirect cost rate purposes), unless the auditee is charging indirect costs at a rate other than the rate(s) specified in the award document(s).

An unobligated balance may be carried over into the next budget period without Grants Management Officer prior approval.

This grant is subject to Streamlined Noncompeting Award Procedures (SNAP).

This award is subject to the requirements of 2 CFR Part 25 for institutions to receive a Dun & Bradstreet Universal Numbering System (DUNS) number and maintain an active registration in the System for Award Management (SAM). Should a consortium/subaward be issued under this award, a DUNS requirement must be included. See http://grants.nih.gov/grants/policy/awardconditions.htm for the full NIH award term implementing this requirement and other additional information.

This award has been assigned the Federal Award Identification Number (FAIN) R01AI110964. Recipients must document the assigned FAIN on each consortium/subaward issued under this award.

Based on the project period start date of this project, this award is likely subject to the Transparency Act subaward and executive compensation reporting requirement of 2 CFR Part 170. There are conditions that may exclude this award; see http://grants.nih.gov/grants/policy/awardconditions.htm for additional award applicability information.

In accordance with P.L. 110-161, compliance with the NIH Public Access Policy is now mandatory. For more information, see NOT-OD-08-033 and the Public Access website: http://publicaccess.nih.gov.

In accordance with the regulatory requirements provided at 45 CFR 75.113 and Appendix XII to 45 CFR Part 75, recipients that have currently active Federal grants, cooperative agreements, and procurement contracts with cumulative total value greater than $10,000,000 must report and maintain information in the System for Award Management (SAM) about civil, criminal, and administrative proceedings in connection with the award or performance of a Federal award that reached final disposition within the most recent five-year period. The recipient must also make semiannual disclosures regarding such proceedings. Proceedings information will be made publicly available in the designated integrity and performance system (currently the Federal Awardee Performance and Integrity Information System (FAPIIS)). Full reporting requirements and procedures are found in Appendix XII to 45 CFR Part 75. This term does not apply to NIH fellowships.
Clinical Trial Indicator: No
This award does not support any NIH-defined Clinical Trials. See the NIH Grants Policy Statement Section 1.2 for NIH definition of Clinical Trial.

The Research Performance Progress Report (RPPR), Section G.9 (Foreign component), includes reporting requirements for all research performed outside of the United States. Research conducted at the following site(s) must be reported in your RPPR:

- Site 1
- Site 2
- Site 3

This award reflects current Federal policies regarding Facilities & Administrative (F&A) Costs for foreign grantees including foreign sub-recipients, and domestic awards with foreign sub-recipients. Please see: Chapter 16 Grants to Foreign Organizations, International Organizations, and Domestic Grants with Foreign Components, Section 16.6 “Allowable and Unallowable Cost” of the NIH Grants Policy.

This award may include collaborations with and/or between foreign organizations. Please be advised that short term travel visa expenses are an allowable expense on this grant, if justified as critical and necessary for the conduct of the project.

The budget period anniversary start date for future year(s) will be July 1.

Dissemination of study data will be in accord with the Recipient’s accepted genomic data sharing plan as stated in the page(s) 203 of the application. Failure to adhere to the sharing plan as mutually agreed upon by the Recipient and the NIAID may result in Enforcement Actions as described in the NIH Grants Policy Statement.

This award is subject to the Clinical Terms of Award referenced in the NIH Guide for Grants and Contracts, July 8, 2002, NOT AI-02-032. These terms and conditions are hereby incorporated by reference, and can be accessed via the following World Wide Web address: https://www.niaid.nih.gov/grants-contracts/nniaid-clinical-terms-award All submissions required by the NIAID Clinical Terms of Award must be forwarded electronically or by mail to the responsible NIAID Program Official identified on this Notice of Award.
Awardees who conduct research involving Select Agents (see 42 CFR 73 for the Select Agent list; and 7 CFR 331 and 9 CFR 121 for the relevant animal and plant pathogens at [http://www.selectagents.gov/Regulations.html](http://www.selectagents.gov/Regulations.html)) must complete registration with CDC (or APHIS, depending on the agent) before using NIH funds. No funds can be used for research involving Select Agents if the final registration certificate is denied.

Prior to conducting a restricted experiment with a Select Agent or Toxin, awardees must notify the NIAID and must request and receive approval from CDC or APHIS.

------------------------

Select Agents:
Awardee of a project that at any time involves a restricted experiment with a select agent, is responsible for notifying and receiving prior approval from the NIAID. Please be advised that changes in the use of a Select Agent will be considered a change in scope and require NIH awarding office prior approval. The approval is necessary for new select agent experiments as well as changes in on-going experiments that would require change in the biosafety plan and/or biosafety containment level. An approval to conduct a restricted experiment granted to an individual cannot be assumed an approval to other individuals who conduct the same restricted experiment as defined in the Select Agents Regulation 42 CFR Part 73, Section 13.b ([http://www.selectagents.gov/Regulations.html](http://www.selectagents.gov/Regulations.html)).

Highly Pathogenic Agent:
NIAID defines a Highly Pathogenic Agent as an infectious Agent or Toxin that may warrant a biosafety containment level of BSL3 or higher according to the current edition of the CDC/NIAID Biosafety in Microbiological and Biomedical Laboratories (BMBL) ([http://www.cdc.gov/OD/ohs/biosfty/bmbl5/bmbl5toc.htm](http://www.cdc.gov/OD/ohs/biosfty/bmbl5/bmbl5toc.htm)). Research funded under this grant must adhere to the BMBL, including using the BMBL-recommended biosafety containment level at a minimum. If your Institutional Biosafety Committee (or equivalent body) or designated institutional biosafety official recommend a higher biosafety level, the highest recommended containment level must be used.

When submitting future Progress Reports indicate at the beginning of the report:

If no research with a Highly Pathogenic Agent or Select Agent has been performed or is planned to be performed under this grant.

If your IBC or equivalent body or official has determined, for example, by conducting a risk assessment, that the work being planned or performed under this grant may be conducted at a biosafety containment level that is lower than BSL3.

If the work involves Select Agents and/or Highly Pathogenic Agents, also address the following points:

- Any changes in the use of the Agent(s) or Toxin(s) including its restricted experiments that have resulted in a change in the required biosafety containment level, and any resultant change in location, if applicable, as determined by your IBC or equivalent body or official.

- If work with a new or additional Agent(s)/Toxin(s) is proposed in the upcoming project period, provide:
  - A list of the new and/or additional Agent(s) that will be studied;
  - A description of the work that will be done with the Agent(s), and whether or not the work is a restricted experiment;
  - The title and location for each biosafety level, including the name of the organization that operates the facility, and the biosafety level at which the work will be conducted, with documentation of approval by your IBC or equivalent body or official. It is important to note if the work is being done in a new location.

---

STAFF CONTACTS
The Grants Management Specialist is responsible for the negotiation, award and administration of this project and for interpretation of Grants Administration policies and provisions. The Program Official is responsible for the scientific, programmatic and technical aspects of this project. These individuals work together in overall project administration. Prior approval requests (signed by an Authorized Organizational Representative) should be submitted in writing to the Grants Management Specialist. Requests may be made via e-mail.

Grants Management Specialist: Tsehay Girma
Email: [redacted] Phone: [redacted] Fax: 301-493-0597

Program Official: Erik J. Stemmy
Email: [redacted] Phone: [redacted]

SPREADSHEET SUMMARY
GRANT NUMBER: 2R01AI110964-06

INSTITUTION: ECOHEALTH ALLIANCE, INC.

<table>
<thead>
<tr>
<th>Facilities and Administrative Costs</th>
<th>Year 6</th>
<th>Year 7</th>
<th>Year 8</th>
<th>Year 9</th>
<th>Year 10</th>
</tr>
</thead>
<tbody>
<tr>
<td>F&amp;A Cost Rate 1</td>
<td>32%</td>
<td>32%</td>
<td>32%</td>
<td>32%</td>
<td>32%</td>
</tr>
<tr>
<td>F&amp;A Cost Base 1</td>
<td>$438,711</td>
<td>$363,711</td>
<td>$363,711</td>
<td>$363,711</td>
<td>$363,711</td>
</tr>
</tbody>
</table>
Date: April 19, 2020

From: Michael S Lauer, MD
NIH Deputy Director for Extramural Research

To: Kevin Olival, PhD
Vice-President for Research
EcoHealth Alliance

Naomi Schrag, JD
Vice-President for Research Compliance, Training, and Policy
Columbia University

Subject: Project Number 2R01AI110964-06

Dear Dr. Olival and Ms. Schrag:

EcoHealth Alliance, Inc. is the recipient, as grantee, of an NIH grant entitled “Understanding the Risk of Bat Coronavirus Emergence.” It is our understanding that one of the sub-recipients of the grant funds is the Wuhan Institute of Virology (“WIV”). It is our understanding that WIV studies the interaction between corona viruses and bats. The scientific community believes that the coronavirus causing COVID-19 jumped from bats to humans likely in Wuhan where the COVID-19 pandemic began. There are now allegations that the current crisis was precipitated by the release from WIV of the coronavirus responsible for COVID-19. Given these concerns, we are pursuing suspension of WIV from participation in Federal programs.

While we review these allegations during the period of suspension, you are instructed to cease providing any funds from the above noted grant to the WIV. This temporary action is authorized by 45 C.F.R. § 75.371(d) (“Initiate suspension or debarment proceedings as authorized under 2 C.F.R. part 180”). The incorporated OMB provision provides that the funding agency may, through suspension, immediately and temporarily exclude from Federal programs persons who are not presently responsible where “immediate action is necessary to protect the public interest.” 2 C.F.R. § 180.700(c). It is in the public interest that NIH ensure that a sub-recipient has taken all appropriate precautions to prevent the release of pathogens that it is studying. This suspension of the sub-recipient does not affect the remainder of your grant assuming that no grant funds are provided to WIV following receipt of this email during the period of suspension.
Dear Dr. Olival and Ms. Schrag

Please see attached. (Referring to Exhibit B)

Many thanks, Mike

Michael S Lauer, MD
NIH Deputy Director for Extramural Research
1 Center Drive, Building 1, Room 144
Bethesda, MD 20892
Phone: 
Email:
Dear Mike,

I received the attached letter, however please note:

1. I am not the PI on this award. You should contact Dr. Peter Daszak \(\text{(b)(6)}\) who is the PI and leading this project for EcoHealth Alliance.
2. Columbia University is not involved in this NIH project, and it is not clear to me why Naomi and Columbia University were included.

Thank you,
Kevin

Kevin J. Olival, PhD
Vice President for Research

EcoHealth Alliance
460 West 34th Street, Suite 1701
New York, NY 10001

\(\text{(b)(6)}\) (direct)
\(\text{(b)(6)}\) (mobile)
1.212.380.4465 (fax)
www.ecohealthalliance.org
Re: Please read and acknowledge receipt -- Actions needed regarding 2R01AI110964-06

Lauer, Michael (NIH/OD) [E]  (b)(6)

Mon 4/20/2020 4:31 PM

To: Kevin Olival (b)(6); Peter Daszak (b)(6)
Cc: Naomi Schrag (b)(6); Black, Jodi (NIH/OD) [E] (b)(6); Lauer, Michael (NIH/OD) [E] (b)(6)

Importance: High

2 attachments
Screen Shot 2020-04-20 at 4.23.38 PM.png; EcoHealth Alliance re AI grant 4 19 20.pdf;

Thank you Kevin

- We need to work with a senior responsible business official – usually PI’s and senior business officials are different people.
- When I looked you up on the web, I see the Columbia logo (see attached screenshot). Specifically, it appears to be Columbia University > Ecology, Evolution, and Environmental Biology > EcoHealth Alliance (labeled as an “Affiliation/Department”). Thus the web profile makes it look to me as if EcoHealth Alliance is linked to Columbia University.
- In any case, I’m copy in Dr. Daszak.
- We need to know all sites in China that have been in any way linked to this award (Type 1 and Type 2). We have data in NIH, but we want to make absolutely sure that we’re of the same understanding.

We greatly appreciate your prompt attention to this matter.

Best, Mike

Michael S Lauer, MD
NIH Deputy Director for Extramural Research
1 Center Drive, Building 1, Room 144
Bethesda, MD 20892
Phone: (b)(6)
Email: (b)(6)
Thanks Naomi – not the impression an observer would get looking at the website (see screen shot), but we understand about the grant.

If they “are entirely separate entities” then why does Columbia identify EcoHealth Alliance as an “Affiliation/Department” on its website.

Maybe with the label “Affiliation/Department” you would have a clearly visible disclaimer that says, "EcoHealth Alliance is not affiliated with nor a department of Columbia"? – although even that is internally contradictory.

Best, Mike

---

From: Naomi Schrag (b)(6)
Date: Monday, April 20, 2020 at 5:19 PM
To: "Lauer, Michael (NIH/OD) [E]" (b)(6), Kevin Olival (b)(6), Peter Daszak (b)(6), Black, Jodi (NIH/OD) [E] (b)(6)
Cc: Naomi Schrag (b)(6), "Black, Jodi (NIH/OD) [E]" (b)(6)
Subject: RE: Please read and acknowledge receipt -- Actions needed regarding 2R01AI110964-06

Dear Dr. Lauer,

Columbia and EcoHealth Alliance are entirely separate entities. Some individuals affiliated with EcoHealth Alliance do have adjunct appointments in Columbia’s Ecology, Evolution, and Environmental Biology (“E3B”) department, but we are not aware of any Columbia involvement with the referenced grant, and have found no agreement or record in our grants system to the contrary.

We would be happy to answer any additional questions. Thank you.

Sincerely,
Naomi Schrag

Naomi J. Schrag

https://nex06.emailsrvr.com/owa/#/viewmodel=ReadMessageItem&it...Q59cg8gOF2gAFWhHydwAAA%3D%3D&IsPrintView=1&wid=59&ispopeut=1

Page 1 of 4
Vice President for Research Compliance, Training and Policy
Office of Research Compliance and Training
475 Riverside Drive, Suite 840
New York, New York 10115

www.researchcompliance.columbia.edu
RE: Please read and acknowledge receipt -- Actions needed regarding 2R01AI110964-06

5 Peter Daszak email on 21 April 2020

Peter Daszak

Tue 4/21/2020 1:32 AM

to: Lauer, Michael (NIH/OD) [E] (b) (6) Naomi Schrag (b) (6); Kevin Olival

cc: Black, Jodi (NIH/OD) [E] (b) (6)

Dear Michael Lauer & Jodi Black -- I now have your email and will deal with it directly with you and your staff. Naomi is correct that there is no involvement of Columbia University in this grant. I'm sure NIH has records to confirm that.

From this moment on, I will not cc any staff at Columbia as part of this discussion, and I hope you will also honor that. Respectfully, the discussion of whether or not EHA is an affiliate of CU is entirely irrelevant to the request that you contacted us about, and should remain a private matter between EcoHealth Alliance and Columbia University.

I'll look over your email and respond tomorrow.

Cheers,

Peter

---

**Peter Daszak**

*President*

EcoHealth Alliance

460 West 34th Street

New York, NY 10001

USA

Tel.: (b)

Website: [www.ecohealthalliance.org](http://www.ecohealthalliance.org)

Twitter: [@PeterDaszak](https://twitter.com/PeterDaszak)

*EcoHealth Alliance develops science-based solutions to prevent pandemics and promote conservation*
RE: Please read and acknowledge receipt -- Actions needed regarding 2R01AI110964-06

6 Peter Daszak email on 21 April 2020

Peter Daszak
Tue 4/21/2020 7:03 PM


Importance: High

1 attachment
EcoHealth Alliance re AI grant 4 19 20.pdf;

Dear Michael – Confirming receipt of your email. I’m also cc’ing the following people so they’re aware of this request:

1. Our AOR – Dr. Aleksei Chmura, who has access to all our records
2. My Program Officer for this award, Dr. Erik Stemmy & the Division Director (DMID), Dr. Emily Erberding, so they are informed and aware of the request and our response.

That said we need some time to go through the request for information and will provide this as quickly as we can.

However, I can categorically state that no funds form 2R01AI110964-06 have been sent to Wuhan Institute of Virology, nor has any contract been signed. Furthermore, we will comply with NIAID requirements, of course.

Concerning the request for information on all of the sites linked to this award in China, you should be aware that these are documented in our progress reports over the course of the grant. As you can understand we are under enormous pressure to generate data related to the current pandemic, and we do not want to divert staff to this effort. We are hoping the previously filed reports will satisfy this request.

We are well aware of the political concerns over the origins of this outbreak. Our collaboration with Wuhan Institute of Virology has been scientific and we have been consistently impressed with the scientific capabilities of that laboratory and its research staff. Our joint work has led to a series of critical papers published in high impact journals that served to raise awareness of the future threat coronaviruses pose for global health and therefore US national security. Scientific insights with epidemiological significance have been jointly published and our relationship has always been open and transparent and with one concern only, scientific validity. We are concerned that current actions may jeopardize 15 years of fruitful collaboration with colleagues in Wuhan, who are working at the leading edge to design vaccines and drugs that could help us fight this new threat in future years. It is quite remarkable that of the 5 vaccine candidates listed by WHO that are already in human trials, 3 have been developed in China. That said, we of course will
do all we can to make sure any further questions from NIH or any Federal agency are addressed to our fullest knowledge.

Yours sincerely,

Peter Daszak  
President

EcoHealth Alliance  
450 West 34th Street  
New York, NY 10001  
USA

Tel.: (b)(6)  
Website: www.ecohealthalliance.org  
Twitter: @PeterDaszak

EcoHealth Alliance develops science-based solutions to prevent pandemics and promote conservation
Many thanks Peter for your response.

We note that:

- No monies have gone to WIV on the Type 2 award and no contract has been signed.
- You agree that you will not provide any funds to WIV until and unless directed otherwise by NIH.
- All foreign sites for the Type 1 and Type 2 awards have been documented in the progress reports submitted to NIH.

We appreciate your working with us.

Best, Mike

Michael S Lauer, MD
NIH Deputy Director for Extramural Research
1 Center Drive, Building 1, Room 144
Bethesda, MD 20892
Phone: (b) (6)
Email: (b) (6)
Dear Mike,

I read that we are in agreement and in compliance with all requests. Please let us know if anything further is required. We will continue in our usual close communication with our Program Officer Erik Stemmy.

Sincerely,

Aleksel

EcoHealth Alliance
460 West 34th Street, Suite 1701
New York, NY 10001

EcoHealth Alliance develops science-based solutions to prevent pandemics and promote conservation.
Many thanks Aleksei.

Best, Mike
Dear Dr. Chmura and Dr. Daszak

Please see attached.  

(Referring to Exhibit D)

Sincerely,
Michael S Lauer, MD

Michael S Lauer, MD
NIH Deputy Director for Extramural Research
1 Center Drive, Building 1, Room 144
Bethesda, MD 20892
Phone: (b) (6)
Email: (b) (6)
Dear Michael,

Could Peter and I have a quick chat with you sometime tomorrow (Tuesday) about your email, below?

Sincerely,

-Aleksel

Aleksei Chmura, PhD
Chief of Staff

EcoHealth Alliance
460 West 34th Street, Suite 1701
New York, NY 10001

www.ecohealthalliance.org

EcoHealth Alliance develops science-based solutions to prevent pandemics and promote conservation.
Exhibit D
24 April 2020

Drs. Aleksei Chmura and Peter Daszak  
EcoHealth Alliance, Inc.  
460 W 34th St  
Suite 1701  
New York, NY 10001

Re: Termination of NIH Grant R01 AI 110964

Dear Drs. Chmura and Daszak:

I am writing to notify you that the National Institute of Allergy and Infectious Diseases (NIAID), an Institute within the National Institutes of Health (NIH), under the Department of Health and Human Services (HHS) has elected to terminate the project Understanding the Risk of Bat Coronavirus Emergence, funded under grant R01 AI 110964, for convenience. This grant project was issued under the authorization of Sections 301 and 405 of the Public Health Service Act as amended (42 USC 241 and 284). This grant was funded as a discretionary grant as outlined in the NIH Grants Policy Statement, which states that the decision not to award a grant, or to award a grant at a particular funding level, is at the discretion of the agency, in accordance with NIH's dual review system.

At this time, NIH does not believe that the current project outcomes align with the program goals and agency priorities. NIAID has determined there are no animal and human ethical considerations, as this project is not a clinical trial, but rather an observational study.

As a result of this termination, a total of $369,819.56 will be remitted to NIAID and additional drawdowns will not be supported. The remaining funds have been restricted in the HHS Payment Management System, effective immediately.

Please let me know if you have any questions concerning the information in this letter.

Sincerely,

Michael S Lauer, MD  
NIH Deputy Director for Extramural Research  
Email: [Redacted]

cc: Dr. Erik Stemmy  
Ms. Emily Linde
Exhibit E
SPECIFIC AIMS

Zoonotic coronaviruses are a significant threat to global health, as demonstrated with the emergence of Severe Acute Respiratory Syndrome coronavirus (SARS-CoV) in 2002, and the continuing spread of Middle East Respiratory Syndrome (MERS-CoV). The wildlife reservoirs of SARS-CoV were identified by our group as bat species, and since then we have sequenced dozens of novel SARS-related CoV (SARSr-CoV) strains. Our previous R01 work demonstrates that bats in southern China harbor an extraordinary diversity of SARSr-CoVs, some of which are able to use human ACE2 to enter into human cells, can infect humanized mouse models to cause SARS-like illness, and evade available therapies or vaccines. We found that the bat hosts of SARSr-CoVs appear to no longer be traded in wildlife markets, and that people living close to bat habitats are the primary risk groups for spillover. At one of these sites, we found diverse SARSr-CoVs containing every genetic element of the wild-type SARS-CoV genome, and serological evidence of human exposure among people living nearby. Thus, there is significant potential for future spillover of SARSr-CoVs, and of public health impacts. Yet salient questions remain: Are there specific bat communities and sites that harbor CoV strains with higher risk for bat-to-human spillover? Which human behaviors drive risk of bat SARS-CoV exposure that could lead to infection? Does human exposure to these viruses cause SARS-like or other illness? Can we characterize viral strain diversity, bat traits and human behaviors to assess risk of potential future CoV spillover? The proposed work in this renewal R01 builds on these findings to address these issues by conducting: 1) focused sampling of bats in southern China to identify viral strains with high predicted risk of spillover; 2) community-based, and clinic-based syndromic, sampling of people to identify spillover, and assess behavioral risk factors and evidence of illness; and 3) conduct in vitro and in vivo viral characterization and analyze epidemiological data to identify hotspots of future CoV spillover risk.

This work will follow 3 specific aims:

Aim 1: Characterize the diversity and distribution of high spillover-risk SARSr-CoVs in bats in southern China. We will conduct targeted bat sampling at sites where we predict that undiscovered high risk SARSr-CoV strains exist. Bat sampling will be targeted geographically and by host species to test predictions about evolutionary diversity of SARSr-CoV. We will analyze RdRp and S protein sequences to test their capacity for spillover to people in Aim 3.

Aim 2: Community- and clinic-based surveillance to capture SARSr-CoV spillover, routes of exposure and potential public health consequences. We will conduct focused, targeted human surveys and sampling to identify key risk factors for SARSr-CoV spillover and evidence of illness. To maximize our opportunity of capturing human exposure to bat CoVs, we will conduct community-based surveillance in regions with high SARSr-CoV prevalence and diversity, and individuals having contact with bats. We will assess bat-CoV seropositive status against a small number of questions about human-wildlife contact and exposure. We will conduct clinic-based syndromic surveillance close to these sites to identify patients presenting with influenza-like illness and severe acute respiratory illness, assess their exposure to bats via a questionnaire, and test samples for PCR- and serological evidence of SARSr-CoV infection. We will conduct follow-up sampling to capture patients who had not yet seroconverted at the time of clinic visit.

Aim 3: In vitro and in vivo characterization of SARSr-CoV spillover risk, coupled with spatial and phylogenetic analyses to identify the regions and viruses of public health concern. We will characterize the propensity of novel SARS-CoVs to infect people in vitro using primary human airway epithelial cells and in vivo using the transgenic hACE2 mouse model. We will use mAbs and vaccine treatments to test our hypothesis that SARS-CoVs with 10-25% divergence in S protein sequences from SARS-CoV are likely able to infect human cells, and to evade mAb therapeutics and vaccines. We will then map the geographic distribution of their bat hosts and other ecological risk factors to identify the key ‘hotspots’ of risk for future spillover.

Overall, our SARS-CoV program serves as a model platform to integrate virologic, molecular and ecologic factors contributing to CoV emergence while informing high impact strategies to intervene and prevent future pandemics. This includes providing critical reagents, therapeutic interventions and recombinant viruses for future SARSr-CoV pandemic and public health preparedness.
This scanning electron microscope image shows SARS-CoV-2 (yellow), the virus that causes COVID-19, isolated from a patient in the United States, emerging from the surface of cells (pink) cultured in the lab. Credit: NIAID-RML.
# Table of Contents

Executive Summary ........................................................................................................... 1
Research Plan ..................................................................................................................... 2

**Priority 1: Improve fundamental knowledge of SARS-CoV-2 and COVID-19** ........................................... 2
   Objective 1.1: Characterize fundamental SARS-CoV-2 virology and immunological host response to infection ...................................................................................................................... 2
   Objective 1.2: Evaluate disease dynamics through natural history, transmission, and surveillance studies .............................................................................................................. 3
   Objective 1.3: Develop animal models that recapitulate human disease ......................................................................................................................... 4

**Priority 2: Support the development of diagnostics and assays** ........................................ 5
   Objective 2.1: Accelerate the development and evaluation of diagnostic platforms ................................................................................................................. 5
   Objective 2.2: Develop assays to increase understanding of infection and disease incidence ........................................................................................................... 5

**Priority 3: Characterize and test therapeutics** ............................................................ 6
   Objective 3.1: Identify promising candidates with activity against SARS-CoV-2 ................ 6
   Objective 3.2: Conduct treatment studies to advance high-priority therapeutic candidates ................................................................................................................. 7

**Priority 4: Develop safe and effective vaccines against SARS-CoV-2** ......................... 8
   Objective 4.1: Advance promising vaccine candidates through clinical trial testing .......... 8
   Objective 4.2: Advance vaccine development through assay and reagent development ....... 9
   Objective 4.3: Advance vaccine development through adjuvant characterization and development ........................................................................................................ 9

Conclusion ....................................................................................................................... 10
Executive Summary

The National Institute of Allergy and Infectious Diseases (NIAID) at the United States (U.S.) National Institutes of Health (NIH) is committed to safeguarding the health of Americans and people around the world by accelerating research efforts to prevent, diagnose, and treat COVID-19 and characterize the causative agent of this disease, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). This NIAID Strategic Plan for COVID-19 Research builds on current trans-NIAID efforts to better understand SARS-CoV-2 pathogenesis, transmission, and mechanisms of protective immunity by expanding resources and activities that support rapid development of biomedical tools to more effectively combat this disease and pandemic. Given the urgency of the public health response, studies that inform efforts to control virus spread and mitigate morbidity and mortality, including therapeutic and vaccine development, are the priority. In addition, it is essential to develop rapid, accurate, point-of-care diagnostics—a critical asset to mitigating the spread of COVID-19.

The NIAID Strategic Plan for COVID-19 Research aligns with the priorities set by U.S. Government-wide task forces for the development of medical countermeasures. NIAID actively participates in COVID-19 task forces to identify opportunities, ensure open communication, encourage resource sharing, and avoid duplication of effort. The plan is structured around four strategic research priorities:

1. **Improve fundamental knowledge of SARS-CoV-2 and COVID-19**, including studies to characterize the virus and how it is transmitted and understand the natural history, epidemiology, host immunity, disease immunopathogenesis, and the genetic, immunologic, and clinical associations with more severe disease outcomes. This includes accelerating the development of small and large animal models that replicate human disease.

2. **Support the development of diagnostics and assays**, including point-of-care molecular and antigen-based diagnostics for identifying and isolating COVID-19 cases and serologic assays to better understand disease prevalence in the population. Diagnostics also will be essential for evaluating the effectiveness of candidate countermeasures.

3. **Characterize and test therapeutics**, including identifying and evaluating repurposed drugs and novel broad-spectrum antivirals, virus-targeted antibody-based therapies (including plasma-derived intravenous immunoglobulin (IVIG) and monoclonal antibodies), and host-directed strategies to combat COVID-19.

4. **Develop safe and effective vaccines against SARS-CoV-2**, including support of clinical trial testing.

To accelerate research, NIAID will leverage current resources and global collaborations, including existing research programs and clinical trials networks. NIAID’s research response to COVID-19 will build on experience with diseases caused by other zoonotic coronaviruses (CoVs), including severe acute
respiratory syndrome (SARS) and Middle East respiratory syndrome (MERS). NIAID will pursue public-private partnerships to facilitate the translation of research outcomes into life-saving public health interventions. Working with pharmaceutical companies, NIAID has already initiated Phase 1 clinical trials for candidate COVID-19 vaccines and therapeutics. A concerted effort will be made to include minority populations, as well as at-risk and vulnerable populations, in all aspects of NIAID-sponsored research to address health disparities between diverse groups. Characterization of the fundamental virology of SARS-CoV-2 and the immunological response to infection will inform future studies and facilitate the development of effective medical countermeasures. With collaboration from all agencies within the U.S. government and other key U.S. and global partners, NIAID will rapidly disseminate these results so that the information can be translated into clinical practice and public health interventions to combat the pandemic. As such, NIAID has already implemented open sharing of scientific data through publicly available websites and will continue to promote the prompt disclosure of SARS-CoV-2 and COVID-19 research data by the scientific community.

Research Plan

Priority 1: Improve fundamental knowledge of SARS-CoV-2 and COVID-19

Developing effective medical and public health countermeasures against a newly emergent virus like SARS-CoV-2 will require a better understanding of the complex molecular and immune mechanisms underlying infection and disease. Studies that delineate the viral lifecycle and host immune responses to infection can lead to the identification of novel targets for intervention against SARS-CoV-2 infection and COVID-19. Early studies suggest that the clinical manifestations of COVID-19 can vary significantly, and disease severity can range from mild to critical. Thus, a detailed understanding of the clinical course of disease, as well as the clinical, virologic, immunological, and genetic predictors of disease severity, are needed. Gaps also exist in our understanding of the dynamics of disease transmission in different populations over time, including the role of pediatric and elderly populations in viral spread, and the potential seasonality of viral circulation.

Objective 1.1: Characterize fundamental SARS-CoV-2 virology and immunological host response to infection

- **Support the development and distribution of reagents and viral isolates to researchers.** NIAID will continue to support both intramural and extramural researchers by developing reagents and assays for virus characterization and immunological analyses. NIAID will continue to accelerate SARS-CoV-2 research by sourcing viral isolates and clinical specimens for the research community and placing them in repositories to help advance research and countermeasure development. In addition, NIAID will place other critical reagents needed for assay development (e.g., pseudovirions and antigens) in publicly available repositories for distribution.

- **Characterize virus biology and immunological responses to disease.** A comprehensive understanding of the

<table>
<thead>
<tr>
<th>Box 2 Priority 1: Improve fundamental knowledge of SARS-CoV-2 and COVID-19</th>
</tr>
</thead>
<tbody>
<tr>
<td>Objective 1.1: Characterize fundamental SARS-CoV-2 virology and immunological host response to infection</td>
</tr>
<tr>
<td>Objective 1.2: Evaluate disease dynamics through natural history, transmission, and surveillance studies</td>
</tr>
<tr>
<td>Objective 1.3: Develop animal models that recapitulate human disease</td>
</tr>
</tbody>
</table>
biological processes involved in SARS-CoV-2 infection and the pathogenesis of COVID-19 are paramount to developing new medical countermeasures to fight the spread of disease. Building on prior research related to MERS and SARS coronaviruses, early studies confirmed several critical features of SARS-CoV-2 infection, including the primary host receptor, angiotensin converting enzyme 2 (ACE-2), and the structure of the virus receptor-binding domain. Studies that delineate the viral lifecycle and host immune responses to infection can lead to the identification of novel targets for intervention against SARS-CoV-2 infection and COVID-19. Understanding the function of essential viral proteins will be necessary for improving diagnostic and immunological assays, in vitro and in vivo models, and other resources needed to advance safe and effective medical countermeasure development. In addition, evaluating the dynamics of host-pathogen interactions at the molecular and cellular levels will be critical to advancing our understanding of viral pathogenesis and immune responses that contribute to SARS-CoV-2 infection.

- **Determine viral evolution and molecular epidemiology.** With a newly emergent virus like SARS-CoV-2, studies to characterize genetic diversity, including those that assess the potential for the virus to evolve and escape host immunity, are pivotal for understanding disease progression and transmission dynamics and may have implications for countermeasure development. Viral genomic analysis matched with patient clinical data will be important to identify biomarkers of virulence and establish paradigms of sequence diversity. In addition, evaluating viral sequence associations with disease outcomes, immune status, and viral replication will provide crucial data to accelerate the development of effective medical countermeasures.

- **Develop low-containment assays to study virus neutralization.** Studies using non-infectious pseudovirions can be conducted in labs without BSL-3 capacity, making them an important tool to enhance understanding of SARS-CoV-2 infection. This capability would enable researchers without high-containment infrastructure to study the dynamics of virus neutralization in vitro.

- **Research into optimal public health prevention and mitigation modalities.** Clinical trials including family members of a COVID-19 positive individual can be devised to evaluate transmission, prevention, and other mitigation measures within the household.

**Objective 1.2: Evaluate disease dynamics through natural history, transmission, and surveillance studies**

- **Characterize disease incidence through surveillance studies.** Clinical manifestations of COVID-19 can vary greatly, ranging from asymptomatic or mildly symptomatic to the development of pneumonia, acute respiratory distress syndrome, and even death. The variation in clinical presentation of COVID-19, combined with the challenges in diagnostic capacity, have made accurate initial assessments of disease incidence a formidable challenge. However, rapid point-of-care and point-of-need molecular tests, which became available in March 2020, will enable hospitals and other healthcare facilities to make informed decisions regarding patient isolation and care. Studies that leverage existing high-throughput diagnostic capacity along with these rapid tests will advance our understanding of disease incidence across the nation and will be a critical component of strategies to implement effective medical countermeasures. Combining these studies with broad serosurveillance studies across existing surveillance networks, including blood bank studies, would

---

provide a more complete picture of the scope of disease and the dynamics of infection. Detailed knowledge of host genetics and the human responses to infection across the lifespan will not only provide insights into new approaches for diagnosis, treatment, and prevention, but also may elucidate why individuals respond to SARS-CoV-2 in different ways. Reports to date suggest that COVID-19 resolves in most cases, implying that the immune system can keep the infection from progressing to severe disease in many individuals. However, additional research is needed to better understand why some people progress to severe disease, which will lend critical insights to medical countermeasure development.

- **Assess the dynamics of disease transmission.** Our current understanding of COVID-19 transmission is limited. While recent studies have suggested timeframes for virus survival in aerosols and on surfaces, the contributions of different routes of transmission and the dynamics of animal-to-human and human-to-human transmission remain unclear. The diverse clinical presentations of COVID-19, including a high prevalence of asymptomatic cases, add further complexity to understanding transmission dynamics. Providing a clearer picture of the natural history of viral shedding is a priority, both in acute cases and in asymptomatic infection. Given the challenges of accurately diagnosing asymptomatic individuals because they do not present for treatment, determining the role they play in transmission would provide valuable insights. Elucidating the role of pediatric cases in the spread of SARS-CoV-2 is particularly important. Although pediatric COVID-19 cases are generally asymptomatic or have less severe clinical manifestations than those of adults, the role that children play in spreading the virus is unknown. Additionally, studies to identify potential animal reservoirs and better understand transmission from animals to humans are a research priority, as these reservoirs may lead to future virus introductions and re-emergence of disease in humans. Virus transmission depends on a complex interplay of host, viral, and environmental factors that contribute to disease incidence and spread. Identifying the factors that maintain the disease transmission cycle is critical to developing effective medical countermeasures and public health interventions that will prevent future pandemics.

- **Determine disease progression through natural history studies.** Delineating the natural history of COVID-19 will inform immunopathogenesis, viral tropism and length of shedding, immune phenotypes, and both protective immunity and host susceptibility. Disease assessment using longitudinal cohort studies, including among high-risk populations such as healthcare workers and the elderly, are important to better understand disease pathogenesis and immune responses to infection. Biomarkers identified from these studies may provide valuable insights into predictors of disease severity.

Objective 1.3: Develop animal models that recapitulate human disease

- **Develop small and large animal models that replicate SARS-CoV-2 pathogenesis.** Developing animal models that recapitulate human disease is a vital early step toward understanding disease pathogenesis and testing the efficacy of medical countermeasures. Small animal models enable rapid, scalable analyses that are particularly valuable for screening countermeasure candidates for efficacy and addressing issues concerning vaccine-induced immune enhancement. Among the small animal models being tested, transgenic mice expressing the human ACE-2 receptor are a promising candidate. In parallel, development and characterization of large animal models, including non-human primates (NHPs) that mimic human COVID-19, are a pivotal step to advance promising

---

2 ibid.

countermeasure candidates. Previous experience with related coronavirus diseases such as MERS and SARS suggests that replicating human disease, particularly its more severe manifestations, in an animal model may be challenging. Fundamental research assessing animal models ranging from mice to NHPs is already underway. NIAID will continue to support the development of small and large animal model candidates to better understand this emerging infection and investigate optimal ways to treat and prevent COVID-19. NIAID also will ensure that validated animal models are made available to the scientific community for evaluating priority countermeasures.

Priority 2: Support the development of diagnostics and assays

*Availability of rapid, accurate Food and Drug Administration (FDA)-cleared or authorized diagnostics will increase testing capacity and are critical for identifying and rapidly isolating cases, tracking spread of the virus, managing patient care, and supporting clinical trials. Molecular tests specifically designed to detect SARS-CoV-2 RNA in clinical samples are able to detect low levels of pathogen in clinical samples and offer robust specificity in differentiating SARS-CoV-2 from other related viruses. Continuing to improve the speed and accuracy of molecular and antigen-based diagnostics and making them available at point-of-care will be paramount to accelerating the ability to mitigate disease spread in the current outbreak and any future outbreaks. The development of serologic assays would further bolster surveillance efforts, including the ability to identify individuals who may have resolved prior infection with SARS-CoV-2.*

Objective 2.1: Accelerate the development and evaluation of diagnostic platforms

- **Support the development, characterization and availability of reagents for diagnostic validation.** NIAID will support this effort through the development and testing of reagents for diagnostic validation that will be made available through NIAID-sponsored repositories.

- **Support the development of new rapid diagnostics.** NIAID will provide funding to support the development of new rapid diagnostics, including molecular tests and novel antigen detection tests with improved sensitivity, if deemed feasible based on natural history studies.

- **Support the evaluation of promising diagnostics.** In some cases, stakeholders that develop potential diagnostic tests do not have the infrastructure needed to rigorously validate those tests against clinical samples. NIAID will support the testing of promising diagnostics and provide the capacity for evaluating them with live virus samples using our bioccontainment laboratories.

Objective 2.2: Develop assays to increase understanding of infection and disease incidence

- **Develop and validate SARS-CoV-2 serological assays.** Serological tests, which detect host antibodies to infectious agents, do not detect the presence of a pathogen directly but can be used as a surrogate marker of infection. Developing more effective serologic tests would help provide information on the extent of asymptomatic infections and cumulative disease incidence, for example through serosurveillance studies. NIAID, with the Centers for Disease Control and
Prevention and the FDA, is developing tests that identify antibodies to SARS-CoV-2 proteins to determine seroprevalence rates and potentially help distinguish antibody responses in individuals receiving vaccines. NIAID will support the development and validation of additional serological assays for serosurveillance studies and as tools for testing the efficacy of promising vaccine or therapeutic candidates.

Priority 3: Characterize and test therapeutics

Currently, there are no FDA-approved or licensed therapeutics specific for coronaviruses. While traditional development pathways for therapeutics can take years, the urgency of the current outbreak underscores the need for rapid development and testing of promising therapeutics. Possible avenues for developing therapeutics include the evaluation of broad-spectrum antiviral agents (antivirals) that have shown promise for other coronaviruses and the identification of novel monoclonal antibodies (mAbs). For broad-spectrum antivirals, Phase 2/2b testing of the RNA polymerase inhibitor developed by Gilead, remdesivir, is already underway. Additional studies will be critical to identify promising therapeutic candidates and to advance them through clinical trial testing. To optimize findings during the pandemic, multiple clinical trials will be conducted in parallel among various populations, including both inpatient and outpatient studies.

Objective 3.1: Identify promising candidates with activity against SARS-CoV-2

- **Screen protease inhibitor and nucleotide analogue class agents and other small molecules with documented activity against other coronaviruses SARS-CoV-2.** Screening drugs that are already licensed by the FDA for other indications and might be efficacious against SARS-CoV-2 infection may provide a route to identifying a therapeutic for use in the current pandemic. Broad-spectrum antivirals that are already FDA approved or in clinical development for other indications—including those previously targeting SARS-CoV-1 and MERS CoV—can be evaluated for their potential activity against SARS-CoV-2 infections. Approved therapeutics for other infectious diseases also are being evaluated as possible treatments for COVID-19. By leveraging their existing efficacy, safety, and manufacturability data, the time to development and production can be reduced. NIAID also will continue working with partners to screen compound libraries for potential activity against SARS-CoV-2. For these studies, priority will be given to compounds based on in vitro screening data and the existence of human safety data.

- **Identify viral targets for therapeutic development.** Advances in structural biology technology enable researchers to map key viral structures at an unprecedented level. The Structural Genomics Centers for Infectious Diseases (SGCID) apply state-of-the-art, high-throughput technologies and methodologies, including computational modeling, x-ray crystallography, nuclear magnetic resonance imaging, and cryogenic electron microscopy, to experimentally characterize the three dimensional atomic structure of proteins that play an important biological role in human pathogens and infectious diseases. NIAID will continue to support use of this powerful technology to identify viral targets of SARS-CoV-2 for therapeutics or vaccines.
- **Identify novel mAbs for use as therapy or prophylaxis.** Data from early studies indicate that well-characterized convalescent plasma may provide a treatment benefit in COVID-19.\(^4\) Therefore, IVIG derived from convalescent plasma may also hold promise for treatment. Moreover, peripheral blood mononuclear cells and plasma are being used to identify novel neutralizing antibodies. Through collaborations with structural biologists, binding properties can be quickly assessed. Paired with assessment of neutralization activity, the most promising mAbs will be identified for further characterization in animal models and human trials.

**Objective 3.2: Conduct treatment studies to advance high-priority therapeutic candidates**

- **Characterize and evaluate host-directed strategies for treatment of disease.** Experience with other coronaviruses indicates that infection of the respiratory tract is rapid and damage is primarily mediated by the host inflammatory response.\(^5\) These conditions may make it difficult to modify COVID-19 with pathogen-directed therapeutics. Instead, host-directed strategies that target the immune response may exert a beneficial therapeutic effect. Host-directed strategies, including immune-modulating agents, will be investigated as potential therapeutic candidates.

- **Conduct clinical trials to demonstrate safety and efficacy of lead therapeutic candidates.** Many potential therapeutic candidates have been identified and are being tested in clinical trials.
  - In March 2020, NIAID launched a multicenter, adaptive, randomized controlled clinical trial to evaluate the safety and efficacy of the investigational antiviral drug remdesivir (GS-5734) for the treatment of COVID-19 in hospitalized adults with laboratory-confirmed SARS-CoV-2 infection and evidence of lung involvement. The trial builds on recent studies by NIAID scientists showing that remdesivir can improve the disease course in rhesus macaques when administered promptly after viral challenge with the MERS CoV.\(^6\) The trial is also adaptive, allowing for additional arms should other therapeutics warrant assessment for efficacy.
  - NIAID is finalizing the protocol for the Big Effect Trial (BET), in which putative therapeutics that have existing human data and are readily available will be tested in patients hospitalized with lower respiratory tract disease. Each potential intervention will be given to approximately 75 patients and evaluated for mitigating disease symptoms. Candidate therapeutics that meet the criteria in this initial study will be further evaluated in larger clinical trials for which the infrastructure is already in place.
  - As mentioned above, identification of novel mAbs for therapy or prophylaxis is another strategic priority. These mAbs should be safe, highly effective, amenable to fast manufacturing, and easy to administer. They will be tested in clinical trials to develop immunotherapies for the prevention and early treatment of COVID-19, potentially in high-risk populations including healthcare workers.

- **Conduct outpatient studies for mild COVID-19 cases.** In cases of mild COVID-19 that do not require hospitalization, outpatient studies could be extremely valuable for testing promising, orally administered FDA-approved drugs that have existing safety data. The antiviral activity of hydroxychloroquine and azithromycin against SARS-CoV-2 has been the focus of many early studies.

---

\(^4\) Roback JD and Guarner J. JAMA 2020 Mar 27. Epub. 32219429.


\(^6\) de Wit E et al. *Proc Natl Acad Sci USA* 2020;117(12):6771-6. PMID 32054787.
therapeutic studies.\textsuperscript{7,8,9} Testing of these and other candidates, including protease inhibitors and other molecules, in outpatient studies may provide critical efficacy data and could identify an existing drug or drug combination that is safe and effective against COVID-19.

- **Conduct outpatient studies in high-risk populations.** High-risk populations, including health care workers, the elderly or individuals with chronic conditions, are a critical target for the development of therapeutics. Conducting studies in patients with mild cases of COVID-19 among these high-risk groups would be of interest for identifying the benefits of early treatment strategies to mitigate the impact of infection. Therapeutic candidates that have once a day dosing could also be considered for pre-exposure prophylaxis (PrEP) in some of these populations.

**Priority 4: Develop safe and effective vaccines against SARS-CoV-2**

*Developing a safe and effective SARS-CoV-2 vaccine is a priority for preventing future outbreaks of the virus.* As vaccine candidates for MERS-CoV, SARS-CoV-1 and other coronaviruses have previously been developed, NIAID investigators and the scientific community are well poised to use similar approaches in the current pandemic. NIAID will leverage its broad intramural and extramural infrastructure to advance vaccine candidates through Phase 1 safety and dosing clinical trials, with considerations for Phase 2/2b clinical trials for the most promising candidates.

**Objective 4.1: Advance promising vaccine candidates through clinical trial testing**

- **Conduct a Phase 1 clinical trial of (mRNA) platform candidate mRNA-1273.** Given the urgency of the response effort to develop a safe and effective vaccine, NIAID is prioritizing promising vaccine candidates that can be rapidly produced and tested. NIAID, in collaboration with the biotechnology company Moderna, is conducting a Phase 1 clinical trial of a vaccine candidate that uses a messenger RNA (mRNA) vaccine platform expressing a NIAID-designed recombinant spike protein of SARS-CoV-2. The trial is being conducted at NIAID-funded clinical research sites, with the first enrolled individual receiving the vaccine on March 16, 2020.

- **Prepare for a pivotal Phase 2/2b clinical trial of candidate mRNA-1273.** Preparing for the likelihood of a seasonal recurrence of SARS-CoV-2 is imperative to the public health response. Given the theoretical risk of vaccine-enhanced respiratory disease, large Phase 2 trials are unlikely to launch until this possibility is evaluated in animal models. Planning for those animal studies is underway, and, assuming favorable results, a Phase 2/2b study could be launched later in 2020. This represents a historically fast timeline for the development and testing of a vaccine candidate. Additionally, these studies will provide information on correlates of immunity that will help accelerate the advancement of other vaccine candidates. If the mRNA-1273 vaccine candidate shows protection against SARS-CoV-2 infection in a Phase 2/2b trial, NIAID will work with government partners to ensure that the vaccine is manufactured in sufficient quantities to allow prompt distribution to those at highest risk of acquiring disease.

\textsuperscript{9} Chen Z et al. medRxiv 2020:2020.03.22.20040758. 
https://www.medrxiv.org/content/10.1101/2020.03.22.20040758v2
- Investigate additional candidates through NIAID vaccine programs. Although promising candidates may show efficacy in preclinical studies, many do not translate into effective vaccines in clinical trials. Therefore, it is crucial to support multiple promising preclinical candidates in the research and development pipeline. To that end, NIAID is advancing multiple additional SARS-CoV-2 vaccine candidates through its Rocky Mountain Laboratories (RML), including approaches that have shown promise against coronaviruses that cause SARS and MERS. Building on previous research to develop a MERS-CoV vaccine, scientists at RML are collaborating with Oxford University investigators to develop a SARS-CoV-2 vaccine that uses a chimpanzee adenovirus vector. RML investigators also are partnering with the biopharmaceutical company CureVac on an mRNA vaccine candidate and collaborating with the University of Washington on a universal coronavirus vaccine development. By leveraging its extensive expertise and research infrastructure, NIAID will continue working with partners and collaborators to advance promising SARS-CoV-2 vaccine candidates.

- Leverage existing vaccine approaches to target SARS-CoV-2. NIAID is pursuing multiple strategies to develop a COVID-19 vaccine. Building on past research on emerging pathogens, especially MERS-CoV and SARS-CoV-1 (the virus that causes SARS), NIAID is using previously developed vaccine platforms to rapidly assess the potential of SARS-CoV-2 vaccine candidates. This approach has already resulted in several promising strategies that may be leveraged for SARS-CoV-2, including vaccination using recombinant spike protein, chimpanzee adenovirus vaccine vector, virus-like particles, and live attenuated virus. In addition, NIAID is funding the development of novel vaccine candidates that will be efficacious across the lifespan, including in the elderly.

**Objective 4.1:** Advance promising vaccine candidates through clinical trial testing

**Objective 4.2:** Advance vaccine development through assay and reagent development

**Objective 4.3:** Advance vaccine development through adjuvant characterization and development

Objective 4.2: Advance vaccine development through assay and reagent development

- Develop critical reagents to support vaccine development. Appropriate tools are needed to identify the most promising vaccine candidates and advance the development of lead candidates as rapidly as possible. To accelerate the vaccine pipeline, NIAID is generating master and working SARS-CoV-2 virus stocks and other reagents critical for developing SARS-CoV-2 immune assays, developing quantitative tests for characterizing SARS-CoV2 assay material, developing a quantitative SARS-CoV-2-specific ELISA, developing virus-specific neutralization assays, and developing quantitative assays for assessing SARS-CoV-2 viral load.

Objective 4.3: Advance vaccine development through adjuvant characterization and development

- Provide adjuvants to support vaccine development. Adjuvants are vaccine components that improve vaccine efficacy by inducing long-lived protective immunity. Selection of appropriate adjuvants is crucial for developing safe and effective vaccines. NIAID is working with multiple collaborators to provide adjuvants to the research community for use in SARS-CoV-2 vaccine candidates. These adjuvants are at various stages of development and include compounds that
specifically improve vaccine efficacy in elderly individuals or modulate host immunity toward protective responses while limiting or preventing harmful inflammatory responses.

Conclusion
The sudden emergence and rapid global spread of the novel coronavirus SARS-CoV-2 has created a daunting public health challenge. To address this challenge, NIAID is focusing its considerable expertise and emerging infectious disease resources to facilitate the development of medical countermeasures including diagnostics, therapeutics, and vaccines. The resulting discoveries will not only help mitigate the current pandemic, but also inform prevention, diagnosis, and treatment of future emerging infectious diseases.

A comprehensive strategy requires a coordinated effort among governmental, academic, private, and community-based organizations. The NIAID Strategic Plan for COVID-19 Research defines the areas of COVID-19 research within the NIAID mission and outlines the institute’s research priorities and goals. This strategic plan builds on many other national efforts and represents a commitment from multiple U.S. government agencies to improve coordination of COVID-19 research and discovery efforts and the development of medical countermeasures.
Thanks Renate – looks fine.

Best, Mike

---

From: "Myles, Renate (NIH/OD) [E]" <renate.myles@nih.gov>
Date: Tuesday, June 15, 2020 at 4:56 PM
To: "Lauer, Michael (NIH/OD) [E]" <michael.lauer@nih.gov>, "Wojtowicz, Emma (NIH/OD) [E]" <emma.wojtowicz@nih.gov>
Cc: OER Press Group <oer.press@nih.gov>
Subject: RE: FOR REVIEW/INPUT: LA Times inquiry on grant termination

Hi all:

See suggested revisions for clarity.

Response:
Hi Emma –

Thanks, Mike

Hi Mike-

The LA Times reporter that reached out to you over the weekend followed up with his questions, please see the email below. We plan to respond with

Please let us know if you have any edits or concerns with the response below.

Thanks-
Emma

Response:

From: Rainey, Jim <jim.rainey@latimes.com>
Sent: Monday, June 15, 2020 9:52 PM
To: Fine, Amanda (NIH/OD) [E]
Thanks for your response.....I am trying to find out more about the cancellation of the grant to EcoHealth Alliance.

Was there a specific complaint about EcoHealth? About the Wuhan Institute for Virology?

Is the cancellation part of the larger review of grants to foreign individuals, as described here?

https://www.sciencemag.org/news/2020/06/fifty-four-scientists-have-lost-their-jobs-result-nih-probe-foreign-ties

Is there a criminal investigation of EcoHealth? Is there a criminal investigation of the Wuhan Institute for Virology?

Who filed the complaint about this grant?

Thanks,

Jim

Hi Jim-

Dr. Lauer forwarded your email to us. Thanks for reaching out. If you share your questions we can look into them for you.

Hope you’re staying well and having a good weekend,

Amanda

Amanda Fine
Chief, News Media Branch
National Institutes of Health
Tel: (b) (6)
Email: (b) (6)
Web: http://www.nih.gov

NIH . . . Turning Discovery Into Health

From: "Rainey, Jim" <jim.rainey@latimes.com>
Date: Saturday, June 13, 2020 at 6:53 PM
To: "Lauer, Michael (NIH/OD) [E]" <(b) (6)
Subject: Grant termination

Dr. Lauer,
I am a reporter for the Los Angeles Times. I have written in the past about some of the work of the EcoHealth Alliance. As you know, the termination of the NIH grant (award renewal #2R01AI110964-06) to the EcoHealth Alliance for “Understanding the Risk of Bat Coronavirus Emergence” is a matter of considerable public interest.

I would like to talk to you as soon as possible about this award and why it was discontinued. You can reach me at this email or the attached phone numbers.

I am also available via Signal, the secure and encrypted messaging service. My contact number there is the same as my cell number, [redacted]. The source of all communications can be kept confidential, if necessary. That is a pledge I take very seriously.

I hope you will see fit to communicate with me.

With kind regards,

Jim
Hi Anna — I think this looks great. The remitted amount we stated in our April 24 letter was $369,819.56. I

In the interest of time, it’s fine by me for the letter to go to Bob Charrow for clearance with the understanding that we will fill the exact amount of restricted funds.

Many thanks!

Mike

From: "Jacobs, Anna (NIH/OD) [E]" <...(b)(6)>
Date: Monday, June 29, 2020 at 11:12 AM
To: "Lauer, Michael (NIH/OD) [E]" <...(b)(6)>
Cc: "Lankford, David (NIH/OD) [E]" <...(b)(6)>
Subject: RE: Letter

Mike,
Attached in redline and clean versions are our suggested edits to the suspension letter, incorporating the questions. We’ve included explanatory comments where we thought it would be helpful. Please let us know if you’d like to discuss anything or have any edits. Once we have an agreed upon version, David has offered to send a final version to Bob.
Thanks,

Anna L. Jacobs, J.D., M.S.
Senior Attorney
HHS Office of the General Counsel
Public Health Division, NIH Branch
31 Center Drive, Bldg. 31, Rm. 2B-50
Bethesda, MD 20892

(b)(6) (phone)
301-402-1034 (fax)

(b)(6)

NOTICE: The contents of this message and any attachments may be privileged and confidential. Please do not disseminate without the approval of the Office of the General Counsel. If you are not an intended recipient, or have
received this message in error, please delete it without reading it and please do not print, copy, forward, disseminate, or otherwise use this information. Also, please notify the sender that you have received this communication in error. Your receipt of this message is not intended to waive any applicable privilege.

From: Lauer, Michael (NIH/OD) [E] <(b)(6)
Sent: Monday, June 29, 2020 9:31 AM
To: Lankford, David (NIH/OD) [E] <(b)(6)
Cc: Jacobs, Anna (NIH/OD) [E] <(b)(6) Lauer, Michael (NIH/OD) [E] <(b)(6)
Subject: Re: Letter

Outstanding, David, thanks so much

Mike

From: "Lankford, David (NIH/OD) [E]" <(b)(6)
Date: Monday, June 29, 2020 at 9:30 AM
To: "Lauer, Michael (NIH/OD) [E]" <(b)(6)
Cc: "Jacobs, Anna (NIH/OD) [E]" <(b)(6)
Subject: RE: Letter

Hi Mike— Anna and I are working to incorporate those questions into the letter. That version will also reflect our other suggested edits. We will have a draft to you for review soon. Once we’re all in agreement on the letter, I’d be glad to send it to Bob for his review.

David W. Lankford
NIH Legal Advisor
Office of the General Counsel
Public Health Division, NIH Branch
NIH Building 31, Room 2B-50
Bethesda, MD 20892-2111
Telephone: (b)(6)
Fax: (b)(6)
E-Mail: (b)(6)

This e-mail message is intended for the exclusive use of the recipient(s) named above. It may contain information that is protected, privileged, or confidential, and it should not be disseminated, distributed, or copied to persons not authorized to receive such information. If you are not the intended recipient, any dissemination, distribution, or copying is strictly prohibited. If you think you have received this e-mail message in error, please notify the sender immediately.

From: Lauer, Michael (NIH/OD) [E] <(b)(6)
Sent: Friday, June 26, 2020 8:05 PM
To: Lankford, David (NIH/OD) [E] <(b)(6) Tabak, Lawrence (NIH/OD) [E] <(b)(6)
Cc: Lauer, Michael (NIH/OD) [E] <(b)(6)
Subject: Re: Letter

Hi David— I’m attaching the questions and the latest draft of the main letter that I have. I’m guessing you may have something more recent.

Happy to talk on Sunday on how we can get a (hopefully) final version together.

Many thanks, Mike

From: "Lankford, David (NIH/OD) [E]" <(b)(6)
Date: Friday, June 26, 2020 at 7:15 PM
To: "Tabak, Lawrence (NIH/OD) [E]" <(b) (6) "Lauer, Michael (NIH/OD) [E]"
Subject: Re: Letter

Great - thanks. We'll work with Mike to get the letter ready with those questions.

From: "Tabak, Lawrence (NIH/OD) [E]" <(b) (6)
Date: Friday, June 26, 2020 at 6:29:50 PM
To: "Lankford, David (NIH/OD) [E]" <(b) (6) "Lauer, Michael (NIH/OD) [E]"
Subject: Letter

I don’t have a copy of the letter that was apparently drafted reinstating the grant but then suspending it (or are there two separate letters?). I have attached the questions they need to address to have the suspension lifted.

The next step would be to update the letter by including these questions and then we will run by Bob.

thanks
Larry
I have added my edits for your consideration.

Michelle
Good catch! Many thanks, I'll send it this afternoon.

Mike

Hi Mike, looks good, if you haven't sent it yet, I found a typo in the second to last paragraph, see attached

Best,
Jodi

Jodi B. Black, PhD, MMSc
Deputy Director
Office of Extramural Research, NIH

Many thanks – here’s the letter I will send. I changed the wording on one sentence regarding (per OK from OGC).

We (Renate, Amanda, and I) are already scheduled to talk tomorrow, so we can touch base on this.

Best, Mike
Subject: RE: Letter

Hello,

Thanks for the heads up, but let me know if we would include any additional information, general or specific.

Hope you're well,
Amanda

From: Lauer, Michael (NIH/OD) [E]  
Sent: Tuesday, July 7, 2020 3:28 PM  
To: Burklow, John (NIH/OD) [E] <b6>  
Cc: Fine, Amanda (NIH/OD) [E]  
Myles, Renate (NIH/OD) [E]  
Lauer, Michael (NIH/OD) [E]  
Wojtowicz, Emma (NIH/OD) [E] <b6>  
Subject: Re: Letter

Thanks John – I'll be making one minor change so I'll send the final, final version tonight. OGC (Bob Charrow) has given us clearance to change that one sentence.

Best, Mike

On 7/7/20, 3:25 PM, "Burklow, John (NIH/OD) [E]" <b6> wrote:

Hi, again, Mike--

I've looped in Amanda, Emma, and Renate.

Thanks,

John

-----Original Message-----
From: Lauer, Michael (NIH/OD) [E]  
Sent: Tuesday, July 7, 2020 11:40 AM  
To: Burklow, John (NIH/OD) [E]  
Cc: Lauer, Michael (NIH/OD) [E]  
Subject: Re: Letter

Hi John -- here you go.

Mike

On 7/7/20, 11:12 AM, "Burklow, John (NIH/OD) [E]" <b6> wrote:

Hi, Mike—

Could you share the letter? Apologies if you sent it to me already! Thanks!
John

Sent from my iPhone
Yes, good news.

Best,
Jodi

Jodi B. Black, PhD, MMSc
Deputy Director
Office of Extramural Research, NIH

Hi Jodi – great news here.

Many thanks, Mike

Many thanks David – great to hear! The edits are fine by me.

Best, Mike
Anna and Mike – Bob Charrow called me about the letter. He has just a few edits, shown in the attached redline version. In short, the edits are:

These edits are pretty minor. If Mike is OK with the edits and the letter has Bob’s clearance to be sent.

Please let me know if you have any questions or would like to discuss.

David W. Lankford
NIH Legal Advisor
Office of the General Counsel
Public Health Division, NIH Branch
NH Building 31, Room 2B-50
BETHESDA, Maryland 20892-2111
Telephone: (b) (5) 402-1034
Fax: (b) (5) 402-1034
E-Mail: (b) (5)

This e-mail message is intended for the exclusive use of the recipient(s) named above. It may contain information that is protected, privileged, or confidential, and it should not be disseminated, distributed, or copied to persons not authorized to receive such information. If you are not the intended recipient, any dissemination, distribution, or copying is strictly prohibited. If you think you have received this e-mail message in error, please notify the sender immediately.

From: Jacobs, Anna (NIH/OD) [E] <(b) (6)>
Sent: Monday, June 29, 2020 1:12 PM
To: Lauer, Michael (NIH/OD) [E] <(b) (6)>
Cc: Lankford, David (NIH/OD) [E] <(b) (6)>
Black, Jodi (NIH/OD) [E] <(b) (6)>
Subject: RE: Letter

Wonderful—thanks, Mike! We’ll be back in touch after we’ve conferred with Bob.

Best,

Anna L. Jacobs, J.D., M.S.
Senior Attorney
HHS Office of the General Counsel
Public Health Division, NIH Branch
31 Center Drive, Bldg. 31, Rm.2B-50
BETHESDA, Maryland 20892
(b) (6) (phone)
301-402-1034 (fax)

NOTICE: The contents of this message and any attachments may be privileged and confidential. Please do not disseminate without the approval of the Office of the General Counsel. If you are not an intended recipient, or have received this message in error, please delete it without reading it and please do not print, copy, forward, disseminate, or otherwise use this information. Also, please notify the sender that you have received this communication in error. Your receipt of this message is not intended to waive any applicable privilege.

From: Lauer, Michael (NIH/OD) [E] <(b) (6)>
Sent: Monday, June 29, 2020 1:11 PM
To: Jacobs, Anna (NIH/OD) [E] <(b) (6)>
Cc: Lauer, Michael (NIH/OD) [E] <(b) (6)>
Lankford, David (NIH/OD) [E]
Hi Anna — I think this looks great. The remitted amount we stated in our April 24 letter was $369,819.56. In the interest of time, it’s fine by me for the letter to go to Bob Charrow for clearance with the understanding that we will fill the exact amount of restricted funds.

Many thanks!

Mike

From: "Jacobs, Anna (NIH/OD) [E]"  
Date: Monday, June 29, 2020 at 11:12 AM  
To: "Lauer, Michael (NIH/OD) [E]"  
Cc: "Lankford, David (NIH/OD) [E]"  
Subject: RE: Letter

Mike,

Attached in redline and clean versions are our suggested edits to the suspension letter, incorporating the questions. We’ve included explanatory comments where we thought it would be helpful. Please let us know if you’d like to discuss anything or have any edits. Once we have an agreed upon version, David has offered to send a final version to Bob.

Thanks,

Anna L. Jacobs, J.D., M.S.
Senior Attorney
HHS Office of the General Counsel
Public Health Division, NIH Branch
31 Center Drive, Bldg. 31, Rm. 2B-50
Bethesda, MD 20892

301-402-1034 (fax)

NOTICE: The contents of this message and any attachments may be privileged and confidential. Please do not disseminate without the approval of the Office of the General Counsel. If you are not an intended recipient, or have received this message in error, please delete it without reading it and please do not print, copy, forward, disseminate, or otherwise use this information. Also, please notify the sender that you have received this communication in error. Your receipt of this message is not intended to waive any applicable privilege.

From: Lauer, Michael (NIH/OD) [E]  
Sent: Monday, June 29, 2020 9:31 AM  
To: Lankford, David (NIH/OD) [E]  
Cc: Jacobs, Anna (NIH/OD) [E], Lauer, Michael (NIH/OD) [E]  
Subject: Re: Letter

Outstanding, David, thanks so much
Hi Mike – Anna and I are working to incorporate those questions into the letter. That version will also reflect our other suggested edits. We will have a draft for you for review soon. Once we’re all in agreement on the letter, I’d be glad to send it to Bob for his review.

Hi David – I’m attaching the questions and the latest draft of the main letter that I have. I’m guessing you may have something more recent.

Happy to talk on Sunday on how we can get a (hopefully) final version together.

Many thanks, Mike

Great - thanks. We'll work with Mike to get the letter ready with those questions.
I don’t have a copy of the letter that was apparently drafted reinstating the grant but then suspending it (or are there two separate letters?). I have attached the questions they need to address to have the suspension lifted.

The next step would be to update the letter by including these questions and then we will run by Bob.

thanks
Larry
Drs. Aleksei Chmura and Peter Daszak  
EcoHealth Alliance, Inc.  
460 W 34th St  
Suite 1701  
New York, NY 10001

Re: Termination of NIH Grant R01 AI 110964

Dear Drs. Chmura and Daszak:

I am writing to notify you that the National Institute of Allergy and Infectious Diseases (NIAID), an Institute within the National Institutes of Health (NIH), under the Department of Health and Human Services (HHS) has elected to terminate the project *Understanding the Risk of Bat Coronavirus Emergence*, funded under grant R01 AI 110964, for convenience. This grant project was issued under the authorization of Sections 301 and 405 of the Public Health Service Act as amended (42 USC 241 and 284). This grant was funded as a discretionary grant as outlined in the NIH Grants Policy Statement, which states that the decision not to award a grant, or to award a grant at a particular funding level, is at the discretion of the agency, in accordance with NIH’s dual review system.

At this time, NIH does not believe that the current project outcomes align with the program goals and agency priorities. NIAID has determined there are no animal and human ethical considerations, as this project is not a clinical trial, but rather an observational study.

As a result of this termination, a total of $369,819.56 will be remitted to NIAID and additional drawdowns will not be supported. The remaining funds have been restricted in the HHS Payment Management System, effective immediately.

Please let me know if you have any questions concerning the information in this letter.

Sincerely,

Michael S Lauer, MD  
NIH Deputy Director for Extramural Research

cc:  Dr. Erik Stemmy  
Ms. Emily Linde
Thanks Francis – here’s a copy of the final letter.

Best, Mike

Oh yeah,

FC

Get ready for the press to find out.

FC

P.S. to Mike: Can I have a copy of the final letter?
Hi Francis – yes, it’s out!

Many thanks, Mike

---

From: "Collins, Francis (NIH/OD) [E]"
Date: Wednesday, July 8, 2020 at 9:35 PM
To: "Lauer, Michael (NIH/OD) [E]", "Tabak, Lawrence (NIH/OD) [E]" < "Hallett, Adrienne (NIH/OD) [E]" < 

Subject: EcoHealth

Did letter go to PI today?
8 July 2020

Drs. Aleksei Chmura and Peter Daszak
EcoHealth Alliance, Inc.
460 W 34th St
Suite 1701
New York, NY 10001

Re: NIH Grant R01AI110964

Dear Drs. Chmura and Daszak:

In follow-up to my previous letter of April 24, 2020, I am writing to notify you that the National Institute of Allergy and Infectious Diseases (NIAID), an Institute within the National Institutes of Health (NIH), under the Department of Health and Human Services (HHS), has withdrawn its termination of grant R01AI110964, which supports the project Understanding the Risk of Bat Coronavirus Emergence. Accordingly, the grant is reinstated.

However, as you are aware, the NIH has received reports that the Wuhan Institute of Virology (WIV), a subrecipient of EcoHealth Alliance under R01AI110964, has been conducting research at its facilities in China that pose serious bio-safety concerns and, as a result, create health and welfare threats to the public in China and other countries, including the United States. Grant award R01AI110964 is subject to biosafety requirements set forth in the NIH Grants Policy Statement (e.g., NIH GPS, Section 4.1.24 “Public Health Security”) and the Notice of Award (e.g., requiring that “Research funded under this grant must adhere to the [CDC/NIH Biosafety in Microbiological and Biomedical Laboratories (BMBL)].”). Moreover, NIH grant recipients are expected to provide safe working conditions for their employees and foster work environments conducive to high-quality research. NIH GPS, Section 4. The terms and conditions of the grant award flow down to subawards to subrecipients. 45 C.F.R. § 75.101.

As the grantee, EcoHealth Alliance was required to “monitor the activities of the subrecipient as necessary to ensure that the subaward is used for authorized purposes, in compliance with Federal statutes, regulations, and the terms and conditions of the subaward...” 45 C.F.R. § 75.352(d). We have concerns that WIV has not satisfied safety requirements under the award, and that EcoHealth Alliance has not satisfied its obligations to monitor the activities of its subrecipient to ensure compliance.

Moreover, as we have informed you through prior Notices of Award, this award is subject to the Transparency Act subaward and executive compensation reporting requirement of 2 C.F.R. Part
170. To date you have not reported any subawards in the Federal Subaward Reporting System.

Therefore, effective the date of this letter, July 8, 2020, NIH is suspending all activities related to R01AI110964, until such time as these concerns have been addressed to NIH’s satisfaction. This suspension is taken in accordance with 45 C.F.R. § 75.371, Remedies for Noncompliance, which permits suspension of award activities in cases of non-compliance, and the NIH GPS, Section 8.5.2, which permits NIH to take immediate action to suspend a grant when necessary to protect the public health and welfare. This action is not appealable in accordance with 42 C.F.R. § 50.404 and the NIH GPS Section 8.7, Grant Appeals Procedures. However, EcoHealth Alliance has the opportunity to provide information and documentation demonstrating that WIV and EcoHealth Alliance have satisfied the above-mentioned requirements.

Specifically, to address the NIH’s concerns, EcoHealth must provide the NIH with the following information and materials, which must be complete and accurate:

1. Provide an aliquot of the actual SARS-CoV-2 virus that WIV used to determine the viral sequence.
2. Explain the apparent disappearance of Huang Yanling, a scientist/technician who worked in the WIV lab but whose lab web presence has been deleted.
3. Provide the NIH with WIV’s responses to the 2018 U.S. Department of State cables regarding safety concerns.
4. Disclose and explain out-of-ordinary restrictions on laboratory facilities, as suggested, for example, by diminished cell-phone traffic in October 2019, and the evidence that there may have been roadblocks surrounding the facility from October 14-19, 2019.
5. Explain why WIV failed to note that the RaTG13 virus, the bat-derived coronavirus in its collection with the greatest similarity to SARS-CoV-2, was actually isolated from an abandoned mine where three men died in 2012 with an illness remarkably similar to COVID-19, and explain why this was not followed up.
6. Additionally, EcoHealth Alliance must arrange for WIV to submit to an outside inspection team charged to review the lab facilities and lab records, with specific attention to addressing the question of whether WIV staff had SARS-CoV-2 in their possession prior to December 2019. The inspection team should be granted full access to review the processes and safety of procedures of all of the WIV field work (including but not limited to collection of animals and biospecimens in caves, abandoned man-made underground cavities, or outdoor sites). The inspection team could be organized by NIAID, or, if preferred, by the U.S. National Academy of Sciences.
7. Lastly, EcoHealth Alliance must ensure that all of its subawards are fully reported in the Federal Subaward Reporting System.

During this period of suspension, NIH will continue to review the activities under this award, taking into consideration information provided by EcoHealth Alliance, to further assess compliance by EcoHealth Alliance and WIV, including compliance with other terms and conditions of award that may be implicated. Additionally, during the period of suspension, EcoHealth Alliance may not allow research under this project to be conducted. Further, no funds from grant R01AI110964 may be provided to or expended by EcoHealth Alliance or any subrecipients; all such charges are unallowable. It is EcoHealth Alliance’s responsibility as the
recipient of this grant award to ensure that the terms of this suspension are communicated to and understood by all subrecipients. EcoHealth Alliance must provide adequate oversight to ensure compliance with the terms of the suspension. Any noncompliance of the terms of this suspension must be immediately reported to NIH. Once the original award is reinstated, NIH will take additional steps to restrict all funding in the HHS Payment Management System in the amount of $369,819. EcoHealth Alliance will receive a revised Notice of Award from NIAID indicating the suspension of these research activities and funding restrictions as a specific condition of award.

Please note that this action does not preclude NIH from taking additional corrective or enforcement actions pursuant to 45 CFR Part 75, including, but not limited to, terminating the grant award. NIH may also take other remedies that may be legally available if NIH discovers other violations of terms and conditions of award on the part of EcoHealth Alliance or WIV.

Sincerely,

Michael S. Lauer, MD
NIH Deputy Director for Extramural Research
Email: [redacted]

cc: Dr. Erik Stemmy
    Ms. Emily Linde